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Abstract 
Personalized medicine is a branch of medicine that focuses on how a prescribed therapeutic treatment 
affects a specific individual as opposed to its general effects for the broader population. The goal of 
personalized medicine is to improve patient care by enabling concentrations of a therapeutic drug to be 
monitored in various biological compartments, while also measuring their effects in relation to the 
administered dose via therapeutic drug monitoring (TDM). Metabolomics—the study of all small 
endogenous and exogenous molecules within a cell, tissue, or organism—has recently been proposed as a 
method for developing patient-based metabolic profiles, which could enable clinicians to more effectively 
predetermine suitable courses of treatment for a variety of patients. The probability of success or failure 
for a given treatment is determined in large part by metabolic phenotyping, which considers several patient-
based influential factors, such as age, diet, environment, and medical history. This approach allows 
treatment to be tailored to the needs of each individual patient, thereby avoiding under- or over-dosing or 
wasting time with unnecessary treatment options, which often occurs as a result of the current “trial and 
error” approach to personalized therapy. In this thesis, solid phase microextraction (SPME) coupled with 
liquid chromatography-mass spectrometry (LC-MS) is proposed as an alternative sample preparation tool 
for use in the field of personalized medicine. To this end, the work in this thesis presents the development 
of various SPME-based methods for TDM, and it explores SPME-based clinical metabolomics and proof-
of-concept pharmacometabolomics for a range of biological matrices typically encountered in clinical 
practice, such as whole blood, serum, plasma, urine, and lung tissue. Furthermore, SPME is proposed as a 
practical tool for rapid diagnostics, as it can be directly coupled to sensitive detection methods like MS. 
While a number of preliminary steps are required before important diagnostic markers can be monitored—
including the validation of these potential respective candidate biomarkers, which is already a major 
inherent challenge in metabolomics—the use of SPME for real-time TDM and point-of-care analysis of 
important metabolic markers remains feasible. This thesis consists of a brief introduction and 6 
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experimental chapters, with each successive chapter exploring increasingly complex samples of interest 
and discussing the challenges and limitations associated with their analysis. Moreover, each subsequent 
chapter also addresses the difficulties associated with performing solely TDM or metabolomics separately 
and how, particularly in vivo SPME, can overcome these challenges and be used to achieve both goals 
(TDM and metabolomics) simultaneously under even more complicated and dynamic circumstances. 
Specifically, Chapter 2 focuses on the therapeutic drug monitoring of TXA in plasma and urine samples 
from patients with chronic renal dysfunction who are undergoing cardiac surgery, while Chapter 3 presents 
a metabolomics study entailing the profiling of serum samples from various psoriatic patients. Chapters 4, 
5, and 6 illustrate how SPME can be used to enable simultaneous TDM and metabolomics under more 
complicated and dynamic circumstances by using in vivo SPME for specifically tissue analysis. Chapter 4 
explores lung tissue and perfusate metabolomics using a pre-clinical porcine model undergoing 
normothermic ex vivo lung perfusion (NEVLP). In contrast, Chapters 5 and 6 assess the use of in vivo 
SPME for the TDM of chemotherapy drugs administered via in vivo lung perfusion (IVLP) in pre-clinical 
porcine model (Chapter 5) and clinical human trial settings (Chapter 6), followed by proof-of-concept 
pharmacometabolomics. Finally, the potential use of SPME as a rapid diagnostic tool is showcased in 
Chapter 7—which shows the rapid analysis of TXA from plasma—concluding the thesis by further 
demonstrating that the dual goals of TDM and point-of-care testing for metabolic markers can be achieved 
with rapid analysis via the direct coupling of SPME to MS. 
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Chapter 1: Review of current literature 
1.1 Pharmacokinetics 
Pharmacokinetics (PK) is an aspect of pharmacology that is described as “what the body does to a drug.”1 
It assesses the relationship between an administered dose of a drug and its concentration either in blood or 
at the site of administration.2 It is important to establish a pharmacokinetic profile during drug development 
because it provides information as to whether a drug reaches its target receptors as well as to the duration 
for which it remains at these target sites to evoke the desired physiochemical response.1 The processes that 
influence the pharmacokinetics of a drug are absorption, distribution, metabolism and elimination.1 
Absorption explains the uptake of a drug from the area of administration into the blood. Metabolism 
describes the rate at which specific enzymes in the body change the administered form or parent drug 
producing effective and/or toxic metabolites. Distribution focusses on the drug equilibrium established 
between four types of compartments in the body which are the intravascular volume, interstitial volume, 
aqueous intracellular volume and body fat. Excretion or metabolic inactivation describes the ways in which 
the body eliminates the drug.1,2 
Even distribution of a drug among compartments is a rare occurrence. This is due to factors such as the 
differences in rates of blood perfusion to organs in the body and the pharmacodynamics of the drug.1 
Metabolism has interpersonal variability because it is dependent on patient biology and as such, the rate of 
drug elimination or clearance is affected by this process.1-3 Many drugs exhibit large differences in blood 
levels between individuals due to these interpersonal differences and therefore pose a significant threat. 
This is especially dangerous in the cases of drugs that possess low therapeutic indicies.4 Because blood 
concentration is difficult to control once a dose is administered, pharmacokinetic profiling is thus essential 
in determining whether the effective therapeutic steady state concentration was achieved. A comprehensive 
profile can be obtained by monitoring drug concentration in both blood and urine. As previously mentioned, 
metabolism affects drug clearance. By monitoring these particular biological fluids (biofluids), with 
2 
 
emphasis on the rate of drug clearance and urine concentration, drug doses can be corrected or adjusted 
accordingly and safely. 1-2 This need for therapeutic drug monitoring formed the foundation for personalized 
medicine.3-4  
1.2 Personalized medicine 
Personalized medicine is a branch of medicine that acknowledges the influence of patient phenotype and 
genotype on the therapeutic effect of a drug.3 It highlights the need for individualized therapy by 
comprehensively studying a patient’s biological fluids and tissue samples to attain tailored disease 
prognosis or diagnosis.3 It is important because it renounces approaches to treatment that assume a standard 
dose as effective for all persons. It is beneficial in that it allows for dose adjustments or recommends for 
other treatment alternatives that are patient specific thus increasing chances of recovery. Personalized 
medicine is used heavily in the field of chemotherapy as the causes and consequences of cancer are strictly 
individual since they are profoundly impacted by genetics, race, gender, age and various environmentally 
induced stressors.5-6 Some other types of drugs that experience variable therapeutic responses include, 
antibiotic agents for the critically ill, antiviral medication for those suffering from HIV, and antidepressant 
therapies.7-8 In the expanding field of personalized medicine, the aim is to avoid unnecessary prescription 
of ineffective therapeutics. Hence, there is an increasing need for rapid diagnostic tools as well as simple 
and quick sample preparation techniques.9 
1.3 Therapeutic drug monitoring 
In essence, therapeutic drug monitoring (TDM) is the application of pharmacokinetic profiling in a single 
patient. The field of TDM is concerned with finding the relationship between the administered dose of a 
drug, the concentrations of that drug in various biological compartments, and the resultant therapeutic 
effects specific to a single individual.10 However, unlike PK—which focuses on drug behavior for the 
majority of the population and is generally employed for the study of new drugs on the pharmacological 
market—TDM is specifically employed for drugs that have narrow or unknown/unestablished therapeutic 
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ranges, and that present large inter- or intra-patient concentration variability with respect to their PK 
profiles.10 TDM is an important tool for preventing the under- or over-dosing of these drugs, as it enables 
dose adjustments to be made over the course of treatment, thereby tailoring treatment for a specific 
individual. Given the wide range of samples investigated during TDM, it is important to consider sample 
preparation techniques/assays that are not only rapid, but that are also selective and specific to the 
complexity of the sample under analysis. Furthermore, these assays should be cost effective and amenable 
to high throughput, as TDM can often require the analysis of large numbers of samples. Some examples of 
classes of drugs that require TDM include antiepileptics, antibiotics, antiretrovirals11, 
immunosuppressants12, and many chemotherapeutics10. In this thesis, antifibrinolytics and anticancer agents 
are addressed and investigated. 
1.4 Metabolomics 
Metabolomics is the study of all small endogenous and exogenous molecules within a living system at a 
given time for the purpose of obtaining information about the biochemical state of that system. 
Metabolomics is an emerging field in systems biology (wherein genomics, transcriptomics, proteomics, 
epigenomics are quite established approaches) that falls at the bottom of the “omics” cascade, but upstream 
from external stimuli such as lifestyle, dietary, medical, and environmental conditions. As such, 
metabolomics facilitates an understanding of the interconnectedness and complex interactions between the 
genome and exposome (exogenous molecules related to various forms of external stimuli).13,14 Since the 
metabolome contains a wide range of compounds, including  lipids, fatty acids, amino acids, xenobiotics, 
and sugars, it can provide information on disease states as well as the mechanisms of disease 
pathophysiology.14,15 Moreover, the use of metabolomics in personalized medicine to significantly improve 
patient care and outcomes can be further enhanced through the development and use of metabolic 
phenotyping, which involves using metabolomics to characterize an individual or biological system.13–15 
Metabolic phenotyping allows clinicians to predetermine a patient’s susceptibility or response to a given 
treatment, thus avoiding the “trial and error” approach that is commonly used personalized care. 
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Furthermore, metabolomics is especially useful for improving personalized targeted therapies, as it 
measures and considers all potentially influential factors (patient age, gender, weight, diet, gut microbiome, 
medical history etc.), whereas traditional personalized strategies only tend to focus on a single target or 
factor at time.13,14 Further from metabolic phenotyping having the potential to predetermine more 
efficacious treatment courses, pharmacometabolomics is a branch of clinical metabolomics that investigates 
how the metabolome responds to treatments using a particular/combination of pharmaceuticals.13 This 
branch of metabolomics is often associated with drugs that require TDM, and drugs that have highly 
variable patient responses due to an intricate balance of factors, such as variations in the activity and 
concentration of certain enzymes and/or varying patient gut microbiome profiles, which is also known to 
influence metabolism and has been implicated in a number of disorders including but not limited to 
inflammatory bowel disorders and disorders of the immune system.14 However, pharmacometabolomics is 
also especially useful for singular drugs that present multiple mechanisms of action, as well as for 
monitoring polytherapy.13 Thus, pharmacometabolomics overcomes the univariate-based approach to TDM 
wherein a single assay is used for a single drug/target by permitting the efficient simultaneous monitoring 
of multiple drugs and their impact on the treated system. Metabolomics can: 1) be used to identify 
prognostic, diagnostic, predictive, and surrogate markers of diverse disease states; 2) allow for disease 
subclassification and patient stratification; 3) provide a correlation for monitoring response and disease 
recurrence ; 4) determine treatment response or rejection due to treatment toxicity; 5) inform underlying 
disease pathophysiology; and 6) explore pharmacometabolomics (phenotypical drug response)14,15. The 
final three items in this list are discussed in more detail in this thesis. 
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Figure 1.1 The typical metabolomics workflow 
 
Despite the potential advantages of metabolomics, the field of “omics” research is not without numerous 
challenges. As shown in Figure 1.1, the metabolomics workflow consists of 7 steps: the biological question 
(i.e., what is the metabolic difference between healthy and cancerous samples?); the experimental design 
(i.e., how many of which kinds of samples from each group [healthy vs cancerous] will be investigated to 
answer the biological question?); sample collection, which follows stringent protocols for the collection of 
matrices such as blood, plasma, and urine in order to reduce experimental variation/errors; sample 
preparation, serves to simplify sample complexity and improving sample amenability for instrumental 
analysis; instrumental analysis, which involves selecting the metabolomics platform (nuclear magnetic 
resonance (NMR) or MS, the latter explored more in this thesis) to be used for separation and detection; 
data pre-processing, pre-treatment, and statistical analysis, which use one or a combination of several 
available software packages to convert and process the raw data obtained from instrumental acquisition, 
followed by the use of web-based or commercial software for chemometric analysis; and metabolite 
identification and validation which uses web-based databases or commercial packages/databases to 
tentatively/putatively identify metabolites of interest followed by validation via MS/MS and/or secondary 
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or tertiary cohort studies.16–19 Since the compounds in the metabolome have a wide range of 
physicochemical properties (hydrophobic, hydrophilic, neutral, basic, acidic)15 and the samples typically 
employed in metabolomic analysis (whole blood, plasma, serum, urine, stool, etc.) are generally rather 
complex, an initial step consisting of metabolism quenching (a method used to prevent metabolite 
degradation) followed by extensive sample cleanup is required in order to successfully isolate these 
metabolites from these biological matrices. Post quenching and sample cleanup, other non-specific sample-
preparation measures are required for the global extraction of the constituent compounds of the 
metabolome. Thus, sample preparation is one of the most crucial steps in the metabolomics workflow, as it 
directly affects the outcome of the study.16 Following data acquisition via the selected instrumentation and 
data preprocessing, the next major challenge is statistical analysis. The number of available data-processing 
platforms, including, but not limited to, SIMCA, Metaboanalyst, and XCMS Online, as well as the plethora 
of data pre-treatment and data processing options, can turn chemometric analysis into a very time-
consuming process.17 However, metabolite identification and validation remains the bottleneck in the 
metabolomics workflow. This bottlenecking occurs for a number of reasons, including the fact that: 1) only 
a fraction of metabolites in the metabolome are reported and recorded in databases; 2) there is no established 
protocol for performing untargeted analysis, which means that candidate biomarkers may be dependent on 
the sample preparation technique used; 3) metabolite identification/validation may be difficult and/or 
dependent on the detection method employed.20 In the case of the latter, multiple larger cohort studies are 
required to the test robustness of candidate biomarkers before being used in official clinical settings, as 
mass spectrometry-based metabolomics is prone to in-source fragmentation, which can lead to misleading 
conclusions.  
1.5 Rapid analysis 
TDM and metabolomics utilize sophisticated instrumentation for separation and detection. However, the 
complexity of the samples involved precludes the direct injection of these untreated samples into these 
systems; thus, extensive sample preparation is required to ensure that the samples are compatible with the 
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instrumentation.21 While the use of TDM and metabolomics is evidently advantageous in clinical and 
research facilities, these techniques face the common drawback of long analysis times due to involved 
sample preparation methods and long instrument run times. Fortunately, these limitations have been 
mitigated by the development of technologies that enable rapid analysis which allow for minimal sample 
preparation and direct detection without separation. As such, rapid-analysis technologies are able to 
decrease sample turnaround times, thereby enabling increased throughput and rapid information 
acquisition, all at a drastically reduced cost. Unlike the quantitative and semi-quantitative nature of TDM 
and metabolomics, respectively, rapid analysis is generally qualitative in nature and is most commonly 
associated with imaging techniques like magnetic resonance spectroscopy (MRS) positron emission 
tomography (PET). The instrumentation employed in this thesis – LC-MS and stand-alone MS – for TDM, 
metabolomics, and rapid analysis is discussed in more detail in section 1.9 “Instrumentation”. 
1.6 Typically encountered samples in clinical practice 
Biological fluids commonly investigated in PK studies, TDM, and metabolomics include whole blood, 
serum, plasma, urine, stool, cerebrospinal fluid, breast milk, sweat, saliva, and tears.22-23 Among the array 
of available biofluids, blood, blood compartments, and urine are most commonly used in metabolomics, 
and especially TDM, with venous blood being the most extensively and frequently used.22 The frequent and 
widespread use of venous blood is due to the fact that plasma or serum, usually show a good correlation 
between the concentration levels of a drug in the body and its therapeutic effect.22 On the other hand, urine 
is more regularly studied when monitoring drug excretion patterns, drug bioavailability, and drug 
metabolites.22 STEEN SolutionTM, commonly referred to as perfusate (discussed in more detail in section 
1.6.3 “Steen solution”), is another fluid used in bioanalysis that is not typically encountered due to being 
specific to transplantation science or organ preservation strategies.24 Since STEEN Solution is used either 
to flush an organ or is circulated through the organ before transplantation, it may contain valuable 
metabolite information that can shed light on why an organ was or was not rejected after transplantation. 
Additionally, there has been growing interest in TDM via tissue analysis, as plasma drug concentrations 
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may not accurately reflect drug concentrations in the tissue. This information is important because effective 
treatment (i.e., treatment of tumours) depends on accurate knowledge about the  degree of penetration of a 
drug into the targeted organ.25,26 Furthermore, in clinical metabolomics, site-specific metabolites found in 
tissue may be able to provide more insight about various other biochemical processes. However, these 
tissue-specific metabolites cannot be captured or accurately represented due to dilution effects in circulating 
blood.27 For the purposes of this thesis, plasma, serum, urine, perfusate, and lung tissue (Figure 1.2) will be 
the biological matrices of interest, as they provide valuable and complementary information about drug 
concentration and distribution in addition to serving as important metabolite reservoirs  
 
Figure 1.2 Various types of biological samples investigated in this thesis 
 
1.6.1 Blood and blood compartments 
Blood—which is 55% plasma in which red blood cells and macromolecules are suspended—remains one 
of the most useful matrices in bioanalysis, as well as one of the most challenging.28 As a circulatory fluid 
perfusing throughout the entirety of an organism, blood contains rich and dense global information about 
the various biomolecules within that system including, but not limited to, metabolites (lipids, amino acids, 
organic and inorganic acids), proteins and peptides. To isolate plasma, the blood is first treated with 
anticoagulants before being subjected to centrifugation; in contrast, serum is extracted by centrifuging 
clotted blood. Centrifugation is discussed in more detail in section 1.7.1 “Centrifugation/ centrifugation 
ultrafiltration”. It is generally accepted that plasma and serum are roughly equivalent in terms of their 
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small-molecule profiles, but that their protein profiles differ significantly due to the reduction of proteins 
associated with blood clotting during serum processing; thus, there is a higher abundance of these proteins 
in plasma. One drawback to using whole blood as a sample is its poor stability under storage conditions 
(freezing) required for prolonged periods of time. This poor stability can result in erythrocyte hemolysis, 
which renders subsequent plasma and serum isolation—a step that generally simplifies the blood handling 
workflow—impossible. The limitations associated with using serum in metabolomics and TDM include 
potential changes in the metabolite profile or the possible loss of targeted/known analytes from erythrocyte-
related biochemical degradation of drugs due to the length of time required for clotting. As such, plasma, 
which is obtained from collected blood on a much shorter time scale, is the preferred and more widely used 
blood compartment for analysis. However, it is important to note that the use of anticoagulants in plasma 
can cause interferences in TDM and metabolomics, which can be particularly harmful for the latter, as these 
interferences can overshadow potentially important low-abundance metabolites. Additionally, for 
metabolomics in particular, there are strict protocols regarding sample collection, as the blood metabolome 
reflects the circadian rhythm wherein certain metabolites concentrations naturally change over a 24-hour 
period, thus making it necessary to consider appropriate sample-collection times.28 
1.6.2 Urine 
A large proportion of drugs are excreted entirely or significantly via the kidneys as parent drugs or drug 
metabolites. The kidneys experience the highest rate of blood plasma perfusion per gram in comparison to 
other organs in the body and they are also responsible for the regulation and maintenance of a stable blood 
pH.1 It is organized into units called nephrons, each of which contributes to urine processing. The sub 
processes occurring during renal elimination are glomerular filtration and tubular secretion and reuptake.1 
During urine processing, additional water is reabsorbed thus concentrating compounds in urine and 
resulting in the four-fold increase of osmolality in urine compared to blood.1  
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Urine is composed of more than 90% water and is thus classified as an aqueous biomatrix. It is important 
to stress that the complexities of urine make its use in analytical chemistry very difficult and as such, special 
considerations need to be made when dealing with this matrix.29 Unlike blood wherein the average 
physiological pH is 7.4, urine pH can vary from 5-9.1,30 This poses a significant challenge in isolating pH-
dependent target compounds because their pKa values affect the type of species present in urine. This 
consequently influences the sensitivity and reproducibility of an analytical method for analyte isolation and 
in turn affects the quantification of substances from patient to patient.29 Urine properties such as pH, ionic 
strength, inorganic salt content and the presence of exogenous and endogenous compounds can contribute 
to coelution and ion suppression or enhancement during analysis making identification and quantification 
of target compounds difficult.31–33 These properties are further influenced by the age, gender, environmental 
exposure, metabolic behaviour (metabotype), medical history, gut microbiome and dietary and hydration 
habits of a patient.29 These variables further emphasize the complications of urine analysis.  
Unlike the stringent sample collection protocol in place for blood, urine is readily available in large 
quantities and can be easily and non-invasively collected.22-29 The concentration of analytes is usually 
higher due to urine processing, there is an absence of proteins and time averaged information about a 
compound is available due to its storage in the bladder.1,30 Besides TDM, metabolomics investigations can 
be conducted on urine due to the presence patient-dependent exogenous and endogenous compounds.   
1.6.3 Steen solution  
Steen SolutionTM, otherwise referred to as perfusate or perfusion fluid, is used as a general organ flush 
during the transplantation process, namely after explantation from the donor and prior to implantation in 
the recipient patient. It is also used during normothermic ex vivo lung perfusion (NEVLP or EVLP) and 
modified in vivo lung perfusion (IVLP) to help maintain the  physiological integrity of the isolated organ 
throughout these procedures.24 The NEVLP method used at Toronto General Hospital (the method used 
and described specifically in this thesis) uses a STEEN SolutionTM that is acellular in nature in order to 
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prevent the occurrence of hemolysis during the procedure. STEEN SolutionTM is a physiological salt 
solution that contains dextran 40, which is a polysaccharide and mild scavenger that helps to prevent 
thrombogenesis (clot formation) and excessive leukocyte interactions by coating and protecting the 
endothelium. The extracellular electrolyte content and low levels of potassium effectively decrease free 
radical formation, thus preventing vascular spasms under normothermic conditions. The use of human 
serum albumin in the perfusate regulates oncotic pressure in the lung, which reduces the formation of 
edema. Furthermore, STEEN SolutionTM is thought to possess antioxidant properties, which help abate the 
ROS formation associated with ischemia-reperfusion-related lung injuries and improve the success rate of 
the NEVLP procedure.24 
1.6.4 Tissue 
The growing interest in tissue analysis raises the need for standardized sample preparation protocols for the 
various tissue types in order to ensure reproducible and reliable results. Compared to the analysis of 
systemic fluids in which the important metabolites would be otherwise diluted as a result of systemic 
circulation, tissue analysis is able to provide more information about both the site-specific interactions of 
therapeutics, and invaluable biochemical information about disease pathology.25,27 While blood is a 
connective tissue, it falls into the category of biological fluids. Another category of tissue is delineated by 
the solid or semi-solid nature of biologically derived matter. Some examples of biological solids used in 
TDM and metabolomics include soft tissues, such as the liver, lung, spleen, and brain; hard tissues like 
bone, cartilage, hair, and skin; and tough tissues like muscle, heart, stomach, intestines, and arteries.26 
However, since the heterogeneity of tissue can lead to the non-uniform distribution of therapeutic drugs 
within an organ, the accurate quantitation of such drugs via tissue analysis can be rather difficult. Moreover, 
some metabolites are site specific, which means that they may occur in significantly higher or lower 
abundance in a particular region of the organ compared to the bulk organ or other areas of the organ. 
Therefore, careful, reproducible sampling procedures are necessary in order to ensure that the observed 
differences are representative of true changes rather than being the result of inappropriate sampling or 
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sample handling.27 Unlike biological fluids such as blood or urine, tissue analysis requires much more 
involved sample-preparation methods. Tissue-related sample preparation practices are discussed in section 
1.7.8 “Homogenization”. 
1.7 Current sample preparation methods 
In TDM, the measurement of free and total concentration is important in order to determine the relationship 
between dose and effect.34 It remains a controversial issue as to whether total drug concentration in various 
biological compartments is more important than free concentration because the free concentration 
measurements are unnecessary if it is constant within and between individuals.34 However, the free 
concentration within and between individuals, is dependent on the extent of enzymatic influences or protein 
binding of the drug.1–3,34,35 Free concentration is then a function of pharmacokinetics as it is dependent on 
how an individual processes the drug. Sample preparation techniques were developed for the purposes of 
determining free drug concentration as the unbound fraction is bioavailable to partition into tissues, bind to 
receptors and induce a physiological or physiochemical response.1,34,35 Some notable examples of such 
techniques specific for determining free drug concentration are ultrafiltration (UF) and equilibrium dialysis 
(ED), while other sample preparation methods that determine total drug concentration include plasma 
protein precipitation (PPt), dried blood spot (DBS), liquid-liquid extraction (LLE) and solid phase 
extraction (SPE). Other methods more suited for tissue sample preparation require an initial sample 
homogenization step followed by one or more of the above noted sample preparation methods (PPt or LLE) 
and/or centrifugation. Figure 1.3 graphically summarizes some of the conventional sample preparation 
techniques used for clinically-relevant samples analyzed via LC-MS specifically, the main instrumentation 
used in this thesis and discussed in more detail in section 1.9 “Instrumentation”. 
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Figure 1.3 Some conventional sample preparation approaches used in the bioanalytical and clinical field such as 
(from the left) centrifugation, plasma protein precipitation (PPt), dried blood spots (DBS), solid phase extraction 
(SPE). Solid phase microextraction (SPME) is a novel technique that is explored in this thesis. 
 
1.7.1 Centrifugation/ centrifugation ultrafiltration 
Centrifugation is the most widely used sample-cleanup/sample-preparation technique. Briefly, 
centrifugation operates on the sedimentation principle wherein suspended particles such as blood cells in 
whole blood, proteins in plasma (after an initial precipitation from cold-solvent addition), or minerals in 
urine are separated as a result of centrifugal acceleration, with heavier, denser particles moving outward 
and downward towards the bottom and lighter particles moving to the center and settling based on density.36 
Centrifugation ultrafiltration operates under the same principle as centrifugation, but uses a semi-permeable 
membrane with a certain molecular weight cut off (MWCO) to prevent solutes above the MWCO from 
passing through.37 Centrifugation is often used for a range of samples like blood and/or tissue after an initial 
homogenization step, while centrifugation ultrafiltration is more commonly used for the removal of proteins 
from plasma and serum. The respective concentrations of macromolecules and smaller molecules remaining 
in the sample after centrifugation or centrifugation ultrafiltration will vary depending on the type of solvent 
that is used, the ratio of solvent volume to sample volume, the centrifugal force applied, and the MWCO of 
the membrane being used.37 
1.7.2 Ultrafiltration (UF) 
UF is a method of separation involving sample centrifugation in the presence of a semipermeable membrane 
that has a molecular weight cut-off (MWCO) ranging from 3-50 kD.34,35 The concentration gradient that 
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results from the filtration allows for the measurement of free drug concentration in the protein free 
ultrafiltrate.34 The method’s simplicity and speed make it the preferable choice for clinical applications.34 
Unfortunately, drugs are susceptible to nonspecific adsorption (NSA) to the UF devices, introducing 
potentially large errors in the quantification of free drug concentration.34,35 Other issues include a change 
in temperature and pH at which centrifugation occurs which also contribute to analytical errors. It is 
believed however, that temperature and pH can be easily improved to better mimic physiological conditions 
while there are efforts being made to compensate for the problem of NSA.34,35  
1.7.3 Equilibrium dialysis (ED) 
Still considered the gold standard for monitoring free drug concentration, ED is a technique in which a 
semipermeable membrane separates two chambers, one of which contains plasma and the other contains a 
buffer that has a similar consistency as plasma.34,35 After some time, through the process of diffusion, 
equilibrium is established between the chambers and the unbound fraction is determined as a ratio of the 
free drug fraction in the plasma chamber to that of the fraction in the buffer chamber.35 Nonspecific 
adsorption and volume shifts due to osmosis are some method disadvantages pointed out by Musteata 
(2011)34 but are considered negligible according to Nilsson (2013).35 Other drawbacks include the 
disturbance in equilibrium which is proven by the consequent decrease in equilibrium concentration, the 
method is extremely labour intensive and time consuming, it requires long equilibration times, it is not ideal 
for water soluble compounds and artifacts are formed as a result of electrically charged proteins or 
drugs.34,35 
1.7.4 Plasma protein precipitation (PPt) 
Precipitation occurs as a result of protein insolubility due to either the presence of an organic modifier, a 
change in pH by the addition of an acid or base, or an increase in salt content.38,39 Organic solvents such as 
methanol, ethanol or acetonitrile – the most effective organic solvent for precipitation according to Lee and 
Oh (2014)38 – can be used.38,39 Although basic conditions lead to protein precipitation, the addition of an 
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acid (trifluoroacetic acid or perchloric acid) creates a favorable environment for positively charged amino 
acids to become insoluble salts. These newly induced salts remove water molecules that saturate the 
proteins, thus causing precipitation.38 The same mechanism applies with the simple addition of salt 
(ammonium sulfate) and is referred to as salt-induced precipitation.39 Samples can be centrifuged following 
precipitation and the supernatant is used to quantify total drug concentration.39  PPt is the longest and most 
widely used sample preparation method due to its low cost, speed and ease. It is still favoured in biological 
processing and in some cases produces higher recovery rates than other sample preparation techniques.38 
However, with bioanalysis using tandem mass spectrometry (MS/MS) subsequent to PPt, there can be 
significant matrix effects such as ion suppression or enhancement.39 
1.7.5 Dried blood spot (DBS) 
Blood is regularly used in pharmacokinetic and toxicokinetic studies because it circulates throughout the 
body and thus provides appropriate information on the distribution and concentration of drugs in the body.22 
DBS is the utilization of a filter paper that has a distinct pore size and thickness on which a small volume 
of pre-treated or untreated blood can be left to dry, incapacitating the growth of bacteria as a result of dried 
proteins and pathogens.40 Requiring very small sample volumes, DBS is a suitable substitute for 
conventional blood collection approaches and is advantageous in therapeutic drug monitoring for neonates 
as well as pharmacokinetic studies involving small laboratory animals.40 Traditional methods of serial blood 
collection was also a contributing factor to low volunteer recruitment in some studies but the development 
of DBS addressed this concern and became useful for other pharmacokinetic studies and in vivo 
concentration assessments because it is minimally invasive and non-painful.40 DBS can be used on site in 
clinical studies, provides easy storage for transportation of samples, minimizes sample handling, and offers 
important qualitative and quantitative information. The filter paper can be studied directly through 
analytical, immunological and genomic detection with their respective instrumentation.40 Given its benefits, 
DBS suffers from a plethora of limitations. It is insufficient to study sensitive and volatile analytes, as well 
as drugs that have minimal blood cell up take. The use of capillary blood for small volume sampling may 
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contain different information than venous blood, making this technique inadequate for pharmacokinetic 
assessment of certain drugs. It can only be coupled with highly sensitive analytical instruments due to the 
small volume used and it is not as receptive compared to other biofluids like plasma and serum to more 
commonly used analytical instruments such as high-performance liquid chromatography with ultraviolet-
visible detection (HPLC-UV-Vis).40 
1.7.6 Liquid-liquid extraction (LLE) 
LLE is a conventional sample preparation method commonly used and was the first technique to be applied 
in analytical chemistry.38,39,41 It has been used broadly in a range of fields including pharmaceutical, organic, 
inorganic and biochemical industries. There are four types of extraction modes and discontinuous extraction 
is the most traditionally used.41 LLE exploits the incompatibility of water and water-immiscible organic 
solvents to extract organic analytes from aqueous media.38 Separation occurs through the partitioning and 
equilibration of analytes from aqueous to organic phase based on various hydrophilic and hydrophobic 
properties and interactions.38,41 Improvement in extraction efficiency can be achieved by making changes 
to the pH or the type of organic solvent used in order to convert hydrophilic analytes to hydrophobic 
compounds therefore, increasing analyte recovery. LLE is more effective than PPt for eliminating 
interferences in biomatrices by yielding more purified products, hence providing a higher sensitivity in 
terms of instrumental analysis.38 Despite these advantages, the method suffers from the excessive use of 
organic solvents that lead to the generation of a large amount of waste.41 Not only is LLE environmentally 
unfriendly, issues with emulsion and solvent evaporation during extraction lead to losses in analyte 
recovery, extensive clean up procedures are required for glassware and can cause sample cross-
contamination, and labour intensive time consuming extractions result in poor repeatability and low 
throughput.41  
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1.7.7 Solid phase extraction (SPE) 
SPE is an exhaustive sample preparation technique that aims to eliminate interfering species and increase 
analyte enrichment by loading a sample into a sorbent packed column and separating the desired analyte 
through a washing and elution step.34,38,39,41,42 These steps are selective in that they are based on the 
partitioning of target and undesired compounds between the adsorbent packing and the organic liquid 
phase.38,39,41,42 The method consists of the following four steps: conditioning, sample loading, washing and 
elution. Conditioning or preconditioning is done with water, a buffer or a diluted organic solvent. This step 
readies the adsorbent packing by activating the functional groups through solvation for the proper adsorbent 
mechanisms to take place.38,39 Sample is then loaded by gravity, aspirated by vacuum or pumped.39 The 
sample can be loaded in a solvent that has low elution power or strictly as a biofluid.38 The wash step 
consists of flushing the column with an organic solvent that does not have the eluting power to affect the 
target analytes but rigorously removes a majority of matrix interferences. The final step is elution wherein 
a strong eluting organic solvent is used to remove the analytes of interest from the column.38,39 SPE is 
applied for the quantification of trace organic materials in the environment, for food analysis and drugs in 
biofluids.41 It is highly advantageous in its selectivity and ruggedness through newly developed polymeric 
sorbents, its ability for the complete extraction of analytes, its reduced solvent consumption and amenability 
for automation for high throughput leading to increased reproducibility. SPE’s main weaknesses are that it 
is time consuming, more so than PP and LLE and the technique is limited for onsite or clinical applications 
that require quick analyte isolation.41  
1.7.8 Homogenization 
Sample preparation techniques for tissue range depending on the subcategory (soft, tough, hard) of the 
tissue of interest, as different tissue types have different water contents and degrees of vascularization.25 
Within the context of tissue-sample preparation, homogenization is a broad term that is used to refer to the 
complete and total disruption of the tissue structure by manual, physical, or mechanical means. Mechanical 
homogenization can sometimes be followed by enzyme digestion and is usually coupled with one or more 
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of the other sample preparation methods discussed earlier in this section (i.e., PPt, LLE, and SPE).25,26 For 
soft tissue, physical or mechanical homogenization is most commonly performed via grinding, low-
frequency rotating blades, bead beating, sonication/ultrasonication, or enzymatic digestion. Tough tissues 
are generally more fibrous, which means that more force is usually required to break them down; as such 
higher frequency mechanical energy and longer duration is needed. Thus, for tough tissues, high-speed 
rotating blades and high-frequency bead beating are often used with less emphasis on ultrasonication. Much 
more powerful homogenization methods are required for hard tissues, such as cryogenic pulverization (the 
grinding of initially frozen samples, which is especially useful for the analysis of thermally labile 
compounds), acidic treatment (usually employed for hair homogenization), and chemical treatment.25–27 
The majority of the outlined homogenization practices are suitable for TDM wherein extensive testing is 
completed at each stage of the sample preparation protocol to ensure maximum recovery, minimum carry 
over, and analyte stability. However, for metabolomics, wherein sample integrity is key for analysis, 
homogenization takes place under flash-frozen conditions or after quenching steps such as enzyme 
denaturing with acid.27  
1.7.9 Microdialysis (MD) 
Mircodialysis is a well-known and established method that is especially used for in vivo sampling. The 
microdialysis device consists of a probe approximately 200-600 µm in diameter, which is composed of 
tubing and a semi-permeable membrane that is placed in contact with the tissue of interest.43,44 Extraction 
takes place when a constant flow of perfusion is pumped down through the center of the probe, flowing out 
of the bottom of the inner metal shaft and then upwards along the membrane between the inner shaft and 
the membrane, inducing solute exchange. The dialysate is then collected from the tubes outside the sampled 
site. The kinetics and dynamics of solute exchange during sampling vary depending on the flow rate of the 
perfusate (0.3–2 µL), the type of the semi-permeable membrane used and its MWCO, and the consistency 
of the perfusate (album addition to alleviate adsorption issues). Since microdialysis only samples free 
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concentrations of solutes in the interstitial/extracellular space, it has been instrumental in expanding our 
understanding of the distribution of unbound concentrations of drugs in tissue; however, it is also rather 
time consuming, advanced, and suffers from losses of lipophilic species via non-specific adsorption to the 
semi-permeable membrane. For these reasons, microdialysis has largely been employed for the quantitative 
measurement of hydrophilic compounds such as neurotransmitters within brain tissue.43,44 While TDM is 
feasible with microdialysis, the device is inherently unsuitable; conversely, it is still used45,46 for 
metabolomics due to its selectivity. 
Solid phase microextraction (SPME), often confused as another form of SPE (“micro SPE”), is another 
analytical approach that can perform in vivo sampling. SPME confronts the challenges faced by the above 
mentioned techniques and thus was utilized in this research as the main method of analyses.29,38,41 It has 
been proven to be a useful alternative approach for sample preparation and is advantageous in that it 
provides a balanced coverage of both polar and non-polar compounds, delivering solvent-less extraction of 
small molecules while minimizing the extraction of typical biological interferences (macromolecules).41,42 
1.8 Solid phase microextraction (SPME) 
SPME was developed some 25 years ago to address the issues of conventional sample preparation 
techniques by providing a means of rapid sample preparation to better facilitate on-site applications as well 
as increase laboratory efficiency.41,42 This technique epitomizes the fundamentals of green chemistry in that 
it is sustainable in its reusability while eliminating or drastically minimizing the need for organic solvents. 
It achieves this goal by integrating sampling, sample preparation and analyte preconcentration into one step 
and therefore reduces the number of steps in the analytical process, decreases human intervention/sample 
handling and thereby reduces analytical error.42 By enabling rapid sample preparation, time and cost per 
sample is also considerably reduced. Furthermore, automation of the technique in certain configurations 
enables its high-throughput capabilities.47  
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1.8.1 Overview of the technique 
SPME is a non-exhaustive approach that applies fundamental thermodynamic and kinetic principles for 
method selectivity and increased extraction rate (Figure 1.4).42 Of the two types of extraction, equilibrium 
and pre-equilibrium extraction, the former will be discussed in more detail since it is the more widely 
applied extraction technique in SPME, offering improved method sensitivity.41 Of the two different modes 
of SPME extraction, headspace and direct immersion (DI), the latter is used extensively in this thesis. 
 
Figure 1.4 Typical SPME fiber geometry (left) popularly employed for two types of extraction modes – headspace 
and direct immersion (middle). Fundamental SPME extraction kinetics and thermodynamics principle (right) 
 
Under equilibrium conditions, a small volume of extraction phase (a polymer coating), which is 
immobilized on a solid support (fiber), is exposed to a sample volume for a predetermined amount of time. 
Within this time, analytes migrate from the sample matrix to the coating and are either absorbed into or 
adsorbed onto the extraction phase (extraction mechanism depends on the type of coating, “liquid” vs solid 
coating). The sampling is completed when an equilibrium is established between the analytes in the coating 
and those in the sample matrix such that the concentration of analyte in the extraction phase is equal to the 
concentration of analyte in the sample. This relationship can be described by Equation (1) which is in 
keeping with the law of conservation of mass, considering a two phase system – the sample matrix and the 
fiber coating.42  
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 𝐶0𝑉𝑠 = 𝐶𝑠
∞𝑉𝑠 +  𝐶𝑓
∞𝑉𝑓 (1) 
  
C0 is the total analyte concentration in the sample, Vs is the sample volume, Cs
∞ and Cf
∞ are the analyte 
concentrations at equilibrium in the sample and on the fiber, respectively and Vf is the fiber coating 
volume.42 The distribution of analytes in the coating is determined by its distribution constant 𝐾𝑓𝑠 which is 
demonstrated by Equation (2).  
 𝐾𝑓𝑠 =
𝐶𝑓
∞
𝐶𝑠
∞ (2) 
 
Equations (1) and (2) can be rearranged and combined to give Equation (3)  
 𝑛 =  𝐶𝑓
∞𝑉𝑓 =  𝐶0
𝐾𝑓𝑠 𝑉𝑠 𝑉𝑓
𝐾𝑓𝑠 𝑉𝑓 + 𝑉𝑠
 (3) 
 
Where n is number of moles of analyte extracted by the coating and it is linearly proportional to the analyte 
concentration in the sample. This equation represents the analytical foundation on which quantitation using 
SPME is used.42  
The time required to reach equilibrium can be infinite and thus equilibrium is defined as the time at which 
95% of the equilibrium amount of the desired compound is extracted. This relationship is expressed by 
Equation (4).  
 𝑡𝑒 = 𝑡95% =  3
𝜕𝐾𝑓𝑠(𝑏 − 𝑎)
𝐷𝑠
 (4) 
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The time to reach equilibrium te, is equal to the amount of time required to extract 95% of the equilibrium 
amount of the analyte, t95%. 𝜕 is the thickness of the boundary layer which can be reduced by agitation, (b 
– a) is the fiber coating thickness and Ds is the analyte’s diffusion coefficient. It can be noted that this 
equilibration time is dependent on the analyte distribution constant 𝐾𝑓𝑠 and the higher the affinity of the 
analyte for the coating the longer the equilibration time.42 
1.8.2 In vivo SPME 
One of the main advantages of SPME is the ability to use this sample preparation tool on-site and moreover 
for in vivo analysis. This is highlighted throughout the thesis in the later chapters (Chapters 4-6) to 
emphasize the capabilities and potential of SPME for ameliorating current sample preparation workflows 
for a number of difficult samples as well as for rapid analysis like point-of-care testing. In vivo analysis is 
possible according the fundamentals of the technique. Starting with Equation (3), should the volume of the 
sample Vs be significantly greater than the product of the volume of the fiber Vf and the distribution constant 
𝐾𝑓𝑠 (Vs >> 𝐾𝑓𝑠Vf), then the product is essentially negligible and Equation (3) simplifies to Equation (5). 
 𝑛 =  𝐶0𝐾𝑓𝑠𝑉𝑓  (5) 
 
The amount extracted n, according to Equation (5) is now independent of the volume of the sample Vs. This 
is ideal for in vivo investigations since the volume of a system being sampled is generally difficult to 
ascertain.  
1.8.3 Thin-film SPME 
There are several SPME configurations available and the choice of which to use is dependent on the nature 
of the analyte of interest as well as the aim of the research.42  A few to name include the popular fiber 
configuration which is commercially available, stir bar sorptive extraction (SBSE), in-tube SPME and thin-
film SPME (TF-SPME) otherwise referred to as thin-film microextraction TFME.29 TF-SPME is an optimal 
23 
 
configuration because it provides better method sensitivity without sacrificing short extraction times.47 This 
is due to the increased surface area to volume ratio of the extraction phase allowing for higher mass uptake 
of the analyte.47 Theoretically, this increased mass uptake can be demonstrated by referring back to 
Equation (3) wherein the amount of analyte extracted is linearly proportional not only to analyte 
concentration in the sample but also to the volume of the extraction phase Vf.42 Additionally, this thin-film 
geometry can be modified into a 96 brush format that is compatible with the 96-well plate template, 
extending SPME capabilities for high throughput analysis.47  
1.8.4 Biocompatible coatings 
Advancements in SPME technology and the development of biocompatible coatings allow for direct 
immersion of these devices into untreated complex biological matrices.48 There are a number of research 
papers regarding the use of various biocompatible coatings in a range of complex matrices. A short 
summary of recently used biocompatible coatings, respective matrices and methods is shown in  
Table 1.1.29  
 
Table 1.1 Summary of recently used biocompatible coatings, respective matrices and methods. Excerpted 
from Souza-Silva et al.29 
Type of polymer 
coating 
Analyte Matrix Extraction Mode Instrument 
Method 
Polypyrrole (PPY) and 
polythiophene 
amoxicillin plasma DI-SPME LC-UV 
PAN-C18 benzodiazepines plasma DI-SPME (thin film 
with Concept-96) 
LC-MS/MS 
PPY Diazepam, 
nordiazepam, 
oxazepam 
rat circulating blood In vivo SPME LC-MS/MS 
C18 More than 100 
doping compounds 
urine DI-SPME LC-MS/MS 
C18 Cocaine and 
diazepam 
urine DI-SPME CBS-MS/MS 
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Biocompatible binder-
C18 
Carbamazepine, 
carbamazepine-
10,11-epoxide 
Mice circulating 
blood 
In vivo-SPME LC-MS/MS 
PDMS Ibuprofen and 
fluoxetine 
Fish muscle DI-SPME LC-MS/MS 
HLB-PAN 25 doping substances plasma DI-SPME (thin film 
using Concept-96) 
LC-MS/MS 
 
Due to polyacrylonitrile’s (PAN) exceptional properties such as excellent thermal, mechanical and chemical 
stability, biocompatible coatings are based on a mixture of extraction phase polymer particles with PAN.48 
PAN membranes are extensively used in the biomedical field and are usually the membrane material used 
for UF and ED.48  Published works in relation to the use of SPME biocompatible coatings in PK studies 
include: study of amoxicillin in human plasma by polypyrrole (PPY) and polythiophene coating following 
analysis by HPLC-MS/MS; in vivo SPME studies of carbamazepine in mice; and in vivo studies of 
diazepam in rat circulating blood.49–51 Other recent research from the Pawliszyn research team on 
biocompatible SPME coatings and methods used in the related mediums of plasma and urine for ex vivo 
studies include the quantification of prohibited substances in plasma using hyrophillic-lipophillic balance 
(HLB) coating as well the quantitative analysis of prohibited substances in urine using polyacrilonitrile – 
octadecyl carbon chain (PAN-C18) coating.52,53 The use of SPME in clinical field for TDM as well as tissue 
analysis has been pioneered by Bojko et al.(2011; 2013, 2014) with the TDM of tranexamic acid in plasma 
and the use of in vivo SPME for monitoring biomarkers and drugs during surgery in lung tissue.54–56 Lastly, 
the use of SPME for clinical metabolomics was pioneered by Vuckovic and Pawliszyn (2011) wherein a 
systematic evaluation of various coatings for untargeted profiling of biological fluids was performed.57 
These achievements laid the foundation on which the work presented in this thesis is based. The typical 
SPME workflow employed for the instrumentation used in this thesis is discussed in section 1.10 “Typical 
SPME workflow” following the discussion of the types of instrumentation explored in this thesis. 
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1.9 Instrumentation 
The instrumentation used for separation and quantitation in bioanalysis includes gas chromatography (GC), 
liquid chromatography (LC), and capillary electrophoresis (CE), while detection is often achieved via mass 
spectrometry (MS) or spectrophotometry methods such as ultraviolet/visible (UV/Vis) and fluorescence 
(Flr). The research conducted for this thesis primarily used liquid chromatography coupled to mass 
spectrometry (LC-MS), as this has become the standard technology used to support and advance PK studies, 
TDM, and metabolomics.58–60 Suitable for semi- to low- volatility compounds, LC provides excellent 
separation resolution and efficiency for a range of compounds due to the availability of numerous stationary 
phases, while MS enables the identification and quantification of both known and unknown compounds.59–
61 LC coupled with tandem mass spectrometry (MS/MS) or high-resolution mass spectrometry (HRMS) 
allows for improved specificity, selectivity and greater sensitivity, all while providing reliable and 
reproducible quantitative and qualitative data.58–60 TDM assays are usually very specific and/or selective 
for the compounds of interest. MS-based TDM utilizes sensitive and selective MS/MS, which employs a 
combination of mass analyzers. Some examples of tandem mass spectrometers include triple quadrupole 
(QqQ), quadrupole time of flight (Q-ToF), tandem time of flight (ToF-ToF), and ion trap (Q-trap). These 
mass spectrometers are generally viewed as robust workhorses due the fact that they are typically in constant 
use for the determination and quantitation of various known analytes, while requiring less maintenance than 
HRMS.15,21 Since metabolomics involves the detection of hundreds of unknown compounds from a range 
of biochemical classes related to the metabolome, mass spectrometers characterized by high resolution, 
rapid data acquisition, and high mass accuracy are required. Mass analyzers such as the orbitrap, the 
Fourier-transform ion cyclotron resonance (FT-ICR), and the quadrupole time of flight Q-ToF are all able 
to meet these requirements, achieving resolving powers ranging from 35, 000 to 1 000 000 and mass 
accuracies below 15 ppm.21 As mentioned in section 1.5 “Rapid analysis”, unlike TDM and metabolomics, 
which require LC to be coupled to MS/MS or HRMS, rapid analysis bypasses both the laborious sample 
preparation step and the chromatographic separation step, thereby increasing sample throughput. Generally, 
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stand-alone MS with ambient ionization is used specifically for this kind of analysis.21 Some commonly 
used ambient ionization techniques include desorption electrospray ionization (DESI), direct analysis in 
real-time (DART), and matrix-assisted laser desorption ionization (MALDI); notably, DESI and DART 
have been successfully used with the SPME concept.62 In this thesis, an ambient ESI-based in-laboratory-
developed rapid technology interface—microfluidic open interface (MOI)—was used to couple to 
biocompatible SPME fibers (Bio-SPME) to MS/MS in order to further explore the potential of SPME for 
creating a rapid TDM protocol. 
1.10 Typical SPME workflow 
 
Figure 1.5 Graphical representation of the general SPME workflow. 
 
The typical SPME workflow consists of four steps: preconditioning, extraction, rinse and desorption 
followed by analysis with various instrumentation (Figure 1.5). Generally, SPME devices used for DI 
analysis followed by LC require an initial preconditioning step to effectively activate the coating. A mixture 
of organic/aqueous content is usually sufficient for these purposes but largely depends on the type of coating 
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employed as some coating have better wettability and require less or little preconditioning time in 
comparison to other coating types. Post conditioning, the SPME device is exposed to the sample of interest 
(biofluids or biosolids) in vivo or ex vivo and remains in the sample for a pre-determined amount of time 
after which the device is rinsed to remove any loosely attached/adhered matrix components. This rinsing 
step is critical to reduce interferences coextracted as well as prevents the precipitation of matrix components 
onto the fiber following the subsequent desorption step, which normally contains some amount of organic 
solvent. Precipitation can damage the device (via irreversible adsorptive processes) and thus affect device 
reproducibility and/or reusability. Rinsing is also important for obtaining cleaner extracts that are to be 
injected for LC analysis, thereby improving separation conditions by helping to extend column lifetime. In 
the final step, desorption, the presence of some content of organic solvent reduces the distribution constant 
(Kfs) of the analyte for the extraction phase thus facilitating their recovery from the fiber. Suitable desorption 
solutions depend on the coating used, analytes of interest and initial LC instrumental conditions. Thus, each 
step of the workflow should be optimized to improve method sensitivity. In the case of rapid analysis 
however, this final offline desorption step is overlooked, rather desorption is performed online via ambient 
interfaces that couple the SPME device directly to the mass spectrometer (SPME-MS). SPME-MS is 
explored more in Chapter Chapter 7 of this thesis. 
1.11 Research objective 
The work presented in this thesis aims to exemplify the practicality, feasibility, and suitability of SPME for 
personalized clinical applications such as TDM, clinical metabolomics, and pharmacometabolomics. In 
addition, this research aims to further lay the groundwork for the use of SPME in clinical settings by 
developing SPME-based methods for targeted and untargeted approaches, such as TDM and metabolomics. 
As a sampling tool that integrates sampling and sample preparation into a single step, one of the main 
advantages of SPME is its suitability for in vivo and on-site analysis. With the exception of microdialysis, 
this is a characteristic that is uncommon for the bulk of conventional sample preparation practices. As such, 
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SPME offers an especially promising tool for use in TDM, metabolomics, and point-of-care analysis, one 
that can ultimately serve to improve personalized approaches to patient care.  
Therefore, the objective of this thesis is to demonstrate the use of SPME for: 1) developing robust targeted 
approaches for therapeutics; 2) determining useful candidate metabolic markers indicative of toxicity or 
positive response; and 3) showing that these targeted approaches and pre-determined metabolic markers 
can be rapidly monitored, thereby providing real-time, personalized treatment that can be quickly 
customized depending on therapeutic concentration or the presence/absence of these indicative metabolic 
markers. The future direction/goal of this research is to eventually enable the use of SPME as an alternative 
complementary diagnostic tool that is capable of not only providing reliable, rapid quantitative analyses of 
a range of therapeutics, but also performing simultaneous rapid chemical biopsies in vivo or from a range 
of clinically relevant biological matrices, such as urine, blood compartments, and lung tissue.  
The thesis achieves these research objectives by first illustrating the suitability of SPME for TDM through 
the development of a method for monitoring tranexamic acid in plasma and urine samples from patients 
undergoing cardiac surgery (Chapter 2). Next, the applicability of SPME for clinical metabolomics is 
demonstrated through its use for the determination of disease conversion (psoriasis to psoriatic arthritis) 
pathophysiology via the untargeted profiling of serum samples from patients with psoriasis and varying 
degrees of psoriatic arthritis (Chapter 3). The applicability of SPME for clinical metabolomics of more 
complex samples and dynamic environments is then demonstrated in Chapter 4, where it is used for the in 
vivo monitoring of porcine lung tissue undergoing normothermic ex vivo lung perfusion (NEVLP), which 
is an organ-preservation strategy commonly used to improve lung function and increase the donor pool for 
transplantation. Chapter 5 and Chapter 6 then demonstrate the use of in vivo SPME for simultaneous TDM 
and proof-of-concept pharmacometabolomics on lung tissue treated with chemotherapy via in vivo lung 
perfusion (IVLP) for pre-clinical and clinical trials. Chapter 5 presents a pre-clinical trial of folinic acid-5-
fluorouracil-oxaliplatin (FOLFOX) combination therapy in a porcine model during IVLP, wherein the 
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developed quantitative SPME method was used for the TDM of FOLFOX in samples collected in vivo on-
site (in the hospital), followed by pharmacometabolomics. Chapter 6 details a clinical trial in human lungs 
with the use of doxorubicin (DOX) during IVLP, followed TDM of DOX in lung tissue as well as 
pharmacometabolomics. The goal in Chapter 6 was to correlate good/successful clinical outcomes with 
metabolomic data to indicate the effectiveness of the drug combination using the same principles as in the 
proof-of-concept in Chapter 5. Lastly, Chapter 7 demonstrates the potential of SPME for rapid diagnostics 
by using SPME-MS for the rapid quantitation of tranexamic acid in the plasma samples acquired from the 
patients in Chapter 1, thus showing the close correlation between SPME-MS and LC-MS, which is the gold 
standard for quantitative bioanalysis. As Chapter 7 demonstrates, reliable rapid analysis can theoretically 
be achieved using any untreated complex biological matrix once the methods have been established. The 
availability of rapid SPME-based methods for biological fluids means that the same tool that was used for 
rapid plasma analysis in this research can be easily translated towards more complex matrices, such as 
tissue, for the rapid quantitation of therapeutics in tissue. In the same way, once metabolomic methods have 
been better established, useful metabolic markers can also be rapidly monitored quantitatively or 
qualitatively with the use of SPME-MS. 
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Chapter 2: Therapeutic drug monitoring of tranexamic acid in 
plasma and urine of renally impaired patients using solid phase 
microextraction 
2.1 Preamble 
The results from this chapter have been used by clinicians to develop a PK profile of TXA for the purposes 
of correcting the dosing schedule for patients with chronic renal dysfunction who are undergoing cardiac 
surgery; the results of which are published as an article entitled “Tranexamic acid dosing for cardiac surgical 
patients with chronic renal dysfuntion” by A. Jerath, Q. J. Yang, S.K. Pang, N. Looby (the author of 
this thesis), N. Reyes-Garcés, T. Vasiljevic, B. Bojko, J. Pawliszyn, D. Wijeysundera, W. S. Beattie, T. M. 
Yau, and M. Wasowicz., Anesthesia & Analgesia, 2018, 127(6), 1323-1332. The results in this chapter have 
not yet been published but have been formatted for submission to Talanta and co-authored by T. Vasiljevic, 
N. Reyes-Garces, A. Roszkowska, B. Bojko, M. Wasowicz, A. Jerath and J. Pawliszyn. Please see 
Statement of contributions. We are grateful to the Natural Sciences and Engineering Research Council 
(NSERC) of Canada for the financial support provided through the Industrial Research Chair program. 
2.2 Introduction 
Tranexamic acid (TXA) is extensively employed in hospital and clinical settings to reduce blood loss.63 
TXA inhibits fibrinolysis—which is the breakdown of fibrin, a key constituent of blood clots—by inhibiting 
plasmin and preventing the activation to plasminogen, the protein responsible for fibrinolysis.63 Findings 
have shown that  TXA has a much better safety profile than earlier generation antifibrinolytics like aprotinin 
and ecallantide, and that higher concentrations can be particularly effective for use in high-risk operations, 
such as cardiac surgery.64 However, findings have also shown that the continued use of TXA at high 
concentrations may put some patients at risk of developing post-operative seizures63,64 due to elevated 
concentrations of TXA in the cerebrospinal fluid, even after the cessation of intravenous administration.65 
Furthermore, TXA has high inter-patient variability, with drastically different resultant blood plasma 
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concentrations having been observed in patients that have undergone the same dosing schedule, for both 
high- and low-dose schedules.3,64 Given that the body removes tranexamic acid via glomerular filtration, it 
has been hypothesized that this interpatient variation is due to poor renal clearance among patients suffering 
from chronic renal dysfunction.66 Thus, the purpose of the work presented herein was to develop a high-
throughput method for the fast and reliable quantitation of TXA in two complementary biological matrices: 
plasma and urine. Ideally, this new method will prove to be a valuable tool for use in pharmacokinetic (PK) 
studies aimed at correcting dosing schedules in order to avoid overdosing or high blood plasma 
concentrations—and thereby reducing the risk of seizures—in patients suffering chronic renal dysfunction.  
Classical analytical methods for quantitating TXA in biological fluids often require sample preparation 
steps such as plasma protein precipitation (PPt) and liquid-liquid extraction (LLE), which are sometimes 
followed by a sample pH adjustment step depending on the separation method that will be used.65,67 Other 
recently reported sample preparation techniques have incorporated microwave-assisted derivatization and 
phospholipid clean-up prior to PPt.68,69 Some of the instrumental analytical techniques that have been 
reported for TXA separation include gas chromatography (GC),70 high-performance liquid chromatography 
(HPLC),71,72 capillary liquid chromatography (CapLC),69 and capillary or paper electrophoresis (CE, EP).73 
However, the methodologies that have been reported to date are expensive, complex, time-consuming, and 
require multiple steps, which renders them unsuitable for high-throughput analysis. In contrast, ambient 
mass spectrometry represents a promising technology for high-throughput clinical applications due to its  
ability to be coupled to automated sample preparation approaches, high-speed of analysis, and excellent 
selectivity.74,75 Despite these advantages, ambient mass spectrometry is also hampered by several 
drawbacks, such as ion suppression resulting in poor sensitivity, and being prone to instrument 
contamination, which can lead to additional maintenance costs during routine-based analyses. Fortunately, 
solid-phase microextraction (SPME) offers an attractive, streamlined sample preparation technique that is 
capable of both addressing and overcoming the above-noted limitations, and providing the necessities 
required for superior MS detection, with or without prior liquid chromatographic (LC) separation. As a 
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non-exhaustive technique, SPME minimizes matrix effects by minimizing the amount of interferences 
coextracted, providing cleaner extracts, which helps to reduce contamination and ion suppression. 
Furthermore, SPME also features a simple device design, which enables more efficient workflows and 
makes it highly suitable for high-throughput analysis—features which are especially useful in clinical 
settings that require rapid sample turnover.   
Since the quantitation of TXA in plasma via SPME has already been validated in numerous publications54,76 
and cross-validated against traditional methods such as PPt and UF,54 this high-throughput PK study will 
utilize SPME in conjunction with liquid chromatography tandem mass spectrometry (LC-MS/MS) 
particularly for urine analysis. Furthermore, given the limited body of literature on the quantification of 
TXA in urine, special emphasis was placed on developing the SPME method with regards to the analysis 
of TXA in urine. The clinically relevant results for the quantitation of TXA in the plasma and urine of 
renally impaired patients using the high-throughput SPME proposed in this work has already been 
reported.76 To the best of our knowledge, this is the first documented attempt to use SPME to detect TXA 
from urine. 
2.3 Materials and Methods 
2.3.1 Chemicals and materials 
96-well polypropylene deep-well plates and LC-MS grade solvents (methanol, water, acetonitrile, 
isopropanol) were purchased from Thermo Fisher Scientific (New Waltham, USA), and bare stainless-steel 
blades were obtained from Professional Analytical Systems (PAS) Technologies (Magdala, Germany). 
Pooled plasma was purchased from Lampire Biological Laboratories (Everett, USA), while urine lots and 
pooled urine were obtained from 22 volunteers. The following standards and chemicals were obtained from 
Millipore Sigma (Burlington, USA): sodium chloride, potassium phosphate dibasic, potassium chloride, 
sodium phosphate, trans-4-(aminomethyl)-cyclohexanecarboxylic acid (TXA), cis-4-
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aminocyclohexanecarboxylic acid (TXA-internal standard (IS)), supel-select hydrophilic-lipophilic 
balance (HLB) particles, N,N-dimethylformamide (DMF), formic acid, and polyacrylonitrile (PAN).  
2.3.2 Working solutions and calibration curves 
A stock solution of 100 µg/mL was prepared in LC-MS grade water. Calibration curve stock solutions were 
subsequently prepared via serial dilutions in water from the initial concentrated stock solution at the 
following concentrations: 50 µg/mL, 100 µg/mL, 200 µg/mL, 500 µg/mL, 1000 µg/mL, 2500 µg/mL, 5000 
µg/mL, 7500 µg/mL, 10 000 µg/mL, 12 500 µg/mL, 15 000 µg/mL, 20 000 µg/mL, 22 500 µg/mL, and 50 
000 µg/mL. In addition, a quality control (QC) stock solution was prepared at 10 000 µg/mL, and a matrix-
matched calibration curve was prepared by spiking 1 ml of the appropriate matrix (plasma or urine) with 
10 µL of each of the appropriate stock solutions to produce a calibration curve ranging from 0.5 µg/mL – 
1000 µg/mL. The method QC was prepared by spiking 50 µL of QC stock solution into 5 mL of the 
appropriate matrix (urine or plasma), and the internal standard was prepared in phosphate buffered saline 
(PBS) or 0.5 M phosphate buffer respectively such that the sample contained a final concentration of 100 
µg/mL. All samples were left to equilibrate for 45 minutes under agitation at 500 rpm to establish binding 
prior to SPME sample preparation. 
2.3.3 Instrumental analysis 
Gradient elution LC was conducted using two Shimadzu 10ADvp series binary pumps with flow of 300 
µl/min, which is consistent with the LC method described by Gorynski et al.77 Chromatographic separation 
was achieved using a 10 cm x 2.1 mm Discovery HS F5 (PFP) column with a 3 µm particle size; a 2 cm x 
2.1mm Discovery HS F5 guard column which also had a 3 µm particle size, was used. Mobile phase A 
consisted of 99.9% water, while mobile phase B consisted of 99.9% acetonitrile; each mobile phase 
contained 0.1% formic acid. Samples were stored in a CTC-PAL autosampler at 4 °C, with 10 µL sample 
volume being injected for analysis. Mass spectrometric detection was performed on an API 4000 LC-
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MS/MS system (AB Sciex) equipped with a Turboion spray source. For more information on the 
chromatographic method and mass spectrometer parameters, see Table 2.1 and Table 2.2 respectively. 
 
 
Table 2.1 Chromatographic parameters for TXA and its internal standard using a Shimadzu 10ADvp series 
binary pump. 
Time (min) 
Total flow (300 µL/min) 
% Mobile Phase A: Water + 
0.1% formic acid 
% Mobile phase B: Acetonitrile 
+ 0.1% formic acid 
0.01 90 10 
2.00 90 10 
5.50 40 60 
6.00 40 60 
6.10 90 10 
8.10 90 10 
 
Table 2.2 MS/MS parameters for the analysis of TXA and its internal standard on an API 4000 (AB Sciex) 
triple quadruple. 
Compound Transition Time (msec)  DP  EP CE CXP 
Tranexamic acid 
(TXA) 
158 > 95 200 60.7 6.8 20.6 6.2 
Tranexamic acid 
internal standard 
(TXA IS) 
144 > 80.9 200 53.4 7 28.2 4.9 
DP: declustering potential, EP: entrance potential, CE: collision energy, CXP: cell exit potential 
2.3.4 Sampling procedure 
The study protocol, urine and plasma sample collection methods, and experimental procedures for patients 
in both the high- and low-risk cardiac surgery groups were approved by the Toronto General Hospital/ 
University Health Network’s Research Ethics Boards and University of Waterloo’s Research Ethics Boards. 
The dosing schedule for patients in the high-risk group was consistent with the schedule outlined by Blood 
Conservation Using Antifibrinolytics in a Randomized Trial (BART).78 Briefly, TXA was initially 
administered at a bolus dose of 30 mg/kg following the induction of anaesthesia, with an infusion of 16 
mg/kg administered over the course of the procedure until the chest closure; an additional bolus of 2 mg/kg 
was administered via the cardiopulmonary bypass (CPB) pump prime. TXA was administered to patients 
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in the low-risk group at a bolus dose of 50 mg/kg following the induction of anaesthesia, which is in 
accordance with the standard institutional practise at Toronto General Hospital. The collection of blood and 
urine samples remained consistent for all patients across both groups; the collection schedule that was used 
is detailed in 79. Briefly, blood samples were collected in standard citrate tubes at baseline prior to TXA 
administration; 5 min and 10 min following TXA administration; immediately following the sternotomy 
and prior to chest closure; before the commencement of CPB; and at 30 min intervals after CPB was 
initiated and 30 minutes after CPB was discontinued. In addition, post-operative blood samples were also 
collected at 1, 2, 4, 8, 12, 24, and 72 hours. Urine samples were collected in standard plastic urine containers 
intra-operatively, post-TXA administration pre-CPB, during CPB rewarming, and post-operatively at 1, 2, 
4, 8, 12, 24, and 72 hours. All samples were randomly assigned a number to protect patient anonymity.  
2.3.5 Preparation of thin-film microextraction devices 
Thin-film microextraction (TFME) devices were prepared in accordance with a previously established 
spraying method.80 Briefly, a slurry composed of 10% w/v HLB particles, 3% v/v DMF, and  PAN solution 
(7% w/v PAN particles in DMF) was thoroughly stirred inside a flask-type sprayer (Erlenmeyer flask with 
a sprayer head) in order to obtain a homogenous solution. The solution was sprayed onto a total of 8 combs, 
each of which had 12 pins. Spray was induced using a high nitrogen flow attached to the flask-type sprayer. 
Each device (comb) was subsequently cured in an oven at 180 °C after the application of each layer. This 
spray coating process was continued until a final coating dimension of 2 cm in length and 0.3 mm in 
thickness had been achieved for each device. Once the coatings had been applied, the 8 combs were 
assembled to form the TFME brush that would be used for sample preparation. See Figure 2.1 
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Figure 2.1 Preparation of thin film microextraction (TFME) devices from bare blades to TFME brush. 
A) Bare blade/comb. B) Coated comb. C) Brush Assembly of 8 coated combs. 
 
 
2.3.6 Concept-96 for SPME automation 
High-throughput sample preparation and the subsequent analysis of both plasma and urine samples were 
made possible through the use of a Concept-96 autosampler (PAS Technologies, Magdala, Germany). 
Briefly, this offline software-operated unit automatically performs each step of the SPME sample-
preparation protocol—namely, preconditioning, extraction, rinsing, and desorption—via a robotic arm upon 
which the TFME brush is installed. This brush is compatible with 96-well plates that are immobilized in 
their respective stations within the unit. Details on the Concept-96 autosampler are provided in elsewhere79 
and shown in Figure 2.2. Agitation conditions were maintained at 1500 rpm at room temperature (23 °C) 
for each step of the SPME sample-preparation protocol for both plasma and urine samples unless otherwise 
specified.  
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Figure 2.2 Automated software-operated SPME Concept-96 system employed for high throughput 
analysis of TXA from plasma and urine samples collected from patients undergoing cardiac surgery. 
 
2.3.7 Automated SPME protocol for the analysis of TXA in plasma 
The SPME device was first introduced to 1.5 mL of a preconditioning solvent consisting of 50:50 
methanol/water (v/v) for 10 minutes. After preconditioning, the device was exposed to 1 mL of plasma 
sample solution (plasma diluted with PBS) for 5 minutes, and then rinsed in a 1 mL solution consisting of 
90:10 water/methanol (v/v) solution for 10 s under static conditions. Following rinsing, the device was 
desorbed in 1 mL of a solution consisting of 3:3:4 methanol/acetonitrile/water (v/v/v) for 10 minutes. 
2.3.8 Automated SPME protocol for analysis of TXA in urine 
As in the plasma extractions, the SPME brush was initially preconditioned in 1.5 mL of a 50:50 
methanol/water (v/v) solution for 10 minutes before being exposed to a 1 mL urine sample for 5 minutes. 
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Following extraction from the urine sample, the device was rinsed in 1 mL of water for 10 s under agitated 
conditions to remove any salts. Finally, the device was desorbed for 10 minutes in 1 mL of a 90:10 
water/methanol (v/v) solution. 
2.4 Results  
2.4.1 Device coating 
The method for extracting TXA from urine and plasma developed in this work was based on the use of a 
hydrophilic-lipophilic balanced (HLB) coating, as previous research has found these coatings to be 
particularly well-suited for the extraction of polar compounds from aqueous matrices52,81 such as plasma 
and urine. This enhanced compatibility is largely due to the fact that HLB coatings contain a higher number 
of polar groups, which improves the interaction between the analytes and the coating via adsorptive 
mechanisms, in addition to featuring exceptional wettability.81 Furthermore, the superior wettability of HLB 
particles allows for shorter preconditioning and extraction times than are possible with more hydrophobic 
extraction phases such as polystyrene divinyl benzene (PS-DVB) and silica-core octadecyl (C18). Indeed 
prior studies that have utilized C18 in the sample preparation process for the analysis of TXA in plasma 
samples have found that it can lead to preconditioning and extraction times over 10 times higher than an 
HLB (greater than 45 minutes).54,82,83 The decreased preconditioning and extraction times enabled by the 
use of an HLB coating in the SPME protocol results in a decrease in the overall amount of time required 
for each sample; thus, these reduced time requirements assert SPME as a highly attractive sample 
preparation technique for high-throughput analyses. 
Since there are several published works that focus on the development of an SPME protocol for the 
extraction of TXA from plasma,54,77 the present research will place more emphasis on developing an 
effective protocol for extracting TXA from urine and improving the previously reported plasma-based 
protocols.  
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2.4.2 Extraction conditions 
One of SPME’s main advantages as a sample reparation tool is that it enables the extraction of small target 
molecules from biological matrices of interest without the need for sample pre-treatment steps such as 
centrifugation, PPt, or significant pH adjustments. The implementation of PAN-based biocompatible 
coatings allows the SPME device to exclude high molecular weight matrix components like proteins and 
enzymes, which are present in biological fluids like plasma. As such, the SPME device can be directly 
immersed into these samples without concern about damage caused by fouling or the irreversible adsorption 
of matrix components. This feature further increases sample throughput, as it drastically reduces the time 
and number of steps required for each sample relative to other sample preparation methods. Furthermore, 
the HLB coating maintains its stability across the entire pH range (i.e., 0 – 14) and temperatures ranging 
from ambient to physiologic (20 - 37 °C),84 which means that it can be used to analyze biological fluids like 
plasma and urine in their native state. TXA is stable at a physiological pH (7.35 – 7.45) and room 
temperature for onwards of 72 hours, existing as a zwitterion with a full negative charge in the carboxylic 
acid moiety and a full positive charge in the amino moiety.77,85 Unlike plasma, which has a relatively 
constant pH of between 7.3 and 7.4 regardless of the patient, urine can present wider pH ranges both intra-
person and inter-person. As a biological waste product, the pH of one’s urine is capable of fluctuating within 
a range from 4.5-9 due to a number of factors such as their environment, diet, age, or medical conditions.1 
These changes in pH will affect which types of TXA species (pKa of 4.56 and 10.22 for the acidic and basic 
moieties respectively86) are present in the sample, which can in turn affect SPME recovery and the MS 
ionization of this compound. Furthermore, differences in the ionic strengths of urine samples can 
significantly alter how the zwitterionic compound interacts with the SPME extraction phase. Given that pH 
and ionic strength are independent of one another, the pH and ionic strength of the samples were normalized 
with a buffer solution prior to extraction in order to ensure inter-patient consistency in extraction conditions 
and the species of TXA present in the sample at the time of extraction.  
40 
 
2.4.3 pH modification 
Since plasma has minimal inter-person pH variation due to the requirements of the biological system, the 
use of PBS adjusted to physiologic pH was sufficient to correct for small inter-person pH differences at a 
1:3 patient-plasma-sample:buffer dilution. In contrast, a stronger buffer was required to normalize urine pH 
and ionic strength. In order to maintain a relatively consistent sample-preparation procedure for the two 
types of sample matrices, and thus providing a more streamlined workflow, various concentrations of 
phosphate buffer were evaluated for their effectiveness at correcting urine pH and ionic strength at the same 
1:3 dilution used for the plasma samples. Table 2.3 shows the effectiveness of different concentrations of 
PBS and phosphate buffer in achieving a physiologic pH range for urine samples that had been adjusted to 
extreme pHs (pH 5 and pH 9), a range which is expected in patient samples. As can be seen, phosphate 
buffer at a concentration of 0.5 M provided adequate pH correction and proved more suitable than higher 
concentration buffers, which could result in the precipitation of salts out of the solution with any fluctuation 
in temperature. Table 2.4 shows the capacity of this 0.5 M phosphate buffer to correct for both pH (pH has 
been adjusted between 7.35-7.45) and ionic strength (adjusted between 34-37 mS) in real urine samples 
collected from 13 volunteers. 
Table 2.3 Testing the buffering capacity of phosphate-buffered saline (PBS) and varying concentrations of 
phosphate buffer for pH adjusted urine. 
Buffer 
concentration 
(M) 
 
Initial 
urine pH 
pH adjusted Final pH after 1:3 sample dilution 
with buffer 
Acidified 
with 1 M 
HCl 
Basified with 
1 M NaOH 
Final pH for 
acidified 
urine 
Final pH for 
basified 
urine 
Final pH 
for 
unadjusted 
urine 
0.1 (PBS) 7.14 5.03 8.89 6.34 8.43 7.36 
0.1 7.14 5.06 9.07 7.2 7.63 7.42 
0.2 7.14 4.91 9.00 7.25 7.46 7.32 
0.5 7.14 5.01 9.18 7.31 7.43 7.30 
1.0 7.14 5.02 8.96 7.28 7.37 7.31 
2 7.28 4.96 9.01 7.31 7.29 7.48 
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Table 2.4 Testing the capacity of 0.5M phosphate buffer for correcting the pH and ionic strength of urine 
samples from 13 volunteers. 
Volunteer Before addition of buffer in 1:3 ratio After addition of buffer in 1:3 ratio 
pH Conductivity 
(mS) 
pH Conductivity 
(mS) 
Volunteer 1 5.13 26.6 7.33 36.6 
Volunteer 2 6.15 18.3 7.43 37.4 
Volunteer 3 7.06 6.5 7.47 34.4 
Volunteer 4 7.21 10.4 7.46 34.6 
Volunteer 5 7.45 26.7 7.46 37.2 
Volunteer 6 6.87 22.8 7.45 36.1 
Volunteer 7 5.63 9.9 7.43 34.1 
Volunteer 8 4.88 20.4 7.41 35.9 
Volunteer 9 7.08 5.7 7.50 33.8 
Volunteer 10 7.11 9.0 7.47 34.0 
Volunteer 11 6.83 13.6 7.45 35.1 
Volunteer 12 6.72 27.5 7.40 37.1 
Volunteer 13 6.14 18.7 7.42 36.1 
 
2.4.4 Extraction time profile 
To determine the extraction time that provided the best compromise of extraction efficiency and throughput, 
an extraction time profile was developed using a working concentration of 100 µg/mL of TXA in the 
respective biofluids of interest (urine or plasma) diluted at a ratio of 1:3 (v/v) with the appropriate respective 
buffers (0.5 M phosphate buffer and PBS). Since SPME is predicated on extraction via free concentration, 
an extraction time profile was also developed in PBS at the above-noted working concentration in order to 
assess if matrix effects exist and how matrix components influence the amount of TXA extracted. To this 
end, the following times were evaluated: 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 60 min, and 90 
min. The extraction time profiles of urine and PBS shown in Figure 2.3A confirm that matrix components 
do not affect the amount of TXA that is extracted, as the absolute recovery rate of TXA in urine and PBS 
was approximately 1 % for each. These results are consistent with the 1 % recovery rate for TXA in plasma, 
which has been documented in previous studies54 and is shown in Figure 2.3B. The similarity of these 
findings is largely attributable to the fact that TXA experiences less than 3 % binding, which means that it 
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is available for extraction from plasma and urine at relatively similar levels. (This finding is also supported 
by the evaluation of absolute matrix effects presented section 2.4.9 “Method validation”).  
 
Figure 2.3 A) Extraction time profile of tranexamic acid (TXA) in urine and phosphate buffered saline 
(PBS). B) Extraction time profile of TXA in plasma. 
 
 
Although extraction equilibrium was achieved at 15 minutes in urine, adequate method sensitivity could be 
observed at 5 minutes; thus, an extraction time of 5 minutes was selected, as it dramatically reduced sample 
preparation time, which in turn enabled considerable high-throughput analysis. Moreover, this reduction in 
time represents a 12-fold improvement in efficiency over previous methods utilizing a C18 or weak anion 
exchange (WAX) coating, which both require 60 minutes to achieve equilibrium and comparable 
recovery.54,77  
2.4.5 Rinsing conditions 
Rinsing is an important and often overlooked step in the development of an SPME protocol, as the 
conditions under which it is performed can significantly influence the method’s sensitivity, reproducibility, 
and overall cleanliness of the final extract obtained for injection. This step is valuable because it can help 
to ensure the acquisition of clean extracts through the removal of components that may be loosely adhered 
to the coating or other potential coeluting/coextracted matrix interferences. A good compromise between 
length of time, agitation conditions, and solvent choice for the rinsing step is usually recommended. A rinse 
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solution consisting of a 9:1 water/methanol mixture was selected based on previous research. Figure 2.4A 
shows the results for the tests comparing various rinsing times and agitation conditions for this particular 
solvent composition after extraction from plasma. As the results show, a 5s static wash sufficiently removed 
any loose plasma components without significantly affecting the method’s sensitivity or the amount of 
analyte recovered in the desorption solution, which was comparable to the amounts recovered with no 
rinsing step.  
 
Figure 2.4 Rinsing time and agitation conditions evaluated for solution consisting of a 9:1 
water/methanol mixture. A) The amount of TXA recovered from the desorption solution after varying 
rinse conditions. B) The amount of TXA recovered from the rinse solution after varying rinse conditions. 
 
These results are affirmed by the corresponding data in Figure 2.4B, which show that the lowest amount of 
TXA was recovered from the rinse solution after this 5s static rinse. While this solvent composition worked 
well for the coating and minimized the loss of TXA in the final extract, these same conditions could not be 
applied after the extractions from urine. As such, the devices were rinsed in pure water for 10s under 
agitated conditions following extractions from urine. Although this approach inadvertently resulted in lower 
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amounts of TXA in the final extracts, the high salt levels in urine made it necessary to perform a pure water 
rinse in order to maintain good peak shapes during chromatography. 
2.4.6 Desorption conditions and desorption time profile 
Suitable desorption conditions ensure maximum desorption efficiency, which is critical for minimizing 
carryover, maintaining the stability of the final extracts, and ensuring compatibility with the initial liquid 
chromatographic conditions in order to facilitate effective separation. First, desorption solvents were 
investigated with a 10 min preconditioning step in a 1:1 methanol/water (v/v) solution. For urine, an 
extraction time of 5 min from 1:3 sample/diluent (v/v) solution was used, which was followed by rinsing 
in 100% water under agitation for 10s; for plasma, the same extraction conditions were used, but the rinsing 
step consisted of 5s of rinsing under static conditions in a 9:1 water/methanol solution. Three solvent 
formulations were tested during the development of the plasma protocol: 1:1 acetonitrile/water, 1:1:2 
acetonitrile/methanol/water, and 3:3:4 acetonitrile/methanol/water (Figure 2.5A). Although the 1:1 
acetonitrile/water solution yielded the highest recovery rates—albeit with comparable carryover to the other 
two desorption solvents (Figure 2.5B)—the 3:3:4 acetonitrile/methanol/water solution was deemed the 
most appropriate, as the results for this solvent solution showed the greatest agreement with the previously 
developed LC-silica WCX coating method.77  
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Figure 2.5 A) Optimization of three desorption solvents: 1:1 acetonitrile/water, 1:1:2 
acetonitrile/methanol/water, and 3:3:4 acetonitrile/methanol/water. B) Carryover test for each desorption 
solution. 
 
Regrettably, compounded carry over effects became apparent after a large number of plasma samples were 
processed (~ 1500 samples) with the selected desorption solvent. A problem not experienced with past 
SPME-based methods for TXA analysis in plasma due to the significantly smaller number of samples 
requiring processing in these cases; nor was this problem foreseen with the current research. As such, the 
desorption conditions and cleaning procedure were re-optimized before processing the urine samples. For 
more information on the optimization of the cleaning procedure, please see section 2.4.7 “Device cleaning 
optimization”. Increasing ratios of aqueous-to-organic solvent mixtures were studied, accounting for 
TXA’s polarity, in order to increase desorption efficiency (Figure 2.6A). Although the 3:3:4 
acetonitrile/methanol/water mixture once again provided the best desorption capabilities, the long-term use 
of this desorption solvent over hundreds of samples proved to remain challenging. As such, the 9:1 
water/methanol mixture was deemed the most optimal desorption solvent, as it provided the best balance 
between liquid chromatographic compatibility and desorption efficiency, which was confirmed by the carry 
over test (results not shown). The optimal desorption time was determined by constructing a desorption 
time profile based on the amount of analyte recovered after 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 
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and 60 min of desorption, which took place after a 10 min preconditioning step, a 15 min extraction, and a 
10 s rinse in 100% water. As shown in Figure 2.6B, there was no significant increase in the amount of 
analyte desorbed from the coating beyond 10 minutes; therefore, 10 minutes was chosen as sufficient 
desorption time. 
 
Figure 2.6 A) Reassessment of optimum desorption conditions with increased aqueous content: 2:2:1 
acetonitrile/methanol/water, 3:3:4 acetonitrile/methanol/water, 1:1 acetonitrile/water, 6:2:2 
water/acetonitrile/methanol, and 9:1 water/methanol and pure water. B) Desorption time optimization in 
solution consisting of a 9:1 water/methanol mixture. 
 
2.4.7 Device cleaning optimization 
Although carryover was evaluated at the highest concentrations expected in patient samples (which was 
found to be less than 1%), a carryover effect associated with the blades’ reusability for high-throughput 
analysis was still observed for the plasma samples as reported in section 2.4.6 “Desorption conditions and 
desorption time profile”. Once the blades had been exposed to high-concentration samples, the amount of 
analyte that remained after desorption and cleaning interfered with the quantitation of low-concentration 
samples and effectively increased the lower limits of quantification, despite being below the acceptable 
limits for carryover. As such, additional measures were taken prior to preparing the urine samples in order 
to prevent any carry over effects that could potentially influence the quantitation of lower-concentration 
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samples. This would be especially detrimental given the dilution effects that can arise during urine 
processing. 
Various solvents and the number of required cleaning steps were explored in order to determine which 
combination would ensure that the amount of solute remaining on the blade, if any, was less than the amount 
corresponding to the lower limit of quantification. A strong solvent mixture consisting of 2:1:1 
methanol/acetonitrile/isopropanol (v/v/v) that is usually employed for cleaning was studied alongside two 
other mixtures: 45:45:10 isopropanol/acetonitrile/acetone and 45:45:10 isopropanol/methanol/acetone. 
Given the polarity of tranexamic acid, each of the three mixtures was diluted with 50% water to evaluate 
whether this improved cleaning efficiency. Figure 2.7 confirms the hypothesis that the addition of water 
drastically enhances cleaning efficiency, as all three solutions showed a 50% increase in analyte recovery 
in solutions that had been mixed with water. Once the 50:25:12.5:12.5 
water/methanol/acetonitrile/isopropanol (v/v) mixture had been identified as the optimal cleaning solvent, 
it was necessary to determine the number of steps required to sufficiently clean the blades. Formic acid is 
a common mobile-phase additive that is used to improve ionization efficiency for compounds analyzed by 
mass spectrometry in positive mode; thus, it can also be added to the desorption solution.  
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Figure 2.7 Evaluation of three cleaning solutions: 45:45:10 isopropanol/acetonitrile/acetone, 45:45:10 
isopropanol/methanol/acetone, and 2:1:1 methanol/isopropanol/acetonitrile (yellow columns). The red 
columns represent the solutions mixed with 50% water. 
 
However, it is important to assess its effect as an additive in relation to both the coating chemistry of the 
device used for sample preparation, as well as the composition of the solvent used for desorption. Tests of 
these relationships showed that the addition of 0.1% formic acid to the 9:1 water/methanol desorption 
solution decreased desorption efficacy by nearly 50%. In contrast, the addition of formic acid improved the 
50:25:12.5:12.5 water/methanol/acetonitrile/isopropanol solution’s cleaning efficiency by 50%. Figure 2.8 
shows that the blades were sufficiently cleaned after three successive 10-minute immersions in the 
optimized solution with 0.1% formic acid, as well as in the solution with no additives. While this 
phenomenon merits further investigation, this falls outside the scope of the present research. 
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Figure 2.8 Assessment of the number of cleaning cycles required to effectively remove traces of TXA 
from the device coating. Evaluation of how the addition of formic acid impacts desorption and cleaning 
efficacy. Devices initially desorbed in optimized desorption solution containing formic acid (des w/ FA) 
were cleaned in a solution containing formic acid (PC w/ FA) and compared with devices cleaned in a 
solution containing no formic acid (PC w/o FA). These two cleaning conditions were also evaluated 
against devices that had been desorbed in optimized desorption solution with no formic acid (des w/o 
FA). 
 
2.4.8 Evaluation of matrix effects 
SPME differs from other sample preparation approaches in that it extracts via free concentration. This 
suggests that it is unable to extract analytes that are bound to various macromolecules such as proteins, thus 
decreasing the extraction of possible interferences for an analyte of interest. However, matrices that contain 
no binding media (i.e., urine) are more challenging due to the increased likelihood of coextracting 
interfering matrix components that are available in free form such as salts, organic and inorganic content, 
and metabolites. These instances of coextraction, and subsequent coelution via chromatography, can impact 
the analytical signal of interest, resulting in signal enhancement or suppression. In order to assess SPME’s 
reliability as a sample preparation tool for the extraction, determination, and quantitation of TXA in a 
complex and challenging biofluid like urine, absolute and relative matrix effects were evaluated according 
to the method proposed by Matuszewski et al.87 
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To examine absolute matrix effects, urine samples from 14 individuals were assessed at concentrations of 
5, 10, 25, 50, and 100 ng/mL, which is consistent with the 1% absolute recovery rate of TXA from samples 
within the lower part of the expected concentration range. The obtained absolute matrix-effect values 
largely ranged between 80 and 120%; however, as can be seen in Table 2.5, there were a number of outliers, 
with enhancements as high as 423% and as low as 76%.  
Table 2.5 Evaluation of absolute matrix effects (%) tested at 5 lower-level concentrations in 14 different 
volunteers. Outliers (values less than 80 % and greater than 120 %) are highlighted in bold font. Each 
volunteer at each concentration was evaluated with 3 replicates. The values presented for each volunteer at 
each concentration level had RSD’s (n = 3) < 15%. 
 Concentration level 
 5 ng/mL 10 ng/mL 25 ng/mL 50 ng/mL 100 ng/mL 
Volunteer 1 104 102 109 105 92 
Volunteer 2 189 133 115 109 91 
Volunteer 3 213 75 149 96 93 
Volunteer 4 96 96 95 105 88 
Volunteer 5 87 86 99 90 89 
Volunteer 6 206 116 99 98 87 
Volunteer 7 251 103 166 105 79 
Volunteer 8 106 102 113 98 83 
Volunteer 9 103 95 113 101 79 
Volunteer 10 180 100 110 95 82 
Volunteer 11 197 98 93 82 76 
Volunteer 12 106 108 123 106 77 
Volunteer 13 95 93 99 104 80 
Volunteer 14 423 104 102 106 76 
 
These outliers suggest that there was some significant ion suppression or enhancement. Therefore, 
evaluating relative matrix effects are critical to ensure the internal standard used is suitable for correcting 
these deviations and that the target analyte can be reliably quantitated in urine. As such, a 7-point calibration 
curve, from 2 µg/mL to 250 µg/mL, was constructed in 8 lots of urine. Figure 2.9 shows that the homologous 
internal standard employed for the quantification of TXA proved to be suitable for correction, as it produced 
slopes with an average of 0.024 and a 10% relative standard deviation (RSD) in each lot of urine.  
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Figure 2.9 Assessment of relative matrix effects. A 7-point calibration curve was constructed in 8 lots 
of urine, producing an average slope of 0.024 within a 10% relative standard deviation (RSD) and a 
linearity (R2) of 0.99 across the 8 volunteers. 
 
2.4.9 Method validation  
This method was validated in accordance with the guidelines set forth in the Food and Drug administration 
(FDA) Guidance for industry: bioanalytical method validation. Blank urine from 14 individuals was 
assessed for interferences, with no cross-talk being observed for the majority of samples under LC-MS 
chromatographic conditions at the retention times for the analyzed compounds. No significant impact was 
found in cases where interferences were detected, as they were well below the limit of quantitation (LOQ). 
The chosen LOQ was the lowest concentration at which the constructed calibration curve determined the 
nominal concentration with at least 80 % accuracy and a 20% relative standard deviation. This method 
produced a linear dynamic range over two orders of magnitude—from 25 µg/mL-1000 µg/mL in urine, and 
from 10 µg/mL-1000 µg/mL in plasma—and achieved LOQs of 25 µg/mL and 10 µg/mL, in urine and 
plasma respectively. Acceptable linearity (R2) for TXA in urine and plasma were obtained achieving values 
of 0.996 and 0.997, respectively.  
Accuracy and precision were calculated using 5 replicates of plasma or urine spiked at a working 
concentration of 100 µg/mL, which is within the expected TXA concentration range for both biofluids. 
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These replicates were then randomly distributed among a batch of 96 samples prepared in a 96-deep-well 
plate. Furthermore, 2-3 replicates of blank urine were also randomly distributed among the samples in order 
to assess and maintain the integrity of the reusable sampling device. Accuracy was considered acceptable 
if the determined concentration was within 15% of the actual value, and precision was deemed acceptable 
if the coefficient of variation did not exceed 15%. This figure was increased to 20% for concentrations 
closer to the limit of quantification. The proposed method achieved intraday accuracy and precision of 
105% and 8%, respectively, and inter-day accuracy and precision of 103% and 7%, respectively. The 
chemical stability of tranexamic acid has already been investigated elsewhere, with findings showing that 
it is stable under various storage conditions for at least 12 weeks. Furthermore, PK studies have shown that 
over 95 % of the drug is excreted renally and remains unchanged in urine. Gorynski et al.77 studied TXA’s 
stability during the various stages of the sample preparation protocol, as well as in the final extract obtained, 
during their development of a method for the concomitant sample preparation of rocuronium bromide and 
TXA in plasma.  
2.5 Discussion 
2.5.1 Application of SPME method to clinical samples 
The analyzed clinical samples were collected from patients who were undergoing cardiac surgery and had 
been administered TXA as a means of controlling bleeding during the procedure. Patients were first 
categorized into low- and high-risk groups depending on the type of cardiac surgery they had undergone 
and several other health factors. The low-risk group had received a dose of 50 mg/kg as per institutional 
practise at Toronto General Hospital, while the high-risk group were placed on the relevant dosing schedule 
outlined in the BART study. Each group contained patients who had healthy kidney function and those with 
varying degrees of chronic renal dysfunction, from stage 1 to stage 5. As previously noted, suboptimal renal 
functioning can affect drug clearance, thus leading to heightened blood-drug concentrations of compounds 
that are largely renally excreted. Since high concentrations of TXA in blood plasma have been associated 
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with post-operative seizures, it was essential to monitor the TXA concentration over the course of 
administration in order to gain a better understanding of its PK in individuals suffering from renal 
impairment. Urine quantitation is much less straightforward than the monitoring and determination of 
plasma concentrations, which can be done directly, as dilution or pre-concentration can occur while the 
urine sample is being processed. As such, concentrations were determined via normalization, with 
creatinine clearance having already been calculated for up to 72 hours. Urine profiles were then constructed 
and determined as grams of TXA per gram of creatinine (gTXA/gCr). Following this, the developed SPME 
protocol was used to determine TXA concentrations in plasma and urine from a total of 49 high- and low-
risk cardiac patients (25 high-risk and 24 low-risk). Figure 2.10 shows the TXA concentrations in plasma 
and their corresponding clearance in urine from a total of only 10 patients belonging to both the high- and 
low-risk groups. As noted above, each group contained patients with varying degrees of chronic renal 
dysfunction.  
For patients on the same dosing schedule, the profiles of those within the same group differed significantly 
in terms of the maximum TXA concentration in either biofluid. These differences are due to increased mean 
TXA residence times during CPB due to impaired kidney function, which in turn results in increased 
concentrations of TXA in the blood. Figure 2.10A demonstrates that the patients suffering from later stages 
of CRD (Patient 7, Patient 10, and Patient 13 (stages 3-4)) exhibited significantly higher concentrations of 
TXA during CPB and many hours after the operation. Significantly different corresponding clearance trends 
in urine are also evident in Figure 2.10B, with higher post-operation concentrations of TXA being observed 
in patients with stages 3 and 4 chronic renal dysfunction than in patients with earlier stages of the disease. 
While this particular trend might not be as apparent with the low-risk cardiac patients profiled in Figure 
2.10C, it is interesting to note that Patient 10 and Patient 14, who both suffer from stage 1 CRD, have 
significantly different TXA concentrations in plasma, with Patient 14 exhibiting higher TXA concentrations 
throughout the entire procedure. These results not only clearly demonstrate the need to adjust dosing 
schedules to better suit patients suffering from more severe stages of CRD, but also the need to develop 
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methods capable of rapid analysis and real-time monitoring. These results have already been used to aid 
clinicians in developing a PK monitoring protocol for TXA 76, while a rapid-analysis method based on 
SPME coupled directly to MS via a microfluidic open interface (MOI) has also been proposed, developed,  
and employed for the determination of TXA concentrations in plasma.79  
 
Figure 2.10 TXA profiles in plasma and urine from patients with varying degrees of chronic renal 
dysfunction who underwent cardiac surgery. A) TXA profiles in plasma from 5 patients undergoing high-
risk cardiac surgery. B) Corresponding TXA profiles in urine from 5 patients undergoing high-risk 
cardiac surgery. C) TXA profiles in plasma from 5 patients undergoing low-risk cardiac surgery. D) 
Corresponding TXA profiles in urine from 5 patients undergoing low-risk cardiac surgery. 
 
2.6 Conclusion 
While numerous publications have focused on the validation and feasibility of using solid phase 
microextraction for quantitating TXA in plasma, this work marks the first attempt to apply this technique 
to the development of a protocol for determining TXA in urine. This protocol would allow clinicians to 
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obtain a more comprehensive patient profile for TXA, which would help to adjust dosing schedules to better 
suit the needs of individuals with renal impairment. In addition, the open-bed geometry used in the proposed 
SPME protocol and the use of a biocompatible polyacrylonitrile-based extraction phase help to prevent 
macromolecules from adversely interacting with the device. These features make this SPME method 
convenient and easy to use, as it is possible to directly expose the device to a sample without prior sample 
pre-treatment, such as centrifugation in the case of urine, or PPt in the case of plasma. Furthermore, the 
proposed method represents an improvement upon previously developed methods of performing extractions 
from plasma, as the excellent wettability of the HLB phase decreases sample extraction time and increases 
throughput. The work presented in this paper further emphasizes SPME’s suitability and capability for the 
high throughput monitoring of therapeutic drugs in complementary biological fluids, such as plasma and 
urine. Since SPME is a non-exhaustive and quantitative microextraction technique, quantitation at high 
concentrations over three orders of magnitude can be easily achieved without having to dilute the final 
extracts. Moreover, the use of a Concept-96 autosampler to automate the process enabled over 3500 samples 
(urine and plasma combined) from 49 patients undergoing low-risk and high-risk cardiac surgery to be 
processed. This technique’s direct amenability to mass sensitive detection methods, such as mass 
spectrometry, has already facilitated the much needed rapid analysis of TXA in plasma, with the results 
obtained in this study having been used to cross validate this newly developed technique 79. 
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Chapter 3: Serum metabolic fingerprinting of psoriasis and 
psoriatic arthritis patients using solid phase microextraction – liquid 
chromatography – high-resolution mass spectrometry  
3.1 Preamble 
Chapter 3 of this thesis has been formatted for submission to the journal Metabolomics, with all the writing 
done by the author of this thesis and co-authored with N. Reyes-Garces, A. Roszkowska, Miao Yu, V. 
Kulasingam, J. Pawlisyzn and V. Chandran. Collaboration for the work presented in this chapter of the 
thesis was initiated by J. Pawliszyn, V. Chandran, and V. Kulasingam, with experimental design being 
conducted by J. Pawliszyn, V. Chandran, V. Kulasingam, N. Reyes-Garcés, and the author of this thesis. 
All other work presented in this chapter of the thesis were conducted by the author of this thesis with 
assistance from N. Reyes-Garcés, A. Roszkowska, Miao Yu and I. Batruch. Please see Statement of 
contributions. We are grateful to the Natural Sciences and Engineering Research Council (NSERC) of 
Canada for the financial support provided through the Industrial Research Chair program, as well as the 
Canadian Institutes of Health Research (CIHR) through the catalyst grant program. 
3.2 Introduction 
Approximately 3% of North Americans are affected by psoriasis; a chronic, immune-mediated, 
inflammatory skin disease.88,89 While there are many variants of psoriasis—for example, guttate psoriasis, 
palmoplantar pustulosis, and pustular psoriasis—psoriasis vulgaris, or plaque psoriasis, is the most 
common, accounting for 85% to 90% of psoriasis-related conditions.90 Approximately 25% of psoriasis 
patients also suffer from psoriatic arthritis (PsA), which is a specific form of inflammatory arthritis that 
may affect peripheral and axial joints and periarticular structures, such as the enthuses.91 This is a significant 
problem, as psoriasis and PsA significantly reduce quality of life, and can lead to disability and increased 
mortality.92 Thus, it is important to diagnose PsA as early as possible, as doing so can result in better long-
term health outcomes.93 Since PsA often develops after the onset of cutaneous psoriasis, recent research has 
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tended to focus on converters—psoriatic patients who develop PsA—with the aim of identifying the 
mechanisms of arthritis development, early diagnosis methods, and measures for impeding the disease’s 
progression, as advances in these areas have the potential to improve patient care tremendously.94–96 
However, progress towards these goals will require the determination of more quantitative biomarkers 
associated with psoriatic disease pathophysiology.89 
Researchers have employed several types of untargeted analyses, otherwise known as ‘omic-related’ 
approaches, to investigate disease pathology, including transcriptomics, proteomics, and genomics.97 
However, the emergence of metabolomics—which entails the comprehensive investigation of all 
metabolites in a biological system at a given time—has provided researchers and clinicians with a new 
approach that enables disease-related changes to be monitored with greater rapidity.97 Many prior psoriatic-
related metabolomics studies have examined mainly the differences between psoriatic and healthy patients. 
Fewer studies still, investigated PsA at all, with a focus on either how PsA differed in general from patients 
with psoriasis or how PsA differed from patients suffering from rheumatoid arthritis.98 Through the analyses 
of various samples, including skin, blood components (serum and plasma), and urine, the results of these 
studies yielded biomarkers such as amino acids and various lipids which were associated mainly with 
psoriasis disease severity or how PsA differed from other forms of arthritis.98–103 Given the dearth of 
research related specifically to PsA, the research presented herein attempts to fill that gap by investigating 
PsA explicitly, in order to determine how it relates to psoriasis disease, and if PsA pathophysiology may 
provide some insight to disease conversion, thereby indicating a means of prevention or more tailored 
treatments.  
In general, metabolomics studies employ either nuclear magnetic resonance (NMR) or high-resolution mass 
spectrometry (HRMS), both of which are powerful detectors that scan the broad range of metabolites within 
a given biological sample. Regardless of which platform is used, sample preparation remains one of the 
most critical steps in the metabolomics workflow, as sample pre-treatment can inadvertently affect the 
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outcome of any study. Many HRMS-based metabolomics studies employ standard sample preparation 
techniques such as protein precipitation (PPt), liquid-liquid extraction (LLE), and solid-phase extraction 
(SPE). While these methods are effective, they are also labor intensive, as they require multiple steps in 
order to obtain the final extract for analysis. Furthermore, the considerable amount of sample handling 
involved in these preparative procedures can easily lead to errors associated with artefact formation. The 
development of more rapid techniques could both mitigate these issues and increase sample throughput, as 
the sample would be idle for much less time. Thin-film solid phase microextraction (TF-SPME) coupled to 
HRMS is one such rapid sample preparation technique that has been reported in numerous metabolomics-
related studies.29,57,62,104 Therefore, this work assesses the viability of TF-SPME coupled to HRMS as a 
novel and rapid (given the high throughput capabilities) sample preparation tool by using it to perform 
clinical metabolomics analyses on serum obtained from three sample groups: patients with PsA; patients 
with psoriasis, but without PsA (PsC); and healthy volunteers.  
The objectives of this study were to use TF-SPME-HRMS to find markers or metabolites indicative of:  
1. Conversion from psoriasis to PsA;  
2. PsA in patients with psoriasis; 
3. PsA disease activity.  
To the best of our knowledge, this is the first psoriasis-related metabolomics study to investigate the 
pathology of PsA disease, and further to incorporate the use SPME coupled to HRMS to perform profiling.  
3.3 Materials and Methods 
3.3.1 Materials 
Thin-film stainless steel combs were purchased from PAS technologies (Magdala, Germany), while oasis 
hydrophilic-lipophilic balanced (HLB) particles (30 – 60 µm) and weak anion exchanger functionalized 
polystyrene divinylbenzene (PS-DVB-WAX) particles (30 – 60 µm) were purchased from Waters 
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Corporation (Milford, USA) and Chromatographic Specialties, respectively (Brockville, Canada). A flask-
type sprayer and the following internal standards and chemicals were purchased from Millipore Sigma 
(Burlington, USA): tranexamic acid, phenylalanine-d5, testosterone-d3, codeine-d3, sodium chloride, 
potassium chloride, sodium phosphate, potassium phosphate, polyacrylonitrile, and N,N-
dimethylformamide (DMF). 2 mL deep-well plates were purchased from Thermo Fisher Scientific 
(Waltham, USA), and the following LC-MS grade solvents were purchased from Fisher Scientific (Ottawa, 
Canada): formic acid, acetic acid, acetonitrile, methanol, and water. The deionized water that was used to 
prepare the phosphate buffered saline was obtained using an Milli-Q Reference Water Purification System 
(EMD Millipore, Fisher Scientific, Ottawa, Canada). 
3.3.2 Thin-film microextraction device preparation  
The thin-film microextraction (TFME) device was prepared using a well-established spraying method that 
had been developed in-laboratory.80 Briefly, a flask-type sprayer was used to coat the stainless-steel support 
with a slurry mixture consisting of 1:1 HLB and PS-DVB-WAX particles, polyacrylonitrile (to act as a 
binder), and DMF. After the application of each layer, the coating was placed in an oven to cure at 180 °C 
for 1 minute. The final coating on the device was 1 cm long with an average thickness of 0.3 mm. 
3.3.3 Instrumental analysis: liquid chromatography coupled with high-resolution 
mass spectrometry 
High performance liquid chromatography (HPLC) with HRMS detection was performed using an Accela 
autosampler and pump coupled to a Q-Exactive mass spectrometer (Thermo Fisher Scientific, Waltham, 
USA). Chromatographic separation was conducted on a Discovery HS F5-3 column (100 mm x 2.1 mm, 3 
µm) with a Discovery HS F5 (20 mm x 2.1mm, 3 µm) pre-column, which were both purchased from 
Supelco/Sigma Aldrich (Bellefonte, USA). Gradient elution was achieved over 40 minutes in positive mode 
using mobile phases consisting of 99.9/0.1 water/formic acid (v/v) and 99.9/0.1 acetonitrile/formic acid 
(v/v). For negative-mode chromatography, 1mM of acetic acid was used instead of formic acid. Sample 
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extracts were injected at a volume of 10 µL, and the autosampler and column temperature were maintained 
at 5 °C and 25 °C, respectively. Further details on the gradient elution used for chromatography can be 
found in Table 3.1.  
Table 3.1 Liquid chromatographic gradient used for separation in both positive and negative mode 
MS polarity Positive mode Negative mode 
Time (min) % Mobile phase A 
(water + 0.1 % formic 
acid 
% Mobile phase A (water + 
1mM acetic acid 
0.00 100 100 
3.00 100 100 
25.00 10 10 
34.00 10 10 
35.00 100 100 
40.00 100 100 
 
The Q-Exactive mass spectrometer was equipped with an Ion Max heating source, which contained a heated 
electrospray ionization (HESI-II) probe. The mass spectrometer was run at high resolution (50, 000), and 
data was acquired within an m/z range of 100 – 1000 with a balanced automatic gain control and an injection 
time of 100 milliseconds. The capillary and vaporizer temperatures were each set at 300 °C, while the 
sheath, auxiliary, and sweep gas were set to 35, 5, and 0, respectively. The electrospray voltages (and lock 
masses) applied for positive and negative mode were 4 kV (391.2842 m/z) and -2.9 kV (255.2329 m/z), 
respectively. 
MS/MS validation was performed for the desired statistically significant features via parallel reaction 
monitoring (PRM) on the Q-Exactive. The obtained MS/MS spectrum was then compared to the 
fragmentation patterns of metabolites from the mzCloud or MS finder databases. 
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3.3.4 Patients 
Serum samples were obtained from the University of Toronto Psoriatic Disease (PsD) Program biobank. 
Prospective patients with PsA and PsC were enrolled in the program based on careful phenotyping,105 with 
samples being collected for both the patients in the program as well as healthy controls without PsD. A 
scheme outlining the structure of the patient groups is shown in Figure 3.1.  
 
Figure 3.1 Scheme of patient categories and subcategories of samples collected for analysis. Serum 
samples were obtained from healthy volunteers serving as controls (Ctrl) and patients with psoriasis 
(PsD). Patients with psoriasis who may or may not have developed psoriatic arthritis are grouped as 
converters (PsC); psoriatic patients who have developed psoriatic arthritis are classified as converters, 
while psoriatic patients who have not developed psoriatic arthritis are classified as non-converters. 
Samples were collected at baseline from both baseline converters and baseline non-converters, and at a 
subsequent time from both follow-up converters and follow-up non-converters. Patients with psoriatic 
arthritis (PsA) were categorized based on the severity of their conditions: mild, moderate, or severe. From 
each group, n = 10 patients were sampled. 
 
 
Patients with PsD were further categorized into two subgroups at the time of the first sample collection: 
psoriasis without PsA (PsC), and psoriasis with PsA. The first set of samples was collected at baseline and 
the second set of samples were collected later from PsC patients who had developed PsA (converters; n=10) 
and those who had not (non-converters; n=10). Furthermore, patient PsA severity was measured based on 
the number of actively inflamed (i.e., swollen or tender) joints, with cases being categorized as either mild 
(<4 actively inflamed and 0 swollen joints; n = 10), moderate (4-5 actively inflamed and <3 swollen joints; 
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n = 10), or severe (>5 actively inflamed and >3 swollen joints; n = 10). More detailed patient information 
such as sex, age, duration of psoriasis, duration of PsA, treatment, and associated comorbidities is provided 
in Table 3.2.  
Table 3.2 General information describing the distribution of various biochemical parameters for patients 
and volunteers involved in the study 
Group Gender 
(No. of 
patients) 
Age Dur. PsD (yrs) Dur. PsA 
(yrs) 
Receiving 
treat. 
Comorbid. 
(number of 
patients in group) 
PsA 
(mild) 
F (5) 
M (5) 
23 – 74 
20 - 53 
-0.03 - 53 -0.03 - 16 yes Lung disease (1) 
CNS (3) 
Hyperlipidemia (1) 
Neuro (1) 
Autoimmune 
disease (1) 
Infection (1) 
Other med. (8) 
PsA 
(moderate) 
F (5) 
M (5) 
35 - 69 
47 - 69 
19 - 59 0.2 - 26 yes Hyperlipidemia (1) 
Diabetes (1) 
Infection (3) 
Other med. (7) 
PsA 
(Severe) 
F (5) 
M (5) 
24 -71 
23 - 48 
0.3 - 69 0.3 - 28 yes Diabetes (2) 
Cancer (2) 
Infection (3) 
Other med. (8) 
Converter 
Baseline 
F (3) 
M (7) 
43 – 61 
33 - 54 
0.4 - 43 N/A 
-0.04 – 6 
(post 
conversion) 
 only 2 
persons 
Lung disease (1) 
Hyperlipidemia (1) 
Infection (2) 
Other med. (5) 
Non-
Converter 
Baseline 
F (3) 
M (7) 
44 – 60 
32 – 53  
1 - 28 N/A only 2 
persons 
Hyperlipidemia (3) 
Neuro (2) 
Osteoporosis (1) 
Autoimmune (1) 
Infection (5) 
Other med. (7) 
Control F (5) 
M (5) 
N/A N/A N/A N/A N/A 
Dur.PsD: duration of psoriasis (in years). Dur. PsA: duration of psoriatic arthritis (in years). Treat.: 
treatment. Comorbid: patient related comorbidities. Other med: other medications. F: female. M: male. 
Neuro: Neuropsychiatric disease. N/A: no information available. 
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3.3.5 Sample preparation 
Serum samples were processed using TFME, which consisted of a thin stainless-steel blade that had been 
coated with an appropriate polymer or sorbent. The coating/extraction phase used in this work was 
comprised of a mixture of hydrophilic-lipophilic balanced (HLB) functionalized particles and polystyrene 
divinylbenzene with a weak anion exchanger (PS-DVB-WAX) functionalized particles. Each well of a 96-
well plate were filled with 200 µL of serum and 400 µL of phosphate buffered saline (PBS) containing 
deuterated phenylalanine and testosterone. Thus, each well contained a final sample volume of 600 µL. The 
device was first conditioned in a mixture of 1:1 methanol:water (v/v) for 30 minutes at 1500 rpm, while the 
serum samples were incubated at 25 °C during this time. Following conditioning, the device was rinsed in 
water for 30 seconds at 1500 rpm and then exposed to the serum samples for a period of 1 hour at 1500 
rpm. After the extraction process, the device was rinsed in water for 10 seconds at 1500 rpm to remove any 
loosely attached matrix components from its surface. Finally, the extracted metabolites were desorbed in 
550 µL of a mixture consisting of 4:3:3 methanol: acetonitrile:water (v/v/v) for 1 hour at 1500 rpm. The 
use of a Concept-96 autosampler to automate the TFME protocol enabled a sample preparation time of 
under 2 minutes per sample. The desorption solution was then diluted with 220 µL of water to produce a 
final extract composed of 1:1 organic/aqueous content, thus ensuring compatibility with the initial 
chromatographic conditions of the LC-HRMS metabolomics method that would be used for analysis. A 
pooled quality control (QC) sample was prepared by combining 10 µL of each sample extract (not including 
randomly chosen sample replicates) in a separate well. The pooled QC was injected approximately every 
10 sample injections. 
3.3.6 Data pre-treatment and analysis 
The raw LC-MS data files acquired during instrumental analysis were first converted to mzXML files using 
MSConvert.106 The converted files were then pre-processed using the XCMS software package and an 
RStudio script that had been developed in-laboratory; pre-processing involved performing grouping, 
retention time correction, peak alignment, peak filling, peak picking etc.107,108 Optimized parameters for 
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data pre-processing were obtained using the IPO package109 on selected pooled QC samples run at the 
beginning, middle, and end of the sequence, while the extracted peaks were annotated using the 
xMSAnnotator Integrative scoring algorithm110 in conjunction with the Human metabolome database111 
(HMDB). More detailed statistical analysis was achieved using Metaboanalyst [accessed September 5, 
2017]112, and XCMS online113 and METLIN114 were also utilized to perform the initial data analysis and 
feature identification, respectively, on the preliminary results. 
The peak-lists generated using the XCMS software package in RStudio were initially filtered using the 
relative standard deviation (RSD) of the pooled QCs, with any feature in the pooled QC with > 30 % RSD 
being removed from further analysis. Secondary filtering methods were conducted based on solvent and 
device blanks, with any feature with a pooled-QC:device/solvent-blank peak-intensity ratio of < 5 also 
being removed from further statistical evaluation. The resultant peak-lists were uploaded to Metaboanalyst; 
for this web-based platform, the default settings were used for missing values (wherein a fixed non-zero 
value is assigned to features with no signal intensity for some samples to eliminate zero values in the data 
matrix), and no additional feature filtering was applied. A total of 2368 features were detected in positive 
mode while 935 features were detected in negative mode. In addition, no further data normalization, data 
transformation, nor scaling (no differences were observed between the PCA’s generated for no scaling, 
autoscaling, or pareto scaling) were performed prior to univariate or multivariate chemometric analyses. 
Since the distribution of data cannot be assumed, a Kruskal Wallis Test with a false discovery rate (FDR) 
adjusted p-value of 0.05 was applied for univariate analysis. For multivariate analysis, Principal Component 
Analysis (PCA), Partial Least Squares–Discriminant Analysis (PLS-DA), and Orthogonal Projection to 
Latent Structures-Discriminant Analysis (OPLS-DA) were performed as necessary. Given the small 
number of patients in each group (n ≤ 10 if there are outliers), model validation for the supervised 
multivariate analyses (O-PLS-DA and PLS-DA) was conducted using a combination of permutation (at 
1000) and leave-one-out cross-validation (LOOCV). Successful model validation for O-PLS-DA was 
achieved when the original model passed permutation at p < 0.05 for model predictability (Q2) and/or model 
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fit (R2). For a PLS-DA model, successful model validation was achieved with a permutation (for separation 
distance) of p < 0.05 and when Q2 and R2 > 0.6 and/or were within 0.2 units of each other. Only features 
with a variable of importance (VIP) score of > 1 were investigated further. 
3.4 Results 
Metaboanalyst was used to generate a visual representation of the overall structure of all the samples as 
determined by principal component analysis (PCA) (Figure 3.2). This unsupervised multivariate approach 
is ideal for identifying patterns within the data set from which subsequent supervised models may be 
constructed. PCA with univariate analysis was largely employed for this study as there were only n = 10 
samples per group and very close inter-group association (overlap of clusters) among a number of groups, 
which may result in overfitting and likely failure during the cross-validation of supervised models. 
However, data from successfully validated models were used for further analyses.  
 
Figure 3.2 Principal component analysis (PCA - PC1:76.2%, PC2: 12.8%, PC3:2.6%) of the pooled QCs 
and the three patient groups under investigation: healthy volunteers (Ctrl); patients with varying degrees 
of psoriatic arthritis (PsA); and patients with psoriasis, but without psoriatic arthritis (PsC). The pooled 
QCs, Ctrls, PsA patients, and PsC patients are represented by green, red, dark blue, and turquoise, 
respectively. Data shown were obtained via negative mode acquisition and were similar to the results 
obtained via positive mode acquisition (data not shown). 
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PCA was used initially to identify any patient-type differentiation amongst patients with PsC (baseline 
converters and non-converters; n=20), patients with PsA (mild, moderate and severe, n=30), and the healthy 
controls (Ctrls; n=10). The quality of the resulting data was also assessed via a PCA plot investigating the 
spread and location of the pooled QC samples on the plot (shown in green). Since the pooled QCs are a 
pool of each sample, and were injected every 10 samples throughout instrumental acquisition, their very 
tight clustering in the middle of the plot strongly indicates stability during instrumental acquisition. Finally, 
in accordance with this project’s objectives, further investigations were conducted with respect to the 
structure of the PsC group, the relationship between PsC and PsA, and PsA severity.  
3.4.1 Baseline converters vs. baseline non-converters 
No statistically significant differences were found between baseline converters and baseline non-converters, 
which are represented in green and red, respectively, in Figure 3.3. Detailed information for these patients 
can be found in Table 3.3.  
 
Figure 3.3 PCA (PC1:45.2%, PC2: 19.3%, PC3: 9.6%) plot of patients with psoriasis who developed 
psoriatic arthritis prior to disease progression (baseline converters) and patients with psoriasis who had 
not developed psoriatic arthritis (baseline non-converters). Baseline converters and baseline non-
converters are represented by red and green, respectively. Data were obtained via negative mode 
acquisition and were similar to the results obtained in positive mode acquisition (data not shown). 
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Table 3.3 Information for patients with psoriasis defined as converters or non-converters, prior to conversion (at baseline) 
Baseline converters Baseline non-converters 
ID Sex Age Dur. 
PsD 
PASI Comorbid. Treat. ID Sex Age Dur. 
PsD 
PASI Comorbid. Treat. 
523 F 43 42 3.1 Infection none 283 F 61 26 1.6 Osteop. none 
597 F 55 3 7.4 Lung dis. none 524 F 55 1 0.3 Autoimm. 
Infection 
none 
647 F 61 16 3.6 N/A NSAID 541 F 44 20 6.3 Infection none 
495 M 50 10 6 N/A none 561 M 45 28 7.7 CNS 
Neuro. 
NSAID 
529 M 50 44 7.2 Infection none 609 M 49 24 5.7 GU 
Hyplipid 
Infection 
none 
639 M 54 0.5 16.8 Hyplipid 
Diabetes 
none 611 M 33 4 0.6 N/A none 
687 M 33 6 0.9 N/A none 629 M 54 20 2.6 Hyplipid none 
717 M 43 29 5.1 N/A none 797 M 43 27 4.8 N/A none 
755 M 44 14 15.8 N/A none 808 M 51 7 1.7 Lung dis. 
Neuro. 
Infection 
none 
822 M 49 29 N/A N/A Nsaid 824 M 50 4 2.1 N/A none 
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Dur.PsD: duration of psoriasis (in years). Dur. PsA: duration of psoriatic arthritis (in years). PASI: psoriasis area and severity index. Comorbid.: 
patient-related comorbidities. Treat: treatment. Hyplip: hyperlipidemia. Osteop.: osteoperosis. Autoimm.: autoimmune disease. Neuro.: 
neuropsychiatric disease. CNS: central nervous system. NSAID: nonsteroidal anti-inflammatory drugs. Dmards: disease modifying anti-rheumatic 
drugs. MTX: methotrexate. Anti-TNF: anti-TNF inhibitor Bio: biologics work up. N/A: no information available 
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Baseline converters vs. follow-up converters subsequent comparison was made to examine the metabolic 
changes occurring during the transition from PsC (baseline converter) to PsA (follow-up converter). 
However, as the PCA plot in Figure 3.4 illustrates, a paired analysis revealed no statistically significant 
differences between baseline converters (shown in red – group 0) and follow-up converters (shown in green 
– group 1). Detailed patient information can be found in Table 3.4. 
 
Figure 3.4 PCA (PC1: 42.8, PC2: 17.9%, PC3: 10.3%) plot of a paired analysis of converter (PsC) 
patients who had psoriasis without psoriatic arthritis at baseline (baseline converters), and developed 
psoriatic arthritis (follow-up converters). Baseline converters and follow-up converters are represented 
on the plot by red and green, respectively. Data were obtained via negative mode acquisition and were 
similar to the results obtained in positive mode acquisition (data not shown). 
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Table 3.4 Patient information for individuals with psoriasis who develop psoriatic arthritis and patients with mild psoriasis. 
Converter Mild PsA 
Baseline Post conversion 
ID Comorbid. Sex Age PASI 
score 
Dur. 
PsD 
Dur. 
PsA 
Joint 
info 
SJ/TJ 
Treat. ID Sex Age PASI 
score 
Dur. 
PsA 
Joint 
info 
SJ/TJ 
Treat. 
495 N/A M 50 2.6 10 0.7 3/7 NSAID 713 M 37 0.9 7 1/1 Dmards 
NSAID 
MTX 
529 Infection M 50 13.3 44 -0.04 1/12 Dmards 
NSAID 
MTX 
3201
X
 M 39 0.4 1 0/0 NSAID 
639 Hyplip 
Diabetes 
M 54 N/A 0.5 N/A N/A Bio 3376 M 20 0.8 0 1/1 none 
687 Lung 
disease 
M 33 2.1 6 0 2/2 NSAID 3535 M 49 1.9 0 2/2 NSAID 
717 N/A M 43 5.5 29 0.4 0/0 none 3520 M 53 38.4 8 0/1 Dmards 
MTX 
755 N/A M 44 38.7 14 1 1/1 Dmards 725 F 23 0.8 5 6/0 Dmards 
MTX 
822* N/A M 49 3.1 29 -0.3 0/0 NSAID 3160 F 52 2.6 16 1/1 Bio 
Dmards 
NSAID 
MTX 
Anti-TNF 
523 Infection F 43 3.8 42 6 3/8 Nsaid 3234 F 30 2.4 1 1/3 Bio 
NSAID 
Anti-TNF 
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597 Lung 
disease 
F 55 0.6 3 1 0/0 Bio 
Dmards 
MTX 
Anti-
TNF 
3543 F 51 3.6 2 N/A/N/A Nsaid 
647* N/A F 61 2.1 16 0.4 3/3 NSAID 3640 F 75 0 3 0/5 Bio 
NSAID 
Anti-TNF 
(ID*) patients taking treatment at baseline (Nsaid in both cases), prior to conversion. IDx: patients excluded from further statistical analysis.  SJ: 
swollen joints.  TJ: tender joints. Comorbid.: patient-related comorbidities.  Dur.PsD: duration of psoriasis (in years). Dur. PsA: duration of psoriatic 
arthritis (in years)  PASI: psoriasis area and severity index. Treat: treatment. Hyplip: Hyperlipidemia. NSAID: nonsteroidal anti-inflammatory drugs. 
Dmards: disease modifying anti-rheumatic drugs. MTX: methotrexate. Anti-TNF: anti-TNF inhibitor Bio: Biologics work up. N/A: no information 
available. 
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3.4.2 Healthy controls vs. psoriasis without psoriatic arthritis vs mild psoriatic 
arthritis 
Figure 3.5 show that there exists no discrimination between patients with psoriasis and patients with 
psoriasis newly diagnosed with psoriatic arthritis  (follow-up non-converters and follow-up converters 
represented in Figure 3.5A by green and blue, respectively) with healthy controls (shown as red in Figure 
3.5 A and B). Interestingly, no difference was found between these same psoriatic patients newly diagnosed 
with psoriatic arthritis and mild PsA (shown in blue in Figure 3.5B).  
 
Figure 3.5 A) Principal component analysis (PC1: 65.2%, PC2: 14.1%, PC3: 5.9%) for the comparison of three 
groups – healthy controls, follow-up non-converters and follow-up converters represented by red, green and blue 
circles on the plot respectively. B) Principal component analysis (PC1: 50.3%, PC2: 16.9%, PC3: 4.0%) for the 
comparison of three patient groups – healthy volunteers, follow-up converters and mild psoriatic arthritis 
represented by red, green and blue on the plot respectively. 
 
3.4.3 PsC vs PsA 
It is abundantly clear from Figure 3.2 and Figure 3.6—which explicitly highlights PsA progression or 
disease severity for PsA patients in comparison to healthy volunteers and PsC patients—that the PsA group 
dominates the PCA plot. Specifically, compared to the healthy controls (red) and the PsC group (turquoise), 
the PsA group contains the largest distribution of samples across the plot, accounting for 76.9% of the 
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variation seen in the first principal component (PC1). Given the considerable variation observed among the 
PsA group, further investigation was conducted on the PsA group structure.  
 
Figure 3.6 PCA (PC1: 76.9, PC2: 13%, PC3: 2.4%) plot of healthy volunteers (control; red) and patients 
with psoriasis prior to conversion or non-conversion (PsC; turquoise). The plot also distinguishes 
between PsA patients based on level of disease progression (mild PsA-green; moderate PsA-dark blue; 
severe PsA-magenta). Data were obtained via negative mode acquisition and were similar to the results 
obtained in positive mode (data not shown). Pooled QC’s were removed. 
 
3.4.4 PsA group 
The PCA plot in Figure 3.7 shows a clear separation between PsA groups, such that as those suffering from 
mild psoriatic arthritis tend towards the left side of the plot, those suffering from severe psoriatic arthritis 
tend towards the right side of the plot, and those with moderate psoriasis are distributed among and between 
these two groups. Overall patient information for the PsA group investigated is provided in Table 3.5, while 
joint related information is provided in Table 3.6. 
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Figure 3.7 PCA (PC1:25.4%, PC2:16.5%) plot of healthy individuals (Ctrls) and patients suffering from 
varying degrees of psoriatic arthritis (PsA). The control group is represented by red dots, while patients 
with mild, moderate, and severe PsA are represented by green, dark blue, and magenta dots, respectively. 
Data were obtained via positive mode acquisition. Data obtained via negative mode acquisition can be 
found in Online resource 9. 
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Table 3.5 Patient information for individuals with varying degrees of PsA. 
Mild Moderate Severe 
ID Sex Age Dur. 
PsD  
Dur. 
PsA 
Comor. Joint 
info. 
ID Sex Age Dur. 
PsD  
Dur. 
PsA 
Comor. Joint 
info 
ID Sex Age Dur. 
PsD  
Dur. 
PsA 
Comor. Joint 
info 
713 M 37 7 7 N/A A (1) 
D(12) 
603
x
 M 53 25 6 N/A A (2) 
D (0) 
192
x
 M 61 26 33 N/A A (0) 
D (26) 
3201
x
 M 39 1 1 N/A N/A 204 M 48 28 25 N/A A (1) 
D (14) 
242 M 63 10 10 Hyplipid 
Diabetes 
A (0) 
D (5) 
3376 M 20 0 0 Lung 
dis. 
Infec. 
A (1) 
D (1) 
371 M 52 30 18 Infec. A (0) 
D (9) 
3103 M 48 0.3 0.3 Infect. A (21) 
D (0) 
3520 M 53 8 8 N/A A (1) 
D (4) 
421 M 49 31 24 Infec. A (1) 
D (0) 
3120 M 24 2 2 N/A A (8) 
D (0) 
3535 M 49 2 0 N/A A (2) 
D (2) 
430 M 69 59 19 Hyplipid 
Diabetes 
A (2) 
D (11) 
3316 M 37 31 6 N/A A (4) 
D (4) 
725 F 23 13 5 CNS N/A 438 F 62 52 27 N/A A (2) 
D (3) 
422 F 51 25 21 N/A A (0) 
D (32) 
3160 F 52 22 16 Hyplipid
. 
A (1) 23 F 46 35 25 N/A A (0) 
D (2) 
706
x
 F 50 19 19 Diabetes 
Cancer 
Infec. 
A (18) 
D (2) 
3234 F 30 5 1 CNS 
Neuro. 
A (3) 3069
x
 F 50 26 2 N/A A (0) 
D (0) 
726 F 49 32 28 Lung dis. 
Liver dis. 
Autoimm. 
Infec. 
A (15) 
D (6) 
3543 F 51 31 2 N/A A 
(N/A) 
D (0) 
3106 F 69 39 0.24 N/A A (4) 
D (0) 
3073
x
 F 72 69 6 Cancer 
Infec. 
A (7) 
D (2) 
3640 F 75 54 3 CNS 
Autoim
m. 
A (5) 
D (3) 
3110 F 37 20 7 N/A A (3) 
D (1) 
3203 F 25 18 18 N/A A (3) 
D (0) 
IDx Patients excluded from further statistical analysis. Dur. PsD: duration of psoriasis (in years). Dur. PsA: duration of psoriatic arthritis (in years). A: number of 
active joints. D: number of damaged joints. CNS: central nervous system. Neuro.: neuropsychiatric disease. Infec: infection. Hyperlipid.: hyperlipidemia. Autoimm.: 
autoimmune disease. N/A: no information available. 
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Table 3.6 Joint information for patients with varying degrees of psoriatic arthritis 
Group ID SJ DJ AJ notes Group ID SJ DJ AJ notes Group ID SJ DJ AJ notes 
Mild 713 1 12 1 severe Mod. 23 0 2 0 
 
Severe 192
x
 0 26 0 
 
725 6 0 6 severe 204 1 14 1 severe 242 0 5 0 
 
3160 1 0 1 
 
371 0 9 0 severe 422
x
 0 32 0 
 
3201
x
 0 0 0 
 
421 1 0 1 mild 706
x
 2 2 18 
 
3234 1 0 3 
 
430 1 11 2 mild 726 10 6 15 
 
3376 1 1 1 
 
438 1 3 2 
 
3073
x
 3 2 7 
 
3520 0 4 1 
 
603
x
 2 0 0 
 
3103 16 0 21 
 
3535 2 2 2 
 
3069
x
 0 0 0 
 
3120 4 0 8 
 
3543 N/A 0 N/A 
 
3106 1 0 4 
 
3203 1 0 3 
 
3640 0 3 5 
 
3110 1 1 3 mild 3316 3 4 4 mild 
avg 
 
1 2 2 
 
avg 
 
1 4 1 
 
avg 
 
4 8 8 
 
IDx: patients excluded from further statistical analysis. SJ: number of swollen joints. DJ: number of damaged joints. AJ: number of active joints Avg: average. N/A: 
no information available. Notes: information about which patients were cluster deviations and where they were subsequently found. A blank note suggests patients 
did not deviate from the cluster. 
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3.4.5 Statistically significant features across patient groups 
Statistical analysis via univariate analysis yielded 10 statistically significant features across the three PsA 
groups (mild, moderate and severe), which were putatively identified using xMSAnnotator for negative 
mode data. For the positive mode data, XCMS online in conjunction with METLIN helped to tentatively 
identify 7 statistically significant features differentiating healthy individuals from patients with severe PsA. 
See Table 3.7 and  
Table 3.8 and for a complete list of annotated compounds along with their associated annotation confidence 
levels, statistical parameters and LC-HRMS parameters for both positive and negative modes, respectively. 
Table 3.7 Tentatively annotated features showing statistically significant differences via univariate analysis 
between healthy controls and severe psoriatic arthritis patients for positive mode data. 
Feature 
No. 
Tentative ID m/z Adduct  Retention 
time (min) 
P value Q value Annotation 
score (max 
= 3) 
57 S-aminomethyldihydrolipoamide 237.1090 [M+H]
+
 13.25 8.0x10
-5
 1.8x10
-2
 2 
130 Hydroxycapric acid 189.1485  [M+H]
+
 14.84 
  
2.0x10
-4
 2.0x10
-2
 3 
304 Glutamyl-tyrosine 310.1159  [M+H]
+
 14.01 5.7x10
-4
 4.3x10
-2
 2 
365 Methyladenosine  
Isoleucyl glutamate 
282.1197 
282.1186 
 [M+H]
+
 
 [M+Na]
+
 
12.17 7.0x10
-4
 2.6x10
-2
 2 
531/1302 Adenosine or deoxyguanosine 
 Isobutyryl carnitine  
S-aminomethyldihydrolipoamide 
285.1306 
 254.1363 
 254.1355 
 [M+NH4]
+
 
 [M+Na]
+
 
[M+NH4]
+
 
11.05 
  
1.0x10
-3
 3.0x10
-2
 0 
549 Gamma-glutamyltyrosine 311.1238  [M+H]
+
 13.45 1.0x10
-3
 3.0x10
-2
 2 
715 Arginyl-glycine 254.1224  [M+Na]
+
 13.33 2.0x10
-3
 4.0x10
-2
 1 
 
Table 3.8 Tentatively annotated features showing statistically significant differences via univariate analysis 
across patients with varying degrees of psoriatic arthritis for negative mode data. 
Feature 
No. 
Tentative ID m/z Adduct Retention 
time (min) 
P value Q value Annotation 
score (max = 
3) 
4448 
  
  
2-Hydroxydecanedioic acid, 3-
hydroxysebacic acid 
cis-4-Hydroxycyclohexylacetic acid 
217.1077 
  
  
[M-H]
-
 
  
[M+CH3COO]
-
 
11.78 
  
  
1.5x10
-3
 
  
  
3.0x10
-2
  
  
2 
3752 
  
p-Coumaroylagmatine 
Undecanedioic acid 
275.1501 
  
[M-H]
-
 
[M+CH3COO]
-
 
12.15 
  
8.5x10
-4
 
  
3.0x10
-2
  
  
2 
78 
 
1139 3-Hydroxydodecanedioic acid 281.1162 [M+Cl]
-
 14.00 1.9x10
-3
 3.0x10
-2
  2 
3689 Dodecanedioic acid 289.1659 [M+CH3COO]
-
 12.68 2.2x10
-3
 3.0x10
-2
  2 
216 S-aminomethyldihydrolipoamide 295.1163 [M+CH3COO]
-
 13.36 9.3x10
-4
 3.0x10
-2
  0 
2254 1,11-Undecanedicarboxylic acid 303.1818 [M+CH3COO]
-
 13.40 6.4x10
-3
 4.0x10
-2
 2 
2412 Phenylbutyrylglutamine 327.1118 [M+Cl]
-
 13.03 1.9x10
-3
 3.0x10
-2
  2 
2240 Arginyl-Lysine 337.1744 [M+Cl]
-
 12.30 1.4x10
-3
 3.0x10
-2
  2 
2522 6-Keto-PGF1a 429.2488 [M+CH3COO]
-
 18.90 1.5x10
-3
 3.0x10
-2
  2 
2256 
  
  
N1-(alpha-D-ribosyl)-5,6-dimethyl-
benzimidazole 
L-phenylalanyl-l-hydroxyproline 
Prolyl-Tyrosine 
313.0959 
  
  
[M+Cl]
-
 
[M+Cl]
-
 
[M+Cl]
-
 
12.25 
  
  
1.5x10
-3
 
  
  
3.0x10
-2
  
  
  
2 
 
Multivariate analysis of baseline converter and severe PsA patients via O-PLS-DA yielded a model with 
the acceptable criteria of 0.94 (R2) and 0.78 (Q2) in positive mode and 0.94 (R2) and 0.87(Q2) in negative 
mode (data for validation is provided in Online Resource 15). The features with a VIP of >1 that had the 
most significant influence on the model were putatively identified as 3-hydroxytetradecanedioic acid and 
3-hydroxydodecanedioic acid for positive and negative mode, respectively. A list of the other features with 
VIPs of >1, their respective parameters, and their possible biochemical importance for positive and negative 
mode is provided in Table 3.9 and Table 3.10, respectively.  
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Table 3.9 Variables of importance isolated from validated O-PLS-DA model that differentiate baseline converters from severe psoriatic arthritis. 
Data obtained from positive mode acquisition. 
Feature 
No. 
Tentative ID m/z Adduct Retention 
time (min) 
VIP 
score 
Biochemical importance 
8728 3-Hydroxytetradecanedioic acid 275.1854 [M+H]
+
 15.72 30 High levels of 3-Hydroxytetradecanedioic acid (and other 3-
hydroxydicarboxylic acids) were detected in the urine of a patient 
with 3-hydroxydicarboxylic aciduria. 8834 3-Hydroxytetradecanedioic acid 297.1673 [M+Na]
+
 15.70 24 
3800 L-phenylalanine, 3-pyridinebutanoic 
acid 
Pyruvophenone, dihydrocoumarin 
166.0865 [M+H]
+
 
[M+NH4]
+
 
10.85 15 When present in sufficiently high levels, phenylalanine can act as a 
neurotoxin and a metabotoxin. A metabotoxin is an endogenously 
produced metabolite that causes adverse health effects at 
chronically high levels. Chronically high levels of phenylalanine are 
associated with at least five inborn errors of metabolism. 
9905 9,12-Dioxo-dodecanoic acid 229.1437 [M+H]
+
 13.8 8 Di-oxo-dicarboxylic acid. 
10122 Deoxyadenosine 
3-Hydroxydodecanedioic acid 
269.1361 [M+NH4]
+
 
[M+Na]
+
 
13.8 8 When present in sufficiently high levels, deoxyadensoine can act as 
an immunotoxin and a metabotoxin. Chronically high levels of 
deoxyadenosine are associated with adenosine deaminase (ADA) 
deficiency, an inborn error of metabolism. 
9043 3-Hydroxydodecanedioic acid 247.1542 [M+H]
+
 13.8 7 A dicarboxylic acid that appears in the urine of children affected 
with peroxisomal disorders. 
8393 2-Phenylglycine 152.0709 [M+H]
+
 9.1 7 Has a role as a human metabolite and is described in normal human 
urine. 
8434 Ribonic acid, lyxonate, apionic acid, 
arabinonic acid 
184.081 [M+NH4]
+
 13.8 2 Sugar carboxylic acids. 
10328 Biopterin 255.1204 [M+NH4]
+
 12.9 2 Biopterin concentrations in cerebrospinal fluid from patients with 
Parkinson's disease are lower than those from age-matched older 
controls. Lowered levels of urinary biopterin concomitant with 
elevated serum phenylalanine concentration occur in a variant type 
of hyperphenylalaninemia. 
2321 Creatinine 114.0666 [M+H]
+
 3.7 1.4 A breakdown product of creatine phosphate in muscle. 
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2830 L-tyrosine, hydroxy butanoic acid, 
amino(hydroxyphenyl)propanoate, 
hydroxyphenylalanine 
M-coumaric acid, phyenyl pyricin acid 
182.0814 [M+H]
+
 
[M+NH4]
+
 
8.78 1.4 Tyrosine is not found in large concentrations throughout the body, 
likely because it is rapidly metabolized.  Most common is the 
increased amount of tyrosine in the blood of premature infants, 
which is marked by decreased motor activity, lethargy, and poor 
feeding. Hydroxybutyric acid (also known as gamma-
hydroxybutyrate or GHB) is a precursor and a metabolite of gamma-
aminobutyric acid. Hydroxyphenylalanine is an L-phyenylalanine 
derivative. 
8861 3-Hydroxytetradecanedioic acid 292.212 [M+NH4]
+
 15.71 1.2 See feature No. 
1185 Isoleucine 132.1022 [M+H]
+
 8.93 1.1 Branched amino acids have different metabolic routes: leucine 
which is solely involved in fats; and isoleucine which is involved in 
both fats and carbohydrates. 
9590 Indoleacetaaldehyde 177.1025 [M+NH4]
+
 9.4 1 Indoleacetaldehyde participates in a number of enzymatic 
reactions.  In particular, indoleacetaldehyde can be biosynthesized 
from tryptamine, which is mediated by the enzyme kynurenine 3-
monooxygenase. indoleacetaldehyde is involved in tryptophan 
metabolism. 
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Table 3.10 Variables of importance isolated from validated O-PLS-DA model that differentiate baseline converters from severe psoriatic arthritis. 
Data obtained from negative mode acquisition. 
Feature 
No. 
Tentative ID m/z Adduct Retention 
time (min) 
VIP 
score 
Biochemical importance 
1638 3-hydroxydodecanedioic acid 
10-hydroxy-2E-decenoic acid, 2-oxo 
capric acid 
245.1393 [M-H]
-
 
[M+CH3COO]
-
 
14.00 27 3-hydroxydodecanedioic acid is a medium chain hydroxy fatty acid 
that reportedly appears in children affected with peroxisomal 
disorders. PMID: 10896310. 
77 12-amino-dodecanoic acid 274.2027 [M+CH3COO]
-
 15.93 6.8 This is an omega-amino medium chain fatty acid and has a role as a 
bacterial metabolite. (PubChem). 
404 n-heptanoyl acetic acid, 3-caproyl 
propionic acid, 7-methyl-3-oxooctanoic 
acid, 4-n-valeryl butyric acid 
150.0008 [M+CH3COO]
-
 14.13 6.2 Medium chain oxo-monocarboxylic acids. (PubChem). 
1151 2,4-Dideoxy-2-octylpentaric acid 
2R-Hydroxy-10-undecenoic acid, 3-
capryl propionic acid 
259.1552 [M-H]
-
 
[M+CH3COO]
-
 
14.96 3.5 Medium chain hydroxy and “ene”-monocarboxylic acids. 
2478 2-Hydroxydecanedioic acid, 3-hydroxy-
sebacic acid, 2-hydroxy-decanedioic 
acid 
3-Oxovalproic acid, 4-
Hydroxycyclohexylacetic acid, 2-keto-
n-caprylic acid 
217.1076 [M-H]
-
 
[M+CH3COO]
-
 
12.25 2.6 Medium chain hydroxy dicarboxylic acids. (PubChem) 3-
Hydroxysebacic acid is a normal urinary metabolite and can be 
elevated in patients with peroxisomal disorders. 3-Hydroxysebacic 
acid and caprylic acid are found to be associated with medium chain 
acyl-CoA dehydrogenase deficiency, which are inborn errors of 
metabolism. 4-Hydroxycyclohexylacetic acid is a tyrosine metabolite 
that has been found in the urine of a patient with a defect of 4-
hydroxyphenylpyruvate dioxygenase, an inborn error of 
metabolism. (HMDB). 
2692 p-Cresol sulfate 
Thiophenecarboxylic acid 
187.0062 [M-H]
-
 
[M+CH3COO]
-
 
10.23 2.1 p-Cresol sulfate is a microbial metabolite that is found in urine and 
likely derives from secondary metabolism of p-cresol. It appears to be 
elevated in the urine of individuals with progressive multiple sclerosis 
(HMDB). 
2891 Androsterone sulfate 369.1743 [M-H]
-
 15.93 1.3 Androsterone sulfate is clinically recognized as one of the major 
androgen metabolites found in urine. (HMDB). 
651 1,2-Dihexanoyl-sn-glycerol, 6-
hydroxypentadecanedioic acid 
287.1865 [M-H]
-
 
[M+CH3COO]
-
 
16.85 1.1 1,2-Dihexanoyl-sn-glycerol is a hexanoic acid derivative. Majority of 
other tentative compounds are dicarboxylic and carboxylic acid 
derivatives. (PubChem). 
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Keto tridecanoic acid, hydroxy-9-
tridecenoic acid, menthenyl lactate, 7-
methoxy-dodec-4-enoic acid, 6-
hydroxy-4-tridecanolide 
1282 2-Aminoadenosine 341.1223 [M+CH3COO]
-
 14.02 1.1 Purine nucleoside. (PubChem). 
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3.5 Discussion 
3.5.1 Baseline converters vs. baseline non-converters  
One of the objectives of the study was to investigate the characteristic metabolic differences between 
converters and non-converters at baseline as a means of possibly determining early markers of disease 
conversion however, no differences were found to differentiate the two groups contrary to what was 
expected. Given that both sets of patients have psoriasis and neither group is receiving treatments, this could 
suggest a very subtle onset of PsA (this is discussed more in the following section 3.5.2 “Baseline 
converters vs. follow-up converters”), further highlighting the challenges of early prognosis. 
3.5.2 Baseline converters vs. follow-up converters 
Since at baseline, the converter group, according to the results presented herein, are not significantly 
different from baseline non-converters, strictly monitoring the differences between patients with psoriasis 
that eventually develop PsA may be more insightful. It is important to note however, that the follow-up 
samples were collected while patients were receiving treatment. Since these treatments are usually 
implemented to normalize any metabolic disturbances that may occur due to disease pathophysiology, 
thereby essentially preventing disease progression, it follows that no separation would be observed between 
baseline converters and follow-up converters, thus suggesting the effectiveness of the various prescribed 
treatments.  
Another possible reason for the lack of differentiation between the baseline converters and their follow-up 
samples may be that the follow-up converters had only developed PsA relatively recently (less than 1 year 
– Table 3.4). As such, it is possible that allowing a longer time period before conducting sampling post 
conversion may enable the identification of metabolites indicative of disease conversion. However, 
according to Figure 3.2 and Figure 3.5, the study demonstrates consistency by essentially validating itself, 
as the follow-up converters (green), who are different from patients with mild PsA (blue), do not exhibit 
separation. Since the follow-up converters only had mild PsA, the lack of discrimination between them and 
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the mild PsA patients is therefore logical, suggesting that patients within these two groups may in fact be 
similar. Table 3.4 shows the similarities between the two groups. Furthermore, there is evidence 
contradicting the above notion that a longer wait time prior to sample collection post conversion will not 
yield more valuable information, as disease duration among mild PsA patients ranged from less than a year 
to 16 years.  
The lack of discrimination between the samples collected before and after conversion and between the 
baseline converters and non-converters may also indicate a small effect size (very subtle changes) for both 
between-group comparisons. As such, it may be necessary to analyze a very large number of samples from 
each group before distinctive differences can be observed. Indeed, as a post hoc power analysis revealed 
(data not shown) that, over 1000 serum samples would be required before any statistically significant 
differences (power ≥ 0.8) would be observable in the before and after conversion samples, as well as in the 
baseline samples for the converters and non-converters. It is therefore possible that the metabolic changes 
related to conversion are perhaps too subtle and/or become diluted due to blood circulation, which would 
potentially make serum an ineffective biological fluid for detecting and identifying markers specific to 
conversion. 
3.5.3 Healthy controls vs. psoriasis without psoriatic arthritis vs psoriatic arthritis 
No discrimination was found among patients with psoriasis, mild PsA, and healthy controls. This result was 
interesting given the number of metabolomic studies demonstrating visual differences between patients 
with psoriasis and healthy individuals. Nonetheless, this result is consistent with the patient information 
provided in Table 3.3 and Table 3.4, which shows that the majority of baseline converters and mild PsA 
patients had a PASI score of < 10, indicating mild psoriasis. As such, it follows that no discrimination can 
be discerned amongst these three groups. This is consistent with the results of Li et al.’s analysis of serum 
samples from psoriasis vulgaris patients with varying degrees of psoriasis severity wherein patients with 
mild psoriasis were similar to the controls and significantly different from patients with severe psoriasis.99 
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3.5.4 PsC vs PsA 
Since it is abundantly clear from Figure 3.2 and Figure 3.6  that the PsA group dominates the PCA plot, 
this result may suggest that the conversion pathophysiology from PsC to PsA is driven by PsA severity.  
3.5.5 PsA group—Confounding factors 
Considering the patient information described in Table 3.5, and based on the results shown in Figure 3.7, it 
is clear that neither the duration of psoriasis prior to developing PsA nor the duration of PsA is a predictor 
of disease conversion or disease severity, respectively. While psoriasis is related to a number of associated 
comorbidities, such as cardiovascular disease, obesity, insulin resistance, and metabolic syndrome, and the 
observed patients may be at a risk of other age-related degeneracies ( ≥ 40 years old), the differentiating 
pattern on the plot appears to be independent of these factors rather than confounded by them, since all 
three groups contain patients with and without a range of comorbidities. Additionally, disease severity 
appears to be independent of sex or age.  
3.5.6 PsA group—Severity related to joint information 
As demonstrated in Table 3.6, disease severity appears to be correlated with biochemical parameters 
associated with joints, such as number of swollen joints, number of tender joints, and number of damaged 
joints. In particular, disease severity appears to be directly related to the number of damaged joints. 
3.5.7 PsA group—Cluster deviants 
It is worth noting that one or two patients from each group were removed from statistical analysis due to 
being outliers. Conversely, some patients fell outside the majority of their cluster but were not removed 
because they did not statistically classify as outliers. For example, two patients with mild PsA (green) and 
two patients with moderate PsA (dark blue) are located on the extreme right side of the plot with the severe 
PsA patients (pink), while three moderate PsA patients (dark blue) are located on the left side of the plot 
with the majority of the mild PsA patients (green) and controls (red). These inconsistent patterns suggest 
that the current clinical methods being used to evaluate PsA disease severity may not be accurate, thus 
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highlighting the need to use metabolic markers as a complementary source of information in diagnosis. It 
is possible that these above-noted outlier patients may be able to provide more information or a better 
indication as to the pathophysiology of PsA. Interestingly, while some of these deviations seem to correlate 
more closely with patient joint information (provided in Table 3.6), some do not. This discrepancy further 
emphasizes the challenges of disease categorization, even with very stringent phenotyping protocols. 
3.5.8 Statistically significant features across patient groups 
Prior metabolomics studies have found that some of these putatively identified compounds, such as 1,11-
undecanedicarboxylic acid, tend to be common in individuals suffering from peroxisomal disorders.103 
Other tentatively identified compounds annotated from both the positive and negative mode data, such as 
S-aminomethyldihydrolipoamide, have been associated with the serine and threonine metabolism 
pathways. In particular, Kamleh et al. 100 discovered that these pathways are affected in psoriatic patients, 
which results in higher serine and threonine levels when compared to healthy individuals. All putatively 
identified compounds were found to increase in relation to disease severity, with mild PsA patients 
exhibiting the lowest levels, moderate PsA patients exhibiting much higher levels, and severe PsA patients 
exhibiting the highest levels of the three groups. An example of this relationship is demonstrated Figure 
3.8.  
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Figure 3.8 The box plots on the left are representative of a statistically significant feature across the PsA 
group – m/z 289.2 (exact m/z: 289.1659) at a retention time 761 seconds (12.68 min). On the right is the 
extracted ion chromatogram of that feature. This was tentatively identified as dodecanedioic acid, and 
putatively identified as such with an annotation score of 2 using xMSAnnotator. 
 
Elevated levels of 3-hydroxytetradecanedioic acid have been implicated in the inhibition of CoA, which is 
an enzyme involved in fatty acid biosynthesis. Moreover, 3-hydroxydodecanedioic acid has also been 
linked to inhibited fatty acid oxidation 115–117. Interestingly, the majority of the other VIPs, especially those 
from negative mode analysis, were tentatively identified as various dicarboxylic and carboxylic acid 
derivatives (i.e. 3-hydroxysebacic acid implicated as a result of fatty acid beta-oxidation defects 118), thus 
indicating a potentially strong correlation between the dysregulation of the fatty acid or lipidome profile 
and disease conversion. However, further investigation is required to confirm these findings due to the 
challenges associated with correlating circulating organic acids with specific metabolic processes. For 
examples, elevated levels on their own may represent a non-specific response, while ratios of various kinds 
of organic acids may indeed be more informative 117.  
3.6 Conclusion and future direction for research 
This paper demonstrates that the use of rapid-sampling TF-SPME for untargeted metabolomics of serum is 
a feasible method for assessing disease pathophysiology via PsA severity. The heterogeneity of the patient 
data presented herein (i.e., the large ranges in age, duration of psoriasis, duration of PsA, sex imbalances 
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in some cases, range of treatments, and comorbidities) and the relatively small sample sizes (n = 10 for 
each group) made it difficult to exclude samples for the purpose of producing more uniform data sets, which 
are customary for statistical comparisons of patient groups in clinical applications. Nevertheless, the 
findings were interesting, as they showed no apparent trends or influence of potential confounding factors 
(comorbidities) of the patients’ biochemical parameters on the patterns observed via multivariate analysis. 
The aim of this study was to determine biomarkers of the conversion from psoriasis to PsA, biomarkers 
differentiating PsA from PsC, and biomarkers of PsA severity. Based on the data presented herein, it is 
apparent that dysregulated fatty acid enzymes related to synthesis or degradation of various fatty acids, is 
strongly associated with PsA severity as many of these features differentiated baseline converters (PsC) 
from severe PsA with elevated levels in the latter. This pattern is also more evident for PsA pathology given 
the increasing levels of important fatty-acid-related features across the PsA group with the lowest levels in 
mild PsA and the highest levels in severe PsA. Futhermore, there are at least 20 statistically significant 
features associated with PsA severity, while there are no statistically significant features that differentiate 
between patients with psoriasis prior to and post conversion. This finding suggests that, while serum may 
be useful for finding markers of PsA severity, the differences in terms of PsA conversion from psoriasis 
may be too subtle to generate a significant effect. Therefore, we propose the use of synovial fluid for future 
metabolic analyses. As the joint fluid found closest to the origin of PsA disease manifestation, synovial 
fluid can likely provide a better indication of discriminating metabolic biomarkers, specifically for 
conversion. Since collection of synovial fluid may be quite difficult, it would be beneficial to develop a 
protocol for in vivo SPME sampling, as this would provide a minimally invasive approach for obtaining 
potentially more useful biological material directly from the source, while avoiding removal/collection from 
the patient. Furthermore, an in vivo SPME technique would enable sampling and sample preparation to be 
combined into one step, which would drastically minimize the number of analytical steps required to obtain 
the final extract, thereby preserving the initial integrity of the true metabolome. Finally, while this 
preliminary data provides a good direction for future directions of the research, due to the relatively small 
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sample sizes used, we suggest that a more expansive follow-up study be conducted to confirm the findings. 
This expanded study should increase the number of patients examined, utilize parallel in vivo skin-lesion 
analysis, synovial fluid analysis and include fatty acid profiling and/or lipidome fingerprinting, and more 
in-depth and rigorous MS/MS validation, as these steps would provide a more supplemented and 
comprehensive approach to metabolomics for PsA research. 
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Chapter 4: Metabolomic fingerprinting of porcine lung tissue 
during pre-clinical prolonged normothermic ex vivo lung perfusion 
(NEVLP) using in vivo solid phase microextraction 
4.1 Preamble 
Chapter 4 of this thesis has not yet been published. The work presented in this chapter of the thesis stemmed 
from a collaboration with Toronto General Hospital initated by B. Bojko, J. Pawlisyzn, A. Roszkowska, 
and M. Cypel who were also responsible for the initial experimental design. Further modifications to the 
experimental design and all other work presented in this chapter of the thesis were equally shared between 
the author of this thesis and A. Roszkowska. Please see Statement of contributions. This work was funded 
by the Canadian Institute of Health Research (CIHR) - Natural Sciences and Engineering Research Council 
(NSERC) of Canada Collaborative Health Research Projects program [grant 355935 entitled “Supervised 
in vivo lung perfusion strategy for treatment of cancer metastases to the lungs. Real-time monitoring of 
chemotherapy by on-site analytical platform”] and the Natural Sciences and Engineering Research Council 
of Canada Industrial Research Chair (IRC) program. 
4.2 Introduction 
Lung transplantation remains the single most effective form of treatment for patients suffering from end-
stage pulmonary diseases, such as terminal metastatic lung cancer, chronic obstructive pulmonary diseases 
(COPD), emphysema and cystic fibrosis.119–121 Unfortunately, the number of patients awaiting 
transplantation far exceeds the pool of available donor organs. This shortage of donor organs is exacerbated 
by the fact that only 20% meet the strict criteria for transplantation, largely due to the various intensive care 
unit (ICU) related complications that can occur in both donation after brain death (DBD) and donation after 
cardiac death (DCD) donors, including gastric aspiration, bacterial infection, and longer warm ischemic 
times, among others. Furthermore, 20% of transplanted lungs experience acute lung injury and/or primary 
graft dysfunction, which are both signs of early rejection and eventual patient mortality.119,121  
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Normothermic ex vivo lung perfusion (NEVLP or EVLP) is a modernized organ preservation technique 
wherein perfusion fluid is circulated throughout the isolated lung at physiological temperature via a 
specialized circuit set up. This method improves the function of marginalized lungs (lungs that had multiple 
different injuries and were thus declined for transplantation) by enabling the innate protective metabolic 
processes that occur under normothermic conditions.121–123 Additionally, NEVLP allows specific 
appropriate targeted therapies to be administered within the circuit via the perfusion fluid in order to treat 
the above-noted ICU-related complications or other donor-borne illnesses prior to transplantation.121,124 
Moreover, NEVLP also allows for more detailed assessments of organ function prior to 
transplantation.122,123,125 These advantages have been instrumental in increasing the donor pool, thereby 
decreasing patient waiting list morbidity and mortality. While a number of “omics” studies—including 
genomics, transcriptomics, epigenomics, and proteomics126,127—have explored the pathophysiology of 
these end-stage lung diseases, specifically the differences between COPD’s, while other “omics” studies, 
particularly metabolomics, have been employed to assess the effectiveness of the NEVLP approach itself.120 
Metabolomics is an emerging field in systems biology that is able to assess and elucidate the biochemical 
status of an organism through the analysis of small endogenous molecules (metabolites) at a certain period 
of time.128 Since changes in small metabolites are a more rapid indicator of an immediate system response, 
the use of metabolomics may potentially be more advantageous than genomics or proteomics in determining 
markers of improved lung function or markers of potential graft dysfunction that may emerge over the 
course of NEVLP.  
Previous research has shown that the evaluation of perfusate (SteenTM solution) collected periodically 
during the NEVLP procedure can provide biomarkers of improved lung function.120 Although perfusate 
analysis has been shown to be useful, it is possible to obtain even more information via direct tissue analysis. 
However, tissue analysis can be impractical due to the complexities associated with organ heterogeneity, 
the need for various laborious tissue homogenization techniques and the regular collection of biopsies, 
usually via invasive procedures. Accordingly, this approach is often avoided. In order to overcome the 
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limitations of typical tissue analysis workflows, in vivo solid phase microextraction (SPME) is evaluated 
herein as a non-exhaustive, minimally invasive alternative sample preparation technique for use in 
metabolomics analyses of lung tissue during NEVLP. The device’s simplicity and size—a coated needle 
measuring 240 µm in diameter—allows for repeated insertions into the tissue during the time course of the 
procedure, thereby eliminating the need for multiple tissue biopsies. The use of SPME has previously been 
reported in various bioanalytical and clinical applications, including tissue sampling and tissue 
metabolomics applications56,129–131 ranging from the in vivo sampling and quantitation of pharmaceuticals 
in live fish muscle129 to the in vivo metabolomic fingerprinting of brain tissue in living and moving rats 
subject to deep brain stimulation.132 In addition, prior research has also investigated the effectiveness of 
various coatings for the non-specific global extraction of metabolites, with findings showing that 
hydrophilic-lipophilic balanced (HLB) coatings are able to provide excellent recovery for a wide range of 
analytes (more polar as well as non-polar molecules).57 Thus, SPME is suitable for metabolomics, as the 
device’s biocompatible coating and extraction phase type, allows for the exclusive extraction of small 
molecules—both hydrophobic and hydrophilic compounds, including lipids, fatty acids, amino acids and 
other endogenous or exogenous molecules—directly from live complex biological matrices, such as lung 
tissue, without significantly interfering with the biochemical transformations of the system under study, or 
adversely affecting the system itself or the sampling device.133 
In the present study, HLB-coated SPME fibers were used to sample porcine lung tissue in vivo during pre-
clinical prolonged NEVLP in order to identify potential metabolic markers of lung function, markers of 
primary graft dysfunction, and/or markers of general organ stress, as well as to monitor other ways in which 
the lung may have changed during the procedure. The perfusate was also sampled extensively using two 
types of SPME devices: SPME HLB fibers and HLB thin-film microextraction (TFME). Perfusate was 
collected periodically during NEVLP and split into three portions: portion one was sampled on-site during 
NEVLP using SPME HLB fibers that were similar to those used to sample the lung tissue; portion two was 
snap frozen in dry ice, transported and stored at –80 °C until later sampling in the lab with SPME HLB 
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fibers; and portion three was snap frozen and stored under the same conditions as portion two until later 
sampling in the lab with the HLB TFME device. The perfusate samples were processed in this way in order 
to: 1) evaluate the differences in the information obtained from the tissue and parallel perfusion fluid 
samples; 2) investigate the changes in the perfusate samples and compare them to the metabolic results 
reported in prior biomarker studies; 3) assess whether metabolic changes had occurred due to the sample 
storage procedure, which was consistent with that used in a typical metabolomics workflow (i.e., collecting 
and storing samples for analysis at a later date); and 4) evaluate the analytical differences between the two 
types of SPME devices. This multilevel approach will provide insight into whether lung tissue or perfusate 
samples are sufficient on their own for providing pertinent metabolic information, or whether it is more 
advantageous to employ a complementary approach that uses both types of samples simultaneously. 
Furthermore, few studies have reported on metabolome stability under the typical storage conditions used 
in metabolomics. This study may help in developing and implementing improved strategies for preserving 
and storing samples for metabolomics processing at a later time. Finally, this study explores whether using 
both types of SPME devices in conjunction with one another during on-site sample collection may be 
optimal for obtaining maximum information—for example, using SPME fibers for in vivo metabolomics 
and TFME for ex vivo on-site perfusate analysis. 
4.3 Materials and Methods 
4.3.1 Animals and research ethical approval 
The Animal Care Committee at the Toronto General Hospital Research Institute approved the experimental 
protocol used for male Yorkshire domestic pigs.  Full ethics approval was received through the University 
Health Network (UHN) Research Ethics Board and the University of Waterloo Office of Research Ethics. 
4.3.2 Normothermic ex vivo lung perfusion (NEVLP) strategy 
A more detailed outline of the NEVLP procedure is provided elsewhere 123. In this study, the heart of a male 
Yorkshire domestic pig was initially excised from the heart-lung block at the left atrium post explantation. 
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After the left atrial (LA) appendage and the pulmonary artery (PA) had been cannulated, the lungs were 
transferred to the XVIVOTM chamber (Vitrolife, Denver, CO) and connected to the EVLP circuit, which 
consisted of a centrifugal pump that was responsible for circulating perfusate (SteenTM solution, Vitrolife) 
through the circuit. The perfusate first passed through a membrane gas exchanger that was connected to a 
heater-exchanger, wherein it was de-oxygenated and warmed to normothermic conditions over scheduled 
time intervals. Once the perfusion fluid had reached normothermic conditions, it was passed through a 
leukocyte filter and then into the lungs—which were ventilated using an ICU type ventilator—via the PA. 
After passing through the lungs, the perfusion fluid exited via the LA into a hard-shell reservoir adjusted at 
a specific height to maintain the appropriate pressures. While 4 hours is the usual length of time for NEVLP, 
a prolonged schedule requiring a total of 19 hours of perfusion was employed during these experiments to 
assess lung sustainability for gene therapy.  
4.3.3 Chemicals and materials 
The nitinol wires used as SPME fiber supports were purchased from Confluent (Palo Alto, USA), while the 
stainless-steel combs used for thin-film microextraction (TFME) were purchased from PAS Technologies 
(Magdala, Germany). Oasis hydrophilic-lipophilic balance (HLB) 5 µm particles were kindly provided by 
Waters Corporation, and 45-60 µm HLB particles were obtained from SPE cartridges purchased from 
Millipore Sigma (Burlington, USA). LC-MS-grade acetonitrile, methanol, and water were purchased from 
Millipore Sigma, as were the additives, formic acid and acetic acid, and other chemicals, including 
polyacrylonitrile (PAN), N,N-dimethylformamide (DMF), and hydrochloric acid. A flask-type sprayer was 
also purchased from Millipore Sigma. 
4.3.4 SPME fiber coating methodology 
Nitinol wires were measured and cut to 4 cm in length. The dip-coating procedure was carried out using a 
specialized software-operated dip-coating machine that had been developed in-laboratory, and was 
consistent with the protocol reported by Gomez-Rios et al. 134. Briefly, the protocol used in this study 
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consisted of the following steps: first, a slurry of 10% w/v of 5 µm HLB particles suspended in 7% PAN 
was prepared; next, the fibers were dipped in the slurry to the desired length and then cured for 1 minute at 
125 °C; finally, the dipping/curing process was repeated until the final fiber coating dimensions measured 
15 mm in length and 40 µm in thickness. 
4.3.5 TFME blade coating methodology 
Thin-film microextraction devices were prepared according to a well-established spray coating method 
developed in-laboratory and reported by Mirnaghi et al..80 First, the stainless-steel blades were etched for 
1 hour in concentrated hydrochloric acid and then thoroughly rinsed in deionized water. After rinsing, the 
blades were dried in an oven for 45 minutes. Next, a slurry consisting of 10% w/v 45-60 µm HLB particles 
with 25% v/v DMF in PAN solution (7%) was prepared and mixed thoroughly in a flask-type sprayer. The 
slurry was then sprayed onto each stainless-steel comb individually using a maximum flow of nitrogen gas. 
After both sides of the comb had been coated, it was cured for 1 minute at 150 °C. The final TFME coating 
measured 1 cm in length and 0.5 mm in thickness. 
4.3.6 Lung and perfusate sampling with SPME fiber 
The overall experimental design is graphically represented in Figure 4.1. The 15 mm HLB-coated fibers 
were initially sterilized/preconditioned in 50:50 methanol/water for at least 30 minutes under static 
conditions before being exposed to the lung tissue. Once this preconditioning step had been completed, the 
fibers were inserted into the left lung in triplicate for an extraction time of 30 minutes. The fibers were then 
removed from the lung, rinsed manually in water for 5 s, and wiped with a kim-wipe to remove any loosely 
adhered biological fragments. Next, the fibers were placed in empty 300 µl vials and immediately snap 
frozen in dry ice for transportation to the laboratory where they were desorbed in 137.5 µL of 40:30:30 
v/v/v methanol/acetonitrile/water. Water was then added to the extracts to obtain a 50:50 aqueous/organic 
ratio, as this ratio would be more amenable to the initial chromatographic conditions. A total of 2 pigs 
underwent lung sampling during NEVLP. 
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Figure 4.1 Graphical representation of overall experimental design. The SPME sampling protocol is demonstrated in 
the center under “SPME sampling protocol” whereby steps B), C) and D) represent the rinsing, wipe with Kimwipe 
and dry ice storage after in vivo SPME lung sampling events or on-site extraction of perfusate. Perfusate samples 
were split into three portions: the first portion was sampled on-site using SPME fibers (in parallel with lung sampling 
events); the second portion (collected during lung sampling events) was stored in dry ice and transported to the lab 
for in-laboratory sampling with SPME fibers; the third portion (collected hourly) was stored in dry ice and transported 
to the lab for in-laboratory sampling with TFME. 
 
Lung sampling was performed during cold ischemia (CIT) before the start of NEVLP, and at 1 hr, 3 hr, 5 
hr, 8 hr, 11 hr, 12hr and 13 hr after the start of NEVLP (denoted by blue stars in Figure 4.2B). In addition, 
perfusate samples were collected hourly by clinicians and separated into three portions for analysis. The 
first portion (1500 µL) was sampled on-site (in-hospital) in triplicate (3-300 µL portions) for 30 minutes 
under static conditions using the SPME fibers and the above-described protocol for rinsing, storage, and 
desorption. On-site SPME fiber sampling was only performed using perfusate samples that were acquired 
at the same time the lung sampling was taking place. The second portion (1500 µL) was snap frozen in dry 
ice for transportation to the laboratory. These samples were later prepared using SPME fibers, at the same 
volume (300 µL) as used in-hospital in triplicate and using the same sampling protocol as described earlier 
in this section. Only perfusate samples obtained during lung sampling were used for the in-laboratory 
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extractions with the SPME fibers. TFME was used to perform extractions on the third portion of perfusate 
samples. This process is described in more detail in section 4.3.7 “Perfusate sampling with TFME”. 
 
Figure 4.2 Prolonged normothermic ex vivo lung perfusion (NEVLP/ EVLP) conducted over 19 hours. A) Perfusate 
sampling schedule during NEVLP for samples prepared using thin-film microextraction (TFME). Perfusate samples 
were collected hourly for 7 pig lungs, with red stars denoting samples that were used for further analysis. The samples 
prepared via TFME were collected at 1h, 3h, 4h, 6h, 9h, 11 h, 13h 15h, 16h, 18 h, and 19h after the start of NEVLP; 
the organ had been pronounced non-viable by the last two sampling points. Time 1 to Time 5 illustrate the 3-to-4 hour 
blocking strategy used to group the collected samples for data processing. B) Lung sampling schedule during NEVLP. 
SPME fiber lung sampling were conducted for 2 pig lungs. The blue stars denote the time points at which SPME fiber 
lung sampling events took place. Lung were sampled before the start of EVLP and at 1h, 3h, 5h, 8h, 11 h, 12h and 
13h after the start of NEVLP. 
 
4.3.7 Perfusate sampling with TFME 
Perfusate samples were collected by clinicians hourly during the 19-hour EVLP procedure and immediately 
snap frozen in liquid nitrogen as per institutional practice at Toronto General Hospital. These samples, 
which were later transported to the laboratory in dry ice, constituted the third portion of perfusate samples. 
From the 19 perfusate samples collected per animal (7 animals in total), a few samples at specific time 
points (denoted by red stars in Figure 4.2A) were selected from each case for further analysis, with 550 µL 
of each selected sample being placed into a 96-well plate. Prior to performing the extractions, the TFME 
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brush device, which is compatible with 96-well plates, was preconditioned for 30 minutes in 50:50 v/v 
methanol/water at 1500 rpm followed by a quick 10 s rinse in water at 1500 rpm. After preconditioning, 
the TFME brush device was inserted into the samples for 30 minutes at 1500 rpm and a temperature of 25 
°C. The blades were then rinsed in water for 10 s at 1500 rpm and desorbed in 550 µL of 40:30:30 v/v/v 
methanol/acetonitrile/water for 1 hour at 1500 rpm. A Concept-96 autosampler (PAS technologies) was 
used to automate the above-described SPME sample preparation process. This method was used to perform 
extractions from perfusate samples obtained from a total of 7 pigs subjected to NEVLP. 
4.3.8 Instrumental analysis 
Analysis of the extracts obtained from the lung and perfusate samples was conducted via liquid 
chromatography (LC) coupled to high-resolution mass spectrometry (HRMS). Chromatographic separation 
was achieved on a 10 cm x 2.1 mm (5 µm particle size) Discovery HS F5-3 (PFP) column, which was 
protected by a 2 cm x 2.1 mm (3 µm particle size) guard column (Millipore Sigma). A 40-minute gradient 
elution was employed using a Thermo Fisher Scientific Accela binary pump and autosampler. Mobile phase 
A consisted of water, while mobile phase B consisted of acetonitrile. For positive and negative mode 
polarity, 0.1% formic acid or 1mM acetic acid were added, respectively. A Thermo Fisher Scientific 
Exactive mass spectrometer equipped with an Ion Max heated electrospray ionization (HESI II) source was 
used to perform acquisition in high resolution (50, 000) mode, with a balanced automatic gain control 
(AGC), an injection time of 100 ms, and a scan range of 100 – 1000 m/z.  
A pooled quality control (pooled QC) was prepared for each set of samples (fibers vs TFME) by pooling 
10 µL of each sample in a single vial. These pooled QCs were injected every 10 samples to ensure 
instrumental stability for the duration of the acquisition process. Samples were run completely randomly 
for both sets of data to avoid confounding the resulting data with any instrumental variation.  
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4.3.9 Data pre-processing 
The raw LC-MS data files were first converted into mzXML files via MSConvert106 before being pre-
processed using the XCMS software package107 in RStudio with an in-laboratory developed script.108 The 
IPO package109 used the pooled QC samples to optimize the data pre-processing parameters used to perform 
peak alignment, retention time correction, normalization, peak filling, and peak picking. The paired mass 
difference (PMD) function was also employed to reduce the number of redundant features that might be 
investigated.135 This function was used in combination with other filtering methods to remove features with: 
a) low spray stability or high variation in the pooled QCs (features in the pooled QCs with RSDs > 30% 
were eliminated); b) signal intensities that were similar to those of the blank fibers and blank blades 
(features with a pooled QC:blank fiber/blank blade ratio of < 5 were eliminated); c) a similar signal intensity 
to the blank solvent (features with a pooled QC:blank solvent ratio of < 5 were eliminated); and d) a similar 
signal intensity to the pure steen solution (features with a pooled QC:steen solution ratio at a baseline of < 
5 were eliminated). These filtering methods substantially reduced the total number of features included in 
subsequent chemometric analyses, thereby improving data manageability and mitigating potential artefacts. 
The extracted peaks were annotated using the xMSannotator Integrative Scoring Algorithm in conjunction 
with the human metabolome database (HMDB).110 For metabolite profiling, unique and multiple features 
with medium-to-high confidence annotations were selected. xMSannotator annotated these features based 
on their intensity profiles, retention times, mass defect, and the isotope/adduct patterns of their peaks. For 
high-confidence matches, the following requirements are satisfied: a non-zero score for database matching, 
user specified required adducts are present (i.e. M+H or M-H for positive and negative modes respectively), 
N, O, P, S/C ratio checks, hydrogen/carbon ratio check, abundance ratio checks for isotopes, multimers, 
and multiply charged adducts. For medium-confidence matches, pathway level correlation is satisfied. 
4.3.10 Data pre-treatment, data processing and model validation 
Metaboanalyst was the sole platform used to perform a range of multivariate and univariate statistical 
analysis after pareto scaling. The original unbiased structure of the data was analyzed using principal 
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component analysis (PCA) in order to evaluate the stability of the instrumental acquisition via the pooled 
QCs, and to assess true patterns in the data structure that could be further investigated via other supervised 
multivariate methods. Orthogonal Projections onto Latent Structures Discriminant Analysis (OPLS-DA) 
was used to further compare two groups in order to identify features of differentiation, while Partial Least 
Squares Discriminant Analysis was used to identify features of discrimination among three or more groups. 
Given that the obtained data had a high degree of dimensionality—that is, the number of features was 
substantially larger than the number of samples—cross validation techniques were used to confirm model 
reliability, as well as the stability of the features the model deemed to be important. To this end, quality 
parameters such as goodness of fit (R2) and predictability (Q2) were assessed. Cross validation is 
particularly important for supervised methods, as it ensures that separation between groups is based on 
significant differences as opposed to noise, which is a common pitfall of these techniques. Methods such 
as Leave One Out Cross Validation (LOOCV), k-fold cross validation, and permutation testing were 
performed within their respective limitations with respect to the sample size. A t-test was used to perform 
univariate analysis of changes in individual features between two time groups, while a non-parametric 
analysis of variance (ANOVA), a Kruskal Wallis test, was used to examine these changes among three or 
more time groups. In addition, parametric and non-parametric univariate analyses were employed based on 
the limitations of the sample or the feature size using a false-discovery-rate adjusted p-value of 0.05. Since 
the selection of the appropriate method was based on the distribution of the data being investigated, non-
parametric analysis was used most often, as no assumptions were made with respect to the data being 
normally distributed. Finally, heat maps were also used to visualize the data in order to find dysregulated 
features across the groups. This approach was generally employed in the event of a failed cross-validated 
model or when statistically insignificant features were deemed to be of interest. 
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4.4 Results  
4.4.1 Rationale and data analysis 
A total of 2 pigs underwent lung sampling whereby for the first pig, the lung was sampled in triplicate at 
all time points, while for the second pig, lung was only sampled during the first two sampling points (CIT 
and NEVLP at 1 hr) and at the end of NEVLP (NEVLP at 12 hr). While a total of 19 hours was the 
predetermined NEVLP schedule, at 12 hr, the lung was pronounced non-viable. The relative lack of lung 
sampling for the second pig, as well as the lack of total animals for this aspect of the study (lung sampling 
with SPME fibers), was due to unexplained and extensive lung damage sustained during NEVLP and other 
unforeseen surgical and research circumstances. However, a total of 7 NEVLP cases were used for perfusate 
sampling with TFME. 
The lung samples from both pig cases were grouped based on the time point at which they were collected 
during NEVLP. For example, samples collected during cold ischemic time for both pig 1 and pig 2 (CIT) 
were assigned to one time group, while samples collected in the first hour of NEVLP—NEVLP at 1hr 
(EVLP t0 as outlined in Figure 4.2B)—were assigned to a separate time group, and so forth. See Figure 
4.2B for further details on the grouping of lung samples collected via SPME fibers. Many of the SPME 
fiber time groups only contained a small number of samples (3-6 samples, 3 technical replicates, 2 
biological replicates) since the number of lungs sampled with these devices was small (2 cases), and the 
number of lungs sampled to the completion of the NEVLP procedure was even smaller (1 case). This is an 
unfavorable statistical circumstance and limitation of the study. 
Although perfusate samples were collected on an hourly basis throughout the 19-hour NEVLP process for 
7 pigs, they were ultimately processed in blocks/groups of 3 hours due to the preliminary nature of the 
study, and for sake of practicality with regards to instrumental analysis. Grouping perfusate samples in 3-
hour time blocks was advantageous because it would be easier to validate potentially important features, as 
these features would be persistently present in the lung during NEVLP. As such, each group contained 
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samples that were obtained within a 3-hour time block. For example, group 1, otherwise referred to as Time 
1 in Figure 4.2A, contained perfusate samples from 7 cases that were collected within 1-3 hours after the 
start of NEVLP. See Figure 4.2 for further details on groupings for perfusate samples. While this data 
processing design limits the capturing of possibly important short-lived species, this compromise was 
implemented for improved data manageability. 
The study design also allowed for the analysis of overall metabolite stability and sample storage by enabling 
a comparison of samples collected and sampled on-site and those that were transported back to the 
laboratory for further analysis. The perfusate samples collected during lung sampling were essential for this 
analysis, as a portion of these samples were collected and sampled on-site, while another portion was 
transported back to the laboratory for sampling. 
4.4.2 Unsupervised multivariate analysis 
The Principal Component Analysis (PCA) in Figure 4.3 shows that the pooled QCs for both sets of analyses 
are clustered tightly on the respective plots. While the pooled QCs for the perfusate samples (Figure 4.3A, 
shown in red) are located in the middle of the time groups—which is the most common trend observed for 
these types of analyses—the pooled QCs for the lung samples (Figure 4.3B, black dots) are closer to a 
particular time group. This clustering behavior may be the result of some features (metabolites) from this 
time group exerting a greater influence on the overall variation of the data, possibly due to a higher or lower 
relative abundance of certain features in comparison to other groups. Nevertheless, tight clustering of the 
pooled QCs implies instrumental stability throughout data acquisition, which means that the plot captures 
true and reliable patterns in the data structure. PCA also revealed similar patterns of distinct transitions 
from the initial time groups through to the final time group at the end of NEVLP for both perfusate (Figure 
4.3A) and lung samples (Figure 4.3B). As can be seen in Figure 4.3A Figure 4.3B, the biggest differences 
occur between the initial and final time groups, while time groups directly preceding or following one 
another exhibit some graphical overlap.  
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Figure 4.3 Principal Component Analysis (PCA). A) PCA (PC1: 38.1%; PC2: 25.1%) of the perfusate samples 
collected during NEVLP and prepared via TFME. Samples grouped by Time 1, Time 2, Time 3, Time 4, and Time 5 
are represented by green, blue, turquoise, pink, and yellow, respectively. Each time point is comprised of a progressive 
3-hour time block throughout the NEVLP process. B) PCA (PC1: 70.7%, PC2:15.2%) of the lung sampling events 
with the SPME fibers. The seven time groups—cold ischemic time (CIT), EVLP t0, EVLP t1, EVLP t2, EVLP t3, EVLP 
t5 and EVLP t6—are represented by red, green, blue, turquoise, pink, yellow, and gray, respectively. Each time point 
represents lung samples collected prior to the start of NEVLP, and 1h, 3h, 5h, 8h, 11h, 12h, and 13 h after the start of 
NEVLP. The pooled QCs are represented by red and black on the plot for the perfusate and lung samples, respectively. 
 
Interestingly, for both sample types, the differences between groups becomes less discrete after Time Group 
3. Time Group 3 is denoted by EVLP T2 for lung samples (Figure 4.3B) and Time 3 for perfusate samples 
(Figure 4.3A), which correspond to 5 and 12 hours after the start of perfusion, respectively (Figure 4.2). 
Furthermore, the 7-hour difference in the onset of this apparent equilibrium between lung and perfusate 
samples may indicate that tissue sampling provides more accurate insight into when certain changes start 
to manifest in the organ. This 7-hour time lag can be explained by differences in the processes by which 
metabolites are diffused from the lung to the bulk of the perfusion fluid and from the lung directly to the 
SPME fiber exposed in the tissue. 
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The overlap between the Time 4 and Time 5 clusters for perfusate samples suggests that additional hours 
of perfusion may neither improve nor deteriorate the state of the organ after a certain point; that is, after a 
certain point, it appears as though the rate of change reaches a maximum and an equilibrium is established. 
In general, the decrease in intergroup variation from the initial time group to the last also suggests that all 
pig lungs, regardless of their initial states—as evidenced by the larger intergroup variation in Time 1 for 
perfusate samples—undergo the same distinct changes.  
4.4.3 Supervised multivariate analysis 
Partial least squares discriminant analysis (PLS-DA) was used for both sets of data in order to identify 
statistically relevant discriminatory features from the initial NEVLP conditions through to the final 
conditions. Permutation cross validation (CV) was used to validate the PLS-DA models. Permutation CV 
aims to validate the model by systematically randomly assigning the known class labels to different random 
samples and comparing the separation generated with the randomly assigned classification with the original 
data classification. Both PLS-DA models (perfusate sampled with TFME and lungs sampled with SPME 
fibers) passed permutation CV (2000/1000 permutations for perfusate and lung respectively), yielding 
significant (p < 0.05) quality parameters for the original models (Figure 4.4A and Figure 4.4B for perfusate 
and lung samples, respectively). This means that the observed statistics for the original data classifiers 
(groups) produced significant separation compared to the distribution of the permuted data sets. The PLS-
DA model for the perfusate samples yielded quality parameters of R2 = 0.82 and Q2 = 0.69 after a 10-fold 
cross validation with an optimal of 4 latent components, while the lung samples yielded quality parameters 
of R2 = 0.96 and Q2 = 0.64 after LOOCV with an optimal of 8 latent components. Although the quality 
parameters for the lung samples fall outside the desired range threshold (0.2 units apart), it is important to 
note that the number of samples per group for this data set was quite small in comparison to the perfusate 
samples. Nonetheless, Q2 for this data set was still above the acceptable limit of 0.5.  
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Figure 4.4 Cross validation (CV) of PLS-DA models via k-fold CV, leave one out cross validation (LOOCV), and 
permutation. A) CV for perfusate samples. On the left side, the optimized number of latent variables for a 10-fold CV 
was found to be 4 (denoted by a red star) with quality parameters R2 = 0.82 and Q2 = 0.69. B) CV for lung samples. 
On the left side, 8 latent variables (denoted by red star) were found to be the optimum for a LOOCV with R2 = 0.96 
and Q2 = 0.64. On the right side for both sets of data, the observed statistics for the original data set was p < 0.0005 
and p < 0.001 for perfusate and lung samples, respectively (highlighted by the red arrows). 
 
Only features with VIP scores > 1.5 for each component up until the optimized number of latent components 
were investigated since these are features found to influence the discriminatory patterns observed in the 
data. Therefore, 100 and 200 features were assessed for the perfusate collected on site and lung samples, 
respectively. See Table 4.1 and Table 4.2 for the list of VIPs obtained from multivariate analysis and their 
respective statistical and LC-HRMS parameters for perfusate and lung samples. Tentatively identified 
metabolites or features significant changing (increase or decrease with respect to any time point over the 
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duration of NEVLP) over the time course of NEVLP (Time 1 to Time 5) for lungs sampled with SPME 
fibers and perfusate sampled with TFME are found in Table 4.3 and Table 4.4 respectively and are discussed 
in more detail in section 4.5.1 “Statistically significant metabolites and their biochemical relevance”.  
Table 4.1 VIPS > 1 obtained from validated PLS-DA model for perfusate samples collected during NEVLP. 
Shown are statistically significant features changing from Time 1 to Time 5, all time points inclusive. Data 
from positive mode analysis with a mass tolerance of less than or equal to 5 ppm. 
Compound 
classification 
Feature parameters Tentative ID 
m/z Retention time 
(min) 
Adduct Average VIP score 
Important features 
also found via 
METLIN and 
annotation 
375.2164 13.2 [M+H]+ 12.5 Resolvin D1, HDOPA 
226.0807 14.3 [M+Na]+ 3 Alanyl-asparagine 
324.059 10.1 [M+H]+ 2.4 5'-CMP, 2',3'-Cyclic UMP 
255.087 3.75 [M+H]+ 1.9 3-Hydroxy-DL-kynurenine 
146.0039 9.3 [M+Na]+ 1.7 Taurine 
Other endogenous 
compounds found 
via METLIN  
375.2164 13.2 [M+H]+ 12.5 Prostaglandin E1 
323.1701 9.8 [M+NH4]
+ 8.0 Threoninyl-tryptophan 
378.3213 15.7 [M+Na]+ 5.3 Arachidonoyl-EA(d8) 
359.2215 14.3 [M+H]+ 5.3 4S-Hydroxy-8-oxo-
(5E,9Z,13Z,16Z,19Z)-
neuroprostapentaenoic acid-
cyclo[7S,11S], 
17Beta-hydroxyandrost-4-ene-
3,11-dione propionate 
321.1849 14.5 [M+H]+ 3.9 4,7,10,13,16-
Docosapentaynoic acid 
175.1191 1.3 [M+H]+ 2.9 D-Arginine 
750.429 13.2 [M+Na]+ 2.5 PS(12:0/20:4(5Z,8Z,11Z,14Z)) 
 
 
Table 4.2 VIPS > 1 obtained from validated PLS-DA model for SPME fiber lung sampling events during 
NEVLP. Shown are statistically significant features changing from EVLP t0 to EVLP t5, all time points 
inclusive. Data from positive mode analysis. 
Compound 
classification 
Feature parameters Tentative feature ID 
m/z Retention time 
(min) 
Adduct Average VIP score 
Important features 
found via METLIN 
and annotation 
247.1077 12.29 [M+H]+ 21.8 N-acetyltryptophan 
166.0863 9.7 [M+H]+ 6.0 Phenylalanine 
226.0808 19.6 [M+Na]+ 6.2 Alanyl-asparagine 
269.0897 12.29 [M+Na]+ 5.7 N-acetyltrptophan 
205.0974 12.29 [M+H]+ 4.4 Tryptophan 
132.102 7.6 [M+H]+ 3.6 L-isoleucine 
182.0813 7.6 [M+H]+ 2.4 L-tyrosine 
147.0764 1.4 [M+H]+ 2.0 L-glutamine 
156.0768 2.1 [M+H]+ 1.2 Histidine 
Other Endogenous 
compounds found 
via METLIN  
240.0965 23 [M+Na]+ 13 N-a-acetylcitrulline, 
Alanyl-glutamine,  
5-Hydroxysebacate 
184.0577 12.3 [M+Na]+ 3.8 DL-2-aminoadipic acid, 
N-methylglutamic acid 
137.0458 1.6 [M+H]+ 2.9 Hypoxanthine 
270.093 12.2 [M+NH4]
+ 2.1 Cysteinl-methionine 
209.0543 19.5 [M+Na]+ 1.9 AMPA 
269.0881 1.6 [M+H]+ 1.9 Inosine,  
156.0768 2.1 [M+NH4]
+  Urocanic acid 
268.1041 7.6 [M+H]+ 1.5 Adenosine, 
Deoxyguanosine 
[M+Na]+ Glutamyl-valine 
107 
 
4.4.4 Univariate analysis 
Univariate analysis was conducted via a Kruskal Wallis Test in order to evaluate changes among individual 
features throughout the NEVLP procedure. The results of this analysis yielded (Figure 4.5) upwards of 
2000 statistically significant features for perfusate samples, and more than 1700 statistically significant 
features for lung samples.  
 
Figure 4.5 Univariate analysis via a non-parametric analysis of variance (ANOVA)–Kruskal Wallis test. A false 
discovery rate (FDR) adjusted p-value of 0.05 was used as the cut-off for the selection of statistically significant 
features. Statistically significant features are highlighted in red, while non-significant features are highlighted in 
blue. On the right, shows the patterns over time for a single statistically significant feature. 
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4.5 Discussion 
In the current study, two SPME formats were employed for the metabolomic fingerprinting of lung and 
perfusate samples sampled over the course of NEVLP. Minimally invasive in vivo SPME fibers were 
directly introduced into the lung for the purpose of selectively extracting small endogenous molecules in 
order to gain insight into ongoing biochemical processes originating specifically in the tissue over the 
course of NEVLP (in vivo SPME). Additionally, SPME fibers were also used to extract metabolites from 
fresh perfusate samples collected at the same time as the lung sampling events (on-site ex vivo SPME), as 
well as for a portion of perfusate samples that were snap frozen and transported back to the laboratory for 
further analysis (in-lab ex vivo SPME). Furthermore, TFME was also used to perform extractions on a 
portion of the samples that had been snap-frozen and transported to the laboratory (in-lab ex vivo TFME). 
This multi-tiered approach to collecting perfusate samples and the use of various devices to perform 
extractions yielded important information about metabolite alterations during NEVLP and the biochemical 
stability of the metabolome under typical storage and sample handling procedures (Table 4.4). 
4.5.1 Statistically significant metabolites and their biochemical relevance 
The features that were putatively identified via annotation and the variables of importance (VIP > 1.5) 
selected from/indicated by multivariate analysis (PLS-DA) show that it is possible to identify the presence 
of several endogenous metabolites related to the modulation of immune responses in a living system 
through in vivo SPME and on-site ex vivo SPME sampling at particular time-points during lung perfusion. 
Notably, multiple bioactive lipids (oxylipins) derived from polyunsaturated fatty acids (PUFAs) with either 
pro-inflammatory or anti-inflammatory properties were extracted with the use of SPME fibers over the 
course of NEVLP (Table 4.3). For instance, neuroprostanes, which are prostaglandin-like compounds 
formed in vivo via the peroxidation of fatty acids (primarily docosahexaenoic acid), were detected in lung 
tissue and fresh perfusate extracts during the first hours of lung perfusion. These oxygenated essential fatty 
acids possess potent anti-inflammatory properties and are considered to be biomarkers of oxidative stress, 
as well as inhibitors of macrophage activity.136,137 The presence of neuroprostanes was observed up to the 
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5th hour of NEVLP in lung tissue and up to the 8th hour in perfusate samples, after which the presence of 
other signaling molecules related to the metabolism of prostaglandins began to emerge. Specifically, the 
number of prostaglandin-derived compounds began to increase significantly during the 3rd hour of NEVLP, 
with a tremendous number of these compounds being reached in the 11th-12th hour (Table 4.3). During this 
time period, several pro-inflammatory tissue components, putatively identified as prostaglandin F3α and 
prostaglandin E2, were extracted from the lung tissue and perfusate samples. Conversely, prostaglandin D2 
and its derivatives, which have been previously shown to play an anti-inflammatory role in acute lung 
inflammation, were also detected in the analyzed matrices during this time period.138 These results strongly 
indicate pro-inflammatory and anti-inflammatory responses in lungs, especially in the later hours of lung 
perfusion. However, since particular prostaglandins may produce various, and sometimes opposite, effects 
in different tissues, the exact role of the detected prostaglandins requires further investigation via the 
targeted analysis of detected metabolites and also their respective receptors in lung tissue.  
In addition to prostaglandins, other eicosanoids, mainly leukotrienes and, to a lesser extent, lipoxins and 
thromboxanes, were also observed during NEVLP. Leukotrienes are potent local mediators of immune 
hypersensitivity and inflammation, and, similar to prostaglandins, the highest number of these compounds 
and their derivatives was detected in both lung tissue and fresh perfusate samples in the 11-12th hour of 
lung perfusion (Table 4.3), thus highlighting the intense immune system activity during this particular time-
point of lung perfusion. Moreover, various oxygenated lipid metabolites, including hydroxyeicosatrienoic 
acids (e.g., 11,12-DiHETrE and 5,6-DHET) and epoxy fatty acids (e.g., 9(10)-EpODE), were formed during 
lung perfusion, with significantly higher numbers of these metabolites being observed in lung tissue during 
the 11-12th hour of NEVLP. However, the lab extractions performed on the stored perfusate samples with 
SPME probes and TFME revealed a decrease in the number of these signaling lipid molecules (Table 4.4). 
These results are consistent with the findings of recent research on the effectiveness of performing 
extractions from rat brain in vivo and post-mortem.139 Specifically, the findings of the present research show 
that in vivo SPME is more effective for sampling living systems, such as lungs undergoing NEVLP, as it is 
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able to provide insight into the true oxylipin profile of the lung that cannot be achieved via the ex vivo 
analysis of stored samples. Overall, intense lipid peroxidation may occur under many conditions associated 
with pro- and anti-inflammatory responses within an organism; therefore, the elucidation of the mechanisms 
that drive these processes could enable the development of novel or improved targeted treatments for 
inflammatory diseases or processes. 
Other compounds with significant anti-inflammatory and anti-apoptotic activities were also extracted using 
SPME fibers. In particular, resolvins and neuroprotectins, which belong to a group of autacoids possessing 
strong in vivo immunoregulatory activity, were detected in lung tissue and perfusate samples during the 
first hours of lung perfusion. As previously reported, these new mediator families act locally and may 
strongly affect the action of the immune system.140 Resolvins are formed from omega-3 essential fatty acids 
and occur in trace amounts in tissues; nonetheless, the application of SPME probes facilitated their 
successful extraction. In addition, while neuroprotectins were detected in live tissue and from perfusate 
extracts during sampling conducted on-site in-hospital, these compounds were barely detectable in the 
stored perfusate samples (Table 4.4), which may be due to their lability and/or short lifetime. As such, these 
results suggest that neuroprotectin levels should be monitored using preferably in vivo tools. Overall, the 
presence of pro-inflammatory endogenous compounds may indicate ongoing inflammatory processes in the 
lung during NEVLP; however, these compounds are efficiently regulated or balanced by the production of 
specialized mediators that stimulate anti-inflammatory responses. Along with resolvins and 
neuroprotectins, lipoxins are among the most potent antagonists of endogenous inflammation, and, as novel 
chemical mediators, they have been considered potential targets in the development of new approaches to 
treating inflammation-related diseases.  
The use of SPME fibers to directly sample lung tissue and perfusate samples during lung perfusion enabled 
the monitoring of changes in the number and composition of other endogenous molecules, such as amino 
acids, acyl carnitines, steroid hormones, purines, and pyrimidines (Table 4.3). Moreover, on-site in vivo 
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sampling of lung tissue and perfusate samples revealed the presence of oleamide, which is a fatty acyl 
amide that has previously been reported as a potential biomarker for predicting primary graft dysfunction 
(PGD 3) during lung transplantation120 (Table 4.3). In contrast, this compound was scantily detected in the 
stored perfusate extracts sampled via TFME, which suggests that its stability is negatively affected during 
storage (Table 4.4). Acyl carnitines, which are endogenous compounds related to fatty acid metabolism, 
were also extracted from lung tissue, the perfusate samples collected on-site during NEVLP, and the stored 
perfusate samples. These compounds play a crucial role in the β-oxidation of fatty acids, which is an 
alternative pathway for energy production in the tissues when the supply of glucose is insufficient to 
maintain a normal level of energy. Elevated levels of these compounds may be related to inefficient 
mitochondrial importation of fatty acids by carnitine-acylcarnitine shuttle and could indicate metabolic 
disorders. However, decanoylcarnitine—a metabolite in carnitine metabolism that is involved in lipid 
catabolism and energy production and has previously been proposed as a marker of PGD3 that could 
improve donor lung selection and the outcomes of lung transplantation—was present solely in the stored 
perfusate samples. On the contrary, other acyl carnitines, including oxo (keto) and hydroxy fatty acids, were 
detected during lung perfusion, with significant increases in the number of those compounds during the 3rd 
hour of NEVLP. In addition, the occurrence of malonylcarnitine in lung tissue from the 3rd hour of NEVLP 
onwards may suggest disruptions in fatty acid oxidation caused by the impaired entry of long-chain 
acylcarnitine esters into the mitochondria. 
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Table 4.3 A comparison of unique features annotated by HMDB with medium-to-high confidence matches obtained by lung sampling and on-site 
perfusate sampling during NEVLP 
 
CIT 1st hour 3rd hour 5th hour 8th hour 11th-12th hours 13th-14th hours  
LUNG_in vivo LUNG_in vivo PERFUSATE_on 
site 
LUNG_in vivo PERFUSATE_o
n site 
LUNG_in 
vivo 
PERFUSATE_on 
site 
LUNG_in vivo PERFUSATE
_on site 
LUNG_in vivo PERFUSATE_o
n site 
LUNG_in vivo PERFUSATE_on 
site 
amino acids N-Acetylhistamine N-Acetylhistamine L-Phenylalanine L-Histidine N-
Acetylhistamine 
L-Histidine N-Acetylhistamine L-Histidine L-Histidine N-Acetylhistamine L-Tryptophan N-Acetylhistamine L-Histidine 
DL-Glutamate L-Cystine L-Tryptophan N-
Acetylhistamine 
N-
acetyltryptophan 
L-Tryptophan L-Tryptophan L-Tryptophan N-
Acetylhistami
ne 
L-Tryptophan L-Kynurenine Kynurenic acid N-Acetylhistamine 
L-Glutamic acid L-Asparagine Kynurenic acid L-Tryptophan Indoleacetyl 
glutamine 
L-Kynurenine Indoleacetyl 
glutamine 
Indoleacetyl 
glutamine 
L-Glutamine Indoleacetyl 
glutamine 
L-Glutamine L-Glutamine L-Kynurenine 
L-4-
Hydroxyglutamate 
semialdehyde 
L-Threonine L-Leucine L-Kynurenine L-Glutamic acid L-Glutamic 
acid 
L-Glutamine Quinaldic acid L-Glutamic 
acid 
Quinaldic acid L-Glutamic acid L-Glutamic acid Indoleacetyl 
glutamine 
N-Methyl-D-aspartic 
acid 
L-Proline L-Isoleucine Indoleacetyl 
glutamine 
L-Glutamine L-Glutamic 
acid 
L-Glutamic acid L-Glutamine L-Tryptophan L-Kynurenine Pyroglutamic 
acid 
L-Phenylalanine 2-Aminomuconic 
acid 
O-Acetylserine L-Glutamine L-Methionine L-Glutamic acid Pyroglutamic 
acid 
Pyroglutamic 
acid 
Pyroglutamic acid L-Lysine N-
acetyltryptoph
an 
L-Glutamic acid L-Threonine L-Methionine L-Glutamine 
N-Undecanoylglycine L-Arginine L-Arginine Pyroglutamic 
acid 
L-Valine D-Arginine L-Proline L-
Phenylalanine 
L-Kynurenine D-Glutamic acid L-Proline L-Cystine Pyroglutamic acid 
Tetracosanoylglycine L-Glutamic acid L-Cystine Gamma-
Glutamyltyrosine 
L-Cystine L-Valine L-Phenylalanine Ne,Ne 
dimethyllysine 
Indoleacetyl 
glutamine 
L-4-
Hydroxyglutamate 
semialdehyde 
L-Cystine L-Lysine L-Lysine 
N-Nonanoylglycine 5-
Aminopentanamide 
L-Proline L-Leucine L-Lysine L-Leucine Capryloylglycine L-Leucine L-Leucine O-Acetylserine N(6)-
(Octanoyl)lysine 
L-Proline L-Phenylalanine 
 
Creatine L-Tyrosine L-Isoleucine Creatinine L-Arginine Tridecanoylglycine L-Isoleucine L-
Phenylalanine 
N-Acetylserine L-Methionine L-Tyrosine L-Leucine 
Creatinine L-Glutamic acid L-Phenylalanine N-
Acryloylglycine 
L-Isoleucine N-
Undecanoylglycine 
L-Methionine Pyroglutamic 
acid 
Creatinine L-Arginine Creatine L-Isoleucine 
N-Decanoylglycine L-alpha-glutamyl-
L-hydroxyproline 
D-Serine Tridecanoylglyci
ne 
L-
Phenylalanine 
N-Nonanoylglycine L-Cystine L-Isoleucine N-
Undecanoylglycine 
Creatine N-
Undecanoylglycine 
N-(5-Methyl-3-
oxohexyl)alanine 
N-Nonanoylglycine Creatine L-Methionine N-
Decanoylglycine 
NNAL-N-
glucuronide 
Palmitoylglycine L-Asparagine L-Methionine Tridecanoylglycine Creatinine N-Acryloylglycine L-Arginine 
Palmitoylglycine N-
Undecanoylglycine 
L-Cystine Palmitoylglycine N-Acetyl-S-
(N-
methylcarbam
oyl)cysteine 
N-Acryloylglycine L-Threonine L-Arginine Tricosanoylglycine N-
Undecanoylglyci
ne 
Tridecanoylglycine L-Tyrosine 
 
Tridecanoylglycine L-Threonine N-
Undecanoylglyci
ne 
N-
Undecanoylgl
ycine 
Tridecanoylglycine Creatine L-Cystine Tetracosanoylglyci
ne 
Valproylglycine Pristanoylglycine Tetracosanoylglycin
e 
Tetracosanoylglycin
e 
L-Tyrosine Tridecanoylglyci
ne 
Valproylglyci
ne 
N-Decanoylglycine Creatinine L-Lysine N-Nonanoylglycine 5-L-
Glutamylglycine 
N-
Nonanoylglycine 
N-Acryloylglycine 
Pristanoylglycine L-Valine 
 
Tridecanoylgl
ycine 
Valproylglycine Tetracosanoyl
glycine 
L-Threonine Palmitoylglycine Capryloylglycine N-Lauroylglycine Capryloylglycine 
N-Nonanoylglycine 5-Oxoprolinate Tetracosanoyl
glycine 
 
N-
Undecanoylgl
ycine 
L-Proline 
 
Tridecanoylglyci
ne 
N-
Decanoylglycine 
N-
Undecanoylglycine 
N-Lauroylglycine Creatinine Stearoylglycin
e 
N-
Decanoylglyci
ne 
Creatine Tetracosanoylgly
cine 
Tridecanoylglycine N-Nonanoylglycine 
Dimethylglycine Creatine N-
Nonanoylglyci
ne 
Tridecanoylgl
ycine 
N-
Undecanoylgl
ycine 
Pristanoylglycine 
 
N-Nonanoylglycine 
 
N-
Acryloylglycine 
N-
Lauroylglycin
e 
Pristanoylglyc
ine 
N-
Acryloylglycin
e 
N-
Nonanoylglycine 
Palmitoylglycine 
Tetracosanoylgly
cine 
N-
Decanoylglyci
ne 
N-
Nonanoylglyci
ne 
Tridecanoylgl
ycine 
N-
Lauroylglycine 
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Pristanoylglycine Palmitoylglyci
ne 
N-
Lauroylglycin
e 
Tetracosanoyl
glycine 
N-
Decanoylglycine 
N-
Undecanoylglyci
ne 
N-
Acryloylglyci
ne 
Palmitoylglyci
ne 
Stearoylglycin
e 
Palmitoylglycine 
N-
Nonanoylglycine 
 
Capryloylglyci
ne 
N-
Nonanoylglyci
ne 
N-
Acryloylglycine 
Palmitoylglycine Tridecanoylgl
ycine 
N-
Lauroylglycin
e 
 
Tridecanoylglyci
ne 
N-
Decanoylglyci
ne 
N-
Decanoylglyci
ne 
N-
Decanoylglycine 
5-L-
Glutamylglyci
ne 
Dimethylglyci
ne 
  
Tridecanoylgl
ycine 
5-L-
Glutamylglyci
ne 
peptides 
  
Phenylalanyl-
Arginine 
 
Arginyl-
Phenylalanine 
 
Phenylalanyl-
Arginine 
Phenylalanyl-
Arginine 
Phenylalanyl-
Arginine 
Arginyl-Arginine Aspartyl-Alanine Phenylalanyl-
Arginine 
 
Arginyl-
Phenylalanine 
 
Arginyl-
Phenylalanine 
Aspartyl-
Alanine 
Aspartyl-
Alanine 
 
Alanyl-Aspartate Arginyl-
Phenylalanine  
L-Cysteinylglycine 
disulfide 
Arginyl-
Phenylalanine 
Arginyl-
Phenylalanine 
L-
Cysteinylglycine 
disulfide 
 
 
Alanyl-
Aspartate 
Alanyl-
Aspartate 
 
Valproylglyci
ne 
 
Gamma-
Glutamyltyros
ine 
L-
Cysteinylglyci
ne disulfide 
acylcarnitin
es 
6-Keto-
decanoylcarnitine 
6-Keto-
decanoylcarnitine 
Propionylcarnitine 6-Keto-
decanoylcarnitin
e 
Propionylcarnitin
e 
6-Keto-
decanoylcarnit
ine 
L-Acetylcarnitine 6-Keto-
decanoylcarnit
ine 
6-Keto-
decanoylcarnit
ine 
12-Hydroxy-12-
octadecanoylcarniti
ne 
12-Hydroxy-12-
octadecanoylcarn
itine 
6-Keto-
decanoylcarnitine 
6-Keto-
decanoylcarnitine 
12-Hydroxy-12-
octadecanoylcarnitine 
L-Acetylcarnitine Arachidonyl 
carnitine 
L-
Acetylcarnitine 
Arachidonyl 
carnitine 
 
Propionylcarnitine Malonylcarniti
ne 
Propionylcarni
tine 
L-Acetylcarnitine L-
Acetylcarnitine 
L-Acetylcarnitine L-Acetylcarnitine 
   
Malonylcarnitine Malonylcarnitine 
  
L-
Acetylcarnitin
e 
L-Carnitine Malonylcarnitine 
 
Malonylcarnitine 
L-
Palmitoylcarnitin
e 
L-
Acetylcarnitine 
  
Arachidonyl 
carnitine 
 
L-Carnitine 
  
autacoids Resolvin D1 
 
Resolvin D5 Resolvin D1 Resolvin D1 Resolvin D1 Resolvin D1 
 
Resolvin D1 Resolvin D5 Resolvin D5 Resolvin D5 
 
Resolvin D2 Neuroprotectin D1 Resolvin D2 Resolvin D2 Resolvin D2 Resolvin D2 Resolvin D2 Neuroprotectin D1 Neuroprotectin 
D1 
Neuroprotectin D1 
   
Resolvin D5 Resolvin D5 
 
Resolvin D5 
   
Neuroprotectin 
D1 
Neuroprotecti
n D1 
Neuroprotectin 
D1 
OXYLIPIN
S: 
             
I. 
EICOSAN
OIDS 
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1. 
prostagland
ins 
7-hydroxy-D4-
neuroprostane 
  
7-hydroxy-D4-
neuroprostane 
7-hydroxy-D4-
neuroprostane 
7-hydroxy-
D4-
neuroprostane 
7-hydroxy-D4-
neuroprostane 
 
4-hydroxy-D4-
neuroprostane 
Prostaglandin B1 Levuglandin E2 
  
4-hydroxy-D4-
neuroprostane 
4-hydroxy-D4-
neuroprostane 
4-hydroxy-D4-
neuroprostane 
4-hydroxy-
D4-
neuroprostane 
4-hydroxy-D4-
neuroprostane 
20-hydroxy-
E4-
neuroprostane 
Prostaglandin A1 13,14-Dihydro-
15-keto-PGD2 
20-hydroxy-E4-
neuroprostane 
20-hydroxy-E4-
neuroprostane 
20-hydroxy-E4-
neuroprostane 
20-hydroxy-
E4-
neuroprostane 
20-hydroxy-E4-
neuroprostane 
17-hydroxy-
E4-
neuroprostane 
23-Dinor-6-keto-
prostaglandin F1 a 
11b-PGE2 
17-hydroxy-E4-
neuroprostane 
17-hydroxy-E4-
neuroprostane 
17-hydroxy-E4-
neuroprostane 
17-hydroxy-
E4-
neuroprostane 
17-hydroxy-E4-
neuroprostane 
14-hydroxy-
E4-
neuroprostane 
8-iso-PGA1 8-iso-PGF3a 
14-hydroxy-E4-
neuroprostane 
14-hydroxy-E4-
neuroprostane 
14-hydroxy-E4-
neuroprostane 
14-hydroxy-
E4-
neuroprostane 
14-hydroxy-E4-
neuroprostane 
7-hydroxy-D4-
neuroprostane 
Prostaglandin C1 Prostaglandin 
F3a 
 
5,6-
Dihydroxyprosta
glandin F1a 
 
PGF2a 
ethanolamide 
13,14-Dihydro 
PGF-1a 
 
9-Deoxy-delta12-
PGD2 
Prostaglandin D2 
  
13,14-Dihydro-15-
keto-PGD2 
 
Prostaglandin H2 
11b-PGE2 Prostaglandin I2 
8-isoprostaglandin 
E2 
Prostaglandin E2 
8-iso-15-keto-
PGF2a 
8-
isoprostaglandin 
E2 
15-Keto-
prostaglandin F2a 
8-iso-15-keto-
PGF2a 
13,14-Dihydro-15-
keto-PGE2 
15-Keto-
prostaglandin 
F2a 
8-iso-PGF3a 13,14-Dihydro 
PGF-1a 
Prostaglandin F3a (5Z)-(15S)-
11alpha-
Hydroxy-9,15-
dioxoprostanoate 
Prostaglandin D2 (13E)-11a-
Hydroxy-9,15-
dioxoprost-13-
enoic acid 
Prostaglandin H2 
 
PGF2a 
ethanolamide 
Prostaglandin E2 
2. 
thromboxan
es 
      
Thromboxane A2 
  
2,3-Dinor-TXB2 Thromboxane 
A2 
  
3. 
leukotrienes 
Leukotriene C5 
 
Leukotriene E4 Omega-Carboxy-
trinor-leukotriene 
B4 
Leukotriene E4 Omega-
Carboxy-
trinor-
leukotriene B4 
Omega-Carboxy-
trinor-leukotriene 
B4 
12-Oxo-20-
trihydroxy-
leukotriene B4 
Leukotriene 
E4 
67-dihydro-12-epi-
LTB4 
67-dihydro-12-
epi-LTB4 
6,7-dihydro-12-
epi-LTB4 
Leukotriene E4 
Leukotriene E4 
 
10,11-dihydro-
20-trihydroxy-
leukotriene B4 
67-dihydro-12-
epi-LTB4 
Leukotriene 
C5 
10,11-dihydro-20-
trihydroxy-
leukotriene B4 
1011-dihydro-
20-trihydroxy-
leukotriene B4 
 
12-Keto-tetrahydro-
leukotriene B4 
10,11-dihydro-
leukotriene B4 
10,11-dihydro-
leukotriene B4 
 
  
12-Oxo-20-
trihydroxy-
leukotriene B4 
 
20-Hydroxy-
leukotriene B4 
Leukotriene 
E4 
Omega-Carboxy-
trinor-leukotriene 
B4 
20-Hydroxy-
leukotriene B4 
12-Keto-
tetrahydro-
leukotriene B4 
1011-dihydro-
leukotriene B4 
 
Leukotriene 
C5 
Leukotriene C5 Omega-Carboxy-
trinor-leukotriene 
B4 
Leukotriene E4 
12-Keto-
tetrahydro-
leukotriene B4 
 
Leukotriene E4 Leukotriene C5 
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67-dihydro-5-oxo-
12-epi-LTB4 
10,11-dihydro-
20-trihydroxy-
leukotriene B4 
1011-dihydro-12-
oxo-LTB4 
12-Keto-
tetrahydro-
leukotriene B4 
12(S)-Leukotriene 
B4 
Leukotriene E4 
6-trans-12-epi-
Leukotriene B4 
 
6-trans-Leukotriene 
B4 
Leukotriene B4 
4. lipoxins 
      
15-Epi-lipoxin A4 
   
15-Epi-lipoxin 
A4 
  
13,14-Dihydro-15-
oxo-lipoxin A4 
13,14-Dihydro-
15-oxo-lipoxin 
A4 
Lipoxin B4 Lipoxin A4 
Lipoxin A4 Lipoxin B4 
II. OTHER 
OXYLIPIN
S 
  
9,10-DiHODE 9,10,13-
TriHOME 
9,10-DiHODE 9,10,13-
TriHOME 
9,10-DiHODE 9,10-DiHODE 15,16-
DiHODE 
9,10,13-TriHOME 9,10-DiHODE 9,10-DiHODE 
 
15,16-DiHODE 9,12,13-
TriHOME 
15,16-DiHODE 9,12,13-
TriHOME 
15,16-DiHODE 15,16-
DiHODE 
12,13-
DiHODE 
9,12,13-TriHOME 15,16-DiHODE 15,16-DiHODE 
12,13-DiHODE 12(13)Ep-9-
KODE 
12,13-DiHODE 
 
12,13-DiHODE 12,13-
DiHODE 
9,10,13-
TriHOME 
5,6-DHET 12,13-DiHODE 12,13-DiHODE 
12(13)Ep-9-KODE 
 
9,10,13-
TriHOME 
9,10,13-TriHOME 9(S)-HPODE 9,12,13-
TriHOME 
8,15-DiHETE 9,10,13-
TriHOME 
9,12,13-TriHOME 
9(S)-HPODE 9,12,13-
TriHOME 
9,12,13-TriHOME 12(13)Ep-9-
KODE 
9-HOTE 5,15-DiHETE 9,12,13-
TriHOME 
9(S)-HPODE 
 
9(S)-HPODE 9(S)-HPODE 
 
13-HOTE 17,18-DiHETE 9(S)-HPODE 12(13)Ep-9-KODE 
5,6-DHET 12(13)Ep-9-KODE 9(S)-HPODE 14,15-DiHETE 5,6-DHET 5,6-DHET 
11,12-DiHETrE 
 
9(10)-EpODE 15H-11,12-EETA 11,12-DiHETrE 11,12-DiHETrE 
8,9-DiHETrE A-12(13)-
EpODE 
11H-14,15-EETA 8,9-DiHETrE 8,9-DiHETrE 
14,15-DiHETrE 9-OxoODE 11,12-DiHETrE 14,15-DiHETrE 14,15-DiHETrE   
8,9-DiHETrE 
  
14,15-DiHETrE 
12,20-DiHETE 
5-HPETE 
8(S)-HPETE 
11(R)-HPETE 
12(R)-HPETE 
15(S)-HPETE 
12(S)-HPETE 
hormones 11beta-Hydroxy-3,20-
dioxopregn-4-en-21-
oic acid 
17a-Estradiol Methyltestosterone 6-
Dehydrotestoster
one glucuronide 
6-
Dehydrotestoster
one glucuronide 
6-
Dehydrotestos
terone 
glucuronide 
Methyltestosterone 6-
Dehydrotestos
terone 
glucuronide 
6-
Dehydrotestost
erone 
glucuronide 
 
Methyltestostero
ne 
6-
Dehydrotestostero
ne glucuronide 
6-
Dehydrotestosteron
e glucuronide 
Estradiol-17beta 3-
sulfate 
Estradiol 6-
Dehydrotestosteron
e glucuronide 
11beta-Hydroxy-
3,20-dioxopregn-
4-en-21-oic acid 
11beta20-
Dihydroxy-3-
oxopregn-4-en-
21-oic acid 
11beta20-
Dihydroxy-3-
oxopregn-4-
en-21-oic acid 
6-
Dehydrotestosteron
e glucuronide 
5a-
Dihydrotestost
erone sulfate 
Methyltestoste
rone 
6-
Dehydrotestoster
one glucuronide 
Estradiol-17beta 3-
sulfate 
 
 
Methyltestosterone 
 
21-Hydroxy-5b-
pregnane-
3,11,20-trione 
  
11beta-Hydroxy-
3,20-dioxopregn-4-
en-21-oic acid 
Androsterone 
sulfate 
11beta-
Hydroxy-3,20-
dioxopregn-4-
en-21-oic acid 
  
 
19-
Hydroxydeoxyco
rticosterone 
   
21-Deoxycortisol 
Corticosterone 
Cortexolone 
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purines, 
pyrimidines 
 
5-Aminoimidazole 
ribonucleotide 
5-
Methylthioadenosin
e 
5-
Methylthioadeno
sine 
5-
Methylthioadeno
sine 
 
5-
Methylthioadenosin
e 
5-
Methylthioade
nosine 
5-
Methylthioade
nosine 
5-
Methylthioadenosin
e 
5-
Methylthioadeno
sine 
5-
Methylthioadenosi
ne 
5-
Methylthioadenosin
e  
Cytidine 2,3-cyclic 
phosphate 
Cytosine Cytidine 2,3-
cyclic phosphate 
Biotinyl-5-AMP Cytidine 2,3-
cyclic 
phosphate 
Cytidine 2,3-
cyclic 
phosphate 
Cytidine 2,3-cyclic 
phosphate 
Cytidine 2,3-
cyclic phosphate 
Cytidine 2,3-cyclic 
phosphate 
Cytidine 2,3-cyclic 
phosphate 
Cytidine 
monophosphate 
Deoxycytidine 
 
2-Deoxyinosine 
triphosphate 
Cytidine 
monophosphat
e 
Deoxycytidine 
 
2-Deoxyinosine 
triphosphate 
Deoxycytidine Deoxycytidine 
   
2-
Deoxyinosine 
triphosphate 
Cytosine Cytidine 
monophosphate 
Cytosine Cytosine 
  
Cytosine 
  
lipids 3-O-
Sulfogalactosylcerami
de (d18:124:0) 
3-O-
Sulfogalactosylcera
mide (d18:122:0) 
3-O-
Sulfogalactosylcera
mide (d18:122:0) 
3-O-
Sulfogalactosylc
eramide 
(d18:126:1(17Z)) 
3-O-
Sulfogalactosylc
eramide 
(d18:124:0) 
3-O-
Sulfogalactosy
lceramide 
(d18:122:0) 
3-O-
Sulfogalactosylcera
mide (d18:124:0) 
3-O-
Sulfogalactosy
lceramide 
(d18:122:0) 
3-O-
Sulfogalactosy
lceramide 
(d18:122:0) 
3-O-
Sulfogalactosylcera
mide (d18:122:0) 
3-O-
Sulfogalactosylc
eramide 
(d18:124:0) 
3-O-
Sulfogalactosylcer
amide (d18:122:0) 
3-O-
Sulfogalactosylcera
mide (d18:122:0) 
3-O-
Sulfogalactosylcerami
de (d18:124:1(15Z)) 
3-O-
Sulfogalactosylcera
mide (d18:124:0) 
3-O-
Sulfogalactosylcera
mide (d18:124:0) 
3-O-
Sulfogalactosylc
eramide 
(d18:122:0) 
3-O-
Sulfogalactosylc
eramide 
(d18:120:0) 
3-O-
Sulfogalactosy
lceramide 
(d18:122:0) 
3-O-
Sulfogalactosylcera
mide (d18:120:0) 
3-O-
Sulfogalactosy
lceramide 
(d18:124:0) 
3-O-
Sulfogalactosy
lceramide 
(d18:124:0) 
3-O-
Sulfogalactosylcera
mide (d18:124:0) 
3-O-
Sulfogalactosylc
eramide 
(d18:124:1(15Z)) 
3-O-
Sulfogalactosylcer
amide (d18:124:0) 
3-O-
Sulfogalactosylcera
mide (d18:124:0) 
Oleamide Oleamide Oleamide 3-O-
Sulfogalactosylc
eramide 
(d18:120:0) 
3-O-
Sulfogalactosylc
eramide 
(d18:122:0) 
Oleamide Oleamide Oleamide Oleamide Oleamide 3-O-
Sulfogalactosylc
eramide 
(d18:122:0) 
 
Oleamide 
Arachidonic acid 
  
3-O-
Sulfogalactosylc
eramide 
(d18:124:0) 
Oleamide 
 
Arachidonic acid Arachidonic 
acid 
Arachidonic 
acid 
 
3-O-
Sulfogalactosylc
eramide 
(d18:120:0) 
 
 
Oleamide Arachidonic acid 
   
Oleamide 
other Taurine 
 
L-Urobilin L-Urobilin cyclic 6-
Hydroxymelatoni
n 
Betaine Farnesyl 
pyrophosphate 
Pentaporphyri
n I 
cyclic 6-
Hydroxymelat
onin 
Norepinephrine 
sulfate 
Taurine Norepinephrine 
sulfate 
cyclic 6-
Hydroxymelatonin 
 
Melanin N-
Acetylserotonin 
sulfate 
Betaine Melatonin 
glucuronide 
Urothion L-Urobilin Norepinephrin
e sulfate 
Taurine cyclic 6-
Hydroxymelatoni
n 
Taurine Melatonin 
glucuronide 
Farnesyl 
pyrophosphate 
Melatonin 
glucuronide 
L-Urobilin Arachidonoyl 
Serinol 
Porphobilinogen Melanin Farnesyl 
pyrophosphate 
5-
Hydroxyindoleaceti
c acid 
Norepinephrine 
sulfate 
 
Porphobilinogen 
Betaine Porphobilinogen Taurine 
  
Melatonin 
glucuronide 
Taurine 
 
Melatonin 
glucuronide 
L-Urobilin 
 
5-
Hydroxyindoleac
etic acid 
 
Norepinephrin
e sulfate 
 
L-Urobilin L-Urobilinogen 
 
Taurine 
  
Betaine 
 
Table 4.4 A comparison of unique features annotated by HMDB with medium-to-high confidence matches obtained from perfusate samples prepared 
in laboratory with SPME fibers and TFME (blades) 
  1st hour 3rd hour 5th hour 8th hour 11th-12th hours 13th-14th hours 17th-19th hours  
FIBERS BLADES FIBERS FIBERS BLADES FIBERS FIBERS BLADES FIBERS BLADES BLADES 
amino 
acids 
L-Histidinol Histidinal N-
Acetylhistamine  
N-
Acetylhistamine  
NaNa-
Dimethylhistami
ne 
N-
Acetylhistamine  
N-
Acetylhistami
ne  
Na,Na-
Dimethylhistami
ne 
N-
Acetylhistamine  
Na,Na-
Dimethylhistami
ne 
Na,Na-
Dimethylhistami
ne 
N-
Acetylhistami
ne  
L-Histidine L-Phenylalanine Indoleacetyl 
glutamine 
N-
Acetylhistamine  
Beta-Leucine L-Histidinol N-
Acetylhistamine  
L-Phenylalanine N-
Acetylhistamine  
Histidinal 
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D-Leucine L-Glutamine L-Tyrosine Quinaldic acid 3-
Methylhistamine 
L-Cystine L-Glutamine L-Histidine L-Tryptophan Histidinal L-Histidinol 
N-
acetyltryptop
han 
L-
Asparagine 
L-Tryptophan Indoleacetyl 
glutamine 
1-
Methylhistamine 
L-Norleucine L-Proline Histidinal Pyroglutamic 
acid 
L-Histidinol L-Histidine 
Beta-Leucine L-Threonine L-Valine L-Cystine Histidinal L-Tryptophan N-
acetyltryptoph
an 
L-Histidinol L-Phenylalanine N-
acetyltryptophan 
N(6)-
(Octanoyl)lysine 
L-Norleucine L-Proline Kynurenic acid D-Leucine L-Histidinol L-Homoserine L-Glutamine N-
acetyltryptophan 
Indoleacetyl 
glutamine 
N-
Acetylserotonin 
L-Tryptophan 
L-Tryptophan L-
Phenylalanin
e 
Pyroglutamic 
acid 
D-Tryptophan N-Acetylvaline L-Leucine L-Tryptophan L-Tryptophan L-Valine N-
Decanoylglycine 
Indoleacetyl 
glutamine 
L-Leucine Creatine Indoleacetyl 
glutamine 
L-Allothreonine Creatinine L-Glutamine Kynurenic 
acid 
Indoleacetyl 
glutamine 
L-Methionine Indoleacetyl 
glutamine 
L-Tryptophan 
L-
Alloisoleucin
e 
5-
Hydroxykyn
urenine 
N-
acetyltryptophan 
Alanylglycine L-Proline L-Alloisoleucine L-Leucine N(6)-
(Octanoyl)lysine 
L-Glutamine N(6)-
(Octanoyl)lysine 
Creatinine 
L-Isoleucine L-3-
Hydroxykyn
urenine 
Creatine Beta-Leucine Methylglutaric 
acid 
L-Allothreonine Pyroglutamic 
acid 
L-Cystine L-Arginine Ornithine Ornithine 
L-
Phenylalanin
e 
Cycloserine L-Methionine D-Glutamine Ketoleucine Pyroglutamic 
acid 
L-Isoleucine L-Glutamine L-Cystine L-Proline L-Proline 
Indoleacetyl 
glutamine 
L-
Tryptophan 
L-Glutamine L-Norleucine Pyroglutamic 
acid 
L-Isoleucine L-Carnitine Creatinine L-Histidine N-Acetylvaline Creatine 
Tridecanoylgl
ycine 
Methylglutar
ic acid 
Indoleacetyl 
glutamine 
L-Tryptophan Ornithine L-Threonine Valproylglyci
ne 
L-Arginine L-Threonine L-Asparagine NeNe 
dimethyllysine 
Tetracosanoyl
glycine 
Hydroxykyn
urenine 
Capryloylglycin
e 
L-Homoserine L-Fucose L-Phenylalanine N-
Acryloylglyci
ne 
Ornithine L-Tyrosine L-Carnitine N(6)-
(Octanoyl)lysine 
N-
Undecanoylgl
ycine 
2-
Methylglutar
ic acid 
Tridecanoylglyci
ne 
L-Leucine 3-
Methoxytyramin
e 
Creatine Capryloylglyci
ne 
L-Lysine L-Glutamic acid Creatinine Farnesylcysteine 
N-
Nonanoylgly
cine 
Pyroglutamic 
acid 
Stearoylglycine L-Glutamine N-Acetyl-L-
glutamate 5-
semialdehyde 
Indoleacetyl 
glutamine 
Tridecanoylgl
ycine 
L-Asparagine Indoleacetyl 
glutamine 
Indoleacetaldehy
de 
N-Acetyl-L-
glutamate 5-
semialdehyde 
  Ketoleucine Pristanoylglycin
e 
L-Alloisoleucine D-Serine N-
Undecanoylglyci
ne 
Stearoylglycin
e 
L-Proline N-
Acryloylglycine 
23-Dimethyl-3-
hydroxyglutaric 
acid 
N6N6N6-
Trimethyl-L-
lysine 
Dimethylgly
cine 
N-
Undecanoylglyci
ne 
Pyroglutamic 
acid 
L-Tryptophan Palmitoylglycine N-
Undecanoylgl
ycine 
Allysine Tridecanoylglyc
ine 
Ketoleucine L-Glutamic acid 
5-phosphate 
NaNa-
Dimethylhist
amine 
N-
Nonanoylglycine 
L-Isoleucine L-Tyrosine Tridecanoylglyci
ne 
N-
Nonanoylglyci
ne 
Methylglutaric 
acid 
Tetracosanoylgl
ycine 
Ribitol Quinaldic acid 
Indoleacetyl 
glutamine 
N-
Acryloylglycine 
L-Threonine Indoleacetyl 
glutamine 
Tetracosanoylgl
ycine 
N-
Lauroylglycin
e 
Urocanic acid N-
Undecanoylglyc
ine 
Urocanic acid L-Glutamine 
N-
acetyltryptop
han 
  L-Phenylalanine N(6)-
(Octanoyl)lysine 
N-
Nonanoylglycine 
N-
Lauroylglycin
e 
Pyroglutamic 
acid 
N-
Nonanoylglycin
e 
N-Acetyl-L-
glutamate 5-
semialdehyde 
L-Cysteine 
8-
Methoxykyn
urenate 
Creatine L-Cystine N-
Nonanoylglycine 
N-
Decanoylglyci
ne 
L-Phenylalanine N-
Lauroylglycine 
D-Serine L-Arginine 
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L-Cystine Tridecanoylglyci
ne 
o-Tyrosine N-
Lauroylglycine 
Palmitoylglyci
ne 
NeNe 
dimethyllysine 
N-
Decanoylglycine 
N-
Undecanoylglyci
ne 
L-Cystine 
Quinaldic 
acid 
Tetracosanoylgl
ycine 
Beta-Tyrosine N-
Lauroylglycine 
  N(6)-
(Octanoyl)lysine 
Palmitoylglycin
e 
Valproylglycine L-Lysine 
N-
Undecanoylg
lycine 
N-
Nonanoylglycine 
L-Threo-3-
Phenylserine 
N-
Decanoylglycine 
D-Serine N-
Undecanoylglyc
ine 
N-
Heptanoylglycin
e 
L-Asparagine 
N-
Nonanoylgly
cine 
N-
Lauroylglycine 
N-
Undecanoylglyc
ine 
Valproylglycine N6N6N6-
Trimethyl-L-
lysine 
  Valerylglycine L-Threonine 
N-
Acryloylglyc
ine 
N-
Decanoylglycine 
N-
Decanoylglycine 
5-L-
Glutamylglycine 
Citrulline Capryloylglycin
e 
L-Tyrosine 
N-
Decanoylgly
cine 
Palmitoylglycine Tridecanoylglyc
ine 
Alanylglycine L-Valine Isovalerylglycin
e 
L-Glutamic acid 
  N-
Acryloylglycine 
N-
Nonanoylglycin
e 
N-
Acryloylglycine 
Quinaldic acid 2-
Methylbutyrylgl
ycine 
L-Carnitine 
Tridecanoylglyci
ne 
Myristoylglycin
e 
Capryloylglycin
e 
Ureidosuccinic 
acid 
Tridecanoylglyci
ne 
Kynurenic acid 
N-
Undecanoylglyci
ne 
N-
Acryloylglycine 
Tridecanoylglyci
ne 
L-Methionine N-
Lauroylglycine 
2-Methylglutaric 
acid 
N-
Nonanoylglycine 
Valerylglycine N-
Decanoylglycine 
L-Cystine Myristoylglycine N-
Undecanoylglyci
ne 
N-
Undecanoylglyci
ne 
Isovalerylglycin
e 
  L-Threonine   N-
Lauroylglycine 
Valproylglycine N-
Nonanoylglycin
e 
L-Tyrosine N-
Decanoylglycine 
5-L-
Glutamylglycine 
N-
Undecanoylglyc
ine 
L-Glutamic acid N-
Undecanoylglyci
ne 
  N-
Lauroylglycine 
Creatine N-
Nonanoylglycine 
N-
Decanoylglycine 
5-L-
Glutamylglycine 
N-
Decanoylglycine 
  N-
Acryloylglycine 
Tridecanoylglyci
ne 
Tiglylglycine Stearoylglycine 
N-
Butyrylglycine 
Myristoylglycine 
Isobutyrylglycin
e 
Palmitoylglycine 
N-
Lauroylglycine 
Valproylglycine 
N-
Decanoylglycine 
  
N-
Undecanoylglyci
ne 
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N-
Lauroylglycine 
Palmitoylglycine 
Tridecanoylglyci
ne 
Stearoylglycine 
peptides   Valyl-
Hydroxyproli
ne 
Arginyl-
Phenylalanine 
Phenylalanyl-
Arginine 
Valyl-Aspartate Phenylalanyl-
Arginine 
Phenylalanyl-
Arginine 
Tryptophyl-
Arginine 
Phenylalanyl-
Arginine 
Arginyl-
Arginine 
Arginyl-Arginine 
Prolyl-
Asparagine 
  Aspartyl-
Alanine 
Threoninyl-
Hydroxyproline 
Aspartyl-
Alanine 
Arginyl-
Phenylalanine 
Phenylalanyl-
Arginine 
Arginyl-
Phenylalanine 
  gamma-
Glutamyl-S-
methylcysteinyl-
beta-alanine 
Phenylalanyl
-Arginine 
Arginyl-
Phenylalanine 
Hydroxyprolyl-
Threonine 
Arginyl-
Phenylalanine 
  Histidinyl-
Alanine 
    
Hydroxyprol
yl-Valine 
Alanyl-Glycine Aspartyl-Valine Alanyl-Glycine Aspartyl-
Alanine 
Aspartyl-
Phenylalanin
e 
Alanyl-Aspartate Histidinyl-
Cysteine 
Alanyl-Aspartate Arginyl-
Tryptophan 
Asparaginyl-
Proline 
Arginyl-
Arginine 
Cysteinyl-
Histidine 
  Arginyl-
Phenylalanine 
Arginyl-
Phenylalanin
e 
  Arginyl-
Arginine 
Alanyl-Histidine 
Arginyl-
Arginine 
  Alanyl-Aspartate 
acylcar
nitines 
Hydroxyprop
ionylcarnitine 
Propionylcar
nitine 
L-
Acetylcarnitine 
6-Keto-
decanoylcarnitin
e 
L-Carnitine 6-Keto-
decanoylcarnitin
e 
Arachidonyl 
carnitine 
L-
Acetylcarnitine 
6-Keto-
decanoylcarnitin
e 
Propionylcarniti
ne 
3-
Dehydrocarnitine 
Decanoylcarn
itine 
L-
Acetylcarniti
ne 
L-Carnitine L-
Acetylcarnitine 
L-
Acetylcarnitine 
L-
Acetylcarnitine 
Malonylcarniti
ne 
Propionylcarniti
ne 
L-
Acetylcarnitine 
L-
Acetylcarnitine 
Propionylcarnitin
e 
  Malonylcarni
tine 
Malonylcarnitine   3-
Dehydrocarnitin
e 
  3-Hydroxy-9-
hexadecenoylc
arnitine 
Tiglylcarnitine   3-
Dehydroxycarnit
ine 
L-
Acetylcarnitine 
  6-Keto-
decanoylcarnitin
e 
3-
Dehydroxycarnit
ine 
  3-
Dehydroxycarnit
ine 
Tiglylcarnitine Malonylcarnitine 
  Tiglylcarnitine Hydroxypropion
ylcarnitine 
Hydroxypropion
ylcarnitine 
2-
Octenoylcarnitin
e 
Propionylcarniti
ne 
L-Carnitine 3-
Dehydrocarnitin
e 
Heptanoylcarniti
ne 
Hydroxypropion
ylcarnitine 
    Hydroxypropion
ylcarnitine 
  Tiglylcarnitine 
Dodecanoylcarni
tine 
3-
Dehydroxycarniti
ne 
autacoi
ds 
    Resolvin D1 Resolvin D1   Resolvin D1 Resolvin D5 Resolvin D1   Resolvin D1 Resolvin D1 
Resolvin D2 Resolvin D2 Resolvin D2 Neuroprotecti
n D1 
Resolvin D2 Resolvin D2 Resolvin D2 
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OXYLI
PINS 
           
I. 
EICOS
ANOID
S 
           
1. 
prostagl
andins 
PGF2a 
ethanolamide 
6-Keto-
prostaglandin 
F1a 
7-hydroxy-D4-
neuroprostane 
7-hydroxy-D4-
neuroprostane 
15-Deoxy-d-
12,14-PGJ2 
7-hydroxy-D4-
neuroprostane 
Prostaglandin 
G1 
7-hydroxy-D4-
neuroprostane 
13,14-Dihydro 
PGF-1a 
7-hydroxy-D4-
neuroprostane 
7-hydroxy-D4-
neuroprostane 
  15-Deoxy-d-
12,14-PGJ2 
4-hydroxy-D4-
neuroprostane 
4-hydroxy-D4-
neuroprostane 
  4-hydroxy-D4-
neuroprostane 
20-Hydroxy-
PGF2a 
4-hydroxy-D4-
neuroprostane 
  4-hydroxy-D4-
neuroprostane 
4-hydroxy-D4-
neuroprostane 
Prostaglandi
n G1 
20-hydroxy-E4-
neuroprostane 
20-hydroxy-E4-
neuroprostane 
20-hydroxy-E4-
neuroprostane 
  20-hydroxy-E4-
neuroprostane 
20-hydroxy-E4-
neuroprostane 
20-hydroxy-E4-
neuroprostane 
20-Hydroxy-
PGF2a 
17-hydroxy-E4-
neuroprostane 
17-hydroxy-E4-
neuroprostane 
17-hydroxy-E4-
neuroprostane 
17-hydroxy-E4-
neuroprostane 
17-hydroxy-E4-
neuroprostane 
17-hydroxy-E4-
neuroprostane 
  14-hydroxy-E4-
neuroprostane 
14-hydroxy-E4-
neuroprostane 
14-hydroxy-E4-
neuroprostane 
14-hydroxy-E4-
neuroprostane 
14-hydroxy-E4-
neuroprostane 
14-hydroxy-E4-
neuroprostane 
  15-Deoxy-d-
12,14-PGJ2 
15-Deoxy-d-
12,14-PGJ2 
6-Keto-
prostaglandin 
F1a 
20-hydroxy-E4-
neuroprostane 
Prostaglandin D2 
    PGF2a 
ethanolamide 
15-Deoxy-d-
12,14-PGJ2 
Prostaglandin H2 
20-Hydroxy-
PGF2a 
  Prostaglandin I2 
  Prostaglandin E2 
PGF2a 
ethanolamide 
13,14-Dihydro-
15-keto-PGD2 
11b-PGE2 
8-iso-15-keto-
PGF2a 
15-Keto-
prostaglandin 
F2a 
8-iso-PGF3a 
Prostaglandin 
F3a 
56-
Dihydroxyprosta
glandin F1a 
(5Z)-(15S)-
11alpha-
Hydroxy-9,15-
dioxoprostanoate 
2. 
thromb
oxanes 
  Thromboxan
e B2 
        Thromboxane 
B2 
Thromboxane 
B2 
    Thromboxane A2 
3. 
leukotri
enes 
Leukotriene 
C5 
10,11-
dihydro-20-
dihydroxy-
LTB4 
Leukotriene E4 Omega-
Carboxy-trinor-
leukotriene B4 
6,7-dihydro-12-
epi-LTB4 
Omega-
Carboxy-trinor-
leukotriene B4 
12-Oxo-20-
trihydroxy-
leukotriene B4 
10,11-dihydro-
20-dihydroxy-
LTB4 
Leukotriene E4   10,11-dihydro-
20-trihydroxy-
leukotriene B4 
Leukotriene 
E4 
  Omega-
Carboxy-trinor-
leukotriene B4 
Leukotriene C5 10,11-dihydro-
leukotriene B4 
Leukotriene C5 10,11-dihydro-
20-dihydroxy-
LTB4 
10,11-dihydro-
20-trihydroxy-
leukotriene B4 
  Leukotriene B4 
ethanolamide 
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Omega-
Carboxy-
trinor-
leukotriene 
B4 
Leukotriene C5 Leukotriene E4 12-Keto-
tetrahydro-
leukotriene B4 
Leukotriene E4 Leukotriene 
E4 
  20-Hydroxy-
leukotriene B4 
12-Oxo-20-
trihydroxy-
leukotriene 
B4 
        10,11-dihydro-
20-trihydroxy-
leukotriene B4 
    
    9-HODE 
15-Deoxy-d-
12,14-PGJ2 
Prostaglandin 
G1 
4. 
lipoxins 
                    15-Epi-lipoxin 
A4 
13,14-Dihydro-
15-oxo-lipoxin 
A4 
II. 
OTHE
R 
OXYLI
PINS 
  9,10,13-
TriHOME 
  9,10-DiHODE 5,6-DHET 9,10-DiHODE   9,10,13-
TriHOME 
12(13)Ep-9-
KODE 
Tetranor 12-
HETE 
9-HODE 
9,12,13-
TriHOME 
15,16-DiHODE 11,12-DiHETrE 15,16-DiHODE 9,12,13-
TriHOME 
9,10,13-
TriHOME 
9,10,13-
TriHOME 
9,10-DiHODE 
  12,13-DiHODE 8,9-DiHETrE 12,13-DiHODE 12,13-EpOME 9,12,13-
TriHOME 
9,12,13-
TriHOME 
15,16-DiHODE 
9(S)-HPODE 14,15-DiHETrE 9(S)-HPODE Tetranor 12-
HETE 
    12,13-DiHODE 
9,10,13-
TriHOME 
9,10,13-
TriHOME 
9,10,13-
TriHOME 
9(S)-HPODE 9(S)-HPODE 
9,12,13-
TriHOME 
9,12,13-
TriHOME 
9,12,13-
TriHOME 
  9,10,13-
TriHOME 
      9,12,13-
TriHOME 
12,13-EpOME 
hormon
es 
17a-Estradiol 19-Oxo-
deoxycortico
sterone 
17a-Estradiol 11beta-Hydroxy-
3,20-
dioxopregn-4-
en-21-oic acid  
Methyltestostero
ne 
17a-Estradiol 17a-Estradiol 11beta-Hydroxy-
3,20-
dioxopregn-4-
en-21-oic acid  
5b-
Dihydrotestoster
one 
Cortisone 21-Deoxycortisol 
Estradiol 19-
Hydroxydeo
xycorticoster
one 
Estradiol Estradiol 19-Oxo-
deoxycorticoster
one 
Estradiol Estradiol 19-Oxo-
deoxycorticoster
one 
4-
Androstenediol 
18-Oxocortisol 6-
Dehydrotestoster
one glucuronide 
  2-Hydroxy-
3-
methoxyestro
ne 
11beta-Hydroxy-
3,20-
dioxopregn-4-
en-21-oic acid  
6-
Dehydrotestoster
one glucuronide 
19-
Hydroxydeoxyc
orticosterone 
6-
Dehydrotestoster
one glucuronide 
6-
Dehydrotestos
terone 
glucuronide 
19-
Hydroxydeoxyc
orticosterone 
5-
Androstenediol 
Aldosterone 19-Oxo-
deoxycorticoster
one 
Adrenosteron
e 
6-
Dehydrotestoster
one glucuronide 
17a-Estradiol 11beta20-
Dihydroxy-3-
oxopregn-4-en-
21-oic acid 
Methyltestostero
ne 
  11beta20-
Dihydroxy-3-
oxopregn-4-en-
21-oic acid 
Dihydrotestoster
one 
11beta-Hydroxy-
3,20-
dioxopregn-4-
en-21-oic acid  
19-
Hydroxydeoxyco
rticosterone 
19-
Oxoandrost-
4-ene-3,17-
dione 
    21-Hydroxy-5b-
pregnane-
3,11,20-trione 
11beta-Hydroxy-
3,20-
dioxopregn-4-
en-21-oic acid  
Adrenosterone Epiandrosterone 11beta20-
Dihydroxy-3-
oxopregn-4-en-
21-oic acid 
11beta-Hydroxy-
320-dioxopregn-
4-en-21-oic acid  
21-Hydroxy-
5b-pregnane-
21-
Deoxycortisol 
  19-Oxoandrost-
4-ene-3,17-dione 
Androsterone   11beta20-
Dihydroxy-3-
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3,11,20-
trione 
oxopregn-4-en-
21-oic acid 
6b-
Hydroxymet
handienone 
11-
Dehydrocorticos
terone 
21-Hydroxy-5b-
pregnane-
3,11,20-trione 
6-
Dehydrotestoste
rone glucuronide 
21-Hydroxy-5b-
pregnane-31120-
trione 
21-
Deoxycortiso
l 
18-Oxocortisol 21-
Deoxycortisol 
11beta20-
Dihydroxy-3-
oxopregn-4-en-
21-oic acid 
21-Deoxycortisol 
11-
Dehydrocorti
costerone 
Cortexolone 11-
Dehydrocorticos
terone 
  11-
Dehydrocorticost
erone 
Corticosteron
e 
3b16a-
Dihydroxyandro
stenone sulfate 
Corticosterone Corticosterone 
Cortexolone Corticosterone 3b16a-
Dihydroxyandro
stenone sulfate 
Androstanedione 
2-
Methoxyestr
one 
  Cortexolone Epitestosterone 
3b16a-
Dihydroxyan
drostenone 
sulfate 
2-
Methoxyestrone 
18-Oxocortisol 
  6-
Dehydrotestoster
one glucuronide 
Testosterone 
  Dehydroepiandro
sterone 
Cortexolone 
3b16a-
Dihydroxyandros
tenone sulfate 
21-Hydroxy-5b-
pregnane-31120-
trione 
19-
Hydroxydeoxyco
rticosterone 
purines, 
pyrimid
ines 
6-
Thioinosinic 
acid 
Cytosine 5-
Aminoimidazole 
ribonucleotide 
Cytidine 2,3-
cyclic phosphate 
Deoxyadenosine 
monophosphate 
Cytidine 2,3-
cyclic phosphate 
5-
Methylthioade
nosine 
5-
Methylthioadeno
sine 
Cytidine 
monophosphate 
dUMP dUMP 
Cytidine 2,3-
cyclic 
phosphate 
Cytidine 
monophosph
ate 
Allopurinol 
riboside 
5-
Methylthioadeno
sine 
Biotinyl-5-AMP 5-
Methylthioadeno
sine 
  Deoxyadenosine 
monophosphate 
5-
Methylthioaden
osine 
3-
Methylcytosine  
3-Methylcytosine  
2-
Deoxyinosine 
triphosphate 
3-
Methylcytosi
ne  
    dUMP   Cytidine 2,3-
cyclic phosphate 
  2-O-
Methylcytosine 
2-O-
Methylcytosine 
5-
Methylthioad
enosine 
5-
Methylcytosi
ne 
3-
Methylcytosine  
Cytidine 
monophosphate 
5-
Methylcytosine 
8-Hydroxypurine 
  Dihydrouraci
l 
Cytosine Cysteine-S-
sulfate 
Thymine Thiocysteine 
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2-O-
Methylcytosi
ne 
  Cytosine Dihydrouracil 5-
Methylthioadeno
sine 
  Dihydrouracil 8-
Hydroxypurine 
Cytosine 
Deoxycytidine   Deoxycytidine 
8-
Hydroxypurine 
13-
Dimethyluracil 
  N-Acetyl-S-(N-
methylcarbamoyl
)cysteine 
24-Diamino-6-
hydroxypyrimidi
ne 
Dihydrothymine 
6-
Dimethylaminop
urine 
5-Thymidylic 
acid 
lipids 3-O-
Sulfogalactos
ylceramide 
(d18:122:0) 
Oleamide 3-O-
Sulfogalactosylc
eramide 
(d18:124:0) 
3-O-
Sulfogalactosylc
eramide 
(d18:120:0) 
  3-O-
Sulfogalactosylc
eramide 
(d18:122:0) 
3-O-
Sulfogalactosy
lceramide 
(d18:122:0) 
3-O-
Sulfogalactosylc
eramide 
(d18:124:0) 
3-O-
Sulfogalactosylc
eramide 
(d18:122:0) 
  3-O-
Sulfogalactosylc
eramide 
(d18:124:1(15Z)) 
3-O-
Sulfogalactos
ylceramide 
(d18:124:0) 
  3-O-
Sulfogalactosylc
eramide 
(d18:126:1(17Z)
) 
3-O-
Sulfogalactosylc
eramide 
(d18:124:0) 
3-O-
Sulfogalactosylc
eramide 
(d18:120:0) 
3-O-
Sulfogalactosy
lceramide 
(d18:124:0) 
3-O-
Sulfogalactosylc
eramide 
(d18:124:1(15Z)
) 
3-O-
Sulfogalactosylc
eramide 
(d18:120:0) 
3-O-
Sulfogalactosylc
eramide 
(d18:122:0) 
Oleamide 3-O-
Sulfogalactosylc
eramide 
(d18:122:0) 
  3-O-
Sulfogalactosylc
eramide 
(d18:124:0) 
  3-O-
Sulfogalactosylc
eramide 
(d18:120:0) 
Arachidonic 
acid 
3-O-
Sulfogalactosylc
eramide 
(d18:120:0) 
  Arachidonic acid   3-O-
Sulfogalactosylc
eramide 
(d18:118:0) 
  3-O-
Sulfogalactosylc
eramide 
(d18:118:0) 
  3-O-
Sulfogalactosylc
eramide 
(d18:112:0) 
3-O-
Sulfogalactosylc
eramide 
(d18:124:0) 
Oleamide 3-O-
Sulfogalactosylc
eramide 
(d18:112:0) 
  Arachidonic acid 
Oleamide 
other Melatonin 
glucuronide 
Urothion Mevalonic acid-
5P 
  D-Fucose Taurine Norepinephrin
e sulfate 
Allantoin NNAL-N-
glucuronide 
Histamine 
Phosphate 
Lipoyl-AMP 
cyclic 6-
Hydroxymela
tonin 
Fucose 1-
phosphate 
2-
Aminomuconic 
acid 
Fucose 1-
phosphate 
  Farnesyl 
pyrophosphate 
Porphobilinogen Taurine Acetylcholine  Biotinyl-5-AMP 
Farnesyl 
pyrophosphat
e 
Allantoin Melatonin 
glucuronide 
Allantoin Melatonin 
glucuronide 
dUMP   Fucose 1-
phosphate 
Porphobilinogen 
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Taurine Serotonin cyclic 6-
Hydroxymelaton
in 
Porphobilinogen L-Urobilin Neuromedin N 
(1-4) 
Allantoin Bilirubin 
  cyclic 6-
Hydroxymel
atonin 
Betaine     Fucose 1-
phosphate 
Taurine Melatonin 
glucuronide 
Melatonin 
glucuronide 
Taurine Taurine Porphobilinogen Allantoic acid 
Melanin L-Urobilin Melanin 3-O-Methyl-a-
methyldopamine 
FAPy-adenine 
Ribitol Melanin Norepinephrine 
sulfate 
  L-Urobilin 
L-Fucose   L-Urobilin Melanin 
Histamine 
Phosphate 
Bilirubin DOPA sulfate 
  Carnosine Taurine 
4E15Z-Bilirubin 
IXa 
Protoporphyrino
gen IX 
cyclic 6-
Hydroxymelaton
in 
Phosphohydroxy
pyruvic acid 
3-O-Methyl-a-
methyldopamine 
4E,15Z-Bilirubin 
IXa 
  Urocanic acid 
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4.5.2 Metabolite stability 
The typical metabolomics workflow requires an initial sampling step wherein samples of interest are 
collected, and then followed by one of the most crucial steps in the protocol: sample preparation. SPME 
was used for lung fingerprinting analysis during NEVLP because it integrates sampling and sample 
preparation into a single step, thereby offering superior and easy sample clean up. Importantly, in 
comparison to other sample preparation methods, SPME also features a simultaneous quenching step via 
the exclusive extraction of a wide range of small molecules representative of the metabolome. This is 
advantageous because interferences or changes to the sample that would occur due to the presence of 
coextracted enzymes, inherent with conventional sample preparation approaches, would be avoided. 
Furthermore, these enzymes would otherwise need to be inactivated separately prior to analyte isolation 
thus increasing sample handling.  
One of the aims of this multi-tiered study was to compare the information recovered from samples collected 
via the typical metabolomics workflow with the information obtained via on-site extraction of these 
samples, while using SPME as the main sample preparation tool. Given the dynamics of a biological system, 
snap freezing is often employed after sample collection to mitigate changes to the sample after it has been 
extracted from the system, thereby maintaining its integrity and ensuring an accurate representation of the 
metabolome. As such, the same methods were employed in order to determine whether there were any 
significant differences between the samples that were collected and prepared with SPME fibers on-site, and 
those that were immediately snap-frozen after collection and sampled in the laboratory. Figure 4.6 shows 
the differences between the three main sample groups, namely: lung tissue sampled in vivo on-site; 
perfusate sampled on-site at the same time as the lung tissue sampling; and perfusate that was snap-frozen 
and transported back to the laboratory for sampling. As can be seen in Figure 4.6, there is a distinct 
difference between the in vivo lung samples and all of the perfusate samples (a more obvious separation 
can be seen in the 3D PCA plot in Figure 4.6), which is likely due to their respective compositional 
differences (i.e, semi-solid vs fluid); however, there is also a distinct difference between the perfusate 
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samples that were collected and prepared on-site and those that were snap-frozen and sampled in the 
laboratory. This difference is interesting considering that these samples were collected at the same time 
point, with the same types of vials being used for collection, storage, and sampling. Although overlapping 
between the two perfusate groups can be observed for certain time points, the differences between them are 
clearly observable overall. 
 
Figure 4.6 PCA (PC1:51.6%; PC2: 35%; PC3: 6.5%) plot of samples collected in vivo from lung (red), perfusate 
samples collected on-site in the operating room (green), and perfusate samples collected, snap-frozen and sampled 
ex vivo in the laboratory (blue). 
 
Figure 4.7 shows a heat map for three sampling time points (1 hour, 3 hours, and 6 hours) for the three main 
sample groups (lung samples, on-site perfusate, and in-lab perfusate denoted by red, green, and blue class 
markers, respectively). Given that the perfusate samples were collected under the same conditions, one 
would expect to observe similar profiles in terms of the relative abundance of their respective features. This 
is true for some features, which is evidenced in the lower section of the heat map in Figure 4.7B and the 
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upper section of the heat map in Figure 4.7C; however, the dark red and dark blue squares in Figure 4.7A 
to Figure 4.7C indicate that there are a number of upregulated or down regulated features distinguishing 
the on-site and in-laboratory perfusate samples. This trend can be seen throughout the NEVLP process and 
for a wide range of compounds/features as demonstrated for hour 1, 3 and 6 of NEVLP in Figure 4.7. This 
result is quite surprising as it reveals that the typical metabolomics workflow can give rise to misleading 
results wherein prospective biomarkers may be a result of artefact formation. Nonetheless, it is important 
to note that, while there are differences between the on-site and in-laboratory prepared samples, the 
untargeted nature of the study makes it difficult to predict whether these particular statistically significant 
features are of any biochemical relevance. It is therefore important to emphasize that prospective 
biomarkers discovered during metabolomics studies may or may not be workflow dependent. As such, it is 
necessary to rigorously and intensively investigate such biomarkers before widespread use. 
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Figure 4.7 Group averaged heat maps of samples collected in vivo from lung (red), perfusate samples collected 
on-site in the operating room (green), and perfusate samples collected, snap-frozen, and prepared in the laboratory 
(blue). Dark red squares on the heat map indicate a very high abundance of that particular feature in a specific 
group of samples, while dark blue indicates a very low abundance. A) Heat map for samples collected after the 
first hour of perfusion (EVLP T0). B) Heat map for samples collected after 3 hours of perfusion (EVLP T1). C) 
Heat map for samples collected after 6 hours of perfusion (EVLP T2). 
 
Since SPME has also been reported to enable the extraction of short-lived and unstable metabolites 104,129,141, 
another aim of the study was to examine the advantages of using specifically tissue sampling to complement 
perfusate sampling as indeed, there are an indefinite number of biochemical processes occurring within the 
lung during NEVLP that may not be detectable in perfusate samples. This could be due to short-lived 
metabolites produced in lung by sometimes very rapid biochemical reactions. This advantage of tissue 
sampling is thus illustrated by the heat map in Figure 4.7 and requires an understanding of the dynamics 
and fundamentals of the SPME protocol. For example, some features/compounds (i.e. m/z 438.3, 503.3, 
502.3, 439.3, 207.1, 132.1, 107.0, 530.3, 156.1…) are highly abundant in lung tissue (represented by red 
class label in Figure 4.7A) but are not present in either set of perfusate samples. This disparity highlights 
the advantage of SPME as an in vivo technique, as these features may represent short-lived species only 
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present in lung tissue. Moreover, it is possible that these features diffuse from the lung to the perfusate more 
slowly during perfusion and are therefore not seen in the perfusion fluid collected at the time of SPME 
tissue sampling. This supposition supports the observation that lung samples exhibit a more rapid transition 
in comparison to metabolomic profiles observed in perfusate samples (as discussed in section 4.4.2 
“Unsupervised multivariate analysis”). Another aspect of interest that highlights the complementary 
information obtained via in vivo lung sampling and on-site sampling concerns the fundamentals of SPME, 
namely, that it performs extraction via free concentration. This is demonstrated in the heat map in Figure 
4.7, which shows a high abundance of features in the perfusate samples collected on-site and a low 
abundance of these same features in the corresponding in vivo lung samples. Since SPME, as a non-
exhaustive technique, extracts only a portion of the free concentration being sampled, it is possible that the 
features with apparent low-to-zero abundance may have very high binding to the lung tissue, thus resulting 
in a lower free concentration available for extraction. However, given the continuous perfusion of the organ 
and various diffusive processes, these features may have a higher free concentration in perfusion fluid due 
to lower binding processes in comparison to a denser semi-solid biomatrix, such as lung. These dynamics 
and interconnected processes not only emphasize the importance of performing simultaneous and 
complementary sampling, but they also emphasize the importance of having sample preparation tools with 
rapid on-site capabilities, as such tools can help to minimize sample handling and the number of required 
sample processing steps while providing reliable real-time pertinent biochemical information. 
4.6 Conclusion 
In summary, the use of prolonged NEVLP to extend the lifetime of the lungs may induce the cellular 
reprogramming of the organ to accommodate for or adjust to the biosynthetic demands of the applied 
procedure. The application of in vivo SPME fibers directly into the lungs allowed changes occurring in the 
organ at the metabolite level to be monitored during NEVLP. Several upregulated biochemical pathways 
mainly involved in pro- and anti-inflammatory responses, as well as in lipid metabolism, were observed 
during extended lung perfusion, especially between the 11th and 12th hours of the procedure. These changes 
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were also observed in the perfusate composition, wherein the majority of compounds were diffused from 
the lung during perfusion. However, a number of unstable and/or short-lived metabolites were solely 
extracted from lung tissue in vivo via SPME fibers. Moreover, the perfusate samples that had been stored 
and prepared in the laboratory according to the typical metabolomics workflow provided less 
complementary information about the metabolome/metabolomic profile of extracted compounds than in 
vivo tissue samples or perfusate samples collected in real-time on-site during NEVLP. In addition, the 
samples that were prepared in the laboratory also exhibited a tendency to be misleading by potentially 
producing artefacts associated with tentative features that have been previously reported as potential 
biomarkers for lung injury. In the future, secondary and tertiary cohort metabolomic studies, more targeted 
metabolomic approaches and substantial MS/MS validation, should be explored to confirm the possibility 
of artefact formation and the other tentative results of this untargeted metabolomic study. Furthermore, 
future research should also monitor the metabolomic status of lungs after transplantation to the recipient 
patient in order to find and confirm potential candidate biomarkers of lung function or injury during 
prolonged NEVLP; and a better association of the metabolic data and clinical data should be implemented. 
 
 
 
131 
 
Chapter 5: Therapeutic drug monitoring of FOLFOX and screening 
of drug metabolites followed by pharmacometabolomic 
fingerprinting of porcine lung tissue during pre-clinical in vivo lung 
perfusion (IVLP) using in vivo solid phase microextraction 
5.1 Preamble 
Chapter 5 of this thesis has not yet been published. The research presented in this chapter stemmed from a 
collaboration with Toronto General Hospital initiated by B. Bojko, J. Pawliszyn, and M. Cypel. Further 
modifications to the experimental design were overseen by G.A. Gomez-Rios. The work presented in this 
chapter of the thesis related to untargeted analysis, LC method development, experimental design for 
quantitative SPME method development, in vivo sample analysis, sample and data processing and stability 
study were conducted by the author of this thesis with assistance from G.A Gomez-Rios, A. Roszkowska, 
and Miao Yu. Please see Statement of contributions. Funding: We are grateful to the Canadian Cancer 
Society for their support in the development of IVLP via innovation grants. We are also grateful to the 
Canadian Institute of Health Research (CIHR) - Natural Sciences and Engineering Research Council 
(NSERC) of Canada Collaborative Health Research Projects program for their financial support [grant 
355935 entitled “Supervised in vivo lung perfusion strategy for treatment of cancer metastases to the lungs. 
Real-time monitoring of chemotherapy by on-site analytical platform”] and the Natural Sciences and 
Engineering Research Council of Canada Industrial Research Chair (IRC) program. 
5.2 Introduction 
The in vivo lung perfusion (IVLP) method employed at the Toronto General Hospital is a modified form of 
isolated lung perfusion (ILP) that was adapted from the Toronto ex vivo lung perfusion (EVLP) method in 
order to treat terminal pulmonary diseases like end-stage metastatic cancer in situ.142,143 This targeted drug 
delivery system enables high doses of chemotherapy to be administered exclusively to the lung, thus 
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minimizing common adverse drug-toxicity related effects of systemic exposure to chemotherapy, such as 
hair loss, nausea, vomiting, and weakened immune system. When used in conjunction with 
metastasectomy—which is currently the most effective treatment for lung cancer metastases—it is believed 
that IVLP can help to prevent disease recurrence by treating any undetected micrometastases remaining in 
the peripheral tissue following tumor resection.143 This combined approach may be able to improve the 
daunting 20% - 40% 5-year survival rate of patients with lung cancer metastases, as they tend to be 
particularly vulnerable to the appearance of new unresectable tumours.142,143 In this Chapter, the use of  in 
vivo SPME is explored for the simultaneous monitoring of combination drugs concentrations in the lung as 
well as the lung metabolome during pre-clinical IV and IVLP administration in porcine models. 
Combination chemotherapy approaches—for example, the use of Folinic acid (FOL), 5-fluorouracil (F), 
and oxaliplatin (OX) (FOLFOX)—have been shown to be effective for treating a wide range of solid tumors 
found in areas of the body including, but not limited to, the breasts, the head and neck, the ovaries, and, 
most notably, the colon.144–147 Despite these advantages, the intravenous (IV) administration of these 
therapies can lead to serious pulmonary side effects in a small subsection of patients (less than 1.5%);147 
however, since the risk of these side effects is so small, it is worth exploring the use of FOLFOX in 
conjunction with IVLP. Each drug in this FOLFOX combination exhibits a complex mechanism of action. 
One of the biologically active pathways (< 20%), specifically for  folinic acid-5-flurouracil (FOLF) 
combination, works by exploiting the thymidylate synthase (TS) pathway, which is an enzyme that is overly 
expressed in cancerous cells due to proliferation.145 Briefly, deoxyuridine monophosphate (dUMP) is 
enzymatically converted to deoxythymidine monophosphate (dTMP) via methylation on the C-5 position 
of uracil in the presence of 5,10-methylenetetrahydrofolate (5,10-methyleneTHF)—one of the metabolite 
of FOL. dTMP is subsequently phosphorylated and integrated into the DNA as deoxythymidine 
triphosphate (dTTP), which is vital for DNA repair and replication.1,145 However, the introduction of F, 
which can mimic both uracil, and thymine, leads to the formation of an irreversible ternary complex 
between F, the TS enzyme, and 5,10-methyleneTHF during attempts to methylate the C-5 position on uracil, 
133 
 
which now has a fluorine substituent instead. This inhibits the TS enzyme, consequently depleting the 
cellular availability of thymidine.1,145,146 The use of FOL in the therapy is to essentially inundate the folic 
acid pool with 5,10-methyleneTHF since increased concentrations of this folate lead to the stabilization of 
the ternary complex.146 Moreover, F can be further integrated into the DNA inadvertently via anabolism 
(building up of smaller molecules to complex molecules) to 5-fluorodeoxyuridine (5FdUrd) and then 
subsequent phosphorylation of 5-fluorodeoxyuridine monophosphate (5FdUMP), which produces 5-
fluorodeoxyuridine triphosphate (5FdUTP). The integration of F into the RNA occurs via the formation of 
5-fluorouridine (5FUrd) and the subsequent phosphorylation to 5-fluorouridine triphosphate 
(5FUTP).145,147,148 Replacing the thymidine and uridine substituent in DNA and RNA respectively, induces 
mutations in the DNA specifically as a result of the misincorporation of the incorrect base pair, which in 
turn leads to DNA and/or RNA damage and, ultimately, apoptosis.1 Meanwhile, the biological inactivation 
(> 80%) of F is mediated by the catabolic (breakdown of larger molecules to smaller molecules) metabolism 
of F via the dihydropyrimidine dehydrogenase (DPD) enzyme, which varies not only in concentration, but 
also in activity from patient to patient.147 DPD leads to the formation of inactive F catabolites, including 
dihydrofluorouracil (FUH2), fluoroureidopropionic acid (FUPA), and fluoro-beta-alanine (FBAL), none of 
which exhibit any therapeutic benefits.144,147,148 OX, which is a third-generation platinum-based 
chemotherapeutic drug,149 has various mechanisms of action but is known to largely exert its cytotoxic 
effect via the formation of DNA-protein crosslinks and especially the formation of DNA intra- and inter- 
strand crosslinks by binding usually to the N7 atom of guanine, forming links with two adjacent guanines 
and to a lesser extent to guanine-adenine base pair.149,150 OX undergoes rapid non-enzymatic transformation 
wherein the oxalate group is displaced, and the following transient reactive species are formed, namely, 
dichloro-, monochloro-, and diaquo- diaminocyclohexane (DACH). These reactive species readily complex 
with amino acids and proteins or other plasma and tissue macromolecules.149,151 The dichloro(DACH) 
complex enters the cells and the formation of these DNA lesions lead to DNA synthesis arrest and 
subsequently apoptosis. OX-DNA adduct conformation is postulated to more effectively inhibit the binding 
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of the mismatch repair (MMR) protein complex compared to first- and second- generation platinum-based 
agents cisplatin and carboplatin. Additionally, the bulky DACH group on OX better prevents DNA 
synthesis in comparison to cisplatin and carboplatin.150 OX has also been implicated in reducing F 
catabolism by inhibiting DPD activity, emphasizing the synergistic effects of namely the FOX combination 
in chemotherapy.144 
While a number of studies have established that FOLFOX provides satisfactory antitumor activity, standard 
dosing methods are hampered by high inter-patient variability with regards to FOLFOX concentrations in 
the blood plasma, which results in drug under- or over-exposure.10,147,152 Given the serious circumstances 
under which these drugs are administered, their accompanying cytotoxicity, and large inter-patient 
variability due to factors such as sex, weight, medical history, DPD activity and concentration, it is 
imperative to know the impact of these drugs throughout the treatment process. Personalizing treatment by 
monitoring the concentrations of these drugs can help to prevent under- or over-dosing, effectively 
maximizing therapeutic outcomes and minimizing adverse events. Therapeutic drug monitoring (TDM) is 
employed to measure the concentration of a drug in biological matrices such as blood, plasma, or tissue 
following administration, and it is required for drug combinations like FOLFOX, which have narrow or 
unknown therapeutic ranges and large inter-patient variability.10 Some challenges in TDM, specifically in 
the field of chemotherapy, include: a lack of available assays for the many possible therapies that can be 
administered; no agreed upon universal therapeutic range for drugs used in these treatments; and, in 
combination therapies, changes in the synergistic effects of one or more components due to the presence of 
other chemotherapies or patient medications at other various doses.10 Moreover, while plasma 
concentrations may be easier to monitor, this is not always suitable since it may not reflect the  
concentrations of a drug in specific tissues or organs requiring treatment, which can further exacerbate 
TDM-related challenges with respect tissue analysis.25 In clinical settings, performing TDM on tissue 
matrices requires the invasive collection of multiple biopsies over the course of treatment, as well as time-
consuming sample preparation procedures that are laborious and require multiple steps, such as cryogenic 
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pulverization or various other homogenization methods in tandem with solid-liquid extraction (SLE).25 
Nevertheless, it is critical to define the relationship of the administered chemotherapeutic dose and the 
effective concentration in the respective biofluid and tissue.  
Metabolomics is an emergent “omic” strategy in systems biology that has been proposed as an alternative 
means of assessing (combination) chemotherapy efficacy.153 Briefly, metabolomics entails the study of all 
metabolites in a system at a given time.128,154 The use metabolomics or pharmacometabolomics—the study 
of the metabolome in response to pharmaceuticals—to monitor one or a multitude of metabolic biomarkers 
for a particular combination or dose of chemotherapy could yield vital information about drug resistance, 
development of resistance, and overall positive, negative, or indifferent responses to treatment.153 Though 
metabolomics in general studies remain tremendously difficult to implement due to challenges associated 
with validating biomarkers, validating the methods used to obtain these biomarkers, and correctly 
interpreting candidate biomarkers, metabolomics could nevertheless help to guide treatment and provide 
information about treatment response.153  
Despite the availability of targeted approaches like TDM and the potential for untargeted approaches such 
as metabolomics, it remains difficult to obtain precise information regarding drug concentrations and the 
efficacy of combination therapy especially during IVLP, particularly in lung tissue. Another challenge of 
employing metabolomics is the requirement that the system under study not be disturbed by external 
stimuli, including the sample preparation method. However, biopsies entail removing a piece of the organ 
from the bulk, which can lead to changes in the metabolic profile of the collected lung sample, as well as 
in the metabolic profile of the lung itself due to injury sustained during the biopsy. In the case of TDM, 
current methods for tissue-based determinations of drugs utilize lung biopsies collected prior to the start of 
IVLP, and biopsies taken from peripheral locations in the lung following the completion of IVLP prior to 
chest closure at the end of reperfusion. Thus, the current tissue-sampling protocol is not sufficient for 
determining drug concentrations in the lung during the actual IVLP procedure. Furthermore, the biopsies 
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obtained after IVLP are usually from areas that are farther away from the bulk of the organ, often producing 
misleading or erroneous information due to the non-homogenous distribution of the drug within this 
heterogeneous organ.  
Solid phase microextraction (SPME) is a novel alternative sample preparation approach that involves the 
introduction of a small needle (200 µm in diameter) coated with a biocompatible polymeric extraction phase 
(40 µm thickness)55,62,129,155 into the lung, thus eliminating the need for biopsy collection. The simple design 
of the device and negligible depletion not only facilitate in vivo sampling, thereby overcoming an inherent 
limitation of other tissue sampling preparation techniques, but also integrates sampling and sample 
preparation into a single step. The polyacrylonitrile-based (PAN) extraction phase allows for the diffusive 
partitioning of a broad range of small molecule compounds (< 1000 Da) from complex biological matrices 
through adsorption,57,104 thus enabling the extraction and monitoring of targeted and untargeted small 
molecules. In addition, SPME eliminates the need for the solvent or solvent/perfusate-based extraction 
methods used in other in vivo methods, like microdialysis (MD), or other ex vivo methods, such as 
SLE.55,131,155 When coupled with liquid chromatography (LC) and highly specific and sensitive detectors 
like tandem mass spectrometry (MS/MS) or high-resolution mass spectrometry (HRMS), this method 
permits the targeted and untargeted analysis of all compounds removed from the biological tissue.62 
Furthermore, the amenability of SPME for direct coupling to mass spectrometry156 via a microfluidic open 
interface (MOI)79 easily enables rapid therapeutic analysis of drugs or metabolites in typically challenging 
matrices like tissues, especially under in vivo conditions.  
The present study had a number of objectives, which were informed by the following factors: the 
cytotoxicity of the FOLFOX combination therapy; the large inter-patient variations in FOLFOX drug 
concentrations within the plasma; unknown drug concentrations in the lung tissue; the unknown rate at 
which metabolites form in the lung, particularly during IVLP (wherein metabolism via the liver is bypassed) 
as well as IV; and the lack of information regarding organ status during IVLP and IV FOLFOX treatments. 
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To address these issues, SPME is proposed as an in vivo sampling technique for the simultaneous 
therapeutic monitoring of FOLFOX and metabolites in pig lungs during administration via pre-clinical 
IVLP and IV, with the chemotherapeutic efficacy of these administration routes being subsequently 
assessed via pharmacometabolic fingerprinting. To this end, a retrospective SPME protocol was developed 
for the quantitation of FOLFOX in lung tissue undergoing IVLP; this method was also used to determine 
FOLFOX concentrations in sample extracts obtained during the pre-clinical IVLP and IV trials. In addition, 
a retrospective dual mode quantitative LC-MS/MS method was developed for the comprehensive targeted 
monitoring of FOLFOX and the screening of drug metabolites, including the metabolites of FOL, such as 
5-methyltetrahydrofolate (5-methylTHF), 5,10-methyleneTHF, and tetrahydrofolate (THF), and the 
metabolites of F, including anabolites such as 5FUrd, 5FdUrd, FdUMP, FUTP, and FdUTP, and catabolites 
such as FBAL and FUPA. Pharmacometabolic fingerprinting was performed using LC-HRMS as a proof 
of concept to illustrate the ability of SPME to characterize changes in lung tissue over the course of the 
IVLP procedure. The ability to characterize changes in the lung throughout the IVLP procedure could 
enable interpretation about the state of the tissue during therapy or provide possible useful biochemical 
information to indicate potentially promising markers/features of drug effectiveness or toxicity. 
Furthermore, a supplementary study was conducted to assess metabolic profile stability under the standard 
storage conditions currently employed in metabolomics; the objective of this supplementary study was to 
determine whether these standard storage conditions (-80 ⁰C) reliably preserve precious samples. To the 
best of our knowledge, this is the first time a dual LC-MS/MS method encompassing FOLFOX and all of 
its metabolites has been proposed in conjunction with the novel pharmacometabolic fingerprinting 
methodology to assess chemotherapeutic efficacy during pre-clinical IVLP and IV administration in a 
porcine model. This is also the first time an SPME-based method has been developed for quantitation of 
FOLFOX in lung tissue. 
138 
 
5.3 Materials and Methods 
5.3.1 Materials 
(6R,S)-5,6,7,8-tetrahydrofolic acid hydrochloride (THF) and the internal standard (IS), 5-fluoro-2’-
deoxyuridine (5FdUrd), were purchased from Cayman Chemical Company (Ann Arbor, USA), while 
Uridine-15N25’-monophosphate (UMP-IS), uridine15N25’-triphosphate (UTP-IS), folinic acid 
(FOL)/leucovorin calcium, and 5-fluorouracil (F) were purchased from Sigma-Aldrich (St. Louis, USA). 
The following compounds were purchased from Sierra Bioresearch (Tucson, USA): 5-fluoro-2’-
deoxyuridine-5’-triphosphate (5FdUTP), 5-fluoro-2’-deoxyuridine-5’-monophosphate (5FdUMP), and 5-
fluorouridine-5’-triphosphate (5FUTP). Finally, 5,10-methylenetetrahydrofolic acid (5,10-methylTHF), 5-
methyltetrahydrofolic acid (5-methylTHF), folic acid-d2 (FA-d2), (2R)-3amino-2-fluoropropanoic acid 
(FUPA), ureidopropionic acid (FUPA-IS), alpha-fluoro-b eta-alanine (FBAL), alpha-fluoro-beta-alanine-
13C3 (FBAL-IS), 5-fluorouridine-13C,15N2 (5FUrd-IS), 5-fluoro-2’-deoxyuridine-13C,15N2 (5FdUrd-IS), 
oxaliplatin (OX), carboplatin, and chlorouracil (CU) were purchased from Toronto Research Chemicals 
(Toronto, Canada). 
5.3.2 Animals 
Four Yorkshire pigs with an average weight of 35 kg were used for the IVLP (3) and IV (1) experiments. 
This study was approved by the Animal Care Committee of the Toronto General Research Institute and all 
animals received humane care in compliance with the Principles of Laboratory Animal Care outlined by 
the National Society for Medical Research and the Guide for the Care of Laboratory Animals instituted by 
the National Institutes of Health. 
5.3.3 IVLP procedure 
This procedure is described in more detail elsewhere.142,143 Briefly, post induction of general anesthesia, the 
left pulmonary artery (PA) and the left pulmonary veins (PV) were dissected and isolated via a left 
thoracotomy, with ventilation to the left lung being maintained by an intensive care unit (ICU) ventilator. 
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After heparin administration, the left PA and PVs were cannulated and clamped before initiating IVLP in 
order to isolate the left lung from systemic circulation. 1.2 L of SteenTM solution/perfusion fluid (XVIVO 
Perfusion, Gӧteburg, Sweden) was then circulated through the isolated organ by a centrifugal pump, which 
first passed the perfusion fluid through a membrane gas exchanger that was connected to a heater/cooler 
which modulated perfusate temperature to normothermic conditions. The warmed solution then passed 
through a leucocyte filter, entered the lung via the left PA, and exited through the left PV into a hard-shell 
reservoir maintained at a certain height to ensure suitable PA and PVs pressures. After entering the 
reservoir, the fluid was then recirculated through the circuit. Drug doses were calculated based on the body 
weight and body surface area (BSA) of the pigs using Brody’s formula.157 400 mg/m2 of FOL was 
administered intravenously. Once maximum circuit flow was reached, FOX was administered directly into 
the perfusion circuit through the reservoir as a bolus at a concentration of 400 mg/m2 for F, and 
concentrations of either 255 mg/m2 or 170 mg/m2 for OX. After 4 hours of IVLP, a 10 to 15-minute washout 
with 500 mL of pure perfusate (Perfadex; XVIVO Perfusion) was conducted, followed by the removal of 
the cannulas from the PA and PVs. The lung was then reconnected to systemic circulation and reperfusion 
(normal systemic circulation) was initiated for a two-hour period. 
5.3.4 IV procedure 
A left thoracotomy was performed in order to allow the sampling fibers access to the lung; however, no 
further surgical processes took place. FOLFOX was administered intravenously at 400 mg/m2 for FOLF 
and 85 mg/m2 for OX for a period of approximately 2 hours. 
5.3.5 Lung sampling protocol 
The SPME fibers used to perform in vivo lung sampling during IVLP and IV consisted of an octadecyl-
strong-cation-exchange (C18-SCX) coating and were kindly provided by Supelco. The fibers were initially 
sterilized for a minimum of 30 minutes in a solvent mixture consisting 50:50 methanol/water. Following 
sterilization, the fibers were removed from the conditioning solvent and inserted by surgeons into the lung 
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in triplicate approximately 1-2 cm apart from each other at predetermined time points as outlined in Figure 
5.1 and described in more detail below. After the extractions had been completed, the fibers were removed 
from the lung tissue, rinsed manually in water for 5 s to remove any loosely adhered biological matter, 
wiped with a Kimwipe, and placed in empty 300 µL polypropylene vials. The vials were then snap frozen 
in dry ice for transportation to the lab. The fibers remained stored in the empty vials at –80 ⁰C until the time 
of instrumental analysis. 
The left lung was sampled according to the schedule outlined in Figure 5.1 (In vivo Lung Perfusion (IVLP) 
SPME fiber Sampling Schedule). Briefly, the lung was initially sampled at baseline (IVLP Lung Blank) 
post sternotomy and prior to the addition of FOLFOX; it was then sampled 10 minutes after the intravenous 
administration of FOL (Time L0), and again 60 minutes after the initial FOL administration (Time L1). 
Due to surgical time restrictions, an extraction time of 10 minutes was used for each of these three sampling 
points prior to IVLP. The next round of sampling was conducted following the administration of FOX into 
the perfusion circuit, 10 minutes (IVLP T0) after the commencement of IVLP (full flow established), with 
subsequent samplings taking place at 1-hour intervals during the 4 hours of perfusion (IVLP T1-IVLP T3), 
and at 1-hour intervals during the 2 hours of reperfusion (IVLP T4-IVLP T5). An extraction time of 30 
minutes was used for sampling during IVLP and reperfusion. 
During the intravenous administration (IV) of FOLFOX, the lung was sampled according to the schedule 
outlined in Figure 5.1 (Intravenous SPME Fiber Sampling Schedule). Briefly, the lung was sampled at 
baseline (IV lung blank) prior to the administration of FOLFOX, and again at 40 minutes (IV TL) after the 
start of bolus administration of FOLFOX. The lung was subsequently sampled hourly at 100 minutes, 160 
minutes, 220 minutes, and 280 minutes (IV T0 – IV T3). Infusion lasted approximately 2 hours.  
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Figure 5.1 Lung sampling schedule using SPME fibers during in vivo lung perfusion (IVLP) (top schedule) and 
intravenous (IV) FOLFOX administration (bottom schedule). 
 
5.3.6 Perfusate sampling protocol 
Single perfusate samples were collected in parallel with the IVLP sampling schedule outlined in Figure 5.1 
following the same protocol that was used for lung sampling. C18-SCX fibers were sterilized/conditioned 
in 50:50 methanol/water and then exposed to 300 µL of perfusion fluid for a total of 30 minutes under static 
conditions. The fibers were then removed, rinsed manually for 5 s in pure water, and stored in empty 300 
µL vials, which were snap frozen in dry ice and stored at –80 ⁰C until further analysis. 
5.3.7 Fiber coating procedure 
Hydrophilic-lipophilic balance (HLB) was investigated separately, alongside octyl-strong-cation-exchange 
(C8-SCX) as alternative extraction phase that can compete with C18-SCX, as it has been reported to be 
particularly useful for isolating compounds characterized by low logP values. To this end, an in-house 
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developed coating procedure was used to coat nitinol wires with 5 µm HLB particles—which were kindly 
provided by Waters Corporation—until the coating dimensions measured 1.5 cm in length and 40 µm in 
thickness.134,158,159 Briefly, this dip-coating method utilized an automated software-operated computer 
system to dip the 4 cm nitinol wires into a homogenously mixed slurry composed of 10 % (w/v) particles, 
1 % glycerol (v/v), and 89 % (v/v) of 7 % (w/v) PAN. This dipping process was repeated until the desired 
coating dimensions had been achieved.   
5.3.8 Sample preparation and sample extracts 
Sampling and sample preparation, which are integrated into a single step in SPME, was conducted at the 
hospital during pre-clinical IVLP and IV trials as described above. Just prior to instrumental analysis, the 
fibers were removed from storage at –80 ⁰C and desorbed at room temperature in 50:50 acetonitrile/water 
for 60 minutes at 1500 rpm. At the end of the 60-minute desorption period, the fibers were removed from 
desorption solution and discarded, and LC-HRMS was used to perform instrumental analysis on the final 
solvent extracts. Once the quantitative method for FOLFOX had been developed, a portion of these extracts 
were transferred from their original vials (20 µL) to separate vials and mixed with 6 µL of internal standard 
mixture to produce a final concentration of 200 ng/mL (IS). The quantitative analysis of FOLFOX and the 
screening of FOLFOX metabolites was then conducted by subjecting these newly prepared solutions to LC-
MS/MS. 
5.3.9 Mass spectrometric parameters and conditions 
Folinic acid, 5,10-methyleneTHF, 5-methylTHF, and THF were tuned and analyzed in positive mode, while 
oxaliplatin, F, 5FdUMP, 5FdUTP, 5FUTP, 5FUrd, 5FdUrd, FUPA, and FBAL were tuned and analyzed in 
negative mode. All compounds were initially tuned at a concentration of 1 µg/mL in a 50:50 
acetonitrile/water solution containing 0.1% acetic acid, with flow rates of 5 µL/min and 7-10 µL/min for 
positive and negative mode ionization, respectively. For poor ionizers, infusion was instead performed at 
either 5 µg/mL or 10 µg/mL. The tuning parameters and conditions are outlined in Table 5.1.  
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Table 5.1 Mass spectrometric parameters and conditions used for tuning compounds and metabolites in 
positive and negative mode. 
MS Parameters Positive mode Negative mode 
Source position B D 
Voltage (kV) 3-3.5 2 - 2.5 
Sheath gas (AU) 2-5 15-30 
Auxiliary gas (AU) 0 - 2 0 - 2 
Capillary temperature (⁰C) 275 275 
Sweep gas (AU) 0 0 
 
5.3.10 LC-MS/MS method for FOLFOX and metabolites screening 
The chromatographic separation of F, 5-FUrd, 5-FdUrd, 5-FUTP, 5-FdUTP, 5-FdUMP, FBAL, FUPA, OX 
and their respective internal standards was performed using a Sequant® Zic®-pHILIC column (100 x 2.1 
mm, 5 µm particle size; MilliporeSigma: Darmstadt, Germany) protected by a corresponding Sequant® 
Zic®-pHILIC column guard column (20 x 2.1 mm, 5 µm particle size). LC-MS/MS was conducted using 
a Thermo Vanquish quaternary pump and an autosampler coupled to a Thermo TSQ Vantage triple 
quadrupole mass spectrometer equipped with an Ion Max™ atmospheric pressure ionization (API) heated 
electrospray source (HESI). Water (mobile phase A) and acetonitrile (mobile phase B), each with 0.1% 
acetic acid and 5mM ammonium acetate, were employed at a total flow rate of 300 µL/min. An injection 
volume of 5 µL was utilized, with the samples and column being maintained at 5 °C and 25 °C, respectively. 
The above-noted compounds were ionized in negative mode at 2 kV in position D. More information on 
the LC gradient, the HESI source parameters, and the MS parameters is provided in Table 5.2 and Table 
5.3. 
Table 5.2 LC gradient conditions used with the Sequant® Zic®-pHILIC column (100 x 2.1 mm, 5µm 
particle size) for OX, F, and F metabolites. 
Time (min) 
Total flow = 300 µL/min 
% Mobile phase A: water + 0.1 
% acetic acid + 5mM ammonium 
acetate 
% Mobile phase B: acetonitrile + 
0.1 % acetic acid + 5mM 
ammonium acetate 
0.00 10 90 
1.00 10 90 
4.00 70 30 
4.70 70 30 
4.90 10 90 
8.00 10 90 
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Table 5.3 MS conditions and observed chromatographic retention times for OX, F, and F metabolites. 
Negative mode ionization was employed.  
Compound Parent mass Product mass S-LENS Collision energy Retention 
time (min) 
FBAL 106 86 46 11 5.66 
FBAL-IS 109 89 47 11 5.66 
5-fluorouracil 129 42 49 19 1.26 
5-chlorouracil 145 42 52 20 1.21 
FUPA 149 86 41 18 5.51 
106 * 12 
FUPA-IS 131 88 38 12 5.30 
5-FdUrd 245 155 69 17 1.09 
5-FdUrd-IS 248 132 69 16 1.11 
158 * 17 
5-FUrd 261 129 72 10 1.55 
171* 16 
5-FUrd-IS 264 132* 72 17 1.57 
171 16 
5-FdUMP 325 79 82 53 5.54 
129 * 23 
UMP-IS 325 97 105 24 5.74 
 113 * 28 
5-FUTP 501 159 * 112 39 6.63 
403 20 
5-FdUTP 485 159 104 35 6.56 
257 27 
387 * 20 
Oxaliplatin 396 89 95 19 4.60 
196 * 37 
284 21 
Carboplatin 370 352 133 12 5.22 
Some compounds had more than one transition. Transitions which are denoted by (*) were used as the 
quantifier ion. The other transition(s) were used as qualifier ions. IS means internal standard. The Ion Max 
heated electrospray ionization source was run at 2 kV at position D with a vaporizer and capillary 
temperature of 275 °C, and a sheath gas, ion sweep gas, and auxiliary gas of 35, 0, and 5, respectively. 
 
A Discovery® HS F5-3 (PFP) column (100 x 2.1 mm, 3 µm particle size; MilliporeSigma: Bellefonte, PA) 
protected by a corresponding Discovery® HS F5-3 guard column (20 x 2.1 mm, 3 µm particle size), was 
employed for the separation of FOL, 5,10-methylTHF, 5-methylTHF, THF and folic acid-d2 on the above-
mentioned LC-MS/MS system. Mobile phases A and B consisted of water and acetonitrile, respectively, 
with 0.25% acetic acid and 0.05% formic acid added to each. The same flow rate and autosampler 
conditions noted above were applied, but the column was maintained at 30 ⁰C and an injection volume of 
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10 µL was used. The compounds were ionized in positive mode at 1.3 kV in position B. More information 
on the LC gradient, HESI source parameters, and the MS parameters is provided in Table 5.4 and Table 
5.5. 
Table 5.4 LC gradient conditions for the Discovery HS F5-3 (PFP) column (100 x 2.1 mm, 5µm particle 
size) used for FOL and its metabolites, 5-methylTHF, 5-methylTHF, and THF. 
Time (min) 
Total flow = 300 µL/min 
Mobile phase A: water + 0.25% acetic 
acid + 0.05% formic acid 
Mobile phase B: acetonitrile + 0.25% 
acetic acid + 0.05% formic acid 
0 95 5 
0.33 95 5 
0.83 85 15 
2.17 76 24 
2.50 50 50 
2.67 10 90 
4.20 10 90 
7.00 95 5 
8.50 95 5 
 
Table 5.5 MS conditions and observed chromatographic retention times for FOL and its metabolites, 5-
methylTHF, 5-methylTHF, and THF. Positive ionization was employed. 
Compound Parent mass Product mass S-LENS Collision energy Retention time 
Folinic acid 474 327 109 18 1.33 
5,10-methylTHF 458 311 79 20 5.00 
5-methylTHF 460 180 56 39 5.46 
313 * 19 
THF 446 299 113 19 5.14 
Folic acid-d2 444 297 95 17 1.35 
The Ion Max heated electrospray ionization source was run at 1.3 kV at position B with a vaporizer and 
capillary temperature of 275 °C, and a sheath gas, ion sweep gas, and auxiliary gas of 30, 2, and 30, 
respectively 
5.3.11 Calibration curve and quality control 
Study limitations (the release of external compounds (internal standard) was not permitted) inherent to this 
in vivo study conditions precluded the use of pre-loaded internal standards on the SPME fiber and as such, 
kinetic calibration methods could not be used for quantitation. Consequently, a matrix-matched external 
calibration curve was instead constructed in 15 g of lamb lung homogenate with a range of 2 µg/g-2000 
µg/g. Previous research showed that there was no statistical difference between the amount of drug 
(doxorubicin) extracted from intact tissue (biopsy collected during pre-clinical IVLP trials with 
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doxorubicin) vs. tissue homogenate (same biopsy homogenized) using SPME fibers.160 Internal standards 
were then only added to the desorption solution, thus correcting for LC-MS injection, but not for extraction. 
This matrix-matched external calibration curve was made to correspond to an instrumental curve that 
ranged from 0.001 µg/mL to 1 µg/mL for F and 0.01µg/mL to 3.5 µg/mL for FOL in order to reduce the 
use of large amounts of lung homogenate and to simplify the quantitation process. Ultimately, a limit of 
detection (LOD) of 25 µg/g and a limit of quantitation (LOQ) of 50 µg/g was achieved for both F and FOL. 
This is discussed in section 5.4.8 “Standard solutions, calibration curves, method validation and quality 
control”. A quality control at concentrations of 100 µg/g and 500 µg/g were internally assessed via the back 
calculation of the validated matrix-matched lung homogenate calibration curve with these points excluded.  
5.3.12 LC-HRMS for untargeted analysis 
Pharmacometabolic fingerprinting was performed on the porcine lung and perfusate extracts collected 
during the pre-clinical IVLP and IV trials using a Thermo Exactive orbitrap mass analyzer mass 
spectrometer coupled to an Accela binary pump and autosampler. Chromatography was done on a 
Discovery® HS F5-3 column (100 x 2.1, 3 µm particle size: MilliporeSigma: Bellefonte, PA) protected by 
a Discovery® HS F5-3 guard column (20 x 2.1 mm, 3 µm particle size), using a 40-minute method that had 
previously been developed in laboratory.57 Mobile phases A and B consisted of water and acetonitrile, 
respectively, with 0.1% formic acid added to each for positive mode analysis, and 0.1% acetic acid added 
to both for negative mode analysis. The column was maintained at 30 ⁰C, and the samples were kept in the 
autosampler at 4 ⁰C. A pooled quality control (QC) consisting of 10 µL of each sample extract was collected 
in a separate vial and injected every 10 samples during instrumental acquisition. An injection volume of 10 
µL was used for LC-HRMS analysis. 
5.3.13 Data pre-processing for untargeted analysis 
After instrumental analysis via LC-HRMS, the raw files were converted to mzXML files via MSConvert. 
Initially, the IPO package from the XCMS software package was used with an in-laboratory-developed 
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script in RStudio in order to optimize the peak-picking parameters based on the pooled QCs.106–108 These 
optimized parameters were then used to perform data pre-processing functions, such as noise filtering and 
baseline correction, peak detection and deconvolution, retention time and mass-to-charge ratio (m/z) 
alignment and correction, and normalization. The final data matrix, which contained all sample names, all 
features, their respective retention times, and feature intensity across the samples, was filtered by 
eliminating features in the pooled QCs with relative standard deviations (RSD) > 30% and a pooled QC-
to-blank ratio of < 5. The xMSAnnotator Integrative Scoring Algorithm110 was used to annotate features 
from each group in the data via retention time clusters, adduct formation, isotope patterns and abundance 
and pathway analysis. Only high- and medium-confidence matches with unique or multiple feature 
identities were considered for further data interpretation. 
5.4 Results  
5.4.1 Chemometric analysis and model validation 
Statistical analysis, including multivariate and univariate analysis, was performed using Metaboanalyst. 
Principal Component Analysis (PCA) was initially used to assess the quality of the instrumental run via 
analysis of the pooled QCs’ structures, with Partial Least Squares Discriminant Analysis (PLS-DA) and 
Orthogonal Projection to Latent Structures Discriminant Analysis (O-PLS-DA) being subsequently 
employed to fingerprint/classify the clustered groups. Univariate analysis by way of the Kruskal-Wallis test 
was employed to identify any features that changed significantly (false discovery rate (FDR) adjusted p 
value < 0.05) across two or more time points during IVLP or IV. Only models that passed crossed validation 
were further considered. The PLS-DA model generated for time points taken during IVLP (IVLP T0 to 
IVLP T3) was validated using a permutations test (at 1000) and a 10-fold cross validation (CV). Both CV’s 
passed with the original data classification generating a significant difference (p < 0.01) in comparison to 
the remaining permuted distribution of the data while the 10-fold CV produced a model fit of R2 = 0.90 and 
a predictability of Q2 = 0.79. A such the Variables of Importance (VIP) with scores greater than 1.5 (VIP > 
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1.5) were further investigated and tentatively identified using METLIN and cross referenced via annotation. 
Features of interest are shown in the Table 5.6 and tentatively and putatively identified with a mass accuracy 
of less than 5 ppm. 
Table 5.6 VIPs > 1 obtained from a validated PLS-DA model for lung sampling events performed during 
IVLP with FOLFOX. Shown are statistically significant features changing from IVLP T0 to IVLP T3. Data 
obtained from positive mode analysis 
Compound 
classification 
Feature parameters Tentative ID 
m/z Retention time 
(min) 
Adduct Average VIP score 
Important features 
found via METLIN 
and annotation 
375.2164 13.9 [M+H]+ 28 16-phenyl tetranor 
prostaglandin E1, 8-
oxo-resolvin D1 
378.3 16.6 [M+Na]+ 7.1 Arachidonoyl-
EA(d8) (not found 
in annotation) 
282.2792 21.4 [M+H]+ 5 oleamide 
377.2324 12.9 [M+H]+ 2.1 Resolvin D1 - D4, 
HDOPA 
Other endogenous 
compounds found 
via METLIN 
247.1075 11.7 [M+H]+ 32 N-acetyl-DL-
tryptophan 
166.0863 9.0 [M+H]+ 6.1 L-phenylalanine 
132.102 7.1 [M+H]+ 4.4 L-isoleucine, L-
alanine 
205.0973 12.0 [M+H]+ 3.9 L-tryptophan 
195.1189 5.1 [M+H]+ 2.5 L-arginine 
323.1702 10.0 [M+NH4]
+ 2.0 Threoninyl-
tryptophan 
182.0813 7.1 [M+H]+ 1.5 L-Tyrosine, L-threo-
3-Phenylserine, N-
Hydroxy-L-
phenylalanine 
[M+NH4]
+ Phenylpyruvic acid 
104.1072 6.4 [M+H]+ 1.1 Choline 
 
5.4.2 LC method development  
Although the FOLFOX compounds are used in combination with one another for chemotherapy, these 
compounds and their metabolites possess a wide range of polarities (log(p) values provided are a mix of 
experimental and predicted values obtained from drugbank161) and mass ranges (Figure 5.2). Generally, 
these compounds have been ionized exclusively in either positive (OX, FOL, and FOL metabolites) or 
negative mode (F and F metabolites), which effectively renders the use of a single LC-MS/MS method 
impractical unless instruments capable of polarity switching are utilized. Furthermore, various column 
types have been successfully used for separation of only subsets of these compounds,162 thus requiring the 
use of three or more LC-MS/MS methods for the screening and/or quantitation of all FOLFOX drugs and 
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drug metabolites. To address this challenge, several columns were evaluated during the development of an 
LC method that could encompass all the target compounds (FOLFOX drug and drug metabolites): a 
Hypercarb column (100 x 2.1 mm, 5µm particle size; Thermo Scientific), a Kinetex pentafluorophenyl 
(PFP) column (100 x 2.1 mm, 2.6 µm particle size; Phenomenex), a Discovery® HS F5-3 (PFP) column 
(100 x 2.1 mm, 3 µm particle size; MilliporeSigma), an Atlantis C18 column (70 x 2.1 mm, 5 µm particle 
size; Waters Corp), and a Sequant® Zic®-pHILIC column (100 x 2.1 mm, 5 µm particle size; 
MilliporeSigma). Acetonitrile, water, and methanol were tested as mobile phases, while formic acid, acetic 
acid, ammonium acetate, or a mixture thereof were tested as mobile phase additives.  
 
Figure 5.2 Distribution of FOLFOX compounds and their metabolites according to their mass-to-charge 
ratio (m/z) and physiochemical properties (LogP). 
 
Given the limitations associated with the physiochemical properties of the compounds and their preferred 
MS polarity analysis modes, the aim was the development of an LC-MS/MS method that ideally used a 
single column and a dual mode additive, such as acetic acid, that is suitable for both positive and negative 
modes. This would result in a more streamlined LC-MS/MS analytical process as positive- and negative-
mode analysis could be efficiently executed without the need for solvent change over or column 
conditioning. Therefore, FOL, FOL metabolites, and OX were initially grouped together for analysis in 
positive mode, while F and F metabolites were grouped together for analysis in negative mode. However, 
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separation on any particular column was only successful for either positive- or negative-mode groups 
individually, but not for both at the same time. While the Hypercarb column provided good separation for 
OX, F, and F metabolites, it was unable to elute folates, even with the increased elution strength of the 
various MS-compatible mobile phases listed above. This phenomenon was also observed for the Zic-
pHILIC column, which provided improved separation and retention of OX, F, and F metabolites, with all 
folates being eluted close to the void volume. The opposite effect was seen with the Atlantis C18, 
Discovery, and Kinetex F5 columns; that is, these columns provided good separation for FOL and FOL 
metabolites, with OX, F, and F metabolites all being eluted in the void volume. It became clear that two LC 
methods utilizing two separate columns would be necessary for the comprehensive separation and 
quantification of FOLFOX and the screening its of metabolites. However, the literature contains no reports 
of oxaliplatin being ionized in negative mode.163 Considering that it was not feasible to attain OX retention 
on reversed-phase columns in the same manner as other positively ionized compounds, such as FOL and 
FOL metabolites, a third LC-MS/MS method would have been necessary to analyze oxaliplatin on a 
separate column. To avoid the laborious and time-consuming prospect of having to use three separate LC 
methods, the goal of the method-development process was altered to focus on minimizing the number of 
LC methods required for the comprehensive analysis and separation of FOLFOX and metabolites. 
Therefore, for the first time, OX was tuned and analyzed in negative mode, and grouped together with 
similar polarity compounds like F and F metabolites in an effort to maintain a maximum of two LC-MS/MS 
methods.  
Methanol was found to be a sub-optimal eluent for FOL and FOL metabolites, as it produced extremely 
poor peak shapes that were either very late-eluting or required a longer LC method; in contrast, acetonitrile 
produced much better results for the same gradient, with narrower, sharper, gaussian peak shapes and 
acceptable elution times. A concentration of less than 5 mM of ammonium acetate buffer produced much 
broader peaks for some metabolites; conversely, while it was more challenging to dissolve 10 mM of 
ammonium acetate buffer in acetonitrile containing 0.1% acetic acid, this formulation produced a 
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tremendous increase in the spray current of the ESI needle. However, this volume did not provide significant 
improvement in peak shape in comparison to the 5 mM ammonium acetate concentration. A similar trend 
was observed for acetic acid as an additive, as less than 0.25% produced broader peaks during the analysis 
of FOL and FOL metabolites. A literature review revealed that existing methods for separating and 
quantitating F and F metabolites generally use mobile phases that require pH adjustment, high salt 
concentrations (> 10 mM), or the use of a regularly scheduled separate LC run for cleaning.162,164–168 These 
types of modifications can be time consuming, potentially error-prone, and lead to MS fouling, which can 
affect instrument sensitivity. Furthermore, no singular method encompassing all F metabolites has been 
developed; rather, the developed methods are only able to quantitate/screen for a class of metabolites, like 
the anabolites specifically, or the catabolites separately. The method developed herein is capable of 
quantitating and separating all F metabolites, without the need for pH adjustment or the use of high salt 
concentrations.  
5.4.3 Selectivity and specificity of LC-MS/MS method 
To ensure that the developed LC-MS/MS method was free of interferences from co-extracted or co-eluted 
endogenous compounds, C18-SCX-, HLB- and C8-SCX-coated fibers were used to perform extractions 
from the blank (non-spiked) homogenized lamb lung tissue that had been used to prepare the matrix-
matched external calibration curve. In addition, neat solvent blanks were also tested. Neither the solvent 
blanks nor the blank lung extractions showed any interferences for the specific transitions of any of the 
desired target compounds or metabolites. The chromatograms illustrating the LC-MS/MS method’s 
specificity and selectivity can be seen in Figure 5.3 (data shown for HLB- and C8-SCX-coated fibers). 
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Figure 5.3 Evaluation of LC-MS/MS selectivity and specificity. Neat solvent blank and extracts obtained from blank 
(non-spiked) lung homogenate with the hydrophilic-lipophilic balance (HLB) and C8-SCX (MM) coatings were injected 
and monitored at the mass spectrometric transitions of the target analytes. The blank signal from the HLB coating is shown 
in turquoise, the signal from MM is shown in dark gray, and the signal from the neat solvent is shown in dark purple 
bolded. 
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5.4.4 FOLFOX compounds and drug metabolites stability 
The OX, F, and F metabolites investigated in this study have previously been reported as being stable in 
solvent and in extracts from a range of biological matrices, including plasma, cell lines, and tissue.163–169  
As such, the stability of these metabolites was not evaluated further in this study.  Since SPME provides 
quenching by exclusively extracting small molecules from very complex matrices via free concentration 
while selectively excluding red blood cells, macromolecules such as proteins, and large molecules (>1000 
Da). The direct desorption of the fibers into the desorption solvent is comparable to the storage of each 
compound or metabolite under solvent conditions. For example, DPD, the major enzyme that catabolizes 
F, is found in red blood cells and in tissues. However, SPME does not extract red blood cells or tissue 
fragments; rather, its PAN-based coating essentially acts as a high-molecular-weight sieve that allows it to 
extract only small molecules available in free concentrations. Thus, the extracted drugs and metabolites 
desorbed into the desorption solution will behave similarly to how they would in pure solvent, as they will 
not undergo enzymatic degradation. However, folates such of FOL and FOL metabolites are prone to rapid 
degradation in light, air, and under various pH conditions and temperatures; therefore these compounds 
require the presence of an antioxidant in the solution.170 Thus, 1% ascorbic acid was added to the 50:50 
acetonitrile/water desorption solution used throughout the development of the proposed method. 
5.4.5 Coating performance and absolute recoveries 
At the inception of this study, the clinical application of SPME was rather novel. Moreover, access to 
various coating types and in-house coating protocols were limited at the time, which led to the exclusive 
use of LC- and bio-compatible C18-SCX-coated fibers that were also newly commercially available. Given 
that this study involved both targeted and untargeted analyses, these devices were deemed ideal, as they 
featured good inter-fiber reproducibility, which is essential for reliable data collection, especially for 
metabolomics. Unfortunately, production of these C18-SCX coatings was halted near the end of the study 
and were replaced by octyl-strong-cation-exchange (C8-SCX) coatings. This posed a problem, as there 
were very few remaining C18-SCX fibers available for extensive method development. As such, a 
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retrospective evaluation was completed to compare these newly available C8-SCX coatings against both 
the previously employed C18-SCX coating and a newly developed (at the time) in-laboratory coating 
method that produced HLB-coated devices.  
The performances of all three coatings were evaluated via recovery tests in phosphate buffered saline (PBS), 
with the results shown in Figure 5.4. The absolute recoveries from PBS and homogenized tissue, as shown 
in Figure 5.5, were only tested for HLB and C8-SCX due to the limited number of C18-SCX fibers 
remaining (results in Figure 5.5 shown only for C8-SCX as these were the commercially available 
replacements for C18-SCX). PBS and tissue were spiked at clinically expected concentrations for FOLFOX 
and all associated metabolites. PBS was spiked at 300 µg/mL and 100 µg/mL for FOLFOX and the 
metabolites, respectively, while lamb lung homogenate was spiked at 300 µg/g for FOLFOX and 100 µg/g 
for the metabolites. The sampling protocol for both PBS and lung tissue homogenate were as outlined for 
lung and perfusate in section 5.3 “Materials and Methods” namely sections 5.3.5 “Lung sampling 
protocol” and 5.3.6 “Perfusate sampling protocol”, with 5 replicates being performed for each coating at 
each time point.  
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Figure 5.4 Evaluation of coating performance based on extractions from PBS spiked at clinically 
expected concentrations. Values were normalized based on the intensity observed with HLB. The HLB 
coating is shown in red, the C18-SCX is shown in blue, and the C8-SCX coating is shown in yellow. The 
relative recoveries are shown for each compound along with their log P values in parentheses. 
 
 
Figure 5.5 Absolute recoveries of FOLFOX and its metabolites from PBS and homogenized lamb lung 
tissue spiked at clinically expected concentrations. The log(p) value for each compound is provided in 
parentheses. Results shown only for the C8-SCX coating. 
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The HLB coating exhibited superior recovery for the majority of the compounds (Figure 5.4), a result that 
is consistent with previous findings showing its ability to provide excellent extraction, especially for very 
polar compounds like FOLFOX from aqueous matrices.52,53 HLB showed as little as 1.5 times improvement 
in extraction efficiency compared to C18-SCX, and as much as 10 times improvement for some compounds 
compared to C8-SCX. Interestingly, C18-SCX demonstrated the next best recovery for these compounds, 
followed by its replacement C8-SCX. This trend is likely due to the strong interactions between the polar 
moieties of the target compounds and metabolites and the polar N-vinylpyrrolidone group on the HLB 
coating. Furthermore, it also appears that many of these compounds and metabolites contain aromatic or 
ring groups that better interact with the divinylbenzene group on the HLB coating via dispersion forces. 
This speculation is supported by the lower recoveries for slightly smaller but comparatively linear 
metabolites, such as FUPA and FBAL (results not shown), which would have less overall interaction due 
to their decreased molecular surface area. Thus, weak interaction between short hydrocarbon chains and 
aromatic extraction phases could explain the decreased recovery of these compounds via HLB. Moreover, 
the greater recovery for the majority of compounds and metabolites with the C18-SCX coating, as opposed 
to its short-chain counterpart, C8-SCX, supports the deduction that extraction efficiency is influenced by 
the degree of surface area interaction between the compounds and the coatings. While this would suggest 
improved recoveries for ring-containing metabolites with larger molecular weights, such as 5-FdUTP and 
5-FUTP, the observed negligible recoveries (results not shown) could also be due to slower diffusion 
kinetics since the PBS extractions were performed under static conditions, or simply that these compounds 
are extremely polar with log(p) values of less than -5.0 and thus have a very low affinity (partition 
coefficient) for the coating. The coating performance trends observed in tissue homogenate mirrored those 
observed in PBS, with HLB providing better extraction efficiency and coverage of compounds than C8-
SCX. However, the much lower recovery rates from homogenized tissue compared to PBS (Figure 5.5-
yellow bars, shown only for C8-SCX) suggest significant matrix binding for many analytes, which therefore 
affects the free concentration available for SPME extraction. Additionally, some metabolites that were 
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already difficult to extract from PBS, such as 5FdUTP, 5FUTP, FUPA, and FBAL due to their polarity or 
structure, failed to be extracted altogether even when spiked at the same concentration in tissue as the parent 
compound F, which is much higher than the expected metabolite concentration.  
5.4.6 Extraction time profile 
30 minutes was arbitrarily selected as the generic extraction time for sampling during the pre-clinical IVLP 
and IV trials. It is important, however, to determine whether this 30-minute extraction time falls under the 
pre-equilibrium, kinetic or equilibrium conditions of the time profile in order to appropriately account for 
any reproducibility issues that may result from slight variations during the active sampling protocol as a 
result of unforeseen surgical circumstances. As such, an extraction time profile was constructed using lamb 
lung homogenate in order to investigate the time at which the equilibrium was achieved for the HLB and 
C8-SCX coatings (Figure 5.6). Extraction times of 1 min, 5 min, 10 min, 20 min, 30 min, 45 min and 60 
min were selected given the time limitations imposed by the surgical procedure. After being exposed to the 
lung homogenate for the predetermined extraction time, the fibers were removed, manually rinsed in 300 
µL of water for 5 s, wiped with a Kimwipe, and then desorbed in 100 µL of 50:50 acetonitrile/water 
containing 200 ng/mL of internal standards. 
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Figure 5.6 Extraction time profile of FOLFOX from lamb lung homogenate. The following extraction 
times were tested: 1 min, 5 min, 10 min, 20 min, 30 min, 45 min, and 60 min. The HLB and C8-SCX 
coatings were evaluated using 5 replicates for each coating at each time point. 
 
The extraction conditions used in this retrospective analysis were set to closely mimic clinical conditions 
in terms of the drug concentration administered into the perfusate. Therefore, lamb lung homogenate was 
spiked at concentrations of approximately 300 µg/g and 170 µg/g for FOLF and OX, respectively. The 
spiked homogenate was then left to equilibrate at 500 rpm for 3 hours before performing extractions at 
various times. While it is common practice to allow a minimum of 8 hours for drug equilibration in tissue 
to permit various binding equilibria to be established, in vivo lung sampling occurred as early as 10 minutes 
after drug administration during IVLP. As such, 3 hours was deemed a suitable compromise between 
common bioanalytical practice and the clinical conditions of the experiment. 15 g of lung homogenate was 
weighed for each time point of the extraction time profile, with 5 replicates being investigated for each the 
two extraction phases. Extraction was timed and performed under static conditions for all time points 
simultaneously to avoid any differences due to fluctuating binding equilibria as a function of time.  
As shown in Figure 5.6, extraction equilibrium was reached at 20 minutes for FOL and 30 minutes for F 
using HLB-coated fibers, and at 10 minutes for both compounds using C8-SCX. These results are in 
accordance with SPME fundamentals, which hold that longer equilibration times and higher amounts of 
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extracted analyte are directly proportional to an increased affinity between the targeted compound and the 
coating. This explains why HLB coatings provide better method sensitivity, but also require equilibration 
times that are 2-3 times longer than those required for the C8-SCX coatings. Unfortunately, OX could not 
be recovered from tissue due to high binding and rapid non-enzymatic transformation, which results in a 
half-life of only 14 minutes in biological systems.150 Considering the 3-hour equilibration time after spiking 
the lung tissue with FOLFOX, the results for OX correlate with the experimental conditions. Based on the 
results shown in Figure 5.4, it would be safe to assume that the C18-SCX coating used for sample collection 
during experiments would have achieved equilibrium between 10 and 30 minutes as a function of analyte 
affinity and coating performance. Therefore, it can be concluded that a 30-minute extraction time was 
suitable for SPME sampling during pre-clinical IVLP and IV trials as it remains within the desired SPME 
equilibrium conditions. 
5.4.7 Calibration under in vivo conditions 
SPME fibers were used to perform in vivo sampling in the left lung during IVLP. The advantage of SPME 
as a sample preparation method is related to its fundamentals, shown in Eq (6), which permit in vivo 
sampling when the sample volume (Vs) is sufficiently larger than the product of the sampling device coating 
volume (Vf) and the analyte’s affinity for the coating (Kfs) Eq (7), such that the amount of analyte extracted 
(n) becomes independent of the sample volume (Vs) Eq (8).  
 𝑛 =  
𝐾𝑓𝑠𝑉𝑓𝐶0𝑉𝑠
𝐾𝑓𝑠𝑉𝑓 + 𝑉𝑠
 (6) 
 𝑉𝑠 ≫  𝐾𝑓𝑠𝑉𝑓 (7) 
 𝑛 =  𝐾𝑓𝑠𝑉𝑓𝐶0 (8) 
Thus, it is important to perform calibration under the same in vivo conditions in the surrogate lamb lung 
matrix by determining the sample volume/weight above which in vivo conditions would dominate. Under 
the appropriate in vivo conditions, the amount of analyte extracted becomes independent of the sample 
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weight or volume. The experiment was conducted in accordance with the procedure outlined by 
Roszkowska et al.160 Briefly, a bulk amount of lamb lung homogenate was spiked at the expected clinical 
FOLFOX concentration of 300 µg/g and then homogenized and agitated at 500 rpm for 1-2 hours. The bulk 
lung homogenate was then portioned at weights of 1 g, 5 g, 10 g, and 15 g, with extractions being performed 
simultaneously from each weight in replicates of 5 to avoid any errors associated with time delay or binding 
equilibria. An extraction time of 30 minutes was employed. Figure 5.7 (results for F shown, similar results 
obtained for FOL) shows that the extracted amount of F becomes independent at 10 g of lamb lung 
homogenate, which is consistent with SPME-related research for the quantification of doxorubicin from 
lung tissue.160 Nonetheless, 15 g of lamb lung homogenate was used to construct the calibration curve in 
order to ensure that conditions were within the acceptable in vivo range for quantification. Furthermore, the 
external matrix-matched calibration curve was made to correspond to an instrumental curve in order to 
avoid the use of lamb lung homogenate each time. This procedure is detailed in the following section 5.4.8 
“Standard solutions, calibration curves, method validation and quality control”. 
 
Figure 5.7 The assessment of in vivo conditions for appropriate calibration. The following weights of 
homogenized lamb lung were tested: 1g, 5g, 10g, and 15g. This test sought to find the conditions under 
which the amount of extracted F becomes independent of the sample weight. 
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5.4.8 Standard solutions, calibration curves, method validation and quality control 
Folates are especially susceptible to degradation by oxidation and thus need to be protected with 
antioxidants. Dimethylsulfoxide (DMSO) has been documented as an antioxidant that is tissue compatible, 
miscible with LC-MS-compatible solvents,171 and is generally and effective cosolvent. Thus, in order to 
mimic the high FOLFOX concentrations that are administered in perfusate and expected to be observed in 
tissue during IVLP, DMSO was employed as a solvent to produce the highest resultant concentrations for 
FOL (100 mg/mL), OX (100 mg/mL), F (100 mg/mL), 5,10-methyleneTHF (10 mg/mL), 5-methylTHF (20 
mg/mL), and THF (20 mg/mL). Conversely, water was used to produce the highest concentrations for 
5FUrd (20 mg/mL), 5FdUrd (25 mg/mL), FBAL (10 mg/mL), FUPA (5 mg/mL), 5FdUMP (5 mg/mL), 
5FdUTP (29 mg/mL), and FUTP (16 mg/mL). All standards were stored at –80 ⁰C until further use. To 
reduce the number of freeze-thaw cycles these high-concentration standards would be subjected to, each 
standard was diluted to 100 µg/mL working solutions, which were further diluted for method development 
and MS tuning. The limited availability (small amounts) and high costs of all metabolite standards, as well 
as their very low recoveries in matrix-deficient and especially matrix-abundant environments via SPME 
extraction, precluded their quantitation in tissue in compliance with the in vivo SPME calibration method. 
However, it did allow for metabolite screening.  
A matrix-matched external calibration curve with no internal standard correction was constructed for 
FOLFOX compounds such that 1 mL of standard mix at a specific concentration could be added to 15 g of 
lamb lung homogenate. This approach was appropriate, as internal standards were neither present nor could 
be used during in vivo sampling due to clinical limitations imposed by the hospital as a safety precaution 
for the animals. Thus, 1.5 mL of FOLFOX stock standards diluted with water were made at the following 
concentrations: 30 µg/mL, 75 µg/mL, 150 µg/mL, 375 µg/mL, 750 µg/mL, 1 125 µg/mL, 1 500 µg/mL, 3 
750 µg/mL, 7 500 µg/mL, 15 000 µg/mL, and 30 000 µg/mL; in order to produce an external lung 
homogenate calibration curve corresponding to concentrations of 2 µg/g, 5 µg/g, 10 µg/g, 25 µg/g, 50 µg/g, 
75 µg/g, 100 µg/g, 250 µg/g, 500 µg/g, 1000 µg/g, and 2000 µg/g. In accordance with the FDA’s guidelines 
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for bioanalytical method validation, the limits of detection (LOD) and limits of quantitation (LOQ) were 
found to be 25 µg/g and 50 µg/g, respectively, for FOL and F, with an achieved linearity (R2) of 0.99 for 
both compounds (Figure 5.8A and Figure 5.8C).  
 
Figure 5.8 Matrix-matched external calibration curve in lamb lung homogenate for FOL (A) and F (C). 
A linear dynamic range from 50 µg/g to 1000 µg/g with a linearity (R2) of 0.99 was achieved for both 
compounds. Each calibration curve was correlated with the amount of extracted FOL (B) and F (D) in 
order to streamline the analytical process. Linear dynamic ranges corresponding to 295 ng to 3000 ng 
and 30 ng to 800 ng were achieved for FOL and F, respectively. 
 
In an attempt to provide more practical measurements, the matrix-matched calibration curve was related to 
an instrumental curve based on the amount extracted. This approach eliminates the need to continuously 
use lamb lung homogenate, which can be arduous to prepare, and it also reduces the use of the very high-
concentration standards required for the appropriate weight of lung used, which proved difficult to achieve 
for some standards due to solubility limitations. Figure 5.8B and Figure 5.8D show the absolute amounts 
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(ng) of FOL and F that were extracted at each point of the matrix-matched external lung calibration curve. 
While this method of quantification allows for a more efficient and sustainable workflow, it is worth 
mentioning that it is only useful for 1.5 cm length C8-SCX coated fibers with a thickness of 40 µm. 
Furthermore, the instrumental calibration curve should be constructed in the same way each time, to avoid 
issues with accuracy and precision. As such, the instrumental curve used herein was constructed via serial 
dilutions of a 40 µg/mL stock solution such that 10 µL of each instrumental stock from 10 ng/mL to 40 
µg/mL could be diluted to 100 µL, thereby producing an instrumental curve that ranged from 1 ng/mL to 4 
µg/mL. The obtained LODs and LOQs corresponded to an extracted amount of 90 ng and 295 ng for FOL, 
and 12.5 ng and 30 ng for F. The instrumental curve was used to determine the absolute amounts of FOL 
and F obtained in clinical IVLP and IV samples that were below the LOQs of the lung calibration curve. In 
addition, only the absolute amounts (ng extracted) of FOL and F were determined for perfusate samples 
instead of the appropriate concentration (µg/mL). This drawback was due to the restricted availability of 
Steen solution to persons strictly within clinical settings. These restrictions were a result of the very high 
cost of this commodity (approx. 2000-3000 CAD per 500 mL) and its exclusive use for organ preservation. 
The instrumental curves for FOL and F, which were correlated to the matrix-matched external lamb lung 
homogenate calibration curve, was used to provide the absolute amounts (ng extracted) of drugs from lung 
samples and perfusate samples that fell below the LOQ (50 µg/g) of the matrix-matched calibration curve. 
The instrumental curve produced a linearity (R2) of 0.999, with an LOD and LOQ of 1 ng/mL and 5 ng/mL 
for FOL, and an LOD and LOQ of 5 ng/mL each for F. A quality control (QC) at concentrations of 100 
µg/g and 500 µg/g was internally assessed via the back calculations of the validated matrix-matched lung 
homogenate calibration curve with the respective point excluded prior to calculation. An accuracy and 
precision of 99.8% and 8% was achieved for the QC internally assessed at 100 µg/g while an accuracy and 
precision of 101% and 20% was achieved for the QC internally assessed at 500 µg/g.  
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5.4.9 Sterilization and preconditioning  
Clinical protocol requires the sterilization of all devices that will be used on patients. While solvent 
sterilization was sufficient for these animal experiments, there are cases that may require more rigorous 
sterilization approaches. This type of preconditioning may affect the extraction efficiency of the fibers, 
which may in turn affect the various conditions that were evaluated. In this work, the following 
preconditioning solutions were tested and assessed: 50:50 methanol/water, which is the typical solution 
employed for SPME conditioning; saline solution, which is often used in clinical settings; pure sterilized 
water; and no solution at all. These various solutions were tested for both autoclaved and non-autoclaved 
C8-SCX fibers since these fibers were the commercially available replacement for the C18-SCX fibers used 
to perform active sampling during the pre-clinical trials. During these tests, all fibers were preconditioned 
under their respective conditions for a minimum of 30 minutes, which was followed by a 30-minute static 
extraction in PBS solution spiked with 300 ug/mL of FOLFOX and metabolites, a 5 s manual rinse in water, 
and desorption in 50:50 acetonitrile/water for 60 minutes at 1500 rpm. Figure 5.9A and Figure 5.9B reveal 
that the autoclaved and non-autoclaved fibers that were conditioned in 50:50 methanol/water performed 
significantly better than those that had been conditioned in saline, pure water, and no solution at all. 
Although saline appeared to outperform pure water and no solution conditioning on average, there were no 
significant differences (p < 0.05) in the amounts of FOLFOX or metabolites extracted using the autoclaved 
and non-autoclaved devices, both within and between groups, that had been preconditioned using these 
solutions. However, there were significant differences (p < 0.05) in the amount of F and FOL extracted by 
the autoclaved and non-autoclaved fibers that had been conditioned with 50:50 methanol/water; 
specifically, non-autoclaved fibers extracted more of both compounds. This contrasts with previous results 
for the quantitation of doxorubicin in lung tissue,160 wherein autoclaved fibers out-performed non-
autoclaved fibers. These results suggest that device pre-treatment and preconditioning have various effects 
that are compound-specific. Interestingly, the metabolite, 5,10-methyleneTHF, showed significantly (p < 
0.05) improved recoveries under autoclaved conditions and preconditioning with 50:50 methanol/water 
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compared to non-autoclaved conditions with the same preconditioning solvent. Conversely, no significant 
differences were observed for OX under the same conditions (Figure 5.9C). It is also important to mention 
that the autoclaved and non-autoclaved fibers were visibly different after being removed from the 50:50 
methanol/water preconditioning solution. In contrast to the other solutions/conditions (saline, pure water, 
no preconditioning solution), which left the fibers with a white appearance, the 50:50 methanol/water 
solution left both the autoclaved and non-autoclaved fibers with a hydrated dark grey appearance. 
 
Figure 5.9 Evaluation of sterilization and preconditioning of C8-SCX-coated fibers for F (A), FOL (B), and OX (C). 
Sterilization by autoclave was tested against non-autoclaved fibers. For each category of steam sterilization, 
preconditioning solutions of 50:50 methanol/water, saline solution, pure water, and no solution were tested 
 
5.5 Discussion 
5.5.1 Application of the developed SPME-LC-MS/MS protocol on samples obtained 
from pre-clinical trials of FOLFOX chemotherapy using IVLP 
The retrospective SPME-LC-MS/MS method development revealed that the HLB coating provided the best 
sensitivity for the compounds and metabolites of interest. However, the tests conducted during method 
development also showed that the C18-SCX-coated fibers, which were used during these pre-clinical IVLP 
and IV trials, were rather suitable as well. In addition, preconditioning in 50:50 methanol/water was shown 
to be an acceptable sterilization method for non-autoclaved SPME devices, as it enabled good coating 
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extraction efficiency to be maintained. Furthermore, an extraction time of 30 minutes, which was used 
during sampling prior to method development, was also revealed to be within equilibrium conditions for 
the investigated HLB and C8-SCX coatings, with the supposition that the C18-SCX coating would achieve 
equilibrium within comparable times. Nonetheless, since the C8-SCX-coated fibers were used to build the 
calibration curve and the C18-SCX-coated fibers were used to perform sampling, it is only possible to form 
a close estimate of FOLFOX concentrations in the collected pre-clinical samples, while allowing for a 20% 
to 50% difference in these obtained values for FOL and F, respectively. These limits are based on the 
differences observed in the recovery of these compounds during the coating performance tests (Figure 5.4). 
Briefly, FOL was administered intravenously prior to the start of IVLP. Once the IVLP circuit was 
assembled and full flow was established, FOX was administered directly into the perfusion fluid, with 
perfusion of the left lung continuing for 4 hours. A final lung flush was performed after IVLP and prior to 
the start of reperfusion. In all three pre-clinical IVLP cases, no FOLFOX was detected in any of the pig 
lung blanks; however, F was quantifiably recovered only in samples collected after the administration of 
FOX and during the 4 hours of IVLP from IVLP T0 to IVLP T3 (Figure 5.10A). As Figure 5.10A shows, 
F appears to maintain a steady concentration between 250 µg/g and 350 µg/g throughout IVLP. This trend 
could be indicative of F’s low protein binding of 8-12% (information provided by DrugBank161), which 
leaves the majority of the drug available in free form during IVLP. The larger error bars for some of the 
sampling points are likely related to the non-homogenous distribution of the drug in the lung and the 1 to 2 
cm spacing of the fibers during sampling. 
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Figure 5.10 Application of in vivo SPME protocol and developed LC-MS/MS method for the quantification of F in 
pre-clinical IVLP samples. (A) Lung concentration of F throughout the IVLP procedure. (B) Absolute recovery of 
F obtained from perfusate samples collected during IVLP. Refer to Figure 5.1 on page141 for the “Figure 5.1 Lung 
sampling schedule using SPME fibers during in vivo lung perfusion (IVLP) (top schedule) and intravenous (IV) 
FOLFOX administration (bottom schedule).” 
 
This steady state trend is mirrored in the results for the perfusate samples shown in Figure 5.10B. Notably, 
the amount of available F appears to drop at Perf T2 and Perf T3 for Pigs 1 and 3 (compared to Perf T1), 
while no such drop is observable for Pig 2. This might be a result of different rates of enzymatic activation 
or degradation among the pigs, however, it is difficult to reliably conclude what this trend signifies, as only 
one perfusate sample was taken at each time point. It is important to remember that, given the differences 
in the devices used for calibration and sample collection, the actual concentration can be estimated to be 
about twice that reported above, resulting in a concentration between 500 µg/g and 700  µg/g. Trace 
amounts of F were detected in the samples collected during the two hours of reperfusion, which suggests 
that the flushing step with fresh perfusion fluid before reperfusion prevents systemic exposure to high drug 
concentrations. 5FdUrd and 5FUrd were also detected in lung samples, but these compounds were mostly 
found in perfusate samples on an inconsistent basis. For example, 5FdUrd was detected in one pig’s lung 
as early as one hour after the start of IVLP (IVLP T0) and approximately 30 minutes after FOX 
administration, but not in the other two pigs at the same time point. Furthermore, it could be detected at 
IVLP T1 for all pigs but was undetectable by IVLP T3. 5FUrd was mostly detected at IVLP T2, IVLP T3, 
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and, in some cases, IVLP T4 and IVLP T5 for pigs 1 and 2. These fluctuations might be the product of the 
dynamics of drug administration and distribution rather than the processes of metabolism due to the minimal 
presence of various concentrations of the F-dependent enzymes responsible for anabolism. Traces of 
5FdUTP and 5FUTP were also observable in a few perfusate and lung samples from as early as IVLP T1 
to as late as IVLP T5. Neither F nor its metabolites were found in the lungs during the IV case using the 
developed LC-MS/MS method. FBAL and FUPA were not detected in any of the samples in the IVLP and 
IV cases, which may simply be the result of the poor analyte affinity for the coating rather than an indication 
of their nonexistence, as was earlier demonstrated in the coating performance tests (Figure 5.4).  
No F was detected prior to the start of IVLP when only FOL had been administered; at these earlier time 
points, namely, 10 minutes (Time L0) and 50 minutes (Time L1) after the initial IV administration of FOL, 
only FOL was detectable (Figure 5.11A). However, the amount of FOL recovered from the lung was 
inconsequential, falling below the 25 µg/g LOQ for determining its concentration in the tissue (interpolated 
to be between 5-25 µg/g). Thus, the tissue concentration of FOL could not be reliably quantified with this 
method, and the amount recovered (ng) was used instead. There is a decreasing trend in the amount of FOL 
recovered for the IVLP cases over the course of 60 minutes from Time L0 to Time L1 (Figure 5.11A). This 
decreasing trend is observed again during the IV application (Figure 5.11B), with the FOL concentration 
appearing to peak 100 minutes after the commencement of FOLFOX infusion (IV T0) and then slowly 
decreasing. This trend suggests that the drug is either partitioning into cells, experiencing elimination, or is 
being metabolized. It should be noted that 5-methylTHF has been reported as the final product of FOL 
metabolism172,173 and has been shown to be most stable of all FOL-related metabolites174, especially under 
a wide pH range (pH 2-10). While 5,10-methyleneTHF could not be detected, 5-methylTHF was detected 
at Time L0 and Time L1 (10 minutes and 60 minutes after the infusion of FOL) in the IVLP cases and 
throughout the IV cases starting as early as IV T0, 100 minutes after FOL administration at the peak of 
FOL concentration. It is important to consider a few limitations in the analysis of these samples for folate 
derivatives including: the tendency of 5,10-methyleneTHF to rapidly convert to THF under various 
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temperature and pH conditions (low pH, pH below 8); the instability of THF also at low pH (pH below 5); 
the fact that these samples were unfortunately not stored with an antioxidant after being initially desorbed; 
and that the chromatographic conditions used produced a pH between 3-5. Therefore, it is difficult to screen 
for or accurately quantify the absolute amounts of each of these folate species in this particular application, 
with the exception of 5-methylTHF that is stable between a pH range of 2-10 and thus could indeed be 
detected/screened for. The use of an antioxidant is therefore strongly recommended for future research.  
 
Figure 5.11 Application of in vivo SPME protocol and developed LC-MS/MS method for the quantification of 
FOL in preclinical IVLP samples. (A) Absolute recoveries of FOL from lung tissue during IVLP. (B) Absolute 
recoveries of FOL from lung tissue during IV administration of FOLFOX. 
 
5.5.2 Untargeted pharmacometabolomic analysis 
In order to monitor the biochemical profile of the living system during IVLP and IV with anticancer 
polytherapy (FOLFOX), a novel microextraction technology, SPME, was applied to isolate endogenous 
and exogenous small molecules from lung tissue and perfusate samples. SPME fibers, which are the size 
of acupuncture needles, were inserted directly into the left lung of the pig during IVLP, as well as during 
the IV administration of drugs. Additionally, SPME fibers were used to extract metabolites from perfusate 
samples that were collected in parallel with the lung sampling events during IVLP. The annotation and 
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identification of the molecular features (metabolites) detected in the SPME extracts via the developed LC-
MS/MS method revealed changes in the metabolomes of these analyzed matrices (Table 5.7 to Table 5.9). 
In examining the overall data structure of the samples, which were initially analyzed in 2015, it is evident 
that the instrumental analysis was reliable, as the pooled QCs clustered well in the center of all the samples 
on the PCA plot (Figure 5.12A and Figure 5.12B). It is important to note that, given the three biological 
replicates (3 pigs sampled) included in the analysis and the three technical replicates (3 fibers) collected 
during each sampling time for each pig, specifically for the lung sampling events, there is a clear and 
significant difference between the samples. This can be seen in the categorical clustering of each group, 
namely, samples collected prior to the start of IVLP (lung blanks and samples collected after FOL 
administration); those collected during IVLP (IVLP T0 to IVLP T3); and those collected during reperfusion 
after IVLP (IVLP T4 and IVLP T5). Interestingly, contrary to expectations, there is no clustering 
corresponding to the progression of the IVLP procedure from the first hour to the fourth hour. However, 
the IV case from the same time period (2015) (Figure 5.12B and Figure 5.12C with pooled QCs removed) 
shows distinct clustering of the lung samples collected prior to FOLFOX administration (IV Blank – 
represented in red) and clear separation between these samples and the last two sampling time points (IV 
T2 and IV T3), with overlap occurring between the three interim sampling time points (IV TL0, IV T0, and 
IV T1). 
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Figure 5.12 Principal component analysis (PCA) plots of the overall structure of the data for lung samples taken during 
IVLP and IV administration of FOLFOX. A) PCA (PC1:94.8%, PC2: 3.8%, PC3: 0.6%) plot for lung sampling events 
over the course of IVLP. Samples taken before, during, and after IVLP (during reperfusion) are represented in green, 
blue, and red, respectively. Pooled QC’s are represented in turquoise. B) PCA (PC1: 92.7%, PC2:2.7%; PC 3: 1.1%) 
plot of lung sampling events during IV administration. Samples collected at baseline and hourly for 5 hours after  the 
start of infusion are shown in red, yellow, green, blue, turquoise, and pink, respectively. Pooled QC’s are represented 
in purple. C) PCA (PC1: 41.2%, PC2: 16.4%, PC3: 12.6%) plot for samples shown in B) with pooled QCs removed to 
enable closer observation. 
 
Over the course of IVLP, the observed compositional changes of endogenous metabolites in the lung tissue 
were related to the metabolism of amino acids, acylcarnitines, purines and pyrimidines, lipids, and pro- and 
anti-inflammatory compounds, among others (Table 5.7). Moreover, these metabolomic alterations were 
also reflected in the composition of the perfusate samples (Table 5.8). For instance, the number of amino 
acids initially detected in the lung tissue significantly decreased approximately 60 minutes after the 
administration of FOL (Time L1 in Figure 5.1) and remained low until the end of the reperfusion period. 
Concurrently, the number of dipeptides significantly increased starting at 70 minutes post FOX 
administration (IVLP T1 in Figure 5.1), which may be related to the intense metabolism of these compounds 
after the local administration of anticancer drugs into the perfusion circuit. However, analysis of the 
perfusate samples collected during IVLP not only revealed a higher number of dipeptides, but also a higher 
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number of free amino acids (Table 5.8). Since SPME extracts only a portion of the unbound analytes, it is 
possible that the certain metabolites may be present in the lung in lower abundance due to their higher 
binding affinity to the lung tissue components, thus reducing their level of free concentration for SPME 
extraction. Conversely, there may be higher free concentrations of these metabolites in perfusion fluid due 
to their lower binding affinity for perfusate components; this explains why a higher number of free amino 
acids were observed in the perfusate samples than were observed in lung tissue. Interestingly, the systemic 
administration of FOLFOX did not significantly affect the number of amino acids and dipeptides, as the 
composition of these compounds stayed relatively constant in lung tissue for more than 4 hours after IV 
drug administration (Table 5.9). In addition, after systemic drug administration, the number of detected free 
amino acids was much higher in comparison to the number of these compounds extracted from the lungs 
during IVLP, which may be a result of different drug administration routes. 
Although low numbers of several lipid species were detected early in the IVLP procedure, including 
bioactive lipids (oxylipids) with either pro- or anti-inflammatory activity, the number of these compounds 
significantly increased by the second hour post FOX administration (IVLP T2) (Table 5.7). These observed 
alterations were even more profound in perfusate samples (Table 5.8). Interestingly, a similar trend was 
observed in lung tissue after the IV administration of anticancer polytherapy, as a tremendous release of 
pro- and anti-inflammatory compounds was observed approximately three hours (IV T1) post drug 
administration. This strongly indicates that, for oxylipins specifically, the changes with respect to these 
compounds in lung tissue over time are more related to the polytherapy activity than the route of drug 
administration (IVLP vs. IV). 
Apart from the above-mentioned group of compounds, the overall metabolomic profile of lung tissue after 
systemic drug administration differed significantly from the lung tissue profile observed during IVLP 
(Table 5.7). For instance, a group of endogenous compounds known as autacoids—specifically, resolvins 
and neuroprostanes—were detected in lung tissue and perfusate samples solely during the IVLP procedure 
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(i.e., 60 minutes post FOX administration). These locally acting compounds possess potent 
immunoregulatory properties and may strongly affect the activity of the immune system.140 Interestingly, 
these autacoids were not detected in lung tissue after IV administration of FOLFOX,  which indicates that 
FOX's distinct impact on the metabolomic profile of lung tissue—and, consequently, the pharmacokinetics 
and pharmacodynamics of the polytherapy in the targeted organ—is strongly dependent on the 
administration route. It should also be noted that the concentration of metabolites, or intermediates of purine 
and pyrimidine metabolism remained relatively constant in lung tissue after the systemic administration of 
FOLFOX (Table 5.9) but decreased significantly during the local administration of FOLFOX via IVLP 
(Table 5.7). However, the most prominent finding relates to the identification of the main active metabolite 
of F, FdUMP175, solely in lung tissue after IV drug administration. FdUMP was detected in lung tissue 
about 100 minutes after the systemic administration of F and remained present until the end of SPME 
sampling (up to 280 minutes). The lack of FdUMP in lung tissue during IVLP may indicate the crucial role 
of liver metabolism in both the catabolic and anabolic pathways of F biochemical transformations. While 
the presence of this metabolite might seem to contradict the results (or lack thereof) obtained via the 
developed targeted LC-MS/MS method (wherein no F metabolites were detected during IV administration), 
this discrepancy can be explained by the improved sensitivity in terms of resolution experienced with 
HRMS instruments and other nuances related to data processing, which is outside the scope of this research. 
This highlights the benefits of implementing both types of instrumentation (MS/MS and HRMS) for the 
comprehensive analysis of newly explored systems. 
5.5.3 Storage conditions and metabolite stability 
Sampling were performed at Toronto General Hospital in 2015. Upon the completion of sampling, the fibers 
were snap frozen in dry ice and stored in empty 300 µL vials for transportation to the laboratory where they 
were stored at –80 ⁰C until instrumental analysis. After analysis, the sample extracts were re-stored at –80 
⁰C until they were analyzed again two years later in 2017. These sample extracts were consistently stored 
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under the above conditions and were not subjected to multiple freeze-thaw cycles (less than two cycles). 
Figure 5.13 shows a loss of approximately 40% of the information corresponding to nearly 1400 features.  
 
Figure 5.13 (A) Metabolite profile of pre-clinical IVLP samples obtained and analyzed via LC-HRMS in 2015. 
(B) Metabolite profile of the same pre-clinical IVLP samples upon re-analysis in 2017. Both sets of data were 
filtered in the same way. 
 
While the PCAs obtained from both sets of data maintain a similar structure (Figure 5.14A and Figure 
5.14B), the metabolite profiles for the lung samples before, during, and after IVLP are noticeably different 
(Figure 13). For example, a significant loss of features within a large m/z range between retention times of 
1200 s to 1600 s can be observed from 2015 to 2017. Additionally, a loss in the number of features greater 
than 600 m/z between retention times of 600 s to 800 s, and the appearance of features below 500 m/z with 
retention times of less than 200 s can also be observed, which could be products of degradation.  
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Figure 5.14 Principal component analysis (PCA) of lung samples taken before the start of IVLP (IVLP 
Lung Blank, Time L0, Time L1), during IVLP (IVLP T1 to IVLP T3), and post IVLP during reperfusion 
(IVLP T4 and IVLP T5). Each group of samples is represented by green, red, and blue, respectively. A) 
PCA (PC1: 79.6%, PC2:4.9%, PC3:1.1%) of samples acquired in 2015. B) PCA (PC1: 97%, PC2: 1.1%, 
PC3: 1%) of the same samples in 2017. Each data set shows the clustering of the pooled QCs at the center 
of the data (represented by turquoise). 
 
While it is difficult to pinpoint what causes these changes during storage under these conditions, the profiles 
clearly highlight the degradation of data integrity over prolonged storage times. Given the time-consuming 
nature of metabolomics data processing, it may be quite challenging to employ tandem mass spectrometry 
for metabolite validation if discriminating features or features of importance have degraded. Indeed, as was 
observed in this study, the analysis done before and after storage showed a drastic difference in the same 
data sets for samples taken before, during, and after IVLP. Moreover, annotation of the 2017 data revealed 
almost no information of importance due to the loss of almost half the data initially annotated in 2015. 
Briefly, the annotated peaklist from 2017 data showed most amino acids were retained in the data from 
2015 but only a few peptides were present, indicating peptide degradation during sample storage. In 
addition, a few lipids were scantily detected in the 2017 data in comparison to the 2015 data, indicating the 
substantial degradation of these classes of compounds during storage. 
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5.6 Conclusion 
In vivo lung perfusion (IVLP) is a novel isolated lung technique and adapted EVLP strategy developed for 
the local administration of high-dose chemotherapy in situ in order to treat metastatic lung cancer. 
Combination therapy involving folinic acid-5-fluorouracil-oxaliplatin (FOLFOX) is routinely employed to 
treat a number of solid tumors in various types of tissues. However, the most active drug, F, requires close 
monitoring during administration, as it has been found to exhibit large interpatient variability with regards 
to plasma concentration. Since plasma concentrations are not always reflect the drug concentration in tissue, 
it is also essential to employ sample preparation methods that are specific to monitoring drug concentrations 
in tissue. Thus, in vivo SPME was proposed as an effective tool for sampling lung tissue during pre-clinical 
IVLP and IV trials using FOLFOX. To overcome the limitations of current sample preparation and 
separation techniques, a retrospective SPME-LC-MS/MS method capable of providing improved tissue 
analysis was developed. In the proposed method, SPME is utilized for repeated and easy in vivo sampling 
of complex biological matrices, such as lung, which is followed by comprehensive quantitative and 
qualitative separation methods aimed at determining FOLFOX concentration in lung tissue, screening of 
FOLFOX metabolites, and general pharmacometabolic profiling. This marks the first documented attempt 
to develop a complementary, all-encompassing LC-MS/MS method for the quantitation and screening of 
FOLFOX and its metabolites. Furthermore, the extraction of other endogenous and exogenous small 
molecules and their detection via LC-HRMS made it possible to assess the impact of polytherapy on the 
metabolomic profile of the lung, which revealed metabolic pathways specifically associated with the route 
of administration (IVLP vs. IV) as well as those related to the therapy itself. Additionally, while both 
methods of administration seemed to produce relevant metabolites indicative of effective therapy, these 
metabolites were produced to a lesser extent via IVLP, as the formation of important anabolites occurs via 
enzymatic transformation in the liver. In addition, the lack of change in the lung metabolic profile over the 
course of IVLP may indicate that 1) the lungs are still performing well during treatment and perhaps higher 
doses of chemotherapy can be tolerated; 2) and the use of a different fluorinated pro-drug might be more 
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efficient. It would also be worth investigating potential long-term complications by assessing the lungs up 
to days after treatment with IVLP. Furthermore, the results of the supplementary study, which evaluated 
the metabolome stability of extracts stored at –80 ⁰C over a long period of time (2 years), illustrates the 
challenges associated with metabolomic studies, as the observed loss of data emphasizes the importance of 
performing analysis and MS/MS validation as soon as possible after sample collection. Considering not 
only the time-consuming aspect of this type of analyses with the plethora of data processing techniques 
available but also the untargeted nature of these studies, it is difficult to process and interpret data quickly 
enough as well as predict which features or compounds are likely to be problematic in terms of degradation, 
since reliable metabolite identification in itself remains the bottleneck of translating metabolomics into 
clinical practice. In summary, this study successfully demonstrated that SPME is an effective in vivo 
sampling tool for the concomitant quantitative monitoring of polychemotherapy and qualitative lung 
assessment via pharmacometabolomic fingerprinting during the IVLP and IV administration of FOLFOX. 
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Table 5.7 High- and medium confidence annotated features changing over the course of IVLP (Lung blank until the end of reperfusion IVLP T5) with FOLFOX 
administration 
 
Lung Blank IVLP L0 IVLP L1 IVLP T0 IVLP T1 IVLP T2 IVLP T3 IVLP T4 IVLP T5 
amino 
acids 
L-Glutamine L-Tryptophan Lipoyllysine 
Beta-Citryl-L-
glutamic acid L-Asparagine 
Beta-Citryl-L-
glutamic acid Lipoyllysine 
Beta-Citryl-L-
glutamic acid 
Beta-Citryl-L-
glutamic acid 
L-Phenylalanine 
L-
Phenylalanine D-Tryptophan Lipoyllysine L-Threonine Lipoyllysine 
N(6)-
(Octanoyl)lysine Lipoyllysine Lipoyllysine 
L-Tyrosine Lipoyllysine L-Tryptophan N-acetyltryptophan 
Beta-Citryl-L-
glutamic acid L-Tryptophan N-Acetylglutamine L-Tryptophan L-Tryptophan 
D-Serine 
N-Acetyl-L-
methionine Kynurenic acid D-Tryptophan Lipoyllysine Kynurenic acid D-Lysine L-Asparagine Kynurenic acid 
N6,N6,N6-
Trimethyl-L-
lysine L-Aspartic acid L-Phenylalanine 
(E)-2-
Methylglutaconic 
acid L-Aspartic acid L-Phenylalanine Kynurenic acid L-Threonine Tridecanoylglycine 
Lipoyllysine L-Serine 
N-
Acetylhistamine  L-Tryptophan N-acetyltryptophan N-Acetylhistamine  L-Lysine 2-Hydroxyglutarate 
N-
Undecanoylglycine 
L-Methionine L-Lysine 
Tridecanoylglyc
ine L-Phenylalanine N-Acetylglutamine 
N-
Undecanoylglycine L-Histidine N-acetyltryptophan Myristoylglycine 
Homocitrulline L-Histidine 
N-
Undecanoylglyc
ine N-Acetylhistamine  
N-Acetylglutamic 
acid Myristoylglycine L-Phenylalanine D-Glutamine Palmitoylglycine 
L-Cystine L-Asparagine 
N-
Nonanoylglycin
e 
N-
Undecanoylglycine Kynurenic acid Palmitoylglycine N-Acetylhistamine  L-Phenylalanine  
L-Lysine L-Threonine 
N-
Lauroylglycine Tridecanoylglycine 
3-
Hydroxymethylglutar
ic acid Tridecanoylglycine Tridecanoylglycine N-Acetylhistamine   
L-Asparagine o-Tyrosine 
N-
Decanoylglycin
e N-Nonanoylglycine L-Phenylalanine N-Nonanoylglycine N-Undecanoylglycine Tridecanoylglycine  
L-Threonine D-Glutamine  N-Decanoylglycine N-Acetylhistamine  N-Decanoylglycine N-Nonanoylglycine N-Undecanoylglycine  
L-Proline 
N-
Acetylglutamic 
acid  Myristoylglycine Pristanoylglycine  N-Lauroylglycine Palmitoylglycine  
L-Glutamic acid Kynurenic acid   Myristoylglycine  N-Decanoylglycine N-Nonanoylglycine  
N-
Acetylglutamic 
acid 
L-2-
Hydroxyglutari
c acid   Palmitoylglycine   N-Lauroylglycine  
Kynurenic acid L-Glutamine   Tridecanoylglycine   N-Decanoylglycine  
L-Leucine 
D-2-
Hydroxyglutari
c acid   N-Undecanoylglycine   Dimethylglycine  
L-Isoleucine 
3-
Hydroxyglutari
c acid   N-Nonanoylglycine     
N-Acetyl-L-
methionine L-Tyrosine   N-Decanoylglycine     
L-Arginine 
N-
Acetylhistamin
e         
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L-Histidine o-Tyrosine        
L-Tryptophan Beta-Tyrosine        
Ne,Ne 
dimethyllysine L-Tyrosine        
Tridecanoylglyci
ne 
N-
Undecanoylgly
cine        
Pristanoylglycine 
Tridecanoylgly
cine        
N-
Undecanoylglyci
ne 
N-
Nonanoylglyci
ne        
Guanidoacetic 
acid 
N-
Lauroylglycine        
3-
Hydroxymethylg
lutaric acid 
N-
Decanoylglyci
ne        
Pyroglutamic 
acid Beta-Tyrosine        
 
Dimethylglyci
ne        
peptides 
Glu-Val 
Phenylalanyl-
Lysine 
L-gamma-
glutamyl-L-
valine  Glu-Val Tyrosyl-Glutamate 
L-gamma-glutamyl-
L-valine  Glu-Val Glu-Val Leucyl-Aspartate 
L-gamma-
glutamyl-L-
valine  
Lysyl-
Phenylalanine 
L-beta-aspartyl-
L-leucine  
L-gamma-glutamyl-
L-valine  Leucyl-Aspartate 
L-beta-aspartyl-L-
phenylalanine  Prolyl-Asparagine Tyrosyl-Glutamate Isoleucyl-Aspartate 
L-beta-aspartyl-
L-leucine  Alanyl-Glycine 
Arginyl-
Arginine 
L-beta-aspartyl-L-
leucine  Isoleucyl-Aspartate 
L-beta-aspartyl-L-
leucine  
Phenylalanyl-
Aspartate Leucyl-Aspartate Histidinyl-Histidine 
Cysteineglutathi
one disulfide 
L-alpha-
glutamyl-L-
hydroxyproline   
L-alpha-glutamyl-L-
hydroxyproline  
Glycyl-
Hydroxyproline 
L-Aspartyl-L-
phenylalanine Leucyl-Aspartate Isoleucyl-Aspartate 
Hydroxyprolyl-
Cysteine 
L-
Cysteinylglycine 
disulfide Alanylglycine   Glutamyl-Tyrosine Arginyl-Arginine Isoleucyl-Aspartate Glutamyl-Tyrosine 
Cysteinyl-
Hydroxyproline 
Glutarylglycine 
L-Threo-3-
Phenylserine   Aspartyl-Leucine  Histidinyl-Histidine Aspartyl-Leucine Aspartyl-Leucine 
 
Glutarylglycin
e   Aspartyl-Isoleucine  
Glycyl-
Hydroxyproline Aspartyl-Isoleucine Aspartyl-Isoleucine 
 
Arginyl-
Arginine   
L-glycyl-L-
hydroxyproline   
Aspartyl-
Phenylalanine Alanyl-Glycine 
L-gamma-glutamyl-
L-valine  
    
L-gamma-glutamyl-
L-valine   Aspartyl-Leucine 
L-gamma-glutamyl-
L-valine  
L-beta-aspartyl-L-
leucine  
    
L-beta-aspartyl-L-
leucine   Aspartyl-Isoleucine 
L-beta-aspartyl-L-
leucine   
    Glutarylglycine  Asparaginyl-Proline Alanylglycine  
    Arginyl-Arginine  
L-glycyl-L-
hydroxyproline  Oxidized glutathione  
      
L-gamma-glutamyl-
L-valine    
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L-beta-aspartyl-L-
phenylalanine    
      
L-beta-aspartyl-L-
leucine    
      
L-alpha-glutamyl-L-
hydroxyproline    
      
L-Aspartyl-L-
phenylalanine   
      Oxidized glutathione   
acylcarn
itines 
3-
Dehydroxycarnit
ine 
3-
Dehydroxycarn
itine 
3-
Dehydroxycarni
tine 
3-
Hydroxyhexadecadie
noylcarnitine 
3-
Hydroxyhexadecadie
noylcarnitine 
Hydroxybutyrylcarnit
ine Arachidonyl carnitine 
Hydroxybutyrylcarnit
ine 
3-
Dehydroxycarnitine 
L-
Acetylcarnitine 
Heptadecanoyl 
carnitine 
12-Hydroxy-12-
octadecanoylcar
nitine 
3-Hydroxy-9-
hexadecenoylcarnitin
e 
3-Hydroxy-9-
hexadecenoylcarnitin
e 
3-
Hydroxyhexadecadie
noylcarnitine 
3-
Hydroxyhexadecadie
noylcarnitine Pimelylcarnitine 
3-Hydroxy-9-
hexadecenoylcarnitin
e 
2-trans4-cis-
Decadienoylcarn
itine 
Propionylcarnit
ine 
Hydroxybutyryl
carnitine 
12-Hydroxy-12-
octadecanoylcarnitin
e Pimelylcarnitine 
3-Hydroxy-9-
hexadecenoylcarnitin
e Pimelylcarnitine 
2-trans4-cis-
Decadienoylcarnitine 
2-trans4-cis-
Decadienoylcarnitine 
6-Keto-
decanoylcarnitin
e 
L-
Acetylcarnitine 
Propionylcarniti
ne 
Hydroxybutyrylcarnit
ine 
2-trans4-cis-
Decadienoylcarnitine Pimelylcarnitine 
12-Hydroxy-12-
octadecanoylcarnitine 
12-Hydroxy-12-
octadecanoylcarnitine 
Hydroxybutyrylcarnit
ine 
12-Hydroxy-12-
octadecanoylcarn
itine   Propionylcarnitine 
12-Hydroxy-12-
octadecanoylcarnitine 
12-Hydroxy-12-
octadecanoylcarnitin
e 
Hydroxybutyrylcarnit
ine Propionylcarnitine Propionylcarnitine 
Hydroxyvalerylc
arnitine   
Arachidonyl 
carnitine 
Hydroxybutyrylcarnit
ine Propionylcarnitine Propionylcarnitine 
3-Hydroxy-5 8-
tetradecadiencarnitine Malonylcarnitine 
Propionylcarnitin
e    
Hydroxypropionylcar
nitine Malonylcarnitine Malonylcarnitine   
L-Carnitine    
Heptadecanoyl 
carnitine     
    Propionylcarnitine     
    Malonylcarnitine     
autacoid
s 
    
7-hydroxy-D4-
neuroprostane  
7-hydroxy-D4-
neuroprostane 
7-hydroxy-D4-
neuroprostane  
    
4-hydroxy-D4-
neuroprostane  
4-hydroxy-D4-
neuroprostane 
4-hydroxy-D4-
neuroprostane  
    
20-hydroxy-E4-
neuroprostane  
20-hydroxy-E4-
neuroprostane 
20-hydroxy-E4-
neuroprostane  
    
17-hydroxy-E4-
neuroprostane  
19-Oxo-
deoxycorticosterone 
17-hydroxy-E4-
neuroprostane  
    
14-hydroxy-E4-
neuroprostane  
17-hydroxy-E4-
neuroprostane 
14-hydroxy-E4-
neuroprostane  
    Resolvin D1  
14-hydroxy-E4-
neuroprostane Resolvin D1  
    Resolvin D2  Resolvin D1 Resolvin D2  
      Resolvin D2   
eicosano
ids 
Omega-Carboxy-
trinor-
leukotriene B4 
18-Carboxy-
dinor-LTE4 
Omega-
Carboxy-trinor-
leukotriene B4 
Leukotriene B4 
ethanolamide 
Omega-Carboxy-
trinor-leukotriene B4 
Leukotriene B4 
ethanolamide 
Omega-Carboxy-
trinor-leukotriene B4 
18-Carboxy-dinor-
LTE4 
Omega-Carboxy-
trinor-leukotriene B4 
18-Carboxy-
dinor-LTE4 
13,14-Dihydro 
PGF-1a 
13,14-Dihydro 
PGF-1a 
5-Oxo-6-trans-
leukotriene B4 
18-Carboxy-dinor-
LTE4 
67-dihydro-5-oxo-
12-epi-LTB4 
18-Carboxy-dinor-
LTE4 
6,7-dihydro-5-oxo-
12-epi-LTB4 
18-Carboxy-dinor-
LTE4 
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Leukotriene B4 
ethanolamide 12,13-DHOME 12,13-DHOME Leukotriene B5 
Leukotriene B4 
ethanolamide 
1011-dihydro-12-
oxo-LTB4 
Leukotriene B4 
ethanolamide 
10,11-dihydro-12-
oxo-LTB4 
6,7-dihydro-5-oxo-
12-epi-LTB4 
Leukotriene B5 9,10-DHOME 9,10-DHOME 
12-Keto-leukotriene 
B4 PGF2a ethanolamide 
12(S)-Leukotriene 
B4 Leukotriene B5 12(S)-Leukotriene B4 
10,11-dihydro-12-
oxo-LTB4 
12-Keto-
leukotriene B4   PGF2a ethanolamide 
15-Deoxy-d-1214-
PGJ2 
6-trans-12-epi-
Leukotriene B4 
12-Keto-leukotriene 
B4 
6-trans-12-epi-
Leukotriene B4 
12(S)-Leukotriene 
B4 
10,11-dihydro-
20-dihydroxy-
LTB4   Prostaglandin-c2 
1314-Dihydro PGF-
1a 
6-trans-Leukotriene 
B4 PGF2a ethanolamide 
6-trans-Leukotriene 
B4 
6-trans-12-epi-
Leukotriene B4 
Prostaglandin E2 
ethanolamide   bicyclo-PGE2  Leukotriene B4 
13,14-Dihydro PGF-
1a Leukotriene B4 
6-trans-Leukotriene 
B4 
13,14-Dihydro 
PGF-1a   15d PGD2  PGF2a ethanolamide Prostaglandin-c2 
Omega-Carboxy-
trinor-leukotriene B4 Leukotriene B4 
Prostaglandin-c2   
15-Deoxy-d-12,14-
PGJ2  
1314-Dihydro PGF-
1a bicyclo-PGE2 
1314-Dihydro PGF-
1a 
5-Oxo-6-trans-
leukotriene B4 
bicyclo-PGE2   
Delta-12-
Prostaglandin J2  Prostaglandin C1 15d PGD2 Prostaglandin C1 Leukotriene B5 
15d PGD2   Prostaglandin B2  
9-Deoxy-delta12-
PGD2 
Delta-12-
Prostaglandin J2 
9-Deoxy-delta12-
PGD2 
12-Keto-leukotriene 
B4 
Delta-12-
Prostaglandin J2   Prostaglandin A2  
15-Deoxy-d-12,14-
PGJ2 Prostaglandin B2 Prostaglandin B1 Prostaglandin C1 
Prostaglandin B2   Prostaglandin J2  Prostaglandin B1 Prostaglandin A2 Prostaglandin A1 
9-Deoxy-delta12-
PGD2 
Prostaglandin A2   
15-Keto-13,14-
dihydroprostaglandin 
A2  Prostaglandin A1 Prostaglandin J2 8-iso-PGA1 
15-Deoxy-d-12,14-
PGJ2 
Prostaglandin J2   12,13-DHOME  8-iso-PGA1 
15-Keto-1314-
dihydroprostaglandin 
A2 PGF2a ethanolamide Prostaglandin B1 
15-Keto-13,14-
dihydroprostagla
ndin A2   9,10-DHOME  
13,14-Dihydro PGF-
1a 
13,14-Dihydro PGF-
1a 12,20-DiHETE Prostaglandin A1 
Prostaglandin G1     12,20-DiHETE 12,13-DHOME 5-HPETE 8-iso-PGA1 
20-Hydroxy-
PGF2a     17-HETE 9,10-DHOME 8,15-DiHETE PGF2a ethanolamide 
6-Keto-
prostaglandin 
F1a     13-HETE  5,15-DiHETE 
13,14-Dihydro PGF-
1a 
13,14-Dihydro 
PGF-1a     10-HETE  17,18-DiHETE Prostaglandin-c2 
17-HETE     19(S)-HETE  14,15-DiHETE bicyclo-PGE2 
13-HETE     5-HETE  15H-11,12-EETA 15d PGD2 
10-HETE     11,12-EpETrE  12,13-DHOME 
Delta-12-
Prostaglandin J2 
19(S)-HETE     9-HETE  9,10-DHOME Prostaglandin B2 
5-HETE     8,15-DiHETE  8(S)-HPETE Prostaglandin A2 
11,12-EpETrE     5,15-DiHETE  11(R)-HPETE Prostaglandin J2 
9-HETE     17,18-DiHETE  11H-14,15-EETA 
15-Keto-13,14-
dihydroprostaglandin 
A2 
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12-HETE     14,15-DiHETE  12(R)-HPETE 12,20-DiHETE 
11(R)-HETE     12-HETE  15(S)-HPETE 5-HPETE 
16(R)-HETE     15H-11,12-EETA  12(S)-HPETE 8,15-DiHETE 
8-HETE     8(S)-HPETE   5,15-DiHETE 
15(S)-HETE     11(R)-HPETE   17,18-DiHETE 
14R,15S-
EpETrE     11H-14,15-EETA   14,15-DiHETE 
     12(R)-HPETE   15H-11,12-EETA 
     11(R)-HETE   12,13-DHOME 
     16(R)-HETE   9,10-DHOME 
     15(S)-HPETE   8(S)-HPETE 
     12(S)-HPETE   11(R)-HPETE 
     15(S)-HETE   11H-14,15-EETA 
     14R,15S-EpETrE   12(R)-HPETE 
     9-HODE   15(S)-HPETE 
     9,10,13-TriHOME   12(S)-HPETE 
     12,13-EpOME   9-HODE 
        12,13-EpOME 
steriod 
hormon
es 
   Cortisone 
5a-
Dihydrotestosterone 
sulfate 
11beta20-Dihydroxy-
3-oxopregn-4-en-21-
oic acid 
19-
Hydroxydeoxycortico
sterone 
5a-
Dihydrotestosterone 
sulfate 
11beta20-Dihydroxy-
3-oxopregn-4-en-21-
oic acid 
   Aldosterone 
11beta-Hydroxy-
3,20-dioxopregn-4-
en-21-oic acid   
11beta-Hydroxy-
3,20-dioxopregn-4-
en-21-oic acid  Androsterone sulfate  
   
11beta20-Dihydroxy-
3-oxopregn-4-en-21-
oic acid   
11beta20-Dihydroxy-
3-oxopregn-4-en-21-
oic acid 
11beta-Hydroxy-
3,20-dioxopregn-4-
en-21-oic acid   
      
21-Hydroxy-5b-
pregnane-3,11,20-
trione 
11beta20-Dihydroxy-
3-oxopregn-4-en-21-
oic acid  
      21-Deoxycortisol   
      
11-
Dehydrocorticosteron
e   
      Corticosterone   
      Cortexolone   
      Aldosterone   
purines, 
pyrimidi
nes 
Thymidine 35-
cyclic 
monophosphate 
7-
Methylguanosi
ne Cytosine Allopurinol riboside Cytidine triphosphate 
5-Amino-6-
ribitylamino uracil Cytosine 
5-
Methylthioadenosine 
5-
Methylthioadenosine 
5-
Methylthioadeno
sine Cytosine Deoxycytidine 
2-Deoxyinosine 
triphosphate 
5-Amino-6-
ribitylamino uracil Inosine triphosphate Deoxycytidine Cytosine Cytosine 
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Cytosine Deoxycytidine 
Deoxyguanosin
e Inosine 
Thymidine 5-
triphosphate  
2-Deoxyinosine 
triphosphate  Deoxycytidine 
Deoxycytidine Pseudouridine Adenosine  Pseudouridine  
5-Aminoimidazole 
ribonucleotide  Inosine triphosphate 
Pseudouridine Uridine   Uridine     
Uridine 
Inosine 
triphosphate   
2-Deoxyinosine 
triphosphate     
Adenosine 
phosphosulfate Inosine   Inosine triphosphate     
Adenosine 
monophosphate         
Inosine 
triphosphate         
Inosine         
other 
Oleamide Oleamide Oleamide Arachidonoyl Serinol  Arachidonoyl Serinol  Arachidonoyl Serinol  Arachidonoyl Serinol  Arachidonoyl Serinol  
S-
Adenosylhomocystei
ne 
NADH 
Porphobilinoge
n Porphobilinogen Oleamide Oleamide Oleamide Oleamide Oleamide Porphobilinogen 
Fucose 1-
phosphate 
Ureidoisobutyr
ic acid Riboflavin Porphobilinogen Porphobilinogen Porphobilinogen Fucose 1-phosphate Fucose 1-phosphate  
S-
Adenosylhomoc
ysteine DOPA sulfate Taurine Taurine   Porphobilinogen Taurine  
Homocysteine Taurine     Taurine   
Porphobilinogen Creatinine        
Norepinephrine 
sulfate         
DOPA sulfate         
FAD         
Creatinine         
Taurine         
Creatine         
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Table 5.8 High- and medium confidence annotated features from perfusate samples sampled on-site with SPME fibers in the hospital during IVLP with FOLFOX 
administration  
T0 T1 T2 T3 
amino acids Beta-Citryl-L-glutamic acid Beta-Citryl-L-glutamic acid Beta-Citryl-L-glutamic acid Beta-Citryl-L-glutamic acid 
L-Tryptophan N-acetyltryptophan D-Tryptophan N(6)-(Octanoyl)lysine 
Kynurenic acid N-Acetylhistamine  L-gamma-glutamyl-L-valine  N-acetyltryptophan 
Lipoyllysine L-Tryptophan L-Tryptophan D-Tryptophan 
N-Acetylhistamine  L-Valine L-Valine N-Acetylglutamine 
Tridecanoylglycine Kynurenic acid Kynurenic acid L-Tryptophan 
N-Decanoylglycine Lipoyllysine N-Acetylhistamine  Kynurenic acid 
N-Undecanoylglycine N-Undecanoylglycine Lipoyllysine L-Phenylalanine 
N-Nonanoylglycine Tridecanoylglycine N-Undecanoylglycine N-Acetylhistamine  
Myristoylglycine N-Decanoylglycine N-Nonanoylglycine Lipoyllysine 
Palmitoylglycine Palmitoylglycine N-Decanoylglycine N-Undecanoylglycine 
Dimethylglycine Pristanoylglycine Myristoylglycine Tridecanoylglycine 
 
Myristoylglycine Palmitoylglycine N-Nonanoylglycine 
 
Dimethylglycine Methylglutaric acid N-Decanoylglycine 
 
Histidinal L-2-Hydroxyglutaric acid Pristanoylglycine 
  
Histidinal Palmitoylglycine 
   
Methylglutaric acid 
   
Histidinal 
peptides Histidinyl-Histidine Gamma-glutamyl-Cysteine Glu-Val Glu-Val 
Glu-Val Prolyl-Asparagine Gamma-glutamyl-Phenylalanine Tyrosyl-Glutamate 
Prolyl-Asparagine Hydroxyprolyl-Cysteine Tyrosyl-Glutamate Tryptophyl-Arginine 
Phenylalanyl-Lysine Glycyl-Hydroxyproline Tryptophyl-Arginine Prolyl-Asparagine 
Lysyl-Phenylalanine Glutaminyl-Cysteine Threoninyl-Arginine Leucyl-Hydroxyproline 
Leucyl-Aspartate Cysteinyl-Gamma-glutamate Prolyl-Asparagine Leucyl-Aspartate 
Isoleucyl-Aspartate Cysteinyl-Hydroxyproline Phenylalanyl-Gamma-glutamate Isoleucyl-Hydroxyproline 
Aspartyl-Leucine Cysteinyl-Glutamine Phenylalanyl-Glutamine Isoleucyl-Aspartate 
Aspartyl-Isoleucine Asparaginyl-Proline Phenylalanyl-Aspartate Hydroxyprolyl-Leucine 
Asparaginyl-Proline Oxidized glutathione Leucyl-Leucine Hydroxyprolyl-Isoleucine 
L-gamma-glutamyl-L-valine  
 
Leucyl-Isoleucine Hydroxyprolyl-Cysteine 
L-beta-aspartyl-L-leucine  
 
Leucyl-Hydroxyproline Glycyl-Hydroxyproline 
Arginyl-Arginine 
 
Leucyl-Aspartate Glutamyl-Tyrosine 
Gamma-Glutamyltyrosine 
 
Isoleucyl-Leucine Cysteinyl-Hydroxyproline 
Oxidized glutathione 
 
Isoleucyl-Isoleucine Aspartyl-Leucine 
  
Isoleucyl-Hydroxyproline Aspartyl-Isoleucine 
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Isoleucyl-Aspartate Asparaginyl-Proline 
  
Hydroxyprolyl-Isoleucine Arginyl-Tryptophan 
  
Hydroxyprolyl-Cysteine L-glycyl-L-hydroxyproline  
  
Glutamyl-Tyrosine L-gamma-glutamyl-L-valine  
  
Glutaminyl-Phenylalanine L-beta-aspartyl-L-leucine  
  
Cysteinyl-Hydroxyproline Gamma-Glutamyltyrosine 
  
Aspartyl-Phenylalanine Arginyl-Arginine 
  
Aspartyl-Leucine Oxidized glutathione 
  
Aspartyl-Isoleucine 
 
  
Asparaginyl-Proline 
 
  
Arginyl-Tryptophan 
 
  
Arginyl-Threonine 
 
  
L-beta-aspartyl-L-phenylalanine  
 
  
L-beta-aspartyl-L-leucine  
 
  
L-alpha-glutamyl-L-hydroxyproline  
 
  
L-Aspartyl-L-phenylalanine 
 
acylcarnitines Pimelylcarnitine Pimelylcarnitine 3-Hydroxyhexadecadienoylcarnitine Pimelylcarnitine 
2-trans4-cis-Decadienoylcarnitine 3-Hydroxyhexadecadienoylcarnitine Pimelylcarnitine Hydroxybutyrylcarnitine 
12-Hydroxy-12-octadecanoylcarnitine 3-Hydroxy-9-hexadecenoylcarnitine trans-2-Dodecenoylcarnitine Arachidonyl carnitine 
Hydroxybutyrylcarnitine 3-Hydroxy-5 8-tetradecadiencarnitine 12-Hydroxy-12-octadecanoylcarnitine 6-Keto-decanoylcarnitine 
Propionylcarnitine 2-trans4-cis-Decadienoylcarnitine Hydroxybutyrylcarnitine 12-Hydroxy-12-octadecanoylcarnitine 
Malonylcarnitine 12-Hydroxy-12-octadecanoylcarnitine Hydroxypropionylcarnitine Propionylcarnitine 
Hydroxypropionylcarnitine Hydroxybutyrylcarnitine Propionylcarnitine Arachidonyl carnitine 
 
Propionylcarnitine Malonylcarnitine 2,6 Dimethylheptanoyl carnitine 
 
Malonylcarnitine 3-Hydroxy-9-hexadecenoylcarnitine Malonylcarnitine 
autacoids 7-hydroxy-D4-neuroprostane 7-hydroxy-D4-neuroprostane 7-hydroxy-D4-neuroprostane 7-hydroxy-D4-neuroprostane 
4-hydroxy-D4-neuroprostane 4-hydroxy-D4-neuroprostane 4-hydroxy-D4-neuroprostane 4-hydroxy-D4-neuroprostane 
20-hydroxy-E4-neuroprostane 20-hydroxy-E4-neuroprostane 20-hydroxy-E4-neuroprostane 20-hydroxy-E4-neuroprostane 
17-hydroxy-E4-neuroprostane 17-hydroxy-E4-neuroprostane 17-hydroxy-E4-neuroprostane 17-hydroxy-E4-neuroprostane 
14-hydroxy-E4-neuroprostane 14-hydroxy-E4-neuroprostane 14-hydroxy-E4-neuroprostane 14-hydroxy-E4-neuroprostane 
Resolvin D1 Resolvin D1 Resolvin D1 Resolvin D1 
Resolvin D2 Resolvin D2 Resolvin D2 Resolvin D2 
   
Resolvin D5 
   
Neuroprotectin D1 
eicosanoids Omega-Carboxy-trinor-leukotriene B4 Omega-Carboxy-trinor-leukotriene B4 Omega-Carboxy-trinor-leukotriene B4 Omega-Carboxy-trinor-leukotriene B4 
18-Carboxy-dinor-LTE4 18-Carboxy-dinor-LTE4 18-Carboxy-dinor-LTE4 18-Carboxy-dinor-LTE4 
6,7-dihydro-5-oxo-12-epi-LTB4 13E-Tetranor-16-carboxy-LTE4 Leukotriene B4 ethanolamide Leukotriene B4 ethanolamide 
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6,7-dihydro-12-epi-LTB4 Leukotriene B4 ethanolamide 6,7-dihydro-12-epi-LTB4 5-Oxo-6-trans-leukotriene B4 
12-oxo-20-dihydroxy-leukotriene B4 PGF2a ethanolamide 5-Oxo-6-trans-leukotriene B4 Leukotriene B5 
12-oxo-10,11-dihydro-20-COOH-LTB4 1314-Dihydro PGF-1a 10,11-dihydro-leukotriene B4 12-Keto-leukotriene B4 
10,11-dihydro-leukotriene B4 12(13)Ep-9-KODE Leukotriene B5 13,14-Dihydro PGF-1a 
10,11-dihydro-12-oxo-LTB4 9,10,13-TriHOME 12-Keto-leukotriene B4 PGF2a ethanolamide 
20-Carboxy-leukotriene B4 9,12,13-TriHOME 12-Keto-tetrahydro-leukotriene B4 5,6-Dihydroxyprostaglandin F1a 
12(S)-Leukotriene B4 12,13-DHOME PGF2a ethanolamide Prostaglandin-c2 
6-trans-12-epi-Leukotriene B4 9,10-DHOME 13,14-Dihydro PGF-1a bicyclo-PGE2 
6-trans-Leukotriene B4 
 
Prostaglandin-c2 15d PGD2 
12-Keto-tetrahydro-leukotriene B4 
 
bicyclo-PGE2 Delta-12-Prostaglandin J2 
Leukotriene B4 
 
15d PGD2 Prostaglandin B2 
PGF2a ethanolamide 
 
Delta-12-Prostaglandin J2 Prostaglandin A2 
13,14-Dihydro PGF-1a 
 
Prostaglandin B2 Prostaglandin J2 
Prostaglandin C1 
 
Prostaglandin A2 15-Keto-1314-dihydroprostaglandin A2 
9-Deoxy-delta12-PGD2 
 
Prostaglandin J2 13,14-Dihydro PGF-1a 
Prostaglandin B1 
 
15-Keto-13,14-dihydroprostaglandin A2 12(13)Ep-9-KODE 
Prostaglandin A1 
 
13,14-Dihydro PGF-1a 17-HETE 
8-iso-PGA1 
 
17-HETE 13-HETE 
13,14-Dihydro PGF-1a 
 
13-HETE 10-HETE 
12,20-DiHETE 
 
10-HETE 19(S)-HETE 
5-HPETE 
 
19(S)-HETE 5-HETE 
8,15-DiHETE 
 
5-HETE 11,12-EpETrE 
5,15-DiHETE 
 
11,12-EpETrE 9-HETE 
17,18-DiHETE 
 
9-HETE 12-HETE 
14,15-DiHETE 
 
12-HETE 12,13-DHOME 
15H-11,12-EETA 
 
12,13-DHOME 9,10-DHOME 
12,13-DHOME 
 
9,10-DHOME 11(R)-HETE 
9,10-DHOME 
 
11(R)-HETE 16(R)-HETE 
8(S)-HPETE 
 
16(R)-HETE 8-HETE 
11(R)-HPETE 
 
8-HETE 15(S)-HETE 
11H-14,15-EETA 
 
15(S)-HETE 14R,15S-EpETrE 
12(R)-HPETE 
 
5,6-DHET 9,10,13-TriHOME 
15(S)-HPETE 
 
11,12-DiHETrE 9,12,13-TriHOME 
12(S)-HPETE 
 
89-DiHETrE 
 
5,6-DHET 
 
14R,15S-EpETrE 
 
11,12-DiHETrE 
 
14,15-DiHETrE 
 
8,9-DiHETrE 
 
9,10,13-TriHOME 
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14,15-DiHETrE 
 
9,12,13-TriHOME 
 
9-HODE 
   
12,13-EpOME 
   
steriod hormones Aldosterone 11beta-Hydroxy-3,20-dioxopregn-4-en-21-
oic acid  
19-Oxo-deoxycorticosterone Aldosterone 
11beta-Hydroxy-3,20-dioxopregn-4-en-21-
oic acid  
11beta20-Dihydroxy-3-oxopregn-4-en-21-
oic acid 
11beta-Hydroxy-3,20-dioxopregn-4-en-21-
oic acid  
19-Oic-deoxycorticosterone 
11-Dehydrocorticosterone 
  
11beta-Hydroxy-3,20-dioxopregn-4-en-
21-oic acid  
Cortisone 
  
11beta20-Dihydroxy-3-oxopregn-4-en-21-
oic acid 
purines, pyrimidines Inosine triphosphate 5-Amino-6-ribitylamino uracil Inosine triphosphate 7-Methylguanosine 
 
2-Deoxyinosine triphosphate Cytosine 5-Amino-6-ribitylamino uracil 
 
7-Methylguanosine 2-Deoxyinosine triphosphate 2-Deoxyinosine triphosphate 
 
Inosine triphosphate Pseudouridine Cytosine 
 
Pseudouridine Uridine Inosine triphosphate 
 
Uridine 
 
5-Fluorouridine (LEV2,MULTI) 
other Arachidonoyl Serinol  Arachidonoyl Serinol  Arachidonoyl Serinol  L-Urobilinogen 
Oleamide Oleamide Oleamide Arachidonoyl Serinol  
Porphobilinogen Fucose 1-phosphate Norepinephrine sulfate Ubiquinol-10 
Riboflavin 5-Aminoimidazole ribonucleotide 
 
Oleamide 
 
Porphobilinogen 
 
5-Aminoimidazole ribonucleotide 
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Table 5.9 High- and medium confidence annotated features from lungs sampled in vivo with SPME fibers in the hospital during IV administration with FOLFOX.   
IV_Blank IV_TL IV_T0 IV_T1 IV_T2 IV_T3 
amino acids L-Tryptophan L-Tryptophan N-Acetyl-L-methionine L-Tryptophan Beta-Citryl-L-glutamic acid D-Serine 
L-Glutamine L-Phenylalanine N6,N6,N6-Trimethyl-L-
lysine 
L-Glutamine N6,N6,N6-Trimethyl-L-lysine L-Glutamine 
L-Arginine Beta-Citryl-L-glutamic acid L-Methionine L-Tyrosine L-Methionine L-Proline 
L-Lysine N-Acetyl-L-methionine L-Arginine N-Acetyl-L-methionine L-Arginine L-Phenylalanine 
L-Proline N6,N6,N6-Trimethyl-L-
lysine 
L-Histidine L-Methionine L-Lysine Beta-Citryl-L-glutamic acid 
L-Phenylalanine L-Valine L-Phenylalanine L-Arginine L-Histidine N-Acetyl-L-methionine 
Beta-Citryl-L-glutamic acid L-Methionine L-Tyrosine L-Aspartic acid L-Tyrosine L-Methionine 
N6,N6,N6-Trimethyl-L-
lysine 
L-Glutamine D-Leucine L-Histidine L-Glutamic acid L-Lysine 
L-Methionine L-Arginine Beta-Leucine L-Proline N-Acetylglutamic acid L-Asparagine 
L-Cystine L-Proline N-Acetylglutamic acid L-Phenylalanine Kynurenic acid L-Threonine 
L-Aspartic acid L-Tyrosine Kynurenic acid N-Acetylglutamic acid L-Tryptophan L-alpha-glutamyl-L-
hydroxyproline  
L-Histidine L-gamma-glutamyl-L-valine  L-Leucine L-Leucine L-Methionine o-Tyrosine 
L-Asparagine D-Lysine L-Alloisoleucine D-2-Hydroxyglutaric acid L-Arginine Beta-Tyrosine 
L-Tyrosine Kynurenic acid L-Isoleucine L-Isoleucine L-Histidine Kynurenic acid 
L-Glutamic acid L-Leucine N-Acetylhistamine  L-Glutamine L-Phenylalanine L-Leucine 
N-Acetylglutamic acid L-Lysine L-Glutamine L-Arginine L-Tyrosine Pyroglutamic acid 
Kynurenic acid L-Isoleucine L-Arginine L-Histidine N-Lauroylglycine L-Isoleucine 
L-Leucine N-Acetylhistamine  L-Tyrosine L-Histidine Glutarylglycine L-Tyrosine 
L-Isoleucine o-Tyrosine Tridecanoylglycine L-Phenylalanine Palmitoylglycine L-Glutamic acid 
L-Arginine Beta-Tyrosine N-Undecanoylglycine L-Tyrosine N-Undecanoylglycine Urocanic acid 
L-Glutamic acid L-Tyrosine N-Nonanoylglycine L-Glutamic acid N-Decanoylglycine L-Cysteinylglycine 
disulfide 
L-Lysine Pristanoylglycine N-Decanoylglycine L-Tryptophan Tridecanoylglycine Cysteineglutathione 
disulfide 
L-Tyrosine N-Decanoylglycine Pristanoylglycine L-2-Hydroxyglutaric acid Pristanoylglycine Ornithine 
D-Tryptophan Myristoylglycine Margaroylglycine 3-Hydroxyglutaric acid Pentacosanoylglycine Dimethylglycine 
L-Tryptophan Palmitoylglycine Methylglutaric acid N-Undecanoylglycine N-Nonanoylglycine Tridecanoylglycine 
Pristanoylglycine N-Undecanoylglycine 
 
N-Decanoylglycine Myristoylglycine Pristanoylglycine 
N-Decanoylglycine Tridecanoylglycine 
 
Tridecanoylglycine Lipoyllysine N-Undecanoylglycine 
Myristoylglycine N-Nonanoylglycine 
 
Pristanoylglycine Ornithine N-Nonanoylglycine 
Palmitoylglycine N-Lauroylglycine 
 
Palmitoylglycine 
 
N-Decanoylglycine 
Glutarylglycine Lipoyllysine 
 
Glutarylglycine 
 
Myristoylglycine 
N-Undecanoylglycine Ornithine 
 
N-Nonanoylglycine 
 
N-Lauroylglycine 
Tridecanoylglycine Dimethylglycine 
 
N-Lauroylglycine 
 
Palmitoylglycine 
N-Nonanoylglycine 
  
Lipoyllysine 
 
Lipoyllysine 
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Lipoyllysine 
  
Ornithine 
  
Ornithine 
  
Dimethylglycine 
  
Dimethylglycine 
  
3-Methylglutaconic acid 
  
Hippuric acid 
  
Urocanic acid 
  
3-Methylglutaconic acid 
     
peptides Histidinyl-Histidine Histidinyl-Histidine L-Cysteinylglycine 
disulfide 
Cysteinyl-Cysteine Glutamyl-Glutamate Histidinyl-Histidine 
L-Cysteinylglycine 
disulfide 
Glutamyl-Glutamate Glutarylglycine Glutamyl-Glutamate Cysteinyl-Cysteine L-Cysteinylglycine 
disulfide 
Cysteinyl-Cysteine L-Cysteinylglycine disulfide Arginyl-Arginine L-Cysteinylglycine 
disulfide 
Gamma-Glutamyltyrosine L-Threo-3-Phenylserine 
Oxidized glutathione Leucyl-Aspartate Carnosine Asparaginyl-Arginine L-Cysteinylglycine disulfide Glutarylglycine 
Glutathione Isoleucyl-Aspartate Oxidized glutathione Arginyl-Asparagine Oxidized glutathione Cysteinyl-Cysteine 
Cysteineglutathione 
disulfide 
Hydroxyprolyl-Cysteine 
 
Carnosine 
 
Arginyl-Arginine 
 
Cysteinyl-Hydroxyproline 
 
Oxidized glutathione 
 
Oxidized glutathione 
 
Aspartyl-Leucine 
 
Glutathione 
  
 
Aspartyl-Isoleucine 
 
L-Cystathionine 
  
 
L-beta-aspartyl-L-leucine  
    
 
Arginyl-Arginine 
    
 
Oxidized glutathione 
    
 
L-Cystathionine 
    
acylcarnitines Hydroxybutyrylcarnitine L-Acetylcarnitine Pimelylcarnitine Hydroxybutyrylcarnitine Pimelylcarnitine L-Acetylcarnitine 
9,12-
Hexadecadienoylcarnitine 
Pimelylcarnitine 2-trans4-cis-
Decadienoylcarnitine 
L-Acetylcarnitine 2-trans4-cis-
Decadienoylcarnitine 
3-Hydroxy-9-
hexadecenoylcarnitine 
3-Hydroxy-9-
hexadecenoylcarnitine 
2-trans4-cis-
Decadienoylcarnitine 
6-Keto-decanoylcarnitine 9,12-
Hexadecadienoylcarnitine 
6-Keto-decanoylcarnitine 2-trans4-cis-
Decadienoylcarnitine 
Pimelylcarnitine 6-Keto-decanoylcarnitine 12-Hydroxy-12-
octadecanoylcarnitine 
Pimelylcarnitine 12-Hydroxy-12-
octadecanoylcarnitine 
6-Keto-decanoylcarnitine 
2-trans4-cis-
Decadienoylcarnitine 
12-Hydroxy-12-
octadecanoylcarnitine 
Hydroxybutyrylcarnitine 2-trans4-cis-
Decadienoylcarnitine 
Butenylcarnitine 12-Hydroxy-12-
octadecanoylcarnitine 
6-Keto-decanoylcarnitine Hydroxybutyrylcarnitine 3-Dehydroxycarnitine 6-Keto-decanoylcarnitine Propenoylcarnitine Propenoylcarnitine 
12-Hydroxy-12-
octadecanoylcarnitine 
Butenylcarnitine Tiglylcarnitine 12-Hydroxy-12-
octadecanoylcarnitine 
3-Dehydroxycarnitine 3-Dehydroxycarnitine 
Butenylcarnitine Propenoylcarnitine Propionylcarnitine Hydroxyvalerylcarnitine Propionylcarnitine Propionylcarnitine 
Propenoylcarnitine 3-Dehydroxycarnitine L-Acetylcarnitine Butenylcarnitine L-Acetylcarnitine 
 
Tiglylcarnitine Propionylcarnitine L-Carnitine Propenoylcarnitine 
  
Propionylcarnitine L-Carnitine 
 
3-Dehydroxycarnitine 
  
L-Acetylcarnitine 
  
Propionylcarnitine 
  
L-Carnitine 
  
L-Carnitine 
  
   
2-Hexenoylcarnitine 
  
eicosanoids Leukotriene B4 
ethanolamide 
Omega-Carboxy-trinor-
leukotriene B4 
18-Carboxy-dinor-LTE4 Omega-Carboxy-trinor-
leukotriene B4 
Omega-Carboxy-trinor-
leukotriene B4 
18-Carboxy-dinor-LTE4 
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Omega-Carboxy-trinor-
leukotriene B4 
18-Carboxy-dinor-LTE4 13E-Tetranor-16-carboxy-
LTE4 
18-Carboxy-dinor-LTE4 18-Carboxy-dinor-LTE4 Leukotriene B4 
ethanolamide 
18-Carboxy-dinor-LTE4 13E-Tetranor-16-carboxy-
LTE4 
Omega-Carboxy-trinor-
leukotriene B4 
13E-Tetranor-16-carboxy-
LTE4 
13E-Tetranor-16-carboxy-
LTE4 
67-dihydro-5-oxo-12-epi-
LTB4 
13E-Tetranor-16-carboxy-
LTE4 
Leukotriene B4 
ethanolamide 
6,7-dihydro-12-epi-LTB4 Leukotriene B4 
ethanolamide 
Leukotriene B4 ethanolamide 5-Oxo-6-trans-leukotriene 
B4 
Leukotriene B4 
ethanolamide 
5-Oxo-6-trans-leukotriene 
B4 
10,11-dihydro-leukotriene 
B4 
1011-dihydro-12-oxo-LTB4 13,14-Dihydro PGF-1a 1011-dihydro-12-oxo-
LTB4 
10,11-dihydro-20-
dihydroxy-LTB4 
Leukotriene B5 12-Keto-tetrahydro-
leukotriene B4 
12(S)-Leukotriene B4 PGF2a ethanolamide 12(S)-Leukotriene B4 
Prostaglandin E2 
ethanolamide 
12-Keto-leukotriene B4 Prostaglandin E2 
ethanolamide 
6-trans-12-epi-Leukotriene 
B4 
Prostaglandin E2 
ethanolamide 
6-trans-12-epi-Leukotriene 
B4 
13,14-Dihydro PGF-1a PGF2a ethanolamide 13,14-Dihydro PGF-1a 6-trans-Leukotriene B4 17-HETE 6-trans-Leukotriene B4 
PGF2a ethanolamide Prostaglandin E2 
ethanolamide 
9,10,13-TriHOME Leukotriene B5 13-HETE Leukotriene B5 
1314-Dihydro PGF-1a 13,14-Dihydro PGF-1a 9,12,13-TriHOME 12-Keto-leukotriene B4 10-HETE 12-Keto-leukotriene B4 
Prostaglandin G1 bicyclo-PGE2 5,6-DHET Leukotriene B4 19(S)-HETE Leukotriene B4 
20-Hydroxy-PGF2a 15d PGD2 11,12-DiHETrE Omega-Carboxy-trinor-
leukotriene B4 
5-HETE 13,14-Dihydro PGF-1a 
9-HODE Delta-12-Prostaglandin J2 8,9-DiHETrE Prostaglandin E2 
ethanolamide 
11,12-EpETrE Prostaglandin E2 
ethanolamide 
12,13-EpOME Prostaglandin B2 14,15-DiHETrE 1314-Dihydro PGF-1a 9-HETE Delta-12-Prostaglandin J2 
 
Prostaglandin A2 17-HETE Prostaglandin C1 12-HETE Prostaglandin B2 
 
Prostaglandin J2 13-HETE 9-Deoxy-delta12-PGD2 12,13-DHOME Prostaglandin B1 
 
15-Keto-1314-
dihydroprostaglandin A2 
10-HETE Prostaglandin-c2 9,10-DHOME Prostaglandin A2 
 
12,13-DHOME 19(S)-HETE bicyclo-PGE2 11(R)-HETE Prostaglandin J2 
 
9,10-DHOME 5-HETE Delta-12-Prostaglandin J2 16(R)-HETE Prostaglandin A1 
  
11,12-EpETrE Prostaglandin B2 8-HETE 8-iso-PGA1 
  
9-HETE Prostaglandin B1 15(S)-HETE 15-Keto-1314-
dihydroprostaglandin A2   
12-HETE Prostaglandin A2 
 
PGF2a ethanolamide 
  
12,13-DHOME Prostaglandin J2 
 
5-HPETE 
  
9,10-DHOME Prostaglandin A1 
 
8,15-DiHETE 
  
11(R)-HETE 8-iso-PGA1 
 
17,18-DiHETE 
  
16(R)-HETE Leukotriene A4 
 
14,15-DiHETE 
  
8-HETE 15-Keto-1314-
dihydroprostaglandin A2 
 
12,13-DHOME 
  
15(S)-HETE 1314-Dihydro PGF-1a 
 
9,10-DHOME 
  
14R,15S-EpETrE 12,20-DiHETE 
 
8(S)-HPETE 
   
9-HEPE 
 
11(R)-HPETE 
   
15d PGD2 
 
11H-14,15-EETA 
   
12-KETE 
 
12(R)-HPETE 
   
5-HPETE 
 
15(S)-HPETE 
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9-HODE 
 
12(S)-HPETE 
   
8,15-DiHETE 
  
   
5-KETE 
  
   
5,15-DiHETE 
  
   
17,18-EpETE 
  
   
17,18-DiHETE 
  
   
15-KETE 
  
   
14,15-DiHETE 
  
   
12-HEPE 
  
   
5-HEPE 
  
   
15H-11,12-EETA 
  
   
12,13-EpOME 
  
   
8(S)-HPETE 
  
   
11(R)-HPETE 
  
   
11H-14,15-EETA 
  
   
12(R)-HPETE 
  
   
15(S)-HPETE 
  
   
12(S)-HPETE 
  
steriod hormones Tetrahydrocorticosterone 
   
17a,21-
Dihydroxypregnenolone 
 
    
11b,21-Dihydroxy-5b-
pregnane-3,20-dione 
 
    
3a,21-Dihydroxy-5b-
pregnane-11,20-dione 
 
    
3b,17a,21-
Trihydroxypregnenone 
 
    
3b,15b,17a-
Trihydroxypregnenone 
 
purines, pyrimidines Inosine triphosphate Inosine triphosphate Inosine triphosphate Inosine triphosphate Inosine triphosphate Inosine triphosphate 
8-Hydroxy-7-
methylguanine 
Inosine 8-Hydroxy-7-
methylguanine 
8-Hydroxy-7-
methylguanine 
N4-Acetylcytidine N4-Acetylcytidine 
N4-Acetylcytidine N4-Acetylcytidine FAPy-adenine N4-Acetylcytidine FAPy-adenine 8-Hydroxy-7-
methylguanine 
FAPy-adenine FAPy-adenine Thymidine 3,5-cyclic 
monophosphate 
FAPy-adenine 5-Methylthioadenosine FAPy-adenine 
5-Methylthioadenosine Thymidine 3,5-cyclic 
monophosphate 
5-Methylthioadenosine Thymidine 3,5-cyclic 
monophosphate 
7-Methylguanosine 5-Methylthioadenosine 
7-Methylguanosine Cytidine monophosphate 7-Methylguanosine 5-Methylthioadenosine 5-Methylcytosine 7-Methylguanosine 
Cytosine 5-Methylthioadenosine Cytosine 7-Methylguanosine Uridine Cytosine 
Deoxycytidine 7-Methylguanosine Deoxycytidine Cytosine 5-Fluorodeoxyuridine 
monophosphate 
Deoxycytidine 
Pseudouridine Cytosine Pseudouridine Deoxycytidine Adenine 5-Methylcytosine 
Uridine Deoxycytidine Uridine Uridine 
 
Uridine 
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Adenosine monophosphate 
 
Deoxyguanosine 5-Fluorodeoxyuridine 
monophosphate 
 
5-Fluorodeoxyuridine 
monophosphate 
Adenine 
 
Adenosine Adenine 
 
S-Adenosylhomocysteine 
  
5-Fluorodeoxyuridine 
monophosphate 
  
Adenosine monophosphate 
  
Adenosine monophosphate 
  
Adenine 
other Arachidonoyl Serinol  Arachidonoyl Serinol  Arachidonoyl Serinol  Arachidonoyl Serinol  Arachidonoyl Serinol  Oleamide 
Oleamide Oleamide Oleamide Oleamide Oleamide Creatinine 
NADH NADH NADH NADH Porphobilinogen Creatine 
Fucose 1-phosphate Fucose 1-phosphate S-Adenosylhomocysteine Creatinine Creatine Taurine 
5-Aminolevulinic acid S-Adenosylhomocysteine Creatinine Taurine Creatinine 
 
Ubiquinone-1 Creatinine 
 
Porphobilinogen 
  
L-2-Hydroxyglutaric acid Creatine 
 
Creatine 
  
Taurine 
     
S-Adenosylhomocysteine 
     
Creatinine 
     
Taurine 
     
Creatine 
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Chapter 6: In vivo solid phase microextraction chemical biopsy tool 
for monitoring doxorubicin residue in human lung tissue during 
clinical in vivo lung perfusion (IVLP) 
6.1 Preamble 
Chapter 6 of this thesis has been submitted to the journal Angewandte Chemie [EMID:1887f04136457f99 
–Manuscript number: 202003084] and is equally co-authored with B. Bojko. Other co-authors include M. 
Olkowicz, A. Roszkowska, B. Kupcewicz, P. Reck dos Santos, K. Ramadan, S. Keshavjee, T. Waddell, 
G.A. Gomez-Rios, M. Tascon, K. Gorynski, M. Cypel, J. Pawliszyn. The collaboration was initiated by B. 
Bojko, J. Pawliszyn, and M. Cypel who were also responsible for the experimental design. Experimental 
execution, sampling at the hospital for both clinical trials and instrumental analysis for targeted and 
untargeted work and data processing for targeted and untargeted analysis was completed by the author of 
this thesis with assistance from G.A. Gomez-Rios, M. Tascon and M. Olkowicz. Statistical analysis was 
completed by B. Bojko, B. Kupcewicz and the author of this thesis and biochemical interpretation from 
annotation was conducted by B. Bojko, A. Roszkowska, and Mariola Olkowicz. The final formatted 
manuscript was equally written by B. Bojko, Khaled Ramadan, A. Roszkowska and the author of this thesis. 
Please see Statement of contributions. The authors would like to thank our collaborators at MilliporeSigma 
for kindly providing us with the fibers and chromatographic columns employed for this investigation. We 
would also like to thank Thermo Fisher Scientific for lending us the triple quadrupole mass spectrometer 
that was used in this work (TSQ Quantiva). Funding: We are grateful to the Canadian Cancer Society for 
their support in the development of IVLP via innovation grants, as well as its further support in the clinical 
trial with DOX IVLP as part of the innovation-to-impact grant. We are also grateful to the Canadian Institute 
of Health Research (CIHR) - Natural Sciences and Engineering Research Council (NSERC) of Canada 
Collaborative Health Research Projects program for their financial support [grant 355935 entitled 
“Supervised in vivo lung perfusion strategy for treatment of cancer metastases to the lungs. Real-time 
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monitoring of chemotherapy by on-site analytical platform”] and the Natural Sciences and Engineering 
Research Council of Canada Industrial Research Chair (IRC) program. 
6.2 Introduction 
Pulmonary metastases are known to develop in approximately 30% of patients with malignant tumors, most 
frequently in patients suffering from sarcomas. Although surgical resection is a widely accepted treatment 
for pulmonary metastases, a 5-year survival rate of about 20% after complete resection remains 
disappointing.176 Unfortunately, most patients develop recurrent metastasis, probably as a result of 
micrometastatic disease present at the time of the initial operation. Most recurrences occur in the lungs 
themselves, suggesting that the lung is the major reservoir of occult metastatic burden (Figure 6.1). 
Therefore, a treatment capable of specifically targeting the lung to eradicate micrometastatic disease would 
be highly beneficial for this patient population. By building upon our experience with ex vivo lung perfusion 
for repair of donor lungs for transplantation,125,177 our group recently developed and described a technique 
for isolated in vivo lung perfusion (IVLP) to facilitate localized drug delivery to lungs during surgical 
resection.142,143 Based on these pre-clinical studies, a phase I clinical trial (NCT02811523) using 
doxorubicin (DOX) during IVLP for treatment of lung sarcoma metastases is underway. 
 
Figure 6.1 Pre-operative lung computed tomography (CT) scan for 1st patient subjected to IVLP 
showing numerous bilateral pulmonary sarcoma metastases as denoted by arrows 
 
While perfusate and blood analyses can be easily and repeatedly performed throughout the IVLP procedure 
due to their non-invasive sample collection nature, such methods do not allow for accurate enough 
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determination of DOX concentration in lung tissue. Direct determination of DOX in different compartments 
of lung tissue is desired during IVLP, as such an approach can provide precise information about drug level 
and its biodistribution within particular lung lobes. Traditionally, accurate determination of DOX in lungs 
requires collection of tissue via tissue biopsy, an invasive process that can only be performed from 
peripheral locations of the organ at the end of lung perfusion. In addition, traditional analytical methods for 
tissue determinations require lengthy sample processing and analysis, thus preventing real-time 
determinations of concentration and biodistribution of DOX in lung tissue over the course of IVLP. The 
absence of such information during IVLP, in turn, introduces potential for administration of subtherapeutic 
or toxic tissue levels of DOX. A minimally invasive method capable of monitoring DOX levels in tissue in 
close to real-time conditions would allow for safe, effective, and accurate administration of DOX in lung 
during IVLP. Certainly, implementation of such a monitoring tool during IVLP would be of critical 
therapeutic benefit, as such a measure would optimize treatment while preventing adverse effects associated 
with toxic levels of DOX in the target organ. Additionally, analysis of other indicators such as small 
endogenous molecules could reveal individual patient’s response to drug toxicity or organ stress178 by 
providing insight into ongoing biochemical processes during IVLP. Access to such information would be 
useful for effective tailoring of this treatment, as it would enable dose adjustments based on measurements 
of patient response rather than just DOX concentration levels. 
Herein, biocompatible solid phase microextraction (Bio-SPME) technology is proposed as a new analytical 
strategy to assist in real-time measurements of DOX in tissue and perfusate during IVLP. Bio-SPME has 
already been reported for analysis of tissues.129,130  This chemical biopsy procedure involves the extraction 
of small molecules such as xenobiotics and endogenous tissue components from a biological system by 
directly inserting sharpened microprobe the size of an acupuncture needle (ca. 0.3 mm diameter) into the 
tissue (Figure 6.2) without removal of any tissue residue.141,179 The probe consists of a nitinol (Ni/Ti) alloy 
wire coated with a matrix-compatible extraction phase; in this case, a crosslinked slurry composed of 
micron-sized sorbent particles suspended in a biocompatible oligomer binder.  The crosslinked 
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polyacrylonitrile oligomer forms a smooth surface characterized by small size pores, which exclusively 
permit the diffusion of small molecules from tissue to dispersed sorbent particles while preventing the 
adsorption of tissue components such as proteins, red blood cells, and other endogenous macromolecules 
onto the surface of the coating. Recovery of these small compounds is obtained via their desorption from 
the coating into a small amount of organic solvent, which is then subjected to instrumental analysis. 
 
Figure 6.2 Biocompatible solid phase microextraction (Bio-SPME) probe 
 
Quantitative analysis can be performed since Bio-SPME is conveniently amenable to a range of separation 
and detection techniques, including high-performance liquid chromatography (HPLC) coupled to tandem 
mass spectrometry (MS/MS) - the standard method for bioanalytical determinations. Qualitative analysis 
by way of untargeted metabolomics can also be performed via HPLC coupled to high-resolution mass 
spectrometry (HRMS). SPME has shown great potential in the field of clinical metabolomics due to its 
extractive capabilities for a broad range of both polar and non-polar small molecules (100 – 1200 Da.).57,155 
The advantage of carrying out a chemical biopsy via SPME in comparison to several other approaches is 
that Bio-SPME can be used to perform in vivo metabolomics.55,57,62,180  Given its minimally invasive design, 
non-depletive extraction principle, and biocompatibility, information regarding the metabolites present 
within the system at a given time can thus be easily obtained without disrupting molecular binding or 
equilibrium within the system, nor damaging the microprobe itself.62 In addition, Bio-SPME can be 
hyphenated to stand-alone mass spectrometer (MS) instruments, resulting in shorter analysis times and 
closer to real-time in vivo monitoring of DOX levels.62  The herein proposed approach certainly fits within 
the growing trend of incorporating intraoperative real-time analysis of small molecules in animal and 
human studies via automated MS-based diagnostic protocols. Devices such as intelligent Knife (iKnife), 
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MasSpec Pen, and SpiderMass are among modern biocompatible tools that enable easy and fast introduction 
of extracted analytes to MS instrumentation, thus providing access to relevant information regarding the 
status of tissue during surgery.181–183  In line with these surging trends, the development of sampling/sample 
preparation techniques based on microdialysis (MD) and SPME for such applications has observed 
increased demand in recent years, as such techniques facilitate reliable in vivo measurements of drug 
concentration and biodistribution within selected organs.141,184,185  
Here, Bio-SPME is used to monitor DOX and its metabolites, as well as small endogenous molecules, 
present within the system over the course of IVLP. The current work presents the determination and 
quantification of DOX in the following settings: (i) an in vivo pig model over various drug doses as a proof-
of-concept and (ii) an in vivo IVLP human clinical trials. The work also demonstrates that the SPME 
chemical biopsy enriches other low molecular weight compounds, such as potential markers of drug toxicity 
or organ stress over the course of IVLP. 
6.3 Materials and methods 
6.3.1 Study design 
The main objective of this study was to evaluate the potential of Bio-SPME probes as chemical biopsy to 
nondestructively extract and analyze the concentration and biodistribution of DOX in lung tissue during 
IVLP procedure. The experiments were performed on in vivo pig model over various drug doses and during 
in vivo IVLP human clinical trial. In addition, we investigated in vivo profile of small endogenous molecules 
in human lung tissue over the course of IVLP-DOX administration. IVLP procedure and Bio-SPME lung 
sampling were conducted at Toronto General Hospital. Bio-SPME extraction of perfusate samples was 
performed on-site at Toronto General Hospital and in the analytical laboratory at University of Waterloo. 
HPLC-MS/MS and HPLC-HRMS analyses were performed in the analytical laboratory at University of 
Waterloo. 
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6.3.2 In vivo animal study 
Two Yorkshire pigs weighing approximately 35 kg were used. The study was approved by the Animal Care 
Research Committee at Toronto General Research Institute. A porcine left lung IVLP model was used to 
model delivery of high doses of DOX during IVLP. The IVLP model procedure has been described 
elsewhere.176,186  The doses of DOX administered were 150 and 225 mg/m2. SPME sampling was performed 
from the lower lobe of the left lung before perfusion (t0) and 30, 90, 150, and 210 min after the start of the 
IVLP procedure, using the protocol described below. 
6.3.3 In vivo human study 
The clinical trial was registered with www.clinicaltrials.gov, and institutional research ethics board 
approval was obtained. Two individuals were enrolled in clinical study:  22-year old and 66-year-old males 
with bilateral recurrent pulmonary metastases secondary to osteogenic sarcoma (Figure 6.1). All lung 
lesions treated with DOX using the IVLP platform could be resected with wedge or segmental resections. 
Both patients had previous systemic exposure to DOX (<450 mg) and had previously received a bilateral 
metastasectomy.  
The technical details of the procedure have been described elsewhere.176  Briefly, a clam-shell thoracotomy 
was performed, and the left pulmonary hilum was dissected. The pulmonary artery and upper and lower 
pulmonary veins were dissected and subsequently cannulated and attached to the IVLP perfusion system. 
Lung isolation was performed using vascular clamps, and IVLP was initiated and run for 3 hours. DOX 
was added to the IVLP perfusion solution at a concentration of 5 and 7μg/mL for the first and second 
patient, respectively. 
For Bio-SPME sampling of lung, three probes (Figure 6.2) were placed in different areas of the lung (upper, 
middle, and lower sections) at predetermined time points over the course of the surgery. In both cases, the 
lung was sampled prior to drug administration, hourly during IVLP, and once after reperfusion. Extractions 
with the use of Bio-SPME probes were carried out for 20 minutes under static conditions. For Bio-SPME 
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sampling of perfusate, three fibers were used for on-site extraction of collected perfusion fluid. A 20-minute 
static extraction was performed on these samples as well. For both Bio-SPME sampling cases, the probes 
were subsequently rinsed manually in water for 5 s, wiped with a Kimwipe, and immediately snap-frozen 
in dry ice. Additional perfusate samples were also collected and snap-frozen in dry ice until further analysis 
in the laboratory. Concentrations of DOX in lung and in perfusate were determined in accordance with the 
recently published and validated SPME-HPLC-MS/MS protocol with some minor modifications. 
Information regarding the type of probes employed and instrumentation for analysis can also be found in 
this publication.125 In addition, the analytical method to identify and quantify DOX key metabolites 
(doxorubicinol (DOX-ol), doxorubicinone (DOX-one), and doxorubicinolone (DOX-olone)) has been 
developed. 
6.3.4 Statistical analysis 
The metabolomics experiments were performed separately for both cases because of the long-time interval 
between the recruitment of the patients. First dataset was used for selection of important endogenous 
features, while the second dataset was used for confirmation of the initial findings. In metabolomics 
experiments, the number of features detected is typically much larger than the number of samples studied. 
In our study, the first dataset consisted of n = 12 samples and p =138 variables. Selection of variables prior 
to chemometric analysis was carried out using the LASSO method. LASSO (Least Absolute Shrinkage and 
Selection Operator) applies a regularization process where it penalizes the coefficients of regression 
variables, forcing certain coefficients to be set to zero. Thus, LASSO removes variables that are redundant 
by effectively providing a simpler model that does not contain those coefficients. The number of variables 
selected using the LASSO method has to be smaller or equal to the number of samples. Moreover, LASSO 
will often select only a single feature from a set of highly correlated variables.142 Principal component 
analysis (PCA) was applied to the selected data after autoscaling (Unit-Variance scaling). PCA analysis 
employed internal cross-validation using the Leave-one-out-cross-validation (LOOCV) method.  The 
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validation metrics root mean squares errors of calibration (RMSEC) and cross-validation (RMSECV) were 
calculated.  
6.4 Results  
6.4.1 Determination and quantification of DOX during IVLP 
In vivo animal study. As a proof-of-concept for the sampling method, initial experiments were carried out 
using pigs as the experimental model. No bleeding or adverse effects were observed in any of the sampled 
areas of the lung in either pig case (Figure 6.3).  
 
Figure 6.3 In vivo sampling of pig lungs during IVLP with doxorubicin. (A): triplicate of Bio-SPME 
probes during sampling; (B): the same location of lung after removal of SPME probes. (Reprinted with 
permission)129 
 
Single Bio-SPME probe from each time point was used to assess lung tissue concentration of DOX. Lung 
tissue concentrations of DOX were successfully measured during two separate IVLP procedures, where 
DOX doses of either 150 mg/m2 or 225 mg/m2 were administered (Figure 6.4).  
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Figure 6.4 Concentration profile of DOX in lower lobe of the lung during IVLP (sampling points: 30, 
90, 150, and 210 min). Red circles and blue squares – levels of DOX after administration with 150 and 
225 mg/m2, respectively. 
 
As expected, sampling before DOX administration (time zero, pre-IVLP) did not show the presence of the 
chemotherapeutic agent in lung tissue. Subsequent samplings exhibited a trend of a quick peak of drug 
followed by steady decline. For the lung perfused with a drug dose of 150 mg/m2, a maximum measured 
concentration of 723 µg/g DOX was noted at the 30 min mark after IVLP was initiated. For the lung 
perfused with a dose of 225 mg/m2 DOX, a maximum measured concentration of 3521 µg/g was reached 
after 90 min of IVLP. In the case of the high dose (225 mg/m2 DOX), the whole procedure ceased at 150 
minutes, as the animal did not tolerate the injury caused by the high dose being administered. 
In vivo human study. There were no intra-operative complications and use of Bio-SPME probes did not 
cause lung injury. For the first patient, wedge resection was performed for 6 lesions on the right lung and 4 
lesions on the left lung. Total operative time was 7 hours 19 minutes in the case of 22-year-old patient and 
6 hours and 47 min in the case of 66-year-old patient. Both patients tolerated the procedure well and did 
not require ICU admission. Each patient was discharged home on postoperative day 7 (POD7). They had 
an uneventful post-operative period and returned to regular activity after 1 month. At 6 months, 1st patient’s 
forced expiratory volume in one second (FEV1) decreased from 4.7L (82% predicted) to 2.9L (50% 
predicted) and his forced vital capacity (FVC) decreased from 5.6L (80% predicted) to 3.4L (48% 
predicted). The patient developed bilateral lung recurrences after 6 months of follow-up, which have 
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progressed despite further treatment. He remained alive until 1 year of follow-up. Second patient at 6-month 
follow-up remained in overall good health. 
 
Figure 6.5 Concentration of doxorubicin measured by Bio-SPME-HPLC-MS/MS in lung tissue during 
first (A) and second (C) clinical IVLP. Time points include 1-hour pre-IVLP, 1, 2, 3 hours during IVLP, 
and 30 minutes post-IVLP during lung reperfusion. Red, blue, and green dots represent the three locations 
of the fiber in the lung during sampling. The red circle designates the upper section of the lung, the blue 
square designates a section between the upper and lower lobes (middle) of the lung, and the green triangle 
designates the lower section of the lung. Black diamonds show when hospital biopsies were taken. (B, 
D) Concentration of doxorubicin in perfusate as measured by Bio-SPME-HPLC-MS/MS and the 
standard approach (hospital assay - PPT-HPLC/FLD or PPT-LC/MS), during human IVLP, represented 
by the blue and red diamonds, respectively. 
 
For the 22-year old patient, concentrations of DOX in the upper, middle, and lower regions of the perfused 
lung showed similar trends during IVLP (Figure 6.5A). Expectedly, before perfusion started (pre-IVLP), 
lung tissue was free of DOX. Maximum lung tissue concentrations of drug measured by Bio-SPME were 
reached at the first hour of IVLP, and were 200 µg/g, 36 µg/g, and 166 µg/g, for the upper, middle, and 
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lower sections of the lung, respectively. Lung tissue concentration dropped steadily over the course of IVLP 
and reached a nadir of 14 µg/g, 8 µg/g, and 9 µg/g for the upper, middle, and lower areas of the lung, 
respectively, by 30 min post blood reperfusion (after IVLP termination). The hospital assay (current gold 
standard technique done in tissue biopsies to measure DOX), which consisted of protein precipitation (PPt) 
followed by HPLC with fluorescence detection (HPLC/FLD), showed a DOX concentration of 7.0 µg/g in 
the biopsy tissue 30 min post-reperfusion. Further details on the hospital assay employed have been 
published elsewhere.187  For the 66-year old patient, the highest tissue concentrations of DOX estimated 
with Bio-SPME probes were also noticed in the first hour of lung perfusion, and were 179 µg/g, 69 µg/g, 
and 293 µg/g, for the upper, middle, and lower sections of the lung, respectively (Figure 6.5C). Similarly, 
to the first human case, lung tissue concentrations of DOX exhibited a decreasing trend throughout the 
procedure reaching the levels of 30, 18 and 28 µg/g for the upper, middle, and lower areas of the lung, 
respectively 30 min post blood reperfusion. The hospital assay utilizing collected biopsy samples 
predictably revealed no drug at the stage of pre-perfusion and its very low content during pulmonary 
reperfusion (Figure 6.5C).  
In addition to in vivo tissue measurements of DOX and its metabolites, the drug was also extracted by 
SPME probes on-site as well as in the analytical laboratory from perfusate samples collected at the same 
time points used for the in vivo lung sampling. For the 1st clinical case, the total drug amount given to the 
perfusion circuit, was 5.0 µg/mL. Concentration of DOX in the perfusate decreased steadily from the 
beginning of the IVLP procedure (Figure 6.5B). SPME-HPLC-MS/MS analysis revealed that after 30 
minutes, the DOX concentration in the perfusate was 2.4 µg/mL and that over the course of the procedure 
this decreased to a nadir of 0.3 µg/mL by the end of the perfusion. PPt-HPLC/FLD analysis of perfusate 
samples performed by the clinical laboratory showed a concentration of 7.2 µg/mL after 30 minutes, and a 
nadir of 1.0 µg/mL by the end of the perfusion. DOX concentration measurements of frozen perfusate 
samples analyzed by SPME-HPLC-MS/MS after transport to an off-site location showed no statistically 
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significant differences from perfusate samples analyzed by SPME in the operating room (p = 0.75) (Table 
6.1). 
Table 6.1 Concentration of DOX in perfusate collected during 1st clinical IVLP and measured via Bio-
SPME-HPLC-MS/MS for samples obtained on site and samples brought back to the laboratory for 
traditional analysis (denoted as UW). 
On-site analysis In-laboratory analysis 
Sample Average 
(μg/mL) 
SD %RSD 
(n= 3) 
Sample Average 
(μg/mL) 
SD % RSD 
(n = 3) 
Perf_T1 2.5 0.1 6 Perf_T1_UW 2.4 0.5 20 
Perf_T2 1.2 0.05 4 Perf_T2_UW 1.4 0.1 9 
Perf_T3 0.6 0.03 5 Perf_T3_UW 0.4 0.06 16 
Perf_T4 0.4 0.02 5 Perf_T4_UW 0.3 0.1 45 
 
During 2nd clinical IVLP, the dose of the drug administered into the perfusion circuit was 7 µg/mL and 
detected concentration of DOX in the perfusate samples in the first hour of the procedure was equal to 2.66 
µg/mL. In next hours of IVLP, a further decline in DOX level was observed with the level of 1.16 µg/mL 
noticed at 3rd hour of perfusion (Figure 6.5D). For the second patient, a similar decreasing trend in the 
terms of the drug level in perfusate samples over the course of IVLP was also observed with the standard 
approach employing PPt as a streamlined sample preparation method (Figure 6.5D), however using the 
same instrumental method and analytical conditions the results received with two different strategies were 
even more comparable. 
Figure 6.5B and Figure 6.5D show direct comparison SPME results with standard assays showing a good 
agreement between the data.  In case of Figure 6.5B the PPt-HPLC/FLD assay was performed by external 
clinical lab for single samples at each time point, while in Figure 6.5D the PPt-LC/MS assay was performed 
on triplicate sample, similar as SPME extraction.  It should be noted that the estimated precision obtained 
for SPME (RSD below 5%) are much better compared to PPt/LC/MS (RSD below 15%). 
Furthermore, the identification and quantification of key metabolites of DOX, namely doxorubicinol 
(DOX-ol), doxorubicinone (DOX-one), and doxorubicinolone (DOX-olone) was performed for both 
clinical cases. However, the results showed that DOX metabolites were present at trace levels in the tested 
matrices (Figure 6.6). Only DOX-ol formed in the major metabolic route of DOX metabolism was 
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detectable at visible level, but its content in lung tissue did not exceed 5% of the intact drug, and therefore 
was considered as insignificant. 
 
Figure 6.6 Floating bars presenting levels of doxorubicin and its key metabolites (doxorubicinol and 
doxorubicin aglycone) over the course of IVLP procedure. The detection range together with median 
values for each compound analyzed in relevant matrixes (lung tissue (A, B) or perfusate samples (C-E), 
respectively) have been denoted. As indicated above, the intact drug was a predominant one detected in 
investigated systems with some amounts of metabolites resulting from its biotransformation but 
contributing no more than 5% to the resultant pool of analyzed compounds. 
 
6.5 Discussion 
The current study demonstrates that the developed method based on SPME enables quantitative monitoring 
of DOX from lung tissue in a safe and minimally invasive manner. Multiple insertions of Bio-SPME 
chemical biopsy probes did not cause tissue injury during in vivo administration in either pig or human 
lungs. Each patient recovered uneventfully and had no complications from the SPME fiber insertion or the 
IVLP-DOX administration. Bio-SPME sampling was successfully performed on-site (in vivo and in situ), 
but analysis and data processing were still done in the analytical lab. No difference was observed among 
perfusate results for analyses carried out on-site or in-lab; however, the availability of MS instruments 
within or near the operating room would offer the possibility of more rapid target drug concentration 
determinations. A fully on-site setup is feasible since Bio-SPME probes can be directly coupled to a mass 
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spectrometer (SPME-MS), thereby providing results within seconds.62,188,189 More recently we have also 
developed portable fluorometer coupled to laptop designed to be deployed in a surgery room for fast and 
direct quantification of DOX in the tissue via detection of this compound in the SPME coating (manuscript 
submitted). Fluorescence readout, however, can only provide the information about DOX concentration, 
but not about its metabolites or endogenous compounds, hence the information about organ condition in 
respect to biochemical alterations still requires the application of MS analysis. In both pig and human cases, 
DOX tissue levels presented similar trends during IVLP, wherein drug concentrations peaked between sixty 
to ninety minutes after the start of IVLP and subsequently dropped. This is more evident in the clinical trial 
since all sampled areas of the lung – upper, middle, and lower – exhibited the same pattern. As there were 
no measured leaks in the IVLP circuit, two potential reasons may explain this observed pattern: a) 
biotransformation of DOX into metabolites, leading to less intact drug available for extraction (that was 
rather not supported by our results indicating the formation of negligible amount of metabolites-please see 
below) or b) diffusion of DOX into cells. Bio-SPME probe extracts only free concentration of compounds, 
and therefore will not remove DOX bound to the intracellular components. The binding or partitioning of 
DOX into cells, therefore, decreases its free concentration in the extracellular environment of the lung 
where the microprobe performs sampling, which is reflected in the trend of decreasing DOX concentration. 
The results of DOX level obtained by Bio-SPME-HPLC-MS/MS for the lower lobe of the lung after drug 
washout (9 µg/g for first human case and 28 µg/g for second human case) were comparable to results 
obtained on tissue biopsies employing the standard assay further confirming the reliability of the approach 
proposed. Furthermore, the results from this study indicate that perfusion of the lung does not necessarily 
provide homogenous drug distribution, which may also account for the slight difference between the results 
provided by each assay, as the samples, although derived from the same lobes, were not obtained from the 
exact same location. It is important to emphasize that the differences in sample preparation fundamentals 
between SPME and PPT also contribute to some differences in the results gathered for perfusate samples 
employing these two methods. Furthermore, Bio-SPME has the added advantage of providing information 
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about the total as well as free drug concentrations; the latter offering the drug fraction immediately available 
for tissue binding.62,190 Despite some differences in absolute measured DOX concentrations between the 
SPME-HPLC-MS/MS and PPt-HPLC/FLD assays, as seen on Figure 6.5B, there was an identical 
decreasing trend observed by both techniques, showing reliability and relative agreement of the methods. 
In addition, although the developed Bio-SPME-LC/MS method also offers a possibility to monitor DOX 
key metabolites (DOX-ol, DOX-one and DOX-olone), none of them were found at significant level in the 
lung tissue during DOX administration via IVLP. This finding is in line with generally accepted assumption 
that intact drug rather than its metabolites is responsible for pharmacological activity and anticancer effects. 
6.5.1 Screening of small molecules in lung tissue during IVLP-DOX administration 
The same Bio-SPME extracts that were used to perform targeted therapeutic analysis of DOX via HPLC-
MS/MS were also used for screening of other low molecular weight compounds via HPLC-HRMS. Figure 
6.7. shows the results of principal component analysis (PCA) conducted on samples obtained for the 1st 
clinical case at different time points for the duration of IVLP.  
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Figure 6.7 Principal component analysis showing separation of the data obtained at subsequent time 
points for different sections of the lung; red denote baseline sampling, before IVLP; green, blue, and 
turquoise denote 1 hour and 2 hours after the start of IVLP and 30 minutes after the start of blood 
reperfusion (RMSEC = 0.462, RMSECV = 0.838), respectively. The biplot reflects the distribution of 
molecular features (compounds), denoted as grey points, selected with LASSO with respect to 
subsequent data points. 
 
 
It is evident that samples collected from each time point group relatively well together, with separation seen 
as a transitionary pattern from the left to the right part of the plot. It was even more pronounced for 2nd 
clinical case pointing at a clear discrimination among metabolomic patterns for samples collected before 
commencing perfusion, during IVLP, and reperfusion (Figure 6.8).   
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Figure 6.8 3-dimensional PCA score plots comparing LC/MS metabolomic profiles among four (1st clinical 
case (A))/five (2nd clinical case (B)) conditions corresponding to 4/5 sampling time-points (pre-perfusion, 1st, 
2nd and 3rd hour of IVLP, reperfusion). Colored dots represent individual samples collected during sampling of 
different sections of the lung. Excellent discrimination among studied conditions (pre-perfusion vs. IVLP vs. 
reperfusion) has been found. Baseline – samples collected at pre-perfusion, LP1 – samples collected at 1st hour 
of IVLP, LP2 – samples collected at 2nd hour of IVLP, LP3 – samples collected at 3rd hour of IVLP, reperfusion 
– samples collected 30 min post reperfusion 
 
Introduction of Least Absolute Shrinkage and Selection Operator (LASSO) analysis enabled selection of 
the compounds of the highest importance in the separation between T0, T1, T2, and T3, or between T0 and 
T3 only (before IVLP and after reperfusion). It should be emphasized that after the IVLP procedure, lungs 
were flushed with perfusate not containing DOX (reperfusion) in order to remove any remaining drug from 
the isolated organ, thereby avoiding systemic side effects. As expected, among the compounds 
differentiating all four time points were doxorubicin and several other molecules of possible endogenous 
or exogenous origin. The biplot in Figure 6.7 represents the relationship between the data collected at given 
time points during IVLP for all three sections of the lung, and masses of importance selected by LASSO.  
Additionally, correlation analysis performed between all detected compounds and DOX lung concentration 
and distribution resulted in a number of metabolites exhibiting statistical significance. Cases, where the 
statistical significance was observed in at least two lung sections, were subjected to further identification 
and biological interpretation. The biplot plotted and the list of selected masses for the aforementioned 
metabolites can be found in Figure 6.9 and Table 6.2, respectively.  
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Figure 6.9 The biplot reflecting distribution of the molecular features (compounds) from Table 6.2 with 
respect to subsequent data points (RMSEC = 0.470, RMSECV = 1.008). 
 
Table 6.2 List of selected masses by Least Absolute Shrinkage and Selection Operator (LASSO) for 
endogenous low molecular weight compounds. Putative identifications are based on accurate mass vs. 
database and RT/log(p) relation/correlation. 
Compound m/z adduct Δ ppm 
Cardiolipin/CL (68:4) 475,3242 M+2H+Na 2 
Cardiolipin (70:7) 475,3242 M+3H 4 
PG (38:3) 401,2874 M+2H 4 
11-Hydroxyandrosterone 329,2084 M+Na 1 
5-Androstenetriol 329,2084 M+Na 1 
5-Androstene-3b,16a,17a-triol 329,2084 M+Na 1 
5-Androstene-3b,16b,17a-triol 329,2084 M+Na 1 
Oxandrolone 329,2084 M+Na 1 
N-Acetyl-L-isoleucine 329,2084 2M+H-H2O 4 
4-Hydroxydodecanedioic acid 329,2084 M+2ACN+H 4 
5-hydroxydodecanedioic acid 329,2084 M+2ACN+H 4 
2-Hydroxydodecanedioic acid 329,2084 M+2ACN+H 4 
6-Hydroxydodecanedioic acid 329,2084 M+2ACN+H 4 
3-Hydroxydodecanedioic acid 329,2084 M+2ACN+H 4 
3-Methylglutaconyl-CoA 306,0497 M+2H+Na 2 
5-carboxy-2-pentenoyl-coa 306,0497 M+2H+Na 2 
Cytidine 2'-phosphate 306,0497 M+H-H2O 2 
Cytidine monophosphate 306,0497 M+H-H2O 2 
Butenylcarnitine 306,0497 M+2K-H 2 
Cytidine 2',3'-cyclic phosphate 306,0497 M+H 4 
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Arabinosylhypoxanthine 269,0882 M+H 1 
Inosine 269,0882 M+H 1 
Allopurinol riboside 269,0882 M+H 1 
Methyl 5-acetoxyhexanoate 265,0231 M+2K-H 3 
Nonate 265,0231 M+2K-H 3 
Aldehydo-D-Mannose 203,0528 M+Na 1 
Keto-D-fructose 203,0528 M+Na 1 
Allo-Inositol 203,0528 M+Na 1 
Alpha-L-Allose 203,0528 M+Na 1 
D-Galactofuranose 203,0528 M+Na 1 
Muco-Inositol 203,0528 M+Na 1 
Hydroxypropionic acid 203,0528 2M+Na 1 
3-Deoxyarabinohexonic acid 203,0528 M+Na 1 
Beta-D-Glucose 203,0528 M+Na 1 
Glyceraldehyde 203,0528 2M+Na 1 
Allose 203,0528 M+Na 1 
Alpha-D-Glucose 203,0528 M+Na 1 
Beta-D-Galactose 203,0528 M+Na 1 
L-Gulopyranose 203,0528 M+Na 1 
Inositol 203,0528 M+Na 1 
Myo-Inositol 203,0528 M+Na 1 
Dihydroxyacetone 203,0528 2M+Na 1 
Scyllo-Inositol 203,0528 M+Na 1 
L-Lactic acid 203,0528 2M+Na 1 
D-Fructose 203,0528 M+Na 1 
D-Glucose 203,0528 M+Na 1 
D-Galactose 203,0528 M+Na 1 
D-Mannose 203,0528 M+Na 1 
Fructose 203,0528 M+Na 1 
Beta-D-Galactofuranose 203,0528 M+Na 1 
Cis-Inositol 203,0528 M+Na 1 
Neo-Inositol 203,0528 M+Na 1 
Nonanoylcarnitine 172,1333 M+ACN+2H 1 
2,6 Dimethylheptanoyl carnitine 172,1333 M+ACN+2H 1 
3a,20b-Pregnanediol 172,1333 M+H+Na 4 
Pregnanediol 172,1333 M+H+Na 4 
5alpha-Pregnane-3alpha,20alpha-diol 172,1333 M+H+Na 4 
7a,17-dimethyl-5b-Androstane-3a,17b-diol 172,1333 M+H+Na 4 
Glucosamine 6-sulfate 171,5523 M+2ACN+2H 2 
N-Sulfo-D-glucosamine 171,5523 M+2ACN+2H 2 
5'-Methylthioadenosine 160,5426 M+H+Na 3 
Glycerophosphocholine 151,5407 M+2Na 0 
Creatine riboside 151,5407 M+H+K 3 
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Putative identification of the presented features enabled selection of those of important biological 
significance, namely compounds related to lung toxicity or injury. Among the identified endogenous 
compounds were 5'-methylthioadenosine (MTA) and creatine riboside (CR). In addition, the Bio-SPME 
approach was capable of detecting alterations in several lipid classes, including cardiolipins (Table 6.2). 
MTA and cardiolipins levels were elevated during the IVLP, but not before the perfusion, while creatine 
riboside was found in the extracts obtained at all time points that might be assigned to an active metabolism 
of proliferating cancerous cells rather than the activity of chemotherapeutic drug (Figure 6.10). 
 
Figure 6.10 Scatter plots showing relative intensities of selected features/metabolites primarily 
dysregulated upon one-time chemotherapy treatment for an individual patient. Each dot in the scatter 
plots represents an individual metabolite in each sample. 
 
With the use of an optimized Bio-SPME-LC/MS method, obtained extracts were additionally subjected to 
screening of other low molecular weight compounds such as metabolites of DOX and 
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endogenous/exogenous small molecules. As demonstrated in previous studies, SPME is suitable for 
extraction and monitoring of a broad range of metabolites (from highly hydrophilic to hydrophobic ones) 
in different biomatrices.155 SPME has ability to monitor unstable compounds, like oxylipins, which was 
recently reported in brain.191  Changes in the profiles of endogenous compounds corresponding to the 
administration of DOX during IVLP were monitored to verify if the analytical strategy proposed for drug 
monitoring could also be adopted for screening of known markers of drug activity. As a proof of concept, 
compounds that showed correlation with DOX activity including 5-methylthioadenosine (MTA), and 
cardiolipins (CLs), as well as the biomarker of the lung cancer, creatine riboside (CR), were putatively 
identified in sample extracts. Presence of the metabolites was reported in the first case and further confirmed 
in the second one. It has been previously reported that MTA exhibits proapoptotic effects on different cancer 
cells.192,193  On the other hand, based on a study where DOX was used as a model drug, MTA was proposed 
to provide mechanisms to evade drug-induced apoptosis in tumor cells.194 It has been suggested that MTA 
may have a dual role in the regulation of cellular homeostasis; therefore, further investigation of the 
relationship between MTA-DOX during IVLP should be performed on a larger cohort of patients/cases. 
DOX has also been previously shown to exhibit a strong correlation with lipid metabolism. In a rodent 
model, DOX led to elevated serum triglyceride and blood glucose levels through the downregulation of 
PPARγ.195 An in vitro study with parental (MCF-7/S) and DOX-resistant (MCF-7/Dox) human breast 
cancer cells demonstrated that lipid profile changes can mediate the modulation of membrane fluidity in 
drug-resistant cells.196 The authors observed an increase in the levels of several lipids, including 
cardiolipins, in resistant cells. Interestingly, DOX was already described as a specific probe for transversal 
distribution of cardiolipin.197,198  As it can be seen in Figure 6.10 MTA and cardiolipin (68:4) levels were 
elevated during the IVLP, while creatine riboside was found in the extract obtained at all time points, i.e. it 
was independent on DOX administration (Figure 6.10). CR is considered a product of high creatine levels 
and high phosphate flux due to the higher energy demands of rapidly dividing tumor cells.199  The level of 
this compound has been found to be significantly higher in the urine of patients with non-small cell lung 
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cancer (NSCLC) compared to healthy individuals.200,201  Moreover, it has been previously reported that 
increased levels of CR are associated with increased tumor size and poor prognosis. Therefore, it has been 
speculated that this compound may not only be useful as a marker of early detection of lung cancer but also 
aid in the provision of more accurate prognoses.202 Based on our finding it can be postulated that MTA, 
cardiolipins and CR may be promising targets for further study in SPME-based DOX activity evaluation 
during IVLP. Moreover, as the first attempt at real-time profiling of metabolites in human lung tissue 
exposed to chemotherapy, this case study provides insights into the correlation between DOX and other 
endogenous molecules in the living system.  
However, the results of metabolite screening, although promising, contain limited data to draw any 
concluding remarks as the analyses in this case study were carried out in extracts specifically obtained for 
DOX analysis, and most of the small molecules described in this paper had low sensitivity. Therefore, as a 
next step, an optimum sample preparation protocol should be implemented to improve recovery of 
compounds of interest other than DOX. This will facilitate more in-depth study of organ-specific 
mechanisms as well as the adverse effects of DOX action, as such analyses are usually conducted on a large 
number of samples to account for biological variability and improve reliability of significant findings. 
6.6 Conclusion 
In summary, this work presents the first successful clinical use of the in vivo Bio-SPME chemical biopsy 
approach. The sampling/enrichment tool was used to reliably measure drug concentrations in lung tissue 
during a clinical case of localized DOX delivery.  At the same time, a wide range of other molecules were 
extracted for metabolomic analysis, demonstrating the potential of the technique for real-time monitoring 
and early indication of lung toxicity and injury during the procedure. Based on these results, Bio-SPME 
can be used as a tool to assist in the safe and efficacious implementation of IVLP treatment for local 
chemotherapy by offering temporal and spatial monitoring of the drug concentration in individual patients. 
The Bio-SPME chemical biopsy tool provides significant advantages as a novel approach for tissue 
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sampling since it imparts real-time information about both the levels of the administered chemotherapy, as 
well as its effect and toxicity, as represented by the changing metabolomic landscape in the organ. Bio-
SPME also shows potential as a complementary technique to aid in the elucidation of pathways affected or 
mechanisms of action of targeted therapies. 
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Chapter 7: Solid phase microextraction coupled to mass 
spectrometry via a microfluidic open interface for rapid therapeutic 
drug monitoring   
7.1 Preamble 
Chapter 7 has already been published in Analyst (2019, 144(12), 3721-3728) under the title “Solid phase 
microextraction coupled to mass spectrometry via a microfluidic open interface for rapid therapeutic drug 
monitoring”. This paper was co-authored with M. Tascon, V.R. Acquaro, N. Reyes-Garcés, T. Vasiljevic, 
G.A. Gomez-Rios, M. Wasowicz and J. Pawliszyn. Please see Statement of contributions. No permissions 
from the journal were necessary to reuse the material in this thesis as per journal instructions – authors do 
not require permissions requested. The authors would like to thank Dr. Angela Jerath and her team at 
Toronto General Hospital/University Health Network for the collection of patient plasma samples. We 
greatly appreciate Dr. Chang Liu (SCIEX) for his initial support in this project, as well as Waters 
Corporation for providing the HLB particles used to manufacture the SPME fibers herein described. The 
authors are grateful to SCIEX and the Natural Sciences and Engineering Research Council (NSERC) of 
Canada for the financial support provided through the Industrial Research Chair program.  Finally, we 
would like to thank the Science Technical Services at the University of Waterloo for aiding in the 
construction of the microfluidic open interface. V.A.J. thanks FAPESP, process 2016/16180-6 for his 
scholarship 
7.2 Introduction 
Tranexamic acid (TXA), classified as an antifibrinolytic agent, is a synthetic lysine analogue that works by 
inhibiting plasminogen and thus prevents its conversion to plasmin, an enzyme that degrades fibrin in blood 
clots.63 This medication is used to stop or reduce bleeding in a wide variety of hemorrhagic conditions.64 
For instance, it is used in a number of high-risk operations such as cardiac surgery, liver transplantation, as 
well as in emergency rooms to treat cases of hemorrhaging as a result of trauma.63,64 Its safety profile 
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provides significant advantages over older generation antifibrinolytic agents such as aprotinin and 
ecallantide, which have been linked to increased mortality, increased post-operative bleeding, increased 
blood transfusion requirements, and kidney failure.64 Although no major risk factors have been reported in 
relation to the use of TXA in clinical applications, increased incidences of post-operative seizures in cardiac 
surgical patients have been reported in association with its increased clinical use in high doses.63,64  A 
number of investigations directed at reaching the appropriate target concentrations unveiled high inter-
patient variability for TXA, in that therapeutic levels varied greatly from patient to patient, often exceeding 
the target concentrations of both high dose and low dose dosing schedules.3,64 Recently, Jerath et al. carried 
out a study demonstrating that exceedingly high TXA plasma levels – beyond 100 µg/mL – may be 
attributed to poor drug clearance from the system as a result of kidney dysfunction or failure.76 The above 
investigation was carried out by measuring levels of TXA in the plasma of patients presenting varying 
stages of kidney damage who were undergoing cardiac surgery with the use of TXA.203 These findings 
aided in the development of a new dosing regimen that accommodates patients who suffer from renal 
insufficiency. In this context, the development of technologies geared at fast and precise point-of-care 
(POC) analysis play a vital role in further advances in personalized medicine.204 Such developments are 
especially critical in cases where the inter-patient variability is high, necessitating accurate regulation of 
dosage to produce the desired therapeutic effect.  
 In this context, the direct coupling of solid-phase microextraction (SPME) to ambient mass spectrometry 
(MS) has emerged as a solution that efficiently integrates the sample preparation step with analysis.189,205,206 
Indeed, several clinical applications reported to date have demonstrated the ability of this platform to both 
minimize overall time of analysis as well as mass spectrometer contamination.134,207–209 In this work, a novel 
recently developed MOI that directly couples SPME to tandem mass spectrometry (MS/MS) in order to 
measure TXA is presented.188 This interface allows for efficient analyte transmission into the electrospray 
ionization (ESI) interface; hence, allowing a dramatic reduction in acquisition time when compared to the 
traditional liquid chromatography (LC) protocol (time scale on order of seconds by MOI versus time scale 
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on order of minutes by LC).210 Furthermore, after extraction, analytes collected onto the SPME devices are 
eluted for a period of 5 seconds into an open microfluidic desorption chamber which subsequently rapidly 
introduces the plug of desorbed analytes into the ESI interface and allows for improved sensitivity in 
comparison to other SPME-MS approaches.62 In light of the recently reported connection between TXA 
use and post-operative seizures, and considering the well-documented sizable inter-patient variability of 
this drug, the currently presented technology was applied for the high-throughput monitoring of TXA in 
plasma samples taken from patients presenting different stages of renal damage undergoing cardiac surgery. 
Assessments carried out at various time-points, from five minutes after the bolus was injected, up until 72 
hours post-surgery. The technology was also cross-validated against a previously validated thin film solid 
phase microextraction (TFME) with the use of LC-MS/MS method.83 The methodology showed turnaround 
times of 15 minutes per sample for single-injection analysis (i.e. one sample at the time), and less than 30 
seconds per sample for high-throughput analysis (i.e. extraction from a 96-well plate). These results 
demonstrate the capabilities of this technique towards close to real-time analysis of TXA, while evidencing 
its great potential for therapeutic drug monitoring in a wide range of clinical applications.  
7.3 Methods and materials 
7.3.1 Chemicals and materials 
Tranexamic acid (trans-4-(aminomethyl)cyclohexanecarboxylic acid), the internal standard cis-4-
aminocyclohexanecarboxylic acid, LC-MS grade formic acid, HPLC grade acetonitrile and methanol as 
well as chemicals used to prepare phosphate buffered saline (PBS), namely sodium chloride, potassium 
chloride, potassium phosphate monobasic, sodium phosphate dibasic were purchased from Sigma-Aldrich 
(Oakville, ON, Canada). Deionized water was obtained from a Milli-Q Reference A+ water purification 
system (Fisher Scientific). LC-MS grade water, used to prepare PBS as well as the stock solutions, was 
purchased from Fisher Scientific (Ottawa, ON, Canada). Human plasma (sodium citrate) was obtained from 
Lampire Biological Laboratories Inc. (Pipersville, PA, USA). HLB SupelTM-Select particles (~ 60 µm) used 
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for thin-film solid phase microextraction (TFME) were kindly provided by Supelco (Bellefonte, PA, USA), 
while HLB particles (~ 5 µm) used to fashion Bio-SPME fibres were kindly provided by Waters 
Corporation (Winslow, UK). Polypropylene 96-well 2 mL deep plates were purchased from Fisher 
Scientific (ON, Canada). 
7.3.2 Human plasma samples 
All procedures employed in this study, including the retrieval of samples from patients, were approved by 
the Research Ethics Boards of the Toronto General Hospital/ University Health Network and the University 
of Waterloo. Each patient signed an informed consent while recruited to participate in the study. Plasma 
samples were obtained from patients undergoing elective high or low risk cardiac surgery under 
cardiopulmonary bypass (CPB). For high risk (HR) cardiac surgery the dose administered was as outlined 
in the Blood Conservation Using Antifibrinolytics in a Randomized Trial (BART) study78 whereby 30 
mg/kg bolus of TXA infused over a 15 min span post induction of anaesthesia (period 1) followed by an 
infusion of TXA at a dose of 16 mg/kg∙hr (period 2) until the sternotomy was closed with a 2 mg/kg load 
in the pump prime. For low risk (LR) cardiac surgery, the dose was as per institutional practise at Toronto 
General Hospital as outlined by Jerath et al203 whereby patients received a bolus dose of 50 mg/kg post 
induction of anaesthesia. The sampling protocol, which is schematically demonstrated in Figure 7.1, was 
as outlined in previous research.83 Blood samples were first collected at baseline and then at 5 min and 10 
min during period 1  which was the administration of a bolus dose (single dose of TXA given to the patient 
by injection into a blood vessel). During period 2, whereby TXA was infused, samples were collected post 
sternotomy (chest opening), immediately before and after the start of CPB, and at 30 min intervals during 
CPB for up to four sampling points. Samples were collected again after CPB and prior to chest closing. 
Finally, in period 3 - the post operation (postop) period - samples were collected at 1 hr, 2 hr, 4 hr, 8 hr, 12 
hr, 24 hr, 48 hr, and 72 hr. A total, 114 samples were expected to be collected from 6 patients, with each of 
the 19 samples obtained, processed in triplicate. However, only 86 samples were obtained from 6 patients 
undergoing cardiac surgery for reasons undisclosed.  
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Figure 7.1 Patient blood samples were collected during surgery - which is segmented into 3 periods.  First, 
baseline samples were collected prior to Period 1. Samples were then collected at 5 min and 10 min during 
Period 1 whereby a 30 mg/kg bolus dose of tranexamic acid is administered over 15 minutes. During period 2 
of intravenous infusion of 16 mg/kg/hr, samples were collected post-sternotomy (after chest opening), 5 min 
before and after the start of cardiopulmonary bypass (CPB), at 30 minutes intervals during CPB for up to 4 
sampling points, post CPB and prior to chest closure. During period 3, the post operation period where 
intravenous infusion was ceased, samples were finally collected at 1 hr, 2 hr, 4 hr, 8 hr, 12 hr, 24 hr, 48 hr and 
72 hr. 
 
7.3.3 High throughput analysis with concept-96 unit 
The Concept-96 autosampler, shown in Figure 7.2, is a software-operated system that automatically 
performs each step of the SPME protocol: pre-conditioning, extraction, rinsing, and desorption.47 The brush 
format differs slightly using a fiber form factor as opposed to TFME form factor which is presented in 
Figure 2.2 section 2.3.6 “Concept-96 for SPME automation” of Chapter 2. It houses a robotic arm, where 
either the 96 blades or fibres can be immobilized. These devices are compatible with 96-well plates, which 
can be stationed in their respective compartments on the unit. The system allows for preparation of up to 
96 samples at once. After completing the sample preparation workflow, well plates can be deposited directly 
into the auto sampler of the LC system.  
7.3.4 Sample preparation 
All samples, including human plasma samples used to create the matrix-matched external calibration curve, 
were prepared as follows: 250 µL of sample was placed in a 2 mL well, and diluted with 750 µl of a PBS 
solution containing the internal standard. The dilution of samples (1:3) was supported for this application 
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due to the high therapeutic levels of TXA in the samples, as well as negligible binding of TXA to plasma 
proteins (~ 3%).54 Extractions from the prepared samples were carried out with TFME in brush format and 
Bio-SPME fibres; both compatible with the 96-well plate format.  
 
Figure 7.2 The Concept-96 is a software operated system that permits high throughput solid phase 
microextration (SPME) sample preparation of 96 samples simultaneously. It automatically performs each 
step of the SPME protocol – preconditioning, extraction, wash and desorption – with the help of a robotic 
arm that houses the brush format of the SPME configuration to be used (Bio-SPME fibers). This brush 
format is compatible with 96 well plates which are placed on their respective stations. 
 
7.3.5 Calibration and quality control samples 
Stock solutions of tranexamic acid were prepared by dilution of 100 mg/mL initial stock in pure LC-MS 
grade water. The solutions ranged from 500 µg/mL to 100 000 µg/mL and were stored at 4 ⁰C in amber 
vials. A matrix-matched external calibration curve was prepared by adding 10 µL of the respective 
concentration of stock to 1 mL of human plasma. Samples were then submitted to low agitation for 45 
minutes at room temperature to allow for equilibration to occur prior to the sample preparation step. The 
standard curve was validated at a working concentration of 100 µg/mL, which was prepared using the same 
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dilution ratio of a separate stock solution of 10 000 µg/mL of TXA. Phosphate buffered saline was prepared 
by dissolving 1.44 g sodium phosphate, 0.2 g potassium phosphate, 8.0 g sodium chloride, and 0.2 g 
potassium chloride in 1 L LC-MS grade water and adjusted to pH 7.4. The PBS was then spiked with 2 400 
µg/mL of the internal standard cis-4-aminocyclohexanecarboxylic acid.  
7.4 Instrumental analysis 
7.4.1 SPME-LC-MS/MS 
The TFME brush was prepared using a spray protocol developed in-house.80 The device was coated with 
60 µm HLB particles, and characterized by final coating dimensions of 2 cm length and 0.3 mm thickness.211 
Collected patient samples were prepared for analysis in 96-well plates, which were then mounted on their 
respective stations on the Concept-96. The SPME protocol for the LC-MS/MS method was as follows: pre-
conditioning of the coating was carried out in 1.5 mL 50:50 (v/v) methanol/water for 15 min at 1500 rpm; 
extraction was performed at room temperature (25 ⁰C) from 1 mL of biological matrix for 5 min at 1500 
rpm; a 10 s agitated rinse (1500 rpm) was carried out in 1 mL 90:10 (v/v) water/methanol; and desorption 
was completed in 1 mL 3:3:4 (v/v/v) acetonitrile/methanol/water for 10 min at 1500 rpm. The desorption 
plate was then mounted into the autosampler and 10 µL of resultant extracts were withdrawn for LC-
MS/MS analysis.  
High performance liquid chromatography was performed with an Accela autosampler and pump (San Jose, 
CA, USA). Mass spectrometric detection was carried out with a triple quadrupole mass spectrometer TSQ 
Vantage (Thermo Scientific, San Jose, USA). Chromatographic separation was performed on a Discovery 
HS F5-3 column (10 cm x 2.1 mm, 3 µm) with a corresponding PFP guard column (Supelco, Bellefonte, 
PA, USA). A previously developed method detailing the conditions of the chromatographic separation and 
detection of TXA via LC-MS/MS was described elsewhere in detail.77 Mobile phase A was 100 % water, 
while mobile phase B was 100 % acetonitrile, each with 0.1% formic acid. The 8-minute gradient 
chromatographic method had a final flow rate of 300 µL/min, and was carried out as follows: 90 % A from 
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0-2 minutes, 40 % A from 2-5.5 minutes with a hold at 40% A to 6 minutes, ending with a 2-minute re-
equilibration at 90% A. The ESI parameters were: positive ion mode; nitrogen gas set at GS1 = 25, GS2 = 
25; collision gas (CAD) =10; curtain gas = 25; heated nebulizer temperature = 450 °C; and electrospray 
voltage = 5000 V.  
7.4.2 Bio-SPME-MOI-MS/MS 
Bio-SPME fibres were prepared on a nitinol support in accordance to a dipping method developed in our 
laboratory.134 The final dimensions of the fibres were 4 mm coating length and 20 µm of thickness, using 5 
µm HLB particles.  Parameters for analysis via MOI-MS/MS were as follows: extraction time was 15 min, 
followed by two 5 s rinsing steps with water, then desorption for 5 seconds at the MOI device, which was 
directly coupled to the mass spectrometer API 4000 triple quadrupole (AB SCIEX, Concord, Ontario). The 
operational duty cycle and performance of this interface is described in detail elsewhere.188,210,212 The LC 
pump employed for fluid delivery was a 200 Series Perkin Elmer (Santa Clara, CA, USA), while ionization 
was produced with the use of a TurboIonTM spray source. Conditions required for the desorption step 
consisted of an equilibrium between the pump flow at (350 μL·min-1) and the electrospray ionization (ESI) 
aspiration. Essentially, the MOI device is designed with two sections188 as shown  in the second step of the 
analytical workflow in Figure 7.3.  
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Figure 7.3 The Analytical workflow for Bio-SPME-MOI-MS/MS 
 
The top section, which functions as the SPME desorption chamber, consists of a Teflon cylinder with two 
holes connected by a channel of a smaller diameter.188 The connection between the open ambient desorption 
chamber and the electrospray needle employed in this device was inspired by the design of the open-port 
interface reported by Van Berkel et al.188,189,209,210,212 Succinctly, the procedure involves the employment of 
two co-axial tubes that allow for solvent delivery through the gap formed between these two tubes. Once 
the solvent reaches the top of the coaxial tubes, it is aspirated towards the MS by means of the Venturi 
effect produced by the ESI source. ESI parameters were as follows: positive ion mode; nitrogen gas set at 
GS1 = 90, GS2 = 70; collision gas (CAD) = 6; curtain gas = 25; heated nebulizer temperature = 300 °C; 
and electrospray voltage = 5000 V. Chromatograms of the typical signals for blank plasma and patient 
samples are shown in Figure 7.4 and Figure 7.5, respectively. The solvent employed in the MOI-MS/MS 
system was methanol with 0.1% v/v formic acid. These conditions provided better sensitivity for this direct-
to-MS application than acetonitrile or the desorption conditions used for TFME-LC-MS/MS.  
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Figure 7.4 The signal for a blank plasma sample prepared with biocompatible solid phase 
microextraction (Bio-SPME) fibers and analyzed via microfluidic open interface tandem mass 
spectrometry (MOI-MS/MS). 
 
 
 
Figure 7.5 The signal for a blank plasma sample superimposed with a signal from patient sample 
prepared using biocompatible solid phase microextraction (Bio-SPME) fibers and analyzed via 
microfluidic open interface tandem mass spectrometry (MOI-MS/MS). 
 
7.5 Results and discussion 
7.5.1 SPME-MOI as a tool for rapid analysis of clinical samples 
Given that tranexamic acid is known to present high inter-patient variability, concentration levels for TXA 
should be closely monitored in patients over the course of treatment. In this regard, previous studies have 
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demonstrated the emergence of a two-group stratified trend of TXA plasma concentration for patients 
receiving the same therapeutic treatment.64 For the confirmatory high throughput study performed by Jerath 
et al,203 patients were first categorized based on the type of cardiac surgery endured – low risk (LR) or high 
risk (HR). Within each group, patients were further categorised by healthy renal function and on the basis 
of degree of chronic renal dysfunction, stages 1 – 5; stage 1 being normal or increased glomerular filtration 
rate (GFR) and stage 5 being kidney failure.203 As the use of TF-SPME technology for monitoring TXA in 
plasma has already been validated in previous research54,82,83 against traditional methods such as 
ultrafiltration (UF) and plasma protein precipitation (PPt) which is routinely used for analysis in clinical 
applications, the same technology, with a few modifications was employed for this high throughput study.  
 
Figure 7.6 Patient profiles of 6 patients from two different risk groups. Figures 2A, 2B and 2C show profiles for 
patients who underwent low risk cardiac surgery with a dosing schedule as per institutional practice at the Toronto 
General Hospital. Figures 2D, 2E and 2F show profiles of patients who underwent high risk cardiac surgery with 
Blood Conservation Using Antifibrinolytics in a Randomized Trial (BART) dosing schedule. Results obtained via 
SPME-LC-MS/MS is represented by bars in dark blue while results obtained via SPME-MOI-MS/MS are 
represented by grey bars. 
 
Given that all patients within the same risk  category (high risk or low risk) were submitted to the same 
dosing schedule, the drastic differences observed in patient profiles as seen in Figure 7.6 (for example high 
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risk patients in Figure 7.6D, Figure 7.6E and Figure 7.6F, patients with more severe chronic renal 
dysfunction (CRD) experience elevated and persistently high TXA concentrations – Figure 7.6D and Figure 
7.6E– in comparison to patients with normal kidney function – Figure 7.6F) endorses not only the need for 
revision and adjustment of the current TXA dosing schedule for cardiac surgical patients, but also the 
necessity of rapid sample analysis technology to facilitate POC testing. The former would generally 
contribute towards improving the recovery of patients post operation, particularly those with renal 
impairment, while the latter would better navigate clinical practitioners in personalizing treatment peri-
operatively. Herein, we explain how Bio-SPME-MOI-MS/MS can be used as an alternative technology for 
rapid high throughput analyses of clinically relevant samples containing TXA. For instance, Figure 7.3 
shows two sample preparation workflows that can be used with this technology. The first approach, the 
single injection strategy, allows for turnaround times under 15 minutes. The second approach, namely the 
high throughput workflow, as illustrated in Figure 7.3, allows for simultaneous extraction of TXA from up 
to 96 plasma samples. Hence, total sample preparation time drops to less than 10 seconds per sample, with 
total analysis times of approximately 30 seconds per sample given that the operator needs to manually place 
each Bio-SPME device on the MOI. As such, this method not only offers the selectivity provided by mass 
spectrometry and the efficient sample clean-up afforded by SPME but also facilitates rapid sample 
throughput due to semi-automation via the Concept-96. The Bio-SPME-MOI-MS/MS method produced a 
coefficient of determination (R2) of 0.997 and a linear dynamic range over more than two orders of 
magnitude (refer to Figure 7.3), from 25µg/mL – 1000 µg/mL, comparable to the TFME-LC-MS/MS 
method. However, an LOQ of 25 µg/mL was obtained for the MOI-MS/MS as opposed to the LOQ of 5 
µg/mL obtained for LC-MS/MS. These differences reflect the differences observed in recoveries for the 
target compound, which were dependent on the geometry utilized for analysis, whereby a 1% recovery was 
experienced for the TFME method in comparison to a 0.1 % recovery for the Bio-SPME method. 
Nonetheless, the range of concentrations that are expected to be encountered during TXA administration 
are well above these LOQs, with the target therapeutic level estimated to be 100 µg/mL. The method was 
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validated in human plasma at a working concentration of 100 µg/mL, with an inter-day precision of 20 %, 
a corresponding average accuracy of 91 % (n = 15), and an intra-day precision of 20 %, corresponding to 
an average accuracy of 95 % (n = 5).  
As a result, Figure 7.6 shows the relatively close reproducibility of patient profiles by Bio-SPME-MOI-
MS/MS in comparison to the trend generated by TFME-LC-MS/MS from both sets of patients undergoing 
high-risk (HR) or low-risk (LR) cardiac surgical procedures. Each bar plot shows the comparison of MOI 
(represented by grey bars) vs LC (represented by dark blue bars) for the concentration of tranexamic acid 
in plasma at each time point over the course of surgery. The profiles generated by Bio-SPME-MOI-MS/MS 
are very similar to profiles obtained by TFME-LC-MS/MS in that the same trend for a particular individual 
was observed. For instance, HR-Patient 24 had much higher TXA levels between CPB-30 (30 minutes after 
the start of cardiopulmonary bypass) and post-op-4hour (4 hours post operation after removal of CPB and 
cessation of TXA IV infusion) compared to the concentrations prior to Pre-CPB (start of surgery before 
cardiopulmonary bypass was implemented). In other patients however, such as HR-Patient 20 and HR-
Patient 21, although TXA concentrations remain high (greater than 100 µg/mL), there is a more obvious 
decreasing trend of TXA plasma concentrations over the course of surgery, unlike that seen with HR-Patient 
24. All three patients of this risk group belong to stage 4 chronic renal dysfunction. Despite belonging to 
the same stage and receiving the same dosing schedule, there are clear differences in the profiles between 
these patients. LR-Patient 26 and LR-Patient 28 experienced a sharp drop in concentration around CPB-30, 
however the concentration levels essentially plateaued at these lower concentrations with a slight spike at 
pre-closure and postop 1 hour from LR-Patient 26 until concentrations finally decreased during the post op 
period around 12 hours and 24 hours for LR-Patient 26 and LR-Patient 28 respectively. However, LR-
Patient 6 experienced a much sharper decreasing trend than the other patient counterparts in the same risk 
group and especially in comparison to those patients in the high-risk group. The concentration plateau seen 
in LR-Patient 26 and LR-Patient 28 are indicative of increased residence time of TXA in plasma due to 
poor renal filtration as both patients belong to stage 4 renal dysfunction whereas LR-Patient 6 belongs to 
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stage 2 renal dysfunction. These results comparing MOI-MS/MS to LC-MS/MS are astounding, especially 
considering the large difference in time of analysis that exists between the two methods. For instance, 
approximately 19 continuous hours would be needed to process 96 samples via LC-MS/MS as opposed to 
the less than 2 hours needed for the manually operated MOI-MS/MS workflow to produce comparable 
results. Moreover, the proposed method proves robustness, as the samples were run on a blinded basis and 
completely randomized. 
7.5.2 Statistical validation of the MOI methodology  
Figure 7.7 and Figure 7.8 demonstrate the results of the statistical validation performed on the data acquired 
from both methods. The Passing-Bablok regression, shown in Figure 7.7, was constructed in order to 
statistically cross-validate the SPME-MOI-MS/MS method for monitoring TXA in plasma with the 
previously validated SPME-LC-MS/MS method.  
 
Figure 7.7 Passing-Bablock regression of data obtained from LC-MS/MS vs. MOI-MS/MS. 
 
The Passing-Bablok regression uses an orthogonal regression algorithm which assumes that measurement 
imprecision is present in both methods under comparison. Six patients, were analysed initially by SPME-
LC-MS/MS for the purposes of the high throughput study.76 Both methods exhibited consistency in signal 
response over concentration. From the 86 sample pairs that were obtained from measurements with LC vs 
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MOI from 6 patients, 25 pairs exhibited statistically different results (p < 0.05) and were therefore excluded 
from further analysis. As such, n = 63 pairs were used for further statistical cross validation of the two 
methods. The results from the regression, which included 63 sampling pairs suggest equal suitability for 
both methods, with a slope of 0.984 (0.909 to 1.06), and an intercept of 11.049 (1.91 to 16.3). A statistical 
comparison of the two methods via the Spearman correlation coefficient yielded a value of 0.958 (0.931 to 
0.974), further indicating that the methods have a linear relationship and are highly correlated (p < 0.01).  
 
Figure 7.8 Bland-Altman plot of data pairs (n=63) of LC-MS/MS and MOI-MS/MS 
 
Furthermore, to supplement the results of the Passing-Bablok regression, a Bland-Altman plot was 
constructed. The Bland-Altman plot shown in Figure 7.8 shows that the mean absolute difference in TXA 
quantification was observed to be 9.0. A value of ±1.96 standard deviation (SD) was used for the limit of 
agreement values (LOA), thus obtaining an interval from −39.6 (lower agreement limit) to 57.6 (upper 
agreement limit). The number of data pairs observed to be beyond the LOA value was 5 out of 63, which 
confirmed a Bland–Altman index of 7.9%. Thus, 92.1 % of the compared pairs were distributed within the 
acceptable range (within the ±1.96 SD limit). The comparative results presented low discrepancy between 
both methods, with the majority of the values distributed around the mean (9.0) and completely random, 
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indicating that no tendency is present in the analysis. Thus, confirming the suitability of Bio-SPME-MOI-
MS/MS for the monitoring of TXA in plasma samples. 
7.5.3 MS-based POC technologies 
The MOI has already demonstrated to have about one order of magnitude more sensitivity than the open 
port probe interface for Bio-SPME applications for several targeted compounds.188,189 The main differences 
were attributed to the small desorption volume employed as well as the static desorption allowing for a very 
sharp injection plug. Additionally, this technology is complementary to other ambient technologies such as 
DART and DESI which have been implemented in a number of clinical applications and are largely 
employed in a wide range of bioanalytical applications including screening of small molecules in biological 
fluids, 2D imaging of tissues and high throughput screening and drug discovery, respectively.213–216 
However, most of these applications are directed towards the analysis of compounds present in high 
concentrations where strong matrix effects are not compromising the detectability. When sample 
preparation for direct-to-MS approaches is taken into account, the most widespread is SPE.12,217 RapidfireTM 
especially, has been demonstrated to be useful for therapeutic drug monitoring of immunosuppressive drugs 
in whole blood with sample turnaround times of less than 15 s.12 However, for total analysis time, the 
number of steps is not fully contemplated including protein precipitation, incubation and centrifugation. 
Noteworthy, Unlike SPME, in SPE this protocol cannot be skipped in clinical samples such as whole blood 
or plasma due to the chances of cartridge clogging. Regarding SPME-MS interfaces, Coated blade spray 
(CBS)205 is another concept, that has also shown potential for high throughput therapeutic drug monitoring 
affording sample analysis times of less than 55 s.208 As a substrate spray method, the entire blade can be 
exposed to a fluid sample for a predetermined amount of time, thereby conducting an SPME based 
extraction.207,208 Alternatively, similar to Paper spray (PS), a spot analysis can be performed wherein a small 
sample volume can be directly applied to the blade coating surface prior to desorption/ ionization. There 
are fewer methodologies still, like PS, that are used for quantitative therapeutic drug monitoring and POC 
analysis.74,218   Given that SPME fibers can be easily interfaced with the MOI, this technology offers a 
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unique advantage not only as an alternative approach to the bulk of these strategies but also a 
complementary technique as it can be used for both quantitative in vivo and ex vivo analysis.62,188,189,209 
Owing to the SPME device’s small diameter (Ø < 250 µm), MOI presents a breakthrough for rapid 
quantitative and qualitative practices for assessing more complex biological materials such as various 
tissues/organs that have been subjected to therapy. 
7.6 Conclusions 
The work herein presented demonstrates that employment of liquid chromatography instrumentation for 
quantitation of TXA in plasma can be circumvented by directly coupling SPME to mass spectrometry via 
the developed MOI, thereby dramatically improving sample throughput. In fact, to the best of our 
knowledge, it is the first time that a SPME-MS approach is validated for a large number of clinical samples 
demonstrating the feasibility for rapid therapeutic drug monitoring. Since SPME integrates sample 
preparation and sample clean-up in one step, while being amenable for automation with the 96-concept, a 
large number of plasma samples from patients can be prepared and subsequently submitted to instrumental 
analysis within a short period of time, affording total analysis time of less than 30 seconds per sample. The 
currently presented method achieved a linear dynamic range between 25 µg/mL – 1000 µg/mL, which is 
comparable to that produced by TFME-LC-MS/MS. This LOQ of 25 µg/mL result is suitable for the range 
of TXA concentrations expected from such clinical applications; and undoubtedly reproduced the profiles 
of 6 patients from two different risk groups, with an average accuracy and precision of 95% and 20 %, 
respectively. It must also be noted that despite Bio-SPME-MOI-MS/MS did not achieve similar precision 
as found by TFME-LC-MS/MS method, the attained values are nonetheless sufficient and acceptable for a 
POC or screening methodology. Presumably, one of the main contributing factors behind the observed 
difference in performance may be attributed to the absence of an autosampler for conducting the analysis 
since the fibers were introduced manually to the MOI. Uncertainties in the final quantitative data may arise 
because of variations in the reaction times of placing or removing the fibers into or from the MOI, as well 
as variations in the amount of time that elapsed for desorption and switching the flow to allow aspiration. 
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Additionally, the fibers used were prepared in laboratory using a relatively novel dipping strategy developed 
in house.134 The use of commercially available fibers can be a source of potential improvement. 
Furthermore, although use of an internal standard is meant to correct for any possible variations, the internal 
standard used was not an isotopically labelled standard which may not completely address the system 
variations. Nevertheless, the Passing-Bablok regression was performed to cross-validate the developed 
MOI methodology against the LC-MS/MS gold standard. The correlation was slightly lower in the lower 
concentration range (intercept) due to the differences in LOQ achieved by LC-MS/MS vs MOI-MS/MS 
respectively. However, the assays agreed reasonably well in the expected TXA concentration range for both 
methods (slope of the regression line 0.931 to 0.974). Bio-SPME-MOI offers a breakthrough for rapid 
sample analysis and high sample throughput⎯requirements for on-site clinical applications such as 
therapeutic drug monitoring and POC testing. With the necessity for rapid sample analysis afoot, based on 
the work presented herein and the possibility of mass spectrometers being introduced into clinical settings, 
this technology can be implemented for real-time analysis of biological samples in hospitals and clinics, 
providing and easy to use tool for POC-testing, screening, and onsite therapeutic drug monitoring in 
biofluids and/or tissues either in vivo or ex vivo.  
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Chapter 8: Conclusion 
The objective of the research was twofold. First, this research sought to demonstrate the potential and range 
of SPME in the clinical field of personalized medicine, particularly for TDM and metabolomics in a range 
of complex biological samples. In Chapter 2, a high-throughput TFME method was developed for the TDM 
of TXA in plasma and urine, which expanded on previous research that focused only on plasma. The results 
from the work in this chapter were used by clinicians to develop a more comprehensive PK profile in an 
effort to adjust the dosing schedule for patients with chronic renal dysfunction.76 In Chapter 3, an SPME 
method based on a mixture of sorbent phases was used to perform global serum profiling on patients with 
PsD and PsA. This study resulted in two key observations: 1) PsA disease progression may provide more 
insight to disease conversion (the development of PsA), and 2) there is an apparent correlation between 
dysregulated fatty acid enzymes and PsA disease severity, as evidenced by an increase in a number of 
circulating organic acids. While Chapters 2 and 3 focused on the use of SPME for ex vivo analysis of 
biofluids, Chapters 4, 5, and 6 focused on the use of SPME in more difficult and dynamic clinical settings. 
Specifically, the work in these chapters demonstrated the proficiency of SPME as an in vivo sampling tool 
for the analysis of lung tissue during ILP systems. Chapter 4 solely focused on tissue metabolomics, using 
in vivo SPME to investigate the changes taking place over the duration of NEVLP. The results of this study 
showed the capacity of NEVLP as an organ-preservation technique, as the lung exhibited continued 
metabolic functions, which was evidenced by the tentative presence of both anti-inflammatory and pro-
inflammatory metabolites. In contrast, Chapters 5 and 6 illustrate SPME’s capabilities for concomitant 
TDM and pharmacometabolomics. In Chapter 5, an SPME-based method for the in vivo quantitation of 
FOLFOX in porcine lung was developed and applied to real samples collected via in vivo SPME fibers 
during pre-clinical IVLP and IV trials, which was followed by proof-of-concept pharmacometabolomics to 
assess the changes in the lung during IVLP or IV under chemotherapy. The preliminary results revealed 
that the metabolic changes in the lung were not only treatment related (as a result of the chemotherapy), but 
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they were also influenced by the route of administration. For instance, compared to IVLP, the IV route 
seemed to produce more consistent results related to drug metabolites, specifically for FdUMP, which is 
the active metabolite of F. In Chapter 6, a previously developed SPME-based method for the quantitation 
of DOX in tissue was used for monitoring DOX administered to human lungs via clinical IVLP trials, after 
which, a proof-of-concept pharmacometabolomics followed. Chapter 6 presented the first successful 
clinical use of in vivo SPME, thereby showing its potential for monitoring not only drug concentration and 
distribution but also monitoring markers of lung toxicity or injury during the procedure. In vivo SPME can 
therefore by effectively implemented for temporal and spatial monitoring of therapeutic drug 
pharmacokinetics as well as the  impact of this therapy specific to an individual. 
It is worth mentioning that many of these studies were limited to proof-of-concept metabolomics (i.e., 
pharmacometabolomics)  due to various limitations, such as: availability/schedule of surgeons and students; 
research culture (e.g., willingness of participating surgeons or students); time limitations; clinical/surgical 
limitations; unforeseen circumstances, including limited number of patients enrolled in a study; and the 
interdisciplinary nature of the study. Typically, a much larger cohort and a closer examination of the 
relationship between the obtained metabolic profile and the clinical parameters/outcomes are required 
before any results can be confirmed and further implemented into clinical practice. Nevertheless, there is a 
lot to be learned from the work presented in this thesis. Aside from its evident potential in personalized 
medicine, this work shows that SPME is a tool that can be used to improve the metabolomic workflow, as 
it can be deployed on-site for both the ex vivo and, more importantly, in vivo sampling of fluids and solid 
matrices. As shown in Chapter 4, both the on-site and in vivo approaches are superior for obtaining the true 
coverage of the metabolome, as snap-freezing, a common sample preservation practice in the metabolomics 
workflow, can lead to the formation of artefacts that are not representative of the true metabolome under 
physiological conditions. Furthermore, in Chapter 5, that the metabolome can be drastically affected not 
only by the chemotherapy administered but by the route of administration (IVLP vs. IV), and while it may 
be an obvious hypothesis, it is explored and documented in this thesis. Lastly in Chapter 6, while the number 
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of patients was low (2 cases), they represent the first successful use of in vivo SPME for sampling human 
lung during clinical IVLP trials with DOX, showing the direction and promise of SPME in being used for 
determining metabolic-related markers correlated to (in the long run) favorable/adverse clinical outcomes.  
The second research objective, addressed in Chapter 7, was to show that SPME can be easily used for rapid 
diagnostics via real-time TDM or point-of-care metabolic analysis for a variety of complex samples. Since 
point-of-care metabolic analysis poses a number of field-related research challenges (validation of 
important metabolic markers), this research focused more explicitly on demonstrating real-time TDM, 
particularly for the monitoring of TXA in the plasma samples from the patients presented in Chapter 1. 
Finally, the results presented in Chapter 7 statistically prove that SPME coupled to MS via MOI can achieve 
similar results in substantially less time than the analytical gold standard, LC-MS.  
In conclusion the work presented in this thesis satisfies the research objectives, namely, that SPME can be 
successfully used in the clinical field for TDM, metabolomics, pharmacometabolomics, and point-of-care 
testing via rapid analysis. 
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